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Appendix 1 
 
Deltamethrin, CAS no. 52918-63-5 
 
Synonyms: the IUPAC name is alpha-cyano-3-
phenoxybenzyl (1R,3R)-cis-3-(2,2-dibromovinyl)-
2,2-dimethylcyclopropanecarboxylate. Trade names 
include Decis, Decasyn, Butox, K-Othrine, Kordon, 
Sadethrin, and many more. 
Deltamethrin (Figure 1) is a pyrethroid ester 
insecticide used in pest control. It is highly toxic to 
aquatic life, and in humans deltamethrin has been 
found to be neurotoxic and an allergen that may 
cause asthma in some people.  
Since no registration dossiers on deltamethrin are 
available, it is assumed that it is produced and/or 
imported to EU in tonnages less than 100 tpa.  
 
4. Human health hazard assessment 
4.10.3 Endocrine disruption 
4.10.3.1 General approach – human health 
4.10.3.2 In vitro information indicative of endocrine activity 
Christen et al. (2014)  
Summary: Part of this study aimed at assessing androgen receptor (AR) antagonistic activity of 6 
pyrethroids, including deltamethrin (CAS no. and purity not reported) and compare the results from 
data from Du et al. (2010). MDA-kb2 cells were used for the AR reporter gene assay in an 
antagonistic mode with co-exposure to dihydrotestosterone (DHT) (1 nM). Deltamethrin was only 
tested in a single dose of 10 µM (number of replicated experiments not reported), which was below 
the cytotoxicity concentration. Deltamethrin at 10 µM resulted in a lower anti-androgenic activity 
than was previously reported by Du et al. (2010). 
Study quality and assessment: The study does not report information such as CAS no., purity, number 
of replicated experiments, and only one dose has been tested. Based on this the study is assessed to be 
of low quality. The study provides moderate evidence for a weak anti-androgenic MoA of 
deltamethrin.  
 
Figure 1. 2D structure from PubChem 
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Abdallah et al. (2010a)  
Summary: The purpose of the present study was to investigate the in vitro effects of deltamethrin 
(CAS no. and purity not reported) on rat spermatozoa. Spermatozoa from adult male rats were 
obtained and dispersed to a final concentration of 10·106 spermatozoa/ml and incubated for 3 h with 
0, 10, 50, 100 or 200 µM deltamethrin (n=8 rats/group, read from the tables and figures). Sperm 
viability was assessed as was sperm motility and morphology. The activities of superoxide dismutase 
(SOD), catalase (CAT) and lipid peroxidation (LP) were estimated. 
Spermatozoa viability decreased significantly at all concentrations and motility decreased at 
concentrations of 50 µM and above. An increase the number of morphologically abnormal 
spermatozoa was seen at 100 and 200 µM deltamethrin. A concentration-dependent increase in SOD, 
CAT and LP activities was seen starting from the lowest concentration of 10 µM deltamethrin 
indicating oxidative stress.   
Study quality and assessment: The study is well-described although information on the CAS no. and 
purity is not reported. Overall the study is assessed to be of high quality. The study provides weak 
evidence for an ED MoA underlying the effects on sperm parameters in vitro as these effects are more 
likely due to an oxidative stress MoA. 
 
Du et al. (2010)  
Summary: The purpose of this study was to evaluate the activities of 9 pyrethroids, including 
deltamethrin (CAS no. 52918-63-5, 99% purity), on estrogen receptor (ER), androgen receptor (AR) 
and the thyroid hormone receptor (TR). Deltamethrin was tested in concentrations of 10-9-10-4 M for 
ERα activity with or without 10-9 M 17β-estradiol (E2) as well as for TR activity with or without 5·10-
9 M T3 using transfected CV-1 cells. Deltamethrin was tested at the same concentrations for AR 
activity with or without 10-9 M DHT in transfected MDA-kb2 cells. Cytotoxicity of deltamethrin with 
or without E2 or triiodothyronine (T3) in CV-1 cells, and of deltamethrin with or without 
dihydrotestosterone (DHT) in MDA-kb2 cells was evaluated. All experiments were done in triplicate. 
No effects of the tested concentrations of deltamethrin were seen on cell viability or proliferation in 
both CV-1 cells and MDA-kb2 cells. Deltamethrin exhibited weak ER activity and TR antagonistic 
activity in the CV-1 cells, and AR antagonistic activity in the MDA-kb2 cells.  
Study quality and assessment: The study is well-described and assessed to be of high quality. There is 
strong evidence for both an oestrogenic, anti-androgenic and anti-thyroid MoA of deltamethrin in 
vitro. 
 
Birkhøj et al. (2004)  
Summary: The study examined the in vitro anti-androgenic effect of 5 pesticides, including 
deltamethrin (no CAS no. reported, 99.0% purity), individually and in a mixture. Chinese Hamster 
Ovary (CHO) cells were transfected with androgen receptor (AR) and a reporter plasmid, and 
deltamethrin were added in 12 concentrations ranging from 0.025-50 µM with or without 0.1 nM of 
the AR agonist R1881 (3 biological replicates per concentration, read from figure). Luciferase activity 
and cytotoxicity was also assessed. Deltamethrin resulted in cytotoxicity at concentrations of 12.5 µM 
and above. A significant inhibition of the R1881-induced AR activation by deltamethrin was seen at 
sub-cytotoxic concentrations starting from 1.6 µM.  
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Study quality and assessment: The study is well-described although information on CAS no. and 
biological replicates are not stated in the material and methods. Overall, the study is assessed to be of 
high quality. The study provides moderate evidence for an anti-androgenic MoA in a single in vitro 
assay. 
 
Andersen et al. (2002)  
Summary: In this study 24 pesticides, including deltamethrin (CAS no. 52918-63-5, purity not 
reported), were tested for their (anti)oestrogenic and (anti)androgenic as well as aromatase inhibitory 
potential in vitro. First, deltamethrin was tested in concentrations from 10-8-5·10-5 M in MCF-7 cells 
for cell proliferation and estrogen receptor (ER) transactivation activity in both the agonistic and 
antagonistic (using co-treatment with ER agonist 17β-estradiol). Cytotoxicity in the MCF-7 cells was 
assessed. Then deltamethrin was tested in Chinese hamster ovary (CHO) cells transfected with the 
human androgen receptor (AR) at 10-8-5·10-5 M in agonistic and antagonistic mode (using co-
treatment with AR agonist R1881). Cytotoxicity in the CHO cells was assessed. Finally, deltamethrin 
was tested in a single concentration of 50 µM for effects on aromatase activity (CYP19) in human 
placental microsomes. At least two independent experiments were run with each concentration in 
triplicate or quadruplicate. 
Deltamethrin resulted in weak effects on MCF-7 cell proliferation at concentrations below 
cytotoxicity (>25 µM) but did not cause oestrogenic or anti-oestrogenic effects in the ER 
transactivation assay in MCF-7 cells. Also, no androgenic of anti-androgenic effects of deltamethrin 
were seen in the CHO cells, and no inhibition of CYP9 was observed in the human placental 
microsomes.  
Study quality and assessment: The study is well-described and only information on the purity of 
deltamethrin is missing, and it is therefore assessed to be of high quality. The evidence for an 
oestrogenic MoA of deltamethrin is moderate due to the effects on cell proliferation but missing 
effects on ER transcription activity in MCF-7 cells. 
 
4.10.3.3 In vivo effects with regard to an endocrine mode of action  
Ben Slima et al. (2017)  
Summary: The main purpose with this study was to investigate the adverse effects of deltamethrin 
(CAS no. 52918-63-5, 98% purity) on male mice reproductive performance. Adult male mice were 
administered 0 or 5 mg/kg deltamethrin (n=24 males/group) by oral gavage daily for 35 days, and 
then co-housed with untreated, fertile female mice. Male mating (number of females inseminated) and 
fertility (number of pregnant females) indices were recorded. Semen from electroejaculation were 
analysed for density, motility, viability and abnormal morphology, and blood samples were analysed 
for serum testosterone and inhibin B levels. Then the male mice were killed and reproductive organs 
were removed and weighed. The left testis was used for histopathological examination. 
No significant signs of general toxicity were observed in any of the males, and no differences in body 
or reproductive organ weights were seen between the 2 groups. The deltamethrin-treated males had 
decreased mating and fertility indices and gave rice to fewer litters. Their semen had a reduced sperm 
count, motility and viability, while the number of abnormal sperm was increased. The serum 
testosterone and inhibin B levels in the treated males were both decreased, and histopathology was 
found in the testes.  
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Study quality and assessment: The description of the study is unclear, and the results in the text does 
not always correspond to the results reported in the tables with regard to statistical significance. 
Therefore, the study is assessed to be of medium quality. The evidence for male reproductive toxicity 
is strong with reduced fertility and effects on sperm parameters as well as histopathological changes 
in the testes, and decreased testosterone and inhibin B serum levels. 
 
Ben Halima et al. (2014)  
Summary: In this study, the effects of deltamethrin (CAS no. 52918-63-5, purity not reported) on 
testes and sperm parameters were studied as a part of a larger study on the anti-oxidative effect of oat 
oil. Adult male mice were exposed to 0 or 5 mg/kg/day deltamethrin (n=8 male/group) by oral gavage 
for 35 days. After 24h from the last treatment the mice were weighed and euthanized and testes and 
epididymides were removed and weighed. Testes were undergoing histological examinations and 
biochemical analyses, and the epididymides were used for sperm parameter studies. Sperm count, 
motility and viability were assessed and the number of morphologically abnormal sperms counted. 
Testicular lipid peroxidation (MDA formation), catalase (CAT), superoxide dismutase (SOD) and 
glutathione peroxide (GPx) activity was estimated as was gluthatione and protein levels.  
It was found that deltamethrin caused significant decreases in sperm motility and density, and an 
increase in the number of abnormal sperm. In addition, significant increases in testicular lipid 
peroxidation production and GPx and SOD activities were seen, while CAT activity and GSH levels 
were decreased insignificantly. This suggests that deltamethrin causes oxidative stress in the testes 
leading to altered sperm parameters. 
Study quality and assessment: The study is well-described but only investigates a single dose of 
deltamethrin. Overall the study is assessed to be of high quality. The study provides strong evidence 
for adverse male reproductive effects in mice with adverse effects on sperm parameters, but these 
effects are more likely driven by an oxidative stress MoA than an ED MoA. 
 
Sekeroglu et al. (2014)  
Summary: The purpose of the present study was to assess the effects of acute and subacute 
deltamethrin exposure (CAS no. and purity not reported) on thyroid stimulating hormone (TSH) and 
free triiodothyronine (FT3) and thyroxine (FT4) in rats. Adult male rats were given either 0 or 15 
mg/kg (37.5% of LD50) deltamethrin for in a single dose by oral gavage, or 0 or 3 mg/kg (7.5% of 
LD50) deltamethrin per day by oral gavage for 30 days (n=6 males/dose group). At 24 h after last 
treatment the animals were euthanized and blood was sampled and analysed for TSH, FT3 and FT4 
serum levels. Only insignificant increases in TSH after 24 h and decreases after 30 days was 
measured. Similarly, insignificant decreases in FT3 and FT4 serum levels were measured after 24 h 
exposure and increases after 30 days of exposure. 
Study quality and assessment: Besides not reporting the CAS no. or purity of deltamethrin, the study 
does not include a positive control to confirm the use of the model for the given purpose. Also, the 
study description is not always clear, and due to the mentioned shortcomings it is assessed to be of 
low quality. The study only provides weak evidence for thyroid hormone alterations with insignificant 
increases in TSH, FT3 and FT4. 
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Ben Slima et al. (2012)  
Summary: The purpose of the present study was to examine the reproductive effects of deltamethrin 
(CAS no. and purity not reported) on male offspring exposed in utero. Adult female mice were 
exposed to 0 or 5 mg/kg deltamethrin (n=5 females/group) by oral gavage from gestation day 3 to 21. 
Clinical signs of maternal toxicity, body weights and weights of ovaries at the time of necropsy were 
recorded. Four adult male offspring from each group were killed at postnatal day 60-65 and testes and 
epididymides were removed and weighed. Sperm from the right caudal epididymides were analysed 
for sperm count, motility, viability and number of abnormal sperm. Four testes per group were 
undergoing histological examination.No signs of maternal intoxication were observed but the 
deltamethrin-treated females had significantly lower body and ovary weights. In the male offspring, 
the weights of the testes were significantly reduced in the in utero exposed animals. These males also 
had significantly lower sperm count, motility and viability, and higher percentage of abnormal sperm, 
as well as histopathological changes in their testes.  
Study quality and assessment: The description of the study is adequate in details except the missing 
information on the CAS no. and purity of deltamethrin. Overall the study is assessed to be of medium 
quality, and it provides strong evidence for adverse reproductive effects in male offspring exposed in 
utero. 
 
Abdallah et al. (2010b)  
Summary: The present study aimed at investigating the effects of deltamethrin (CAS no. and purity 
not reported) on sperm measures and the reproductive system in male mice. Adult male mice were 
exposed to 0 or 5 mg/kg deltamethrin for 21 days (n= 10/group, read from the tables), and after the 
treatment period the mice were weighed, killed and testes and epididymis were removed and weighed. 
Sperm motility, count, viability and morphology were assessed. No effects on body weight or absolute 
testes and epididymis weights were found after deltamethrin treatment. Sperm count, motility and 
viability were significantly decreased and the number of abnormal spermatozoa was increased in the 
treated group. 
Study quality and assessment: The study does not report the CAS no. or purity of deltamethrin, and it 
is also not clear from the material and methods section how many animals were used in each group. 
Due to these shortcomings the study is assessed to be of medium quality. It provides strong evidence 
for adverse male reproductive effects in mice with adverse effects on sperm parameters. 
 
Issam et al. (2009)  
Summary: The aim of the present study was to evaluate the effects of deltamethrin (CAS no. and 
purity not reported) on male gonads and sex hormones in response to different doses and treatment 
periods. Adult male rats were randomly assigned to 3 treatment groups and 3 corresponding control 
groups (n=6/group): a 30 days s.c. exposure to 0.003 mg/kg deltamethrin, or vehicle; a 45 days s.c. 
exposure with 30 days of 0.003 mg/kg followed by 15 days of 0.03 mg/kg, or 45 days vehicle s.c. 
exposure; a 60 days s.c. exposure with 30 days of 0.003 mg/kg then 15 days of 0.03 mg/kg followed 
by 15 days of 0.3 mg/kg, or 60 days of vehicle s.c. exposure. After treatment, blood was samples for 
measurement of plasma malondialdehyde (MDA) (an oxidative stress marker), follicle-stimulating 
hormone (FSH), luteinizuing hormone (LH) and testosterone levels, and testes were removed and 
undergoing histopathological evaluation. FSH levels increased in the 30-day exposed group but 
decreased in the 45- and 60-day groups. LH and testosterone levels increased after 30 and 45 days of 
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treatment but decreased after 60 days of deltamethrin treatment. MDA was elevated in all treatment 
groups. The histological examination showed histopathological changes with pyknotic cells and 
regression of the interstitial tissue in all treatment groups with arrested spermatogenesis in the 60 days 
treatment group.  
Study quality and assessment: The study does not give information on CAS no. and purity of the 
tested compound and is not always clear in the description of the study design and results. Due to 
these shortcomings, the study is assessed to be of medium quality. The study provides moderate 
evidence of ED MoAs with altered hormone levels and effects on the gonads. These effects on the 
gonads might however be a result of the increased oxidative stress response observed.  
 
Kilian et al. (2007)  
Summary: In the present study a modified one-generation study was performed to assess the 
endocrine disrupting effect of deltamethrin (no CAS no. reported, 99.5% purity) alone or in mixtures 
on the reproductive parameters in male offspring exposed in utero. Adult female and male rats were 
paired and allocated into dosing groups (n= 6 pairs/group). After mating the pregnant females were 
exposed to either 0 or 1 mg/kg deltamethrin (n=6 /group) by oral gavage from gestation day 7 and 
until postnatal day 23, where the pups were weaned. Twelve male offspring from each group were 
selected and given 0 or 1 mg/kg deltamethrin by oral gavage for 10 weeks. At week 14 the male 
offspring were terminated and samples taken. All animals were assessed for general toxicity clinical 
signs. At termination of the male offspring, blood was sampled for liver functional analysis (n=6) and 
chemical analysis (n=6). Anogenital distance (AGD) was measured and testes, epididymides, seminal 
vesicles and liver were weighed, and the right testis was used for histological examination of 
spermatogenesis. Sperm count was determined. 
No clinical signs of toxicity were observed in any of the animals. A significantly shorter AGD was 
found in the 1 mg/kg deltamethrin group, who also had a significant decrease in seminal vesicles 
weight compared to control group. On histology, decreases in seminiferous tubule diameter and 
epithelium thickness were found in the exposed group compared with control. No significant effects 
on liver function enzymes, testes and epididymides weights, spermatogenesis or sperm count were 
found.  
Study quality and assessment: The study is well-described, but lack information such as CAS nos. and 
especially the method used for selecting the 12 males per group from the 6 litters per group. Also, it 
seems that the pup and not the litter was used as the statistical unit, which is incorrect. Thus the study 
is assessed to be of medium quality. The study provides moderate evidence for adverse effects on 
male offspring reproductive organs with a shortening of AGD and effects on seminal vesicles weight 
and histopathological changes in the testes.  
 
Johri et al. (2006)  
Summary: The present study examined the effects of prenatal exposure to deltamethrin (no CAS no. 
or purity reported) on rat offspring locomotor activity, as well as enzyme levels and activity in their 
liver and brain. Briefly, 54 pregnant female rats were exposed to 0, 0.25, 0.5 or 1 mg/kg deltamethrin 
by oral gavage on gestation day (GD) 5-21. The litters were culled to 8 pups with an equal distribution 
of sexes. Male offspring spontaneous locomotor activity was monitored at 3, 6 or 9 weeks and the 
animals were then sacrificed and liver and brain removed. Microsomes and RNA was isolated from 
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the livers and brains, and the activity of 3 CYP P450 monooxygenases, N-nitrosodimethylamine 
demethylase (NMDA-d), 7-pentoxyresorufin-O-dealkylase (PROD) and 7-ethoxyresorufin-O-
deethylase (EROD), in the microsomes were measured as well the mRNA and protein levels of 
CYP1A1/1A2, CYP2B1/2B2 and CYP2E1. 
Prenatal deltamethrin exposure resulted in altered spontaneous locomotor activity with most 
parameters affected at 3 weeks of age and some persisting into both 6 and 9 weeks of age. Increases in 
NMDA-d, PROD and EROD activities showed dose-dependent increases in both brain and liver at 3 
weeks with some of the activity increases lasting into the 6th and 9th weeks. Similarly dose-dependent 
increases in CYP protein and mRNA levels were mainly seen at 3 weeks with some effects lasting 
into the 6th and 9th weeks of age especially at the highest exposure doses.  
Study quality and assessment: The study is in general well-described and thorough but the exact 
number of animals in each group is not clearly stated and the figures are not optimally formatted. The 
study is therefore assessed to be of medium quality. Moderate evidence for neurodevelopmental 
toxicity, more specifically altered spontaneous motor activity, in the prenatally exposed animals exist 
but whether these effects are persistent after week 9 in not known. Also no links between these effects 
and an ED MoA is made here but deltamethrin seems to alter the expression and activity of multiple 
enzymes and may through this mechanism affect normal hormone turnover. 
 
Birkhøj et al. (2004)  
Summary: In the present study, deltamethrin (CAS no. and purity not reported) and 4 other pesticides 
were tested alone and in mixture in the Hershberger assay for anti-androgenic effects. Castrated male 
rats were treated with testosterone proprionate (0.5 mg/kg sc) and 0 or 2.5 mg/kg BW deltamethrin po 
(n= 6 males/group) for 7 consecutive days. The positive control group were treated with the known 
anti-androgen Flutamide (20 mg/kg/day sc). After the exposure period, blood samples were taken for 
hormone analysis (testosterone, thyroxin (T4), prolactin and luteinizing hormone (LH) levels), and the 
animals were euthanized and the ventral prostate, seminal vesicles, levator ani/bulbocavernosus 
muscle (LABC), bulbourethral glands, liver, thyroid gland, paired adrenal glands and paired kidneys 
were removed and weighed. The ventral prostate was used for gene expression analysis. No effects on 
body weight, organ weights or hormone levels were observed after deltamethrin treatment. A 
reduction in gene expression of ODC (ornithine decarboxylase) relative to the positive control was the 
only affected gene measured in the ventral prostate gene expression analysis. 
Study quality and assessment: The study is well-described and only lack information on CAS no. and 
purity, and the number of animals per dose group is not clearly stated in the material and methods 
section but can be read from tables and figures. It is assessed to be of high quality. The study provides 
only very weak evidence for an anti-androgenic MoA in vivo due to the effects on gene expression in 
the ventral prostate but no effects on organ weights or hormone levels were found in the exposed 
animals.  
 
Andrade et al. (2002a)  
Summary: The present study, investigated the effect of in utero exposure to deltamethrin (no CAS no. 
reported, 98.8% purity) on male offspring reproductive performance. Female rats were mated and 
administered to 0 (n=10), 1, 2 or 4 mg deltamethrin/kg (n=12/dose group) daily by oral gavage from 
gestation day (GD) day 1 to lactation day 21 (weaning). During this period maternal toxicity and 
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reproductive performance parameters were assessed. The male offspring (n=16/dose group) were 
assessed for testis descent and preputial separation but ano-genital distance was not measured in this 
study. Animals were kept until they were 150-180 days old, where they were killed and testes, 
epididymis, ventral prostates and seminal vesicles were removed and weighed, and blood samples 
were taken to measure testosterone levels. Sperm number and morphology were assessed. Before 
killing, 10 out of the 16 males/group were used at postnatal day 120 in a mating study with unexposed 
females where sexual behaviour and the reproductive performance were recorded. The testes from the 
6 males/group not included in the mating study were used in a histological examination. No clinical 
signs of maternal toxicity or effects on maternal reproductive performance were seen. Testis descent 
and preputial separation, sperm number and morphology, serum testosterone levels, sexual behaviour 
and reproductive performance in the male offspring were not effected in the treated groups. Only 
significant effects were observed in the highest 4 mg/kg dose group, where the testis weight and 
seminiferous tubules diameters were reduced. 
Study quality and assessment: The study is well-designed and -described. The CAS no. is not reported 
and the number of animals for the different examinations is not always clear from the material and 
methods section but can be found in figures and tables. In general, the study is of medium quality. The 
study provides weak evidence for male reproductive toxicity after in utero and lactational exposure to 
deltamethrin with effect on testes weight and histology. 
 
Andrade et al. (2002b)  
Summary: In the present study, deltamethrin (no CAS no. reported, 98.8% purity) was tested for 
(anti)estrogenicity and (anti)androgenicity in the 2 in vivo assays, Uterotrophic and Hershberger 
assay. In the Uterotrophic assay, immature (~21 days old) female rats were exposed to 0, 2 or 4 mg 
deltamethrin/kg daily by oral gavage for 3 days. To test for anti-estrogenicity, the rats were treated 
with hexahydrobenzoiate estradiol (0.4 mg/kg/day po), which was also used alone as a positive 
control, and then co-administered 4 mg/kg deltamethrin for 3 days. There were 7-10 females/dose 
group, and after the 3 days of exposure all rats were killed and their uterus removed and weighted. In 
the Hershberger assay, adult (~7 weeks old), castrated male rats were given deltamethrin daily for 7 
days. In the anti-androgen mode, the rats were treated with testosterone cypionate (0.25 mg/kg/day sc) 
and co-administered 0, 2 or 4 mg deltamethrin/kg po. Flutamide (10 mg/kg/day sc) was used as the 
positive control for anti-androgenicity. In the androgen mode, the rats were given 4 mg deltamethrin 
/kg po. There were either 8 or 9 males/dose group. After the 7 days of exposure all rats were killed 
and their prostate and seminal vesicles were removed and weighted. 
Neither oestrogenic nor anti-oestrogenic effects of deltamethrin were found in the Uterotrophic assay. 
Similarly, no effects were found in the Hershberger assay in both the androgenic or anti-androgenic 
mode.  
Study quality and assessment: Overall, the study is well described and -performed and only a few 
details are missing such as CAS no., and the study is assessed to be of high quality. No evidence for 
ED MoAs of deltamethrin were found in the study.  
 
Aziz et al. (2001)  
Summary: The present study investigated the effects of low level in utero deltamethrin (no CAS no. or 
purity reported) exposure during gestation day (GD) 14-20 on neurobehavior, neurochemistry and 
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immunohistochemical parameters postnatally in rats. Female rats were mated and then randomly 
divided into 2 groups and administered either 1 mg/kg deltamethrin or only vehicle from GD 14 to 
GD 20 by oral gavage (n=10 females/group). After birth, litters were culled to 8 pups/litter with an 
equal distribution of males and females. The pups were examined daily, and a total of 10 offspring per 
group were evaluated for learning behaviour in a Y-maze. The offspring were sacrificed after either 6 
or 12 weeks of age, and brains were removed and undergoing different analysis for 
acetylcholinesterase (AChE) and protein estimations. 
Deltamethrin reduced the surface righting reflex, number of cholinergic receptors in the brain and 
learning performance, while AChE activity and GAP-43, a neuron specific protein related to neuron 
maturity, were increased. 
Study quality and assessment: The study is assessed to be of medium quality based on the description 
with missing information on deltamethrin purity and sometimes less clear descriptions on the 
selection of animals for the different tests and analysis. Overall, the evidence for developmental 
neurotoxicity is strong with effects on learning, however these effects are not linked to an ED MoA in 
the present study but are rather associated with effects on the cholinergic system.  
 
Lazarini et al. (2001)  
Summary: In the present study the effects of prenatal deltamethrin (no CAS no. or purity reported) 
exposure on rat pup physical, reflex and behavioural development was investigated. Seventeen female 
rats were mated and randomly divided into 2 groups and given 0 (n= 8 females) or 0.08 mg/kg (n=9 
females) deltamethrin by oral gavage from gestation day (GD) 6 to GD 15. After parturition the litters 
were culled to 8 offspring of equal sex distribution. An open-field test (locomotion frequency, rearing 
frequency and immobility time) and reflexes (surface righting reflex, negative geotaxis and palmer 
grasp) in one male and one female from each litter were assessed at weaning on parturition day (PND) 
21. At PND 60 a swimming test followed by an open-field test was made on one animal per gender 
per litter to assess latency to start floating, duration of floating, locomotion frequency, rearing 
frequency and immobility time. At PND 140 the offspring were sacrificed, and brains were removed 
and undergoing neurochemical evaluation.  
Deltamethrin treatment did not affect maternal or offspring weight, and no differences in reflexes or 
the open field test were seen at weaning. In adulthood at PND 60 a decreased latency to float as well 
as decreased locomotion and increased immobility in the open-field test were observed in exposed 
male offspring only. A general sexual dimorphic response in the open-field test was observed with 
males showing relative lower locomotion and rearing compared to females. In the neurochemical 
evaluation the only difference was a higher level of DOPAC (dopamine metabolite) and noradrenaline 
in the exposed male offspring.  
Study quality and assessment: The study is well-described and assessed to be of medium quality due 
to shortcomings such as missing information on deltamethrin identity and the fact that only a single 
dose was tested. Overall, the study provide moderate evidence for developmental neurotoxicity of 
deltamethrin in males based on the effects in the swimming and open-field tests, however no links to 
ED MoAs are made.  
 
10 
 
Madsen et al. (1996)  
Summary: In the present study, deltamethrin (CAS no. 52918-63-5, 99% purity) was tested for its 
effect on the immune system in a 28-days study in male rats. Deltamethrin was given by gavage daily 
to 4-week old male rats in doses of 0, 1, 5 or 10 mg/kg (n=16 males/dose group) for 28 days. On 
treatment day 23, 6 of the 16 rats were immunised. All animals were killed on day 28, and blood was 
sampled and organs removed and weighed. The spleens of the immunised animals were used for 
immunological tests assessing effects on sheep red blood cells (SRBC) plaque forming cells (PFC), 
mitogens and natural killer (NK) cell activity. Detection of lymphocyte subpopulations were made, 
and haematology of the blood from the non-immunised animals were performed. Bone marrow from 
the right femur was extracted to count the number of nucleated cells. Volume of thymus and 
mesenteric lymph nodes were quantified.  
No effects on clinical appearance, haematological parameters, bone marrow cell number and volume 
of thymus and lymph nodes were seen in the exposed groups. Decreases in body weight gain, terminal 
weights, and thymus and adrenals weight were found in the high dose group. Deltamethrin caused an 
increase in the number of SRBC-PFCs and enhanced the activity of the NK cells at the 5 and 10 
mg/kg doses. These results suggest that deltamethrin stimulates the immune system by increasing the 
number of antibody forming cells in the spleen and enhancing NK cell activity. 
Study quality and assessment: The study is well-performed and -described although the methods 
could have included more detailed information. Overall the study is assessed to be of high quality. 
The study does not provide any evidence for adverse effects related to ED MoAs.  
 
Abd El-Aziz et al. (1994)  
Summary: The present study investigated the effect of deltamethrin (CAS no. and purity not reported) 
on male rat fertility. Adult male rats were exposed to 0, 1 or 2 mg/kg BW deltamethrin daily by oral 
gavage for 65 consecutive days (n=15/dose group). Blood samples for testosterone level measures 
were taken before and at 14, 28, 42 and 65 days of exposure as well as 21 days after exposure had 
stopped. From each dose group, 5 animals were killed after the 65 days exposure period, 5 animals 
were kept for 21 days, and the remaining 5 rats were kept for 60 days after treatment had stopped. The 
weight of the testes, epididymis, seminal vesicles and prostate as well as sperm parameters were 
recorded for the animals killed at day 65 and 65 + 21 days. Before this the 5 animals kept for 0 and 60 
days post-treatment, respectively, were mated with non-treated females (n= 8/male/dose group), and 
the conception rates were noted. 
Treatment with deltamethrin significantly decreased the weights of testes, epididymis, seminal 
vesicles and prostate both just after the 65 days treatment and 21 days after treatment had stopped. 
The same was seen in both groups with the sperm parameters with decreases in sperm density and 
motility and increase in abnormal morphology. Decreased testosterone serum levels were seen in all 
treatment groups at all the tested time points compared to the levels before treatment start. Male 
fertility was decreased in the two treatment group compared to control at day 65 of exposure as well 
as on day 60 post-treatment.  
Study quality and assessment: The study is well-described although a number of important details are 
missing such as CAS no., purity, housing conditions etc. Overall the study is assessed to be of 
medium quality. The study provides strong evidence for adverse effects on male reproduction with 
effects on the gonads, sperm and testosterone levels. ED MoAs for these effects were not explicitly 
studied but the effects on the testosterone levels could provide a moderate evidence for ED MoA(s). 
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Husain et al. (1994)  
Summary: The present study examined the mechanisms of deltamethrin (no CAS no. or purity 
reported) on neurodevelopment in young rats. A total of 100 young male rats were randomly divided 
into 2 groups and received either 0 or 7 mg/kg deltamethrin by oral gavage from postnatal day (PND) 
22-37 (n=50/dose group). On PND 38, 5 animals from each group were killed and brains removed to 
estimate polyamine levels. Similarly, 5 other animals were killed at PND 38 and their brains were 
used to assess the 3 enzymes, monoamine oxidase (MAO), acetylcholinerase (AChE) and Na+-K—
ATPase. Another set of 6 pups per group were sacrificed at PND 38 to estimate neurotransmitter 
receptor binding. Finally, the remaining 34 rats/group were used for behavioural testing 24 hrs after 
the last treatment. Ten rats were tested for spontaneous locomotor activity and then reused in a test for 
aggressive behaviour using a total of 12 pairs (i.e. 24 animals/group). Another set of 10 rats/group 
were used to test learning or the conditional avoidance response. 
No general toxicity such as weight reductions were seen in the treated group. The wet weight of 
hippocampus was significantly reduced and the activities of MAO and AChE were elevated. A 
significant increase in the spontaneous locomotor activity and impairment of learning were seen. 
Changes in polyamine levels and neurotransmitter receptor binding were also found in the treated 
animals.  
Study quality and assessment: The study is assessed to be of medium quality based on the many 
animals used but a sometimes unclear explanation of the study design and missing information on the 
purity of deltamethrin as well as the limitations of testing only a single dose. Moderate evidence for 
developmental neurotoxicity with effects on behaviour is provided however no conclusions with 
regard to links to ED MoA can be made since these mechanisms were not investigated here. 
 
Abdel-Khalik et al. (1993)  
Summary: In the present study, deltamethrin (CAS no. and purity not reported) was given orally at 
doses of 0, 1, 2.5 and 5 mg/kg to pregnant female rats (n=20/dose group) from gestation day (GD) 6-
15. At GD 19 the pregnant rats were killed and number of implementations, live foetuses, weight and 
length of foetuses were recorded. One third of the foetuses were subjected to visceral examination and 
the remaining 2/3 were subjected to skeletal examinations. Deltamethrin caused dose-dependent early 
embryonic death and growth retardations. Likewise, a dose-related increase in foetuses with 
hypoplasia of the lungs and dilations of the renal pelvis were also observed in the foetuses exposed in 
utero to deltamethrin. The placentas from the exposed female rats had increased weight.  
Study quality and assessment: The description of the study could be more detailed, and relevant 
information such as CAS no., purity, vehicle type and housing conditions are missing. The study is 
due to these missing details in the description assessed to be of medium quality. The evidence for 
adverse developmental defects in the foetuses is moderate, while evidence for ED MoA related to 
these effects have not been studied. 
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Husain et al. (1992)  
Summary: This study investigated in utero effects of deltamethrin (no CAS no. or purity reported) on 
early rat brain development. Pregnant female rats were randomly divided into a control group and a 
group receiving 7 mg/kg deltamethrin daily by oral gavage from gestation day (GD) 5-21. The 
offspring were evaluated for behavioural teratogenicity (n=10 pups/group). Included in the test were 
pinna detachment, incisor eruption, surface righting, air righting, grip strength, auditory startle, ear 
opening, eye opening and growth as well as motor activity (assessed at both pre-weaning (PND 21) 
and post-weaning (PND 42)). At PND 22, 5 pups from each group were killed and brains removed to 
estimate polyamine levels in the different brain regions. 
No general toxicity was seen in the maternal animals but deltamethrin caused and increase in the 
number of foetal resorptions and death of neonates. In addition significant delays in the onset of fur 
development, incisor eruption, eye and ear opening, and reductions in surface righting reflex and grip 
strength were seen in animals after deltamethrin exposure. Spontaneous motor activity was also 
significantly reduced at both PND 21 and 42 compared to the control animals. The levels of 
polyamines in the different brain areas were also significantly reduced following deltamethrin 
exposure.  
Study quality and assessment: The study does not specify the exact number of pregnant females and 
litters per group or the distribution of male and female pups in the different tests and if this differed 
between the treated group and the control group. That in addition to missing information on the purity 
of deltamethrin and the fact that only a single dose was tested results in the study being assessed as of 
low quality. The study provides moderate evidence for a developmental neurotoxic (DNT) effect of 
deltamethrin due to the observed alterations in behaviour. The study does not investigate effects on 
hormone levels or ED MoAs and therefore no conclusions regarding ED links to the DNT effects can 
be made. 
 
Eriksson and Fredriksson (1991)  
Summary: The purpose of this study was to investigate the effects of postnatal exposure to 
deltamethrin (no CAS no. or purity reported) on young and adult mice behaviour and brain expression 
of muscarinic cholinergic receptors (mAChRs). Ten-day old male mice were administered 0 or 0.7 
mg/kg deltamethrin (n=12/group, from 3 different litters) by oral gavage from postnatal day (PND) 
10-17. Behavioural tests were made at PND 17 and again at 4 months of age, hereafter they were 
killed and brains removed to measure mAChR density. 
No clinical signs of pyrethroid poisoning were seen. No significant changes in behaviour were seen at 
PND 17, but at 4 months of age the deltamethrin-treated mice showed a significant increase in 
locomotion and total activity when compared to control animals. A tendency to a decrease in the 
density of mAChRs was seen in the cortex but not in the other brain areas of the deltamethrin-treated 
animals. 
Study quality and assessment: The study description is rather short and important information is 
absent from the description and figures such as clearly stating the number of animals per group in 
each test/analysis. Overall the study is assessed to be of low quality. There is moderate evidence for 
developmental neurotoxicity of deltamethrin in mice due to the altered adult behaviour but no 
conclusions on links to ED MoAs can be made. 
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Draft Assessment Report (DAR) (1998) 
Summary: In the draft assessment report for deltamethrin several repeated dose studies and an old 
two-generation study (1992) are included. Hardly any effects on weight of reproductive organs were 
found in the repeated dose studies and no data on testis histology is reported. It is assumed that 
histology was performed, but that no treatment-related findings were found on histological assessment 
of reproductive organs. 
Study quality and assessment: The quality of the studies cannot be assessed based on the summaries 
available in the draft assessment report.  The DAR is from 1998 and the studies are therefore 
performed according to the OECD TG before 1998 which means that some ED relevant endpoints are 
not included (e.g. AGD, nipple retention and sperm quality). The studies included in the draft 
assessment report indicate that there are no adverse effects on reproductive or developmental 
parameters with regards to the endpoints that can be assumed to be evaluated at the time the study was 
performed.  
4.10.3.4 Summary of the plausible link between adverse effects and endocrine mode of action  
Available studies on ED MoAs of deltamethrin (Table 1) provide inconsistent results, for example are 
2 in vitro studies indicating weak oestrogenic activity while no oestrogenic or anti-oestrogenic activity 
was found in another in vitro assay and in the Uterotrophic in vivo assay. A number of studies indicate 
anti-androgenic effects of deltamethrin in in vitro assays (AR antagonism) and in vivo with decreased 
testosterone and shortening of ano-genital distance in adult male offspring (Table 1 and 2). However, 
no anti-androgenic effects were seen in 2 independent Hershberger in vivo assays using castrated 
males. Multiple studies have shown altered testes histopathology, adversely altered sperm parameters, 
and decreased testosterone serum levels in both rat and mouse after exposure during adulthood or in 
utero and reduced weights of testes and accessory sex organs. These male reproductive toxicity 
effects have been attributed to oxidative stress induced by deltamethrin but a link to an anti-
androgenic MoA, i.e. effect on steroidogenesis leading to low testosterone, is also plausible.  
Various studies on developmental neurotoxicity (DNT) of deltamethrin have been conducted in both 
rats and mice, and overall these studies indicate that deltamethrin is a developmental neurotoxicant 
with effects on behaviour and the weight of some brain regions after pre-or postnatal exposure. These 
effects have primarily been attributed to alterations in the cholinergic system, enzyme activities and 
polyamine levels in the brain and to our knowledge no links to ED MoAs have been studied. A single 
study in rats showed non-significant effects on TSH, free T3 and T4 in serum, and in an in vitro study 
weak TR antagonism of deltamethrin was found. More studies are needed to evaluate a plausible link 
between these potential effects on the thyroid system and developmental neurotoxicity of 
deltamethrin. 
The total evidence for an AR antagonistic MoA is weak due to conflicting in vivo and in vitro data. 
Based on the published literature, the evidence for adverse effects on male reproductive organs is 
strong, but when taking the DAR into account the evidence is assessed to be moderate due to the lack 
of reported effects on testis weights and histopathology of reproductive organs. The evidence for a 
plausible link between this adverse effect and an anti-androgenic MoA is moderate. The evidence for 
DNT of deltamethrin is moderate due to the low to medium quality of the related studies that often 
does not report the purity of the tested compound or has an unclear study design description. The 
evidence for a plausible link between DNT and a thyroid MoA is weak mainly due to very few 
available studies for this MoA.  
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In conclusion, deltamethrin does not meet the WHO definition of an endocrine disruptor, but fulfil the 
WHO definition of a potential endocrine disruptor. Also deltamethrin fulfil the proposed Danish 
criteria for being a suspected ED.  
 
Additional literature not directly used in the evaluation 
 
OEHHA report 2012: This report reviews results on developmental, female and male reproductive 
toxicity of deltamethrin from animal studies. It reports effects on all three endpoints with most 
evidence for male reproductive toxicity and developmental neurotoxicity. 
S.C. Johnson & Son (2012): This report from the industry with the title ‘Deltamethrin Has Not Been 
Clearly Shown to Cause Reproductive Toxicity’ is a response to the OEHHA report. It highlights the 
in general missing quality assessment of the studies included in the OEHHA report, and concludes 
that deltamethrin has not been clearly shown through scientifically valid testing to cause 
developmental toxicity or male and/or female reproductive toxicity. Public available references in the 
report has been included in the above evaluation if assessed relevant.  
EFSA Scientific Opinion (2008): The studies included in the Opinion were assessed to have several 
limitations and could not provide any clear evidence for a developmental neurotoxic effect of 
deltamethrin. The conclusion from the experts was that deltamethrin has been adequately tested for 
developmental neurotoxicity and that the available data do not indicate that deltamethrin is a 
developmental neurotoxic agent. Publicly available references in the Opinion has been included in the 
above evaluation if assessed relevant.  
Shafer et al. (2005): This is a review of developmental neurotoxicity of pyrethroids including 
deltamethrin and describes results and strengths and limitations of multiple studies of which the 
relevant references have been included in the above evaluation. It also refers to results from an 
unpublished study by Muhammed and Ray but due to the unpublished nature of this data it will not be 
included here. 
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Table 1. Overview of in vitro and in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of deltamethrin.  
Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
Christen et al. 
(2014) 
Weak AR antagonism in MDA-kb2 cells.  Low Moderate 
Abdallah et al. 
(2010a) 
Effects on spermatozoa viability, motility and 
morphology in vitro that are attributed to 
oxidative stress induced by deltamethrin and 
not an ED MoA. 
 High Weak 
Du et al. (2010) Weak ER agonism and TR antagonism in CV-
1 cells, as well as AR antagonism in MDA-kb2 
cells. 
 High Strong 
Issam et al. 
(2009) 
 Altered FSH, LH and testosterone plasma levels 
in adult male rats exposed s.c. to different levels 
and periods of deltamethrin. 
Medium Moderate 
Birkhøj et al. 
(2004) 
Anti-androgenic at sub-cytotoxic 
concentrations in AR transfected CHO cells 
No anti-androgenic MoA in the rat Hershberger 
assay (castrated males) except reduced expression 
of a single gene in the ventral prostate 
High Weak-Moderate 
Andersen et al. 
(2002) 
Weak, but significant effects of deltamethrin 
on cell proliferation but no ER transactivating 
effects in MCF-7 cells. 
 High Moderate 
Andrade et al. 
(2002b) 
 No (anti)oestrogenic or (anti)androgenic MoAs in 
the rat oral Uterotrophic or the Hershberger assay 
(castrated males), respectively  
Medium None 
androgen receptor (AR), thyroid hormone receptor (TR), estrogen receptor (ER), follicule-stimulating hormone (FSH), luteinizuing hormone (LH), Chinese Hamster Ovary (CHO) 
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Table 2. Overview of potential endocrine-related adverse effects of deltamethrin. 
Reference Species, n Adverse effects Quality of study  Evidence for 
adverse effects 
Ben Slima et 
al. (2017) 
Mouse, 24 
males/group 
Decreased fertility, and decreases in sperm count, viability and motility, and 
increase in the number of abnormal sperm. Decreased testosterone and inhibin B 
serum levels and histopathology in the testes 
Medium Strong 
Ben Halima et 
al. (2014) 
Mouse, 8 
males/group 
Decreases in sperm count and motility, and increase in the number of abnormal 
sperm. Altered oxidative stress markers in the testes. 
High Strong 
Sekeroglu et al. 
(2014) 
Rat, 6 
males/group 
Non-significant effects on TSH, FT3 or FT4 serum levels were found after acute 
and subacute exposure to deltamethrin. 
Low Weak 
Ben Slima et 
al. (2012) 
Mouse, 5 
females/group 
and 4 male 
offspring/group 
Effects in the in utero exposed male offspring: reduced testes weights, decreased 
sperm count, vitality and motility, and increased number of abnormal sperm, 
histopathological changes in the testes.  
Medium Strong 
Abdallah et al. 
(2010b) 
Mouse, 10 
males/group 
Decreases in sperm count, motility and viability and increase in the number of 
abnormal spermatozoa. 
Medium Strong 
Issam et al. 
(2009) 
Rat, 6 
males/group 
Altered testicular histopathology in adult male rats exposed s.c. to different 
levels and periods of deltamethrin. 
Medium Moderate 
Kilian et al. 
(2007) 
Rat, 6-12 
animals/group 
In vivo study using a modified one-generation study: shortening of AGD and 
effects on seminal vesicles weight and histopathological changes in the testes of 
adult male offspring.  
Medium Moderate 
Johri et al. 
(2006) 
Rat, 13-14 
females/dose 
group w. 8 
offspring each 
Altered spontaneous motor activity as well as altered enzyme activity and levels 
in liver and brain with most pronounced effects after the 3rd and declining 
through the 6th and 9th weeks of age in prenatally exposed offspring. 
Medium Moderate 
Andrade et al. 
(2002a) 
Rat, n=16 male 
offspring/ group 
Effects on male rat offspring testes weight and histology in the highest treatment 
group (4 mg/kg) 
High Weak 
Aziz et al. 
(2001) 
Rat, 10 
female/group w. 
8 offspring each 
Decreased learning and memory capacity in offspring exposed in utero (GD14-
20) as well as effects on the cholinergic system and maturation parameter (GAP-
43) in the brain. 
Medium Strong 
Lazarini et al. 
(2001) 
Rat, 8-9 
females/group 
w. 8 offspring 
each 
Decreased latency to float in swimming test, and decreased locomotion and 
increased immobility in the open-field test at PN60 as well as a higher level of 
DOPAC (dopamine metabolite) and noradrenaline in the at PN 140 were 
observed in exposed male offspring only. 
Medium Moderate 
Abd El-Aziz et 
al (1994) 
Rat, 
15/males/dose 
group 
Potential irreversible effects on male fertility with decreased weights of the 
accessory sex organs, adversely affected sperm parameters and decreased 
testosterone serum levels. 
Medium Strong 
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Reference Species, n Adverse effects Quality of study  Evidence for 
adverse effects 
Husain et al. 
(1994) 
Rat, 50 young 
males/group, 10-
12 per 
behavioural test 
Increased spontaneous locomotor activity and impaired learning as well as 
altered levels of polyamines, enzyme activities and neurotransmitter receptor 
binding in the brains were seen in postnatally exposed male rats. 
Medium Moderate 
Abdel-Khalik 
et al. (1993)  
Rat, 
20/females/dose 
group 
Early embryonic death and growth retardation of in utero exposed foetuses. 
Increase in cases with visceral malformations were also seen 
Medium Moderate 
Husain et al. 
(1992) 
Rat, 10 
pups/behavioural 
test group 
Behavioural teratogenicity parameters such as eye and ear opening, fur 
development and incisor eruption were delayed and motor activity was reduced 
in the in utero exposed offspring 
Low Moderate 
Eriksson and 
Fredriksson 
(1991) 
Mouse, 12 
offspring/group, 
from 3 different 
litters 
Changes in adult behaviour of postnatally deltamethrin-treated male mice 
indicative of developmental neurotoxicity. 
Low Moderate 
Thyroid stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), Anogenital distance (AGD), gestation day (GD), parturition day (PND 
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Prochloraz, CAS no. 67747-09-5 
Synonyms: N-propyl-N-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide. 
Prochloraz (Figure 1) is a broad-spectrum imidazole fungicide. Prochloraz is widely used in 
gardening and agriculture. It is used on wheat, barley, mushrooms, cherries, turf on golf courses, and 
in flower production, for instance, in Ecuador, where 
roses are treated with prochloraz prior to export to the 
USA. Its fungicidal activity is due to inhibition of 14 
alpha- demethylase (CYP 51), an enzyme required for the 
synthesis of fungal cell walls. Prochloraz is an agricultural 
imidiazol fungicide that inhibits a CYP enzyme involved 
in ergosterol synthesis, but has also been reported to 
inhibit other CYP enzymes, and to act as a potent 
aromatase inhibitor. This EU approval expires 31st 
December 2021. At the EU Member State level it has 
been approved in 25 EU countries (except Malta and 
Denmark) (EU, 2016). 
 
4. Human health hazard assessment 
4.10.3 Endocrine disruption 
4.10.3.1 General approach – human health 
4.10.3.2 In vitro information indicative of endocrine activity 
Kjærstad et al. (2010)  
Summary: In this study widely used conazole antifungals were tested for endocrine disruptive effects 
using a panel of in vitro assays. They all showed endocrine disrupting potential and ability to act via 
several different mechanisms. Overall the imidazoles conazole, ketoconazole, miconazole, 
prochloraz) were more potent than the triazoles (epoxiconazole, propiconazole, tebuconazole). The 
critical mechanism seems to be disturbance of steroid biosynthesis. In the H295R cell assay, the 
conazoles including prochloraz decreased dose-dependently the formation of estradiol and 
testosterone, and increased the concentration of progesterone. Effects at 0.01μM (lowest concentration 
tested). Maximum effects (at 3.0 μM) were less than 10% of the solvent control. This was indicating 
inhibition of enzymes involved in the conversion of progesterone to testosterone. Prochloraz was most 
potent. In the MCF- 7 cell proliferation assay, the conazoles showed anti-estrogenic effect, including 
aromatase inhibition, since they inhibited the response induced by both 17β-estradiol (incl. 
prochloraz) and testosterone (incl. prochloraz).  
Study quality and assessment: The study is well-described. In this study prochloraz was assessed in a 
battery of in vitro tests. Purity (99.5%) and CAS no. is given and cytotoxicity was evaluated by using 
the Cytotox 96 Non-Radioactive Cytotoxicity assay. Overall the quality of the study is assessed to be 
high, and the study provides strong evidence for an anti-androgenic, anti-estrogenic effect and also 
aromatase inhibiting MoA of prochloraz.  
Figure 1. 2D structure from PubChem  
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Hecker et al. 2006 
Summary: In this study an in vitro screening assay based on measuring alterations in hormone 
production was developed using the H295R human adrenocortical carcinoma cell line. The objective 
of the H295R Steroidogenesis Assay (later OECD TG 456) is to detect substances that affect 
production of estradiol (E2) and testosterone (T) and P(progesterone/pregnenolone). Prochloraz is 
included in this Test Guideline as a positive control as it is a strong inhibitor of steroid hormone 
secretion.  The aim of the current study was to develop and standardize an in vitro Tier 1 screening 
assay using the H295R cell line to prioritize chemicals that act to alter hormone production. CAS and 
purity was not given in this study. Model chemicals with different modes of action on steroidogenic 
systems were tested in this study. Exposure to forskolin resulted in dose-dependent increases in all 
three hormones with the greatest relative increase being observed for E2. This differed from cells 
exposed to prochloraz (or ketoconazole) where P concentrations increased while T and E2 
concentrations decreased in a dose-dependent manner at prochloraz concentrations greater than 0.03 and 0.003 μM, respectively.  Based on these results, the H295R in vitro system has potential 
for high throughput screening to not only characterizes the effects of chemicals on endocrine systems 
but also to prioritize chemicals for additional testing. 
Study quality and assessment: The study is well-described and prochloraz was included as positive 
control in this study (as later in the final OECD TG 456). More information on CAS-number would 
have been preferred and cytotoxic chemical concentrations were not included in the hormone 
concentration measurements. Overall the quality of the study is still assessed to be high, and the study 
provides strong evidence for an anti-estrogenic and anti-androgenic MoA of prochloraz.  
Overall, a large battery of published in vitro screening studies indicates that prochloraz is able to 
induce endocrine imbalance by affecting the androgen and oestrogen receptor, to inhibit the aromatase 
activity and to interfere with steroidogenesis probably at the level of P450c17. A review of the 
endocrine-related data available for prochloraz has been conducted in GD 181 by OECD which led to 
the conclusion that “The combined dataset provides sufficient evidence of endocrine activity” (OECD 
2012). Also the review by Melching-Kollmuss et al. (2017) gives an overview of in vitro assays on 
prochloraz.   
 
4.10.3.3 In vivo effects with regard to an endocrine mode of action  
 
Melching-Kollmuss et al. (2017) 
Summary: This paper provides a good review of regulatory and peer reviewed studies of prochloraz. 
Prochloraz was administered per gavage in oil from gestation day (GD) 6 to postnatal day (PND) 83 
to pregnant and lactating Wistar rats and their respective offspring, at doses of 0.01 mg/kg bw/day 
(acceptable daily intake of prochloraz), 5 mg/kg bw/day (expected no-observed-effect-level (NOEL)) 
and 30 mg/kg bw/day. At 30 mg/kg bw/day maternal and offspring effects (decreased viability, lower 
number of live offspring) were seen including a delayed entry into male puberty (plus one day) 
accompanied by lower male offspring body weights, increased ano-genital distance/index in females 
and (transiently) retained nipples in males at PND 12 (not seen at PND 20). The only finding at the 
expected NOEL was increased incidences of transiently retained nipples in males which the authors 
do not consider an adverse finding. No effects were seen in the low-dose group.  
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Study quality and assessment: The study is well-described and evaluates prochloraz at very low levels 
(ADI, NOEL, 6 times NOEL). The study is of moderate quality as it has some limitations. It is 
reported that 20 mated females per dose group are used. Unfortunately, it is unclear how many litters 
are evaluated for each endpoint. Additionally, it is not clear whether they make statistics (e.g. ano-
genital distance (AGD)) on individual pups and take litter effect into account (as described) or if they 
are just looking at individual pups which is not nearly as sensitive. They find retained nipples at day 
12-13. The authors do not believe that a significant incidence of preserved nipples is an adverse 
effect. However, it is possible to set a NOAEL on this finding according to OECD guidance 
documents. Overall the study provides strong evidence for adverse effects such as increased nipple 
retention (even at low doses and thereby an anti-androgenic MoA of prochloraz. 
 
Blystone et al. (2007) 
Summary: Prochloraz was administered by gavage to pregnant rats at doses of 0, 7.8, 15.6, 31.3, 62.5, 
and 125 mg/kg/day from gestational day 14 to 18. On gestational day 18, hormone production from ex 
vivo fetal testes was examined and prochloraz levels in amniotic fluid and maternal serum were 
measured. Fetal P and hydroxy-P production levels were increased significantly at every prochloraz 
dose, whereas T levels were significantly decreased only at the two high doses. These results 
suggested that prochloraz inhibits the conversion of P to T through the inhibition of CYP17. 
Prochloraz had no effect on testicular CYP17 gene expression (mRNA levels) but CYP17 
hydroxylase activity was significantly inhibited when tested in vitro (Ki = 865 nM). Amniotic fluid 
prochloraz concentrations ranged from 78 to 1512 ppb and T production was reduced when 
prochloraz reached approximately 500 ppb, which compared favourably with the determined CYP17 
hydroxylase Ki (326 ppb).  
Study quality and assessment: The study is well-described and results demonstrate that prochloraz 
lowers testicular T synthesis by inhibiting CYP17 activity which likely contributes to the induced 
malformations in androgen-dependent tissues of male offspring. Overall the quality of the study is 
assessed to be high, and the study provides strong evidence for decreased testicular T synthesis and 
thereby an anti-androgenic MoA of prochloraz. 
 
Laier et al. (2006) 
Summary: Prochloraz was administered orally to pregnant rats at doses of 50 and 150 mg/kg/day, 
from gestational day 7 to postnatal day (PND) 16. Male and female offspring were examined, a subset 
of foetuses were examined after Caesarean section of dams at gestational day 21. 
Prochloraz caused mild dysgenesis of the male external genitalia, reduced ano-genital distance (AGD) 
and retention of nipples in male pups. In female pups AGD was increased AGD. In male foetuses, 
testicular and plasma levels of testosterone (T) were decreased and levels of progesterone (P) 
increased. Immunohistochemistry of fetal testes showed increased expression of 17alphahydroxylase/ 
17,20-lyase (P450c17) and a reduction in 17beta-hydroxysteroid dehydrogenase (type 10) expression. 
Increased expression of P450c17 mRNA was observed in fetal male adrenals, and the androgen-
regulated genes ornithine decarboxylase, prostatic binding protein C3 as well as insulin-like growth 
factor I mRNA were reduced in ventral prostates at PND 16. These results indicate that reduced 
activity of P450c17 may be a primary cause of the disrupted fetal steroidogenesis and that altered 
androgen metabolism may also play a role  
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Study quality and assessment: The study is well-described and evaluates prochloraz at high doses. The 
study is of moderate quality as it uses small group sizes 5-8 litters per group. This study find 
decreased AGD (6-12%) in the males (from 50 and 150 mg/kg group respectively). This decrease in 
male AGD has not been seen in several other studies (Christiansen et al. 2009, Noriega et al 2005; 
Vinggaard et al. 2005; Melching-Kollmuss et al. 2017). The effects on NR and/or increase in female 
AGD have also been seen in several studies (Christiansen et al. 2009; Vinggaard et al 2005; 
Melching-Kollmuss et al 2017). Overall the study provides strong evidence for adverse effects such as 
dysgenesis and increased nipple retention and thereby an anti-androgenic MoA of prochloraz. 
 
Noriega et al. (2005) 
Summary: Prochloraz was administered by gavage to pregnant rats at doses of 31.25, 62.5, 125, and 
250 mg/kg/day from gestational day 14 to 18. Prochloraz delayed delivery in a dose-dependent 
manner and resulted in pup mortalities at the two highest doses. In male offspring, anogenital distance 
(AGD) adjusted\for body weight was not affected, but in females adjusted AGD was increased at 250 
mg/kg. In females VO (vaginal opening) was unaffected. Nipple retention (NR) was observed in 
males at 13 days of age at frequencies of 31%, 43%, 41%, and 71% in the lowest-dose to highest-dose 
groups, respectively. Weights of sexual accessory tissues showed dose dependent reductions. 
Hypospadias and vaginal pouches were noted in all males treated with 250 mg/kg, whereas those 
defects were observed in 12.5% and 6.25%, respectively, of males treated with 125 mg/kg. Treatment 
did not affect age of PPS in animals without penile malformations. Despite severe malformations in 
males, no malformations were noted in females. 
Study quality and assessment: The study is well-described and evaluates prochloraz at high doses. The 
study is of moderate quality as it uses very high doses (general toxic doses). This study find decreased 
absolute AGD at 125 and 250 mg/kg, but no effect on AGD when body weight was included as 
covariate (which is normally done).  The effects on increased NR seen at 125 and 250 mg/kg, but not 
at the lower doses 31 and 63 mg/kg have also been seen in several other studies (Christiansen et al 
2009; Vinggaard et al 2005; Melching-Kollmuss et al 2017). Overall the study provides strong 
evidence for adverse effects such as increased nipple retention and thereby an anti-androgenic MoA 
of prochloraz. 
 
Vinggaard et al. (2005) 
Summary: Prochloraz was administered orally to pregnant rats at a dose of 30 mg/kg/day, from 
gestational day 7 to postnatal day (PND) 16. Male and female offspring were examined, a subset of 
foetuses were examined after Caesarean section of dams at gestational day 21. Gestational length was 
increased by prochloraz. Plasma and testicular T levels in gestational day 21 male foetuses were 
reduced. Chemical analysis of the rat breast milk showed that prochloraz was transferred to the milk. 
In males nipple retention was increased, and the bulbourethral gland weight was decreased, whereas 
other reproductive organs were unaffected. CYP1A activities in livers were induced by prochloraz. 
Behavioural studies showed that the activity level and sweet preference of adult males were 
significantly increased.  
Study quality and assessment: The study is well-described and evaluates prochloraz at lower doses 
and in many litters per group (N=16). The study is of high quality and find increased number if 
retained nipples and also behavioural effects. Overall these results provide strong evidence for 
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adverse effects and that prochloraz feminizes the male offspring after perinatal exposure. Moreover 
this study indicates that these effects are due, at least in part, to diminished fetal steroidogenesis. 
Prochloraz has been tested in a full set of regulatory toxicological studies including two multi-
generation reproductive toxicity studies, which was performed according or comparable to the US 
EPA OPPTS 870-3380 or OECD TG 416 (Two generation test) These TG 416 studies was made 
before the update in 2001, so none of them were to current standards (OECD, 2012b) 
These regulatory toxicological studies are summarized below and in the DAR of Prochloraz and in 
EFSA conclusion (EFSA, 2007; EFSA, 2011).  
Prochloraz was evaluated in two key two-generation toxicity studies from 1993 and 1982 where 
overall reproductive performance was impaired following prochloraz administration to rats (Cozens et 
al. (1982) as summarized in DAR and Reader et al. (1993) as summarized in EFSA conclusion). 
Effects on reduction in body weight and body weight gain, increased liver weight and deaths were 
associated with dystocia and extended gestation length. Developmental toxicity was observed as 
reduced mean litter size, increased total litter loss, reduced live birth index, impaired growth and 
adverse effects on organ weights. In the 1993 study the agreed parental and reproductive NOAEL was 
50 ppm (2.26 mg/kg bw/d), and the offspring NOAEL is 150 ppm (6.58 mg/kg bw/d). In the study 
from 1983 the agreed parental NOAEL is 150 ppm (13 mg/kg bw/d), the reproductive NOAEL is 37.5 
ppm (3.1 mg/kg bw/d), and the offspring NOAEL is 150 ppm (13 mg/kg bw/d) (EFSA conclusion 
2011).  
In the developmental toxicity studies, there was no evidence of teratogenicity, and the relevant 
maternal and developmental NOAELs are 25 mg/kg bw/d for the rat and 40 mg/kg bw/d for the 
rabbit. 
Prochloraz has been tested in these regulatory toxicological studies as summarised above. These 
guidelines, however, precede OECD harmonization lack specific parameters to sensitive to endocrine 
disruption and to identify anti-androgenicity (e.g., sperm parameter, onset of puberty, AGD and 
nipple retention). The effect on dystocia was the only endocrine endpoint found in these studies.  
As reported in published papers (some of them mentioned above), rats displayed typical signs of anti-
androgenicity after treatment with prochloraz, like retained nipples, reduced testosterone, increased 
progesterone levels, reduced male reproductive organ weights and delayed entries into male puberty 
(Blystone et al. 2007; Laier et al. 2006; Vinggaard et al. 2002). A NOAEL identified for the most 
sensitive endpoint retained nipples was 5 mg/kg bw/day in rats was determined by Christiansen et al. 
(2009). A summary of the findings seen in both regulatory studies and in in vivo studies published in 
peer-reviewed journals is provided in GD 181 (OECD 2012b) and the review by Melching-Kollmuss 
et al. (2017). 
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4.10.3.4 Summary of the plausible link between adverse effects and endocrine mode of 
action  
 
Prochloraz is recognized as an endocrine disrupter as there is strong evidence from in vitro assays that 
the substance acts by multiple mechanisms of action in non-target species including inhibition of 
enzymes of steroidogenesis (CYP 19, CYP 17 and 5 α-reductase) and AR antagonism. Moreover, in 
vivo studies have shown adverse effect on male reproductive development as development of several 
androgen-dependent tissues has been affected as summarized below.  
Prochloraz has been shown to react through several endocrine disrupting mechanisms (Vinggaard et 
al., 2005; Vinggaard et al. 2006). Moreover in vivo prochloraz can affect the development of several 
androgen-dependent tissues (Vinggaard et al., 2002; Vinggaard et al. 2005, Laier et al. 2006, Taxvig 
et al. 2008). Common features for the azole fungicides are that they increase gestational length and 
affect steroid hormone levels in fetuses and/or dams. In the majority of studies, male offspring, 
exposed in utero to prochloraz often showed no statistically significant changes in anogenital distance 
(AGD) with doses from 25-150 mg/kg but find significant nipple retention (NR) (Vinggaard et al. 
2005; Christiansen et al. 2009; Noriega et al. 2005 and Melching-Kollmuss et al. 2017). One study 
has found both a decrease in male AGD at 50 and 150 mg/kg and also increased NR (Laier et al. 
2006). Several studies find an increase in female AGD after in utero exposure to prochloraz (Laier et 
al. 2006; Melching-Kollmuss et al. 2017).  
In addition to its anti- androgenic MoA, interference with testosterone synthesis and steroidogenic 
MoA, prochloraz has also been shown to affect thyroid hormone levels and cause effects on the 
sexually dimorphic development of the brain (Vinggaard et al. 2005).  
The results of several in vitro assays, which have been published over the last 15 years, point out that 
prochloraz has endocrine mode(s) of action. These in vitro screening studies were carried out in 
various test systems such as steroid hormone synthesis assay (e.g., OECD TG 456 (2011)). And in the 
final TG 456 prochloraz is used as a positive control as it is a strong inhibitor of steroid hormone 
secretion (OECD, 2011).  Prochloraz was found to be able to interact with estrogen and/or androgen 
receptors, with aromatase and with the steroid hormones (Andersen et al. 2002; Birkhøj et al. 2004; 
Grünfeld and Bonefeld-Jorgensen 2004; Hecker et al. 2006; Kojima et al. 2004; Laier et al. 2006; 
Sanderson et al. 2002; Trösken et al. 2004; Vinggaard et al. 2000, 2002, 2005). More recent studies 
suggest that prochloraz interferes with steroidogenesis in in vitro systems by inhibition of P450c17 
(17α-hydroxylase and 17,20-lyase) (Nielsen et al. 2012). Cortisol and corticosterone levels were 
shown to decrease after exposure of H295R cells to prochloraz (Winther et al. 2013; Ohlsson et al. 
2010). In some of these studies also gene expression of relevant steroidogenesis genes were 
investigated: H295R cells exposed to 0.03 μM prochloraz showed decreased expressions of some of 
the genes involved in steroidogenesis were seen (Ohlsson et al. (2009); Ohlsson et al. 2010). 
Overall, this battery of in vitro screening studies shows that prochloraz is able to induce hormonal 
imbalance by affecting both the androgen and estrogen receptor, to inhibit the aromatase activity and 
to interfere with steroidogenesis probably at the level of P450c17.  
In OECD GD 181 (OECD, 2012b) prochloraz was one of the cases used for the OECD GD 150 
(OECD, 2012a). In GD 181 a review of the endocrine-related data available for prochloraz was 
collected (on both in vitro, mammals and fish) and this to evaluate whether the conclusions and next 
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steps recommended in the guidance document for identification of ED was sensible and helpful when 
assessed in light of comprehensive datasets  
In GD 181 it says: “The combined dataset indicates that the ER and AR antagonism and S disruption 
shown in vitro also occur in vivo in mammals and fish. The antagonist response in the Hershberger 
assay provides confirmation that this mechanism may act in vivo, whilst the positive results in male 
PP assay (Pubertal Development and Thyroid Function Assay in Peripubertal Male Rats) and fish 
assays suggest that A, S or E modalities may be responsible for the effects seen on endocrine 
endpoints. The combined dataset provides sufficient evidence of endocrine activity”. Moreover in 
relation to the generation studies: “Although the 2-generation study was negative for endocrine 
effects, the combined dataset provides sufficient evidence of concern for endocrine activity in 
mammals. NOAELs for reproduction and development could be derived from the combined dataset, 
thus avoiding further testing. The combined dataset indicates that the ER and AR antagonism and S 
disruption shown in vitro also occur in vivo in mammalian species. These effects also give cause for 
concern in wildlife species although the physiological consequences of the effects are likely to be 
different.” 
The total evidence for adverse effects of prochloraz is strong (Table 2), the evidence for an anti- 
androgenic MoA (incl. anti-estrogenic MoA) of prochloraz and inhibition of enzymes in 
steroidogenesis is strong (Table 1) and the evidence for a plausible link between the MoA and adverse 
effects is also strong.  
In conclusion, prochloraz meet the WHO definition of an endocrine disruptor. 
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Table 1. Overview of in vitro and in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of 
prochloraz 
Reference MoA Quality of 
study  
Evidence 
for ED 
MoA In vitro In vivo 
OECD, 
2012b, 
Review 
The combined dataset provides 
sufficient evidence of 
endocrine activity.  
The combined dataset 
indicates that the ER 
(estrogen receptor) and 
AR (androgen 
receptor) antagonism 
and S (steroidogenic) 
disruption shown in 
vitro also occur in vivo 
in mammals and fish. 
The combined dataset 
provides sufficient 
evidence of endocrine 
activity. 
High Strong 
 
Table 2. Overview of potential endocrine-related adverse effects of prochloraz 
Reference Species, 
n 
Adverse effects Quality of 
study  
Evidence for 
adverse effects 
OECD, 
2012b 
Review 
Rats Malformed genitalia in males,  
altered AGD (females),  
caused nipple retention in males,  
decreased serum Testosterone,  
reduced sexual accessory tissue weight 
males, sweet preference increased 
males. 
High Strong 
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Prochloraz,  
 
5. Environmental hazard assessment 
5.6.2 Endocrine Disruption 
5.6.2.1 General approach – environment 
The peer reviewed literature was investigated by use of Web of Science including all databases. 
Search terms included prochloraz + endocrine, prochloraz + fish, prochloraz + amphibian, prochloraz 
+ vitellogenin. A google search including the search terms prochloraz + endocrine, prochloraz + fish, 
prochloraz + amphibians and prochloraz + vitellogenin were also performed and revealed the OECD 
case study with prochloraz (OECD GD 181, 2012) 
Studies solely investigating effects of prochloraz in invertebrates were not taken into account due to 
lack of endocrine specific endpoints. Studies using mixtures of chemicals where the effects could not 
be directly related to prochloraz were also not taken into account. For studies where one of the authors 
was also an author of this document, the study quality was evaluated by another person. 
Four studies included in Table 3 are not evaluated in the present document but were copied from the 
summary table of OECD GD 181 where they have been evaluated. The studies are Ankley et al., 
2005, Biever et al., 2007, Jensen & Ankley, 2006 and OECD, 2006 (ring test results). 
Due to the substantial amount of literature on prochloraz and endocrine disruption, only a selection of 
key studies in relation to identification of endocrine disruption according to the WHO/ICPS definition 
was evaluated. A search for fish and amphibian studies including endocrine biomarkers and endpoints 
but showing no endocrine effects of prochloraz was also conducted to investigate the Weight of 
Evidence of ED-effects of prochloraz in vertebrate wildlife. Searching prochloraz + endocrin* + 
vitellogenin as well as prochloraz + sex ratio and prochloraz + zebrafish and prochloraz + fathead 
minnow and prochloraz + Japanese medaka revealed approximately 30 studies in Web of Science 
related to fish and ED. None of these studies were “negative” on prochloraz ED effects.  
 
5.6.2.2 In vitro information indicative of endocrine activity. 
Covered by the toxicological evaluation of prochloraz. 
 
5.6.2.3 In vivo effects with regard to an endocrine mode of action  
Flynn et al. (2017) 
Summary: The authors used a Japanese medaka (Oryzias latipes) multigeneration assay (modification 
of OECD TG 240 with much less replication and lower power of endpoints) to investigate effect of 
prochloraz (5.3, 9.2, 17.5, 25.0 and 41.1 µg/l mean measured) on several endpoints including ED 
relevant endpoints. The exposure was 29 weeks and spanned 2 full generations. The test was 
terminated after reproduction in the F2. Six replicates of breeding pairs (one male and one female) per 
concentration was used where the final OECD TG 240 used 24 pairs for controls and 12 pairs for 
exposures. Prochloraz did not affect the tissues and organs of male fish, but caused endocrine related 
pathologies in the ovaries of female fish (decreased yolk and follicular hyperplasia/hypertrophy). The 
LOEC for fecundity was 41µg/L in F0 and 25 µg/L in F2. The phenotypic sex ratio in prochloraz 
exposed fish was not discussed, possibly because of low power du to only 12 fish per exposure in F1 
and F2. Vtg-gene expression was decreased in females. The authors argue that this could be plausibly 
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linked to aromatase inhibition, causing circulating E2 to decrease, which in turn would lower the 
expression of hepatic vitellogenin.  
Study quality and assessment: The study is very well described and detailed but due to the test design 
of only 6 breeding pairs per test concentration the power of the endpoints was low. For example, the 
power to detect a 30% fecundity decrease was 0.38, which is very far from the desired 0.8.  is strong. 
Based on this the study is assessed to be of moderate quality. Despite low power, the results do 
though support prochloraz to inhibit aromatase activity by decreasing Vtg-gene expression in females 
and causing ED related pathologies in the ovaries of female fish. This link is moderate-strong. 
 
Bauman et al. (2015) 
Summary: The authors investigated the persistence of effects of prochloraz exposure during sexual 
development of zebrafish. Fish were exposed (10, 30, 100, and 300 μg/l prochloraz) from fertilization 
to 60 days post hatch and transferred to clean water for 40 days thereafter. Two replicates of 100 
fertilized eggs were used per concentration. Subsampling of fish was performed at day 30 and 60 post 
hatch and final sampling at 100 days post hatch. No chemical analysis was performed but a reference 
to Baumann (2012) was given because the same exposure system was used. Baumann et al (2012) is 
evaluated other place in this document. Survival was not described so it is difficult to assess whether 
prochloraz affected this. The number of sampled fish are though equal to the number of initial fish so 
it is expected that mortality was extremely low. Histological investigations of the gonads revealed 
persistent effects on sexual differentiation. The sex ratio was skewed towards males and significantly 
more intersex individuals were found and this decrease in phenotypic females was dose dependent 
with no females at 300 µg/l prochloraz. A 40-day depuration period showed that the masculinization 
of the fish was irreversible.  
Study quality and assessment: The study is very well described and detailed and the results are dose-
dependent and expected. It is not explained how survival could be close to 100% and prochloraz was 
not quantified so the overall quality is assessed to be medium-high. The data on the change in 
phenotypic sex ratio is population relevant and adverse. The link to aromatase inhibition which is 
expected for prochloraz in fish is strong. 
 
Bauman et al. (2013)  
Summary: Five zebrafish (Danio rerio) FSDTs with EDCs with different modes of action including 
prochloraz (CAS no. 64447-09-5) were conducted, and the experimental setups followed the OECD 
TG 234. Each tank contained 40 eggs (two replicates), and the prochloraz exposure started at 1 hpf 
and ended 60 dpf and with the following nominal concentrations: 10, 30, 100, and 300 µg/L. 
Chemical determination of the actual exposure concentrations was performed by LC-MS (< 20% 
deviation from the nominal concentration over the entire test period). 
No significant effects on hatchability or mortality were observed after exposure to prochloraz, but the 
body size was reduced in the highest concentrations compared with the control. The results document 
that not only sex ratio and VTG production of the prochloraz exposed fish were massively affected, 
but also gonad maturation. The sex ratio was shifted towards males and intersex in the groups exposed 
to the two highest exposure concentrations; only male and intersex individuals were observed at 300 
µg/L and the number of females was significantly reduced at 100 µg/L (≤ 10% females). The VTG 
response in both males and females was non-monotonic, and the only significant effect was an 
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increase in male VTG at 30 µg/L. At this concentration, a non-significant increase in VTG was also 
observed in females, whereas both male and female VTG levels tended to decrease at higher exposure 
concentrations, albeit not significantly. The maturation index followed the same pattern in both males 
and females but statistical significant differences were not observed when compared with the control. 
Study quality and assessment: The experimental setup follows the OECD TG 234 and the 
experimental design and laboratory procedures are very well described. However, the authors state 
that prochloraz did not influence the mortality, but information about the exact mortality in the groups 
is not mentioned, and n is not provided in any of the figures or figure legends, which complicates 
evaluation of the data quality. Therefore, the study quality is assessed as medium-high. Clearly, it is 
demonstrated that prochloraz exposure during sexual development of zebrafish has an adverse effect 
since the sex ratio is shifted towards males at the two highest exposure concentrations. The only 
significant increase in VTG is observed in males in the intermediate exposure (30 µg/L). The exact 
mechanism is unclear but a clear endocrine MoA is demonstrated and the link to an endocrine 
mediated MoA is assessed as strong. 
 
Holbech et al. (2012) 
Summary: Zebrafish or fathead minnow (0-60 dph or 0-120 dph) were exposed to prochloraz (CAS no 
67747-09-5) in different laboratories in order to investigate the inter-laboratory robustness of the 
endocrine parameters in the OECD FSDT TG 234 (whole body VTG and sex ratio) and to compare 
the sensitivity of the two test species.The experimental setup followed the OECD TG 234 and 
included two or four replicates with a minimum of 40 eggs per replicate in a flow-through system. 
The following nominal prochloraz concentrations were used: 32, 100, and 320 µg/l or 38, 75, 150, 
300 and 600 µg/L. The exposure concentrations were determined by LC-MS or HPLC-UV. Generally, 
no significant effects of prochloraz on hatchability and growth was observed, but mortality was 
affected in a few exposure groups in some of the labs. Prochloraz induced a monotonic concentration-
response reduction in VTG levels of female fathead minnows with effect at the lowest (29 µg/L at 60 
dph) or intermediate concentration (106 µg/L at 120 dph). In zebrafish, a monotonic concentration-
response reduction in female VTG levels was also observed with effects observed at 48, 99 or 183 
µg/L, respectively. In two out of three labs a reduction in zebrafish males was also observed with 
effects at 44 or 135 µg/L. In both fathead minnow experiments the sex ratio was significantly skewed 
towards males in the highest exposure group (284 and 301 µg/L) but no effect at the intermediate 
concentration in any of the experiments (≈100 µg/L). The sex ratio of zebrafish was skewed towards 
males in a monotonic concentration-response relationship in one lab with effects at the lowest 
concentration (60 µg/L) and in the second lab no effect at the intermediate concentration (48 µg/L) 
but significantly more males and undifferentiated individuals at 320 µg/L. The third lab had 
significantly more males at the two intermediate concentrations (99 and 197 µg/L) but not at the 
highest concentration (434 µg/L), however most ot the water samples from this lab were lost. 
Study quality and assessment: The experimental setups are solid with regards to the number of 
animals, replicates, histological procedures, and chemical analysis of water samples, and the results 
are well described. However, based on the information in the M&M section and the figures it is 
unclear how many embryos each laboratory had in each replicate and the exact mortality in each 
experiment is not mentioned, also the number of control animals is much higher than the number in 
the exposure group, which is not explained. But n is generally high and it is stated the prochloraz 
generally did not affect the mortality. The experiment was run with the same setup and in different 
labs and with different strains of fish, and thereby a broad picture of the effects is obtained. The  
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study is assessed to be of high quality. The reduction in female VTG and number of females (adverse 
effect) clearly demonstrate an endocrine MoA. Prochloraz has multiple endocrine modes of action, 
including inhibition of aromatase activity, inhibition of androgen synthesis and AR antagonism, in 
fish and mammals, and based on these experiments it is not clear if the exact mechanism is anti-
estrogenic, androgenic or inhibition of aromatase activity. However, the evidence for an ED MoA is 
assessed as strong.  
 
Thorpe et al. (2011) 
Summary: In the present study, fathead minnow (pimephales promelas) and zebrafish (Danio rerio) 
were exposed to prochloraz (32, 100 and 320 µg/l) from embryo until 95-125 days post hatch (DPH) 
and 60 DPH respectively. The exposure periods cover the sexual development of the two fish species. 
2x25 embryos per replicate in 6 replicates for fathead minnow and 2x30 embryos per replicate in 4 
replicates for zebrafish were used until 30 DPH where each replicate was adjusted to 30 fish by 
random removing excess fish to equalize fish density. Exposure to 320 µg/L inhibited somatic growth 
in both species. Larval survival in zebrafish was decreased from 32 µg/l where such effect was not 
seen in fathead minnow. Prochloraz exposure caused a decrease in the proportion of phenotypic 
females in both species with a zebrafish LOEC of 100 µg/l and a fathead minnow LOEC of 320 µg/L. 
A delay in the completion of sexual differentiation was also seen in both species.  
Study quality and assessment: The study is very well described and detailed and replication is high. 
The quality is high. The data on the change in phenotypic sex ratio is population relevant and adverse. 
The link to aromatase inhibition is strong due to the decreased VTG concentration in female fathead 
minnow and zebrafish. 
 
Brande-Lavridsen et al. (2008) 
Summary: In this amphibian study, tadpoles of the Common frog (Rana temporaria) were exposed to 
prochloraz or EE2 from hatch through metamorphosis. In two different experiments, tadpoles were 
exposed to 15 and 150 µg/l prochloraz (nominal concentrations) and 11, 115 and 252 µg/l prochloraz 
respectively. Two replicates of 150 tadpoles were used per concentration. Exposure was semi-static 
with water exchange 3 times per week.  Tadpoles were sampled at the end of metamorphic climax 
(Gosner stage 44–46). Testosterone and E2 was quantified in whole body homogenate by commercial 
ELISA-kits. Calcium levels was measured in whole body homogenate as a surrogate for vitellogenin. 
Gonadal histology was performed to investigate effects on gonads and to document phenotypic sex. 
Survival rates ranged between 71.3 and 84.3%. The sex ratio was significantly skewed toward males 
from 115 µg/l prochloraz and above and testosterone concentrations decreased in the same groups. E2 
increased in the 115 µg/l group but not at the highest exposure concentration of 252 µg/l. Calcium 
was not affected by prochloraz. 
Study quality and assessment: The study is well described. The use of calcium as surrogate for 
vitellogenin is not recommendable so these results are not taken into account. The study is assessed to 
be of moderate-high quality. The results on the phenotypic sex ratio is population relevant and 
adverse and highly linked to an endocrine mechanism. The reduced T concentrations could be caused 
by different mechanisms but is not directly linked to aromatase inhibition. 
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Kinnberg et al. (2007)  
Summary: The objective of this study was to assess the effects of prochloraz on the sexual 
development of zebrafish (Danio rerio) exposed to prochloraz (Information about purity and CAS no. 
not provided) for 60 days from 24 h post fertilization (0, 16, 64 or 202 μg/l). The experimental setup 
followed the OECD TG 234 and included two replicates per exposure with 80 eggs per replicate in a 
flow-thorugh system. The exposure concentrations were determined by LC-MS. The sex ratio was 
significantly skewed towards males in the highest exposure group and this group also had a 
significantly higher number of intersex individuals. Male VTG concentrations were significantly 
increased at the low and intermediate prochloraz concentration and at the highest concentration both 
male and female VTG concentrations were significantly decreased.  
By histological examination of the gonad development it was shown that females in all exposure had 
gonads with less developed oocytes compared with the control, and when the males of all prochloraz 
treatments were pooled 82% of the males had gonads in the most developed stage (stage III: abundant 
spermatozoa) compared with 66% in the control group. By inhibition of the aromatase activity 17β -
estradiol synthesis is reduced and a decrease in female VTG and female individuals would be 
expected. The observed decrease in male and female VTG levels at the highest concentration is 
consistent with aromatase inhibition, and the enhanced sperm production in males and increased 
number of males could also be related to an increased androgen concentration or decreased E2/T ratio. 
The increase in male VTG concentration at the low and intermediate concentration may be due to the 
ability of prochloraz to target multiple steroidogenic enzymes, thus leading to effects elsewhere in the 
steroidogenic pathway. 
Study quality and assessment: The experimental setup is solid with regards to the number of animals, 
replicates, histological procedures, and chemical analysis of water samples, and the results are well 
described. The mortality is approximately 50% but not different between the exposure groups and the 
control. The study is assessed to be of high quality. The results on the phenotypic sex ratio is 
population relevant and adverse. The link to aromatase inhibition is strong due to the decreased VTG 
concentration in female zebrafish but other endocrine MoAs cannot be ruled out. 
 
Additional information used: 
OECD Case study with prochloraz OECD GD 181 
(http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2012)34&do
clanguage=en).  
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5.6.2.4 Summary of the plausible link between adverse effects and endocrine mode of action 
 
The evidence from the referred studies strongly support that prochloraz is an endocrine disrupter 
according to the IPCS/WHO definition (summarized in Table 3). It was not possible to find any study 
with fish that was investigating phenotypic sex ratio without finding an effect of prochloraz exposure.  
  
5.6.2.5 Environmental relevance   
Adverse effects (Table 4) in fish and amphibians are seen around and below 100 µg/l. Barret (1995) 
calculated the maximal predicted environmental concentration (PEC) to 195 µg/l. The PEC was based 
on an overspray of water 30 cm deep at a maximum recommended application rate of 0.585 kg active 
ingredient ha-l. An EFSA risk assessment of prochloraz did though conclude a low risk of prochloraz 
to aquatic organisms (EFSA, 2011). 
 
38 
 
Table 3 Overview of in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of prochloraz in fish and amphibians 
Reference MoA Quality of study  Evidence for ED 
MoA 
In vitro In vivo 
Flynn et al. 
(2017) 
 Japanese medaka multi-generation test. Dosing 5-40 
µg/l prochloraz. 
Decreased fecundity. Decreased Vtg-gene expression. 
ED related pathologies in the ovaries of female fish 
(decreased yolk and follicular 
hyperplasia/hypertrophy). 
medium Moderate-strong 
Baumann et al. 
(2015) 
 Zebrafish exposed from 0-60 dpf. Depuration period 
from 60-100 dpf. Skewed phenotypic sex ratio. NOEC 
30 µg/l. LOEC 100 µg/l (no females at 300 µg/l. 
Medium-high Strong 
Baumann et al. 
(2013) 
 Zebrafish exposed from 0-60 dpf. The sex ratio was 
shifted towards males and intersex in the groups 
exposed to the two highest exposure concentrations; 
only male and intersex individuals were observed at 
300 µg/L and the number of females was significantly 
reduced at 100 µg/L 
High Strong 
Holbech et al. 
(2012) 
 Zebrafish exposed from 0-60 dpf. Fathead minnow 
exposed from 0-60/120 dpf. Dose-range 32-600 µg/l. 
Five studies were conducted as a part of the OECD TG 
234 validation. Effects on sex ratio (decreased 
proportion of females) and Vtg protein levels were seen 
in all experiments.   
High Strong 
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Reference MoA Quality of study  Evidence for ED 
MoA 
In vitro In vivo 
Thorpe et al. 
(2011) 
 Zebrafish exposed from 0-60 dph. Fathead minnow 
exposed from 0-95 or 125 dph. Dosing: 32, 100 and 
320 µg/l. Phenotypic sex ratio skewed with less 
females. LOEC zebrafish, 100 µg/l. LOEC fathead 
minnow, 320 µg/l. Delayed completion of sexual 
differentiation in both species. 
High Strong 
Brande-
Lavridsen et 
al. (2008) 
 Common frog Rana temporalis tadpoles exposed from 
hatch through metamorphosis. The sex ratio was 
significantly skewed toward males from 115 µg/l 
prochloraz and above and T decreased in the same 
groups. E2 increased in the 115 µg/l group but not at 
the highest exposure concentration of 252 µg/l. 
Moderate-high Strong 
Ankley et al. 
(2005) 
 From OECD GD 181: 
OECD TG 229: Fish Short Term Reproduction Assay 
(FSTRA): Dosing range = 30 -300 µg/L Fecundity ↓ 
>3-fold in fathead minnow (LOEC = 100 µg/L; NOEC 
= 30 µg/L).  ♀VTG↓ approx. 3-fold in (LOEC = 100 
µg/L; NOEC =30 µg/L). Significant reductions were 
also observed in ♂ testosterone, 11ketotestosterone and 
brain aromatase activity, and ♀ estradiol.  
High 
 
Strong 
Biever et al. 
(2007) 
 From OECD GD 181: 
OECD TG 229: Fish Short Term Reproduction Assay 
(FSTRA): Dosing range = 20 -300 µg/L Fecundity↓ 
approx. 5-fold in fathead minnow (geomean LOEC = 
300 µg/L; geomean NOEC = 100 µg/L). 
High strong 
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Reference MoA Quality of study  Evidence for ED 
MoA 
In vitro In vivo 
Kinnberg et al. 
(2007) 
 Zebrafish exposed from 0-60 dpf. Dose-range 16-202 
µg/l (measured). Effects on sex ratio (decreased 
proportion of females) and Vtg protein levels were 
seen. NOEC sex ratio 64 µg/l, LOEC 202 µg/l 
High strong 
Jensen & 
Ankley (2006) 
 From OECD GD 181: 
Three individual studies following OECD TG 229: Fish 
Short Term Reproduction Assay (FSTRA): Dosing 
range = 20 -300 µg/L Fecundity↓ in fathead minnow 
(geomean LOEC = 58 µg/L; geomean NOEC = 16 
µg/L). Secondary sexual characteristics (tubercle score) 
↓ in fathead minnow (geomean LOEC = 144 µg/L; 
geomean NOEC = 34 µg/L). ♀VTG↓ in fathead 
minnow (LOEC = 20 µg/L; NOEC = <20 µg/L) 
High Strong 
OECD (2006)  From OECD GD 181: 
Ring test of OECD TG 230 with fathead minnow, 
Japanese medaka and zebrafish: Dosing range = 20 -
300 µg/L ♀VTG↓ by up to 10-fold in medaka 
(geomean LOEC = 116 µg/L; geomean NOEC = 38 
µg/L), fatheads (geomean LOEC = 208 µg/L; geomean 
NOEC = 58 µg/L), and zebrafish (geomean LOEC = 
182 µg/L; geomean NOEC = 49 µg/L)2 Fecundity was 
reduced in medaka (4/4 labs) and zebrafish (1/2 labs). 
High Strong 
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Table 4. Overview of potential endocrine-related adverse effects of prochloraz in fish and amphibians. 
Reference Species, n Adverse effects Quality of study Evidence for 
adverse effects 
Baumann et al 
(2015) 
Zebrafish  Skewed phenotypic sex ratio. No females at 300 µg/l (nominal)  Medium-high high 
Baumann et al 
(2013) 
Zebrafish  Skewed phenotypic sex ratio.  Medium-high high 
Holbech et al 
(2012) 
Zebrafish  Skewed phenotypic sex ratio.  high high 
Holbech et al 
(2012) 
Fathead 
minnow 
Skewed phenotypic sex ratio.  high high 
Thorpe et al 
(2011) 
Zebrafish  Skewed phenotypic sex ratio.  high high 
Thorpe et al 
(2011) 
Fathead 
minnow  
Skewed phenotypic sex ratio.  high high 
Brande-
Lavridsen et 
al (2008) 
Rana 
temporalis  
Skewed phenotypic sex ratio. No females at 115 µg/l and above (measured)  high high 
Kinnberg et al 
(2007) 
zebrafish Skewed phenotypic sex ratio.  high high 
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Triclocarban (TCC), CAS no. 101-20-2 
Synonyms: Tcc 
Substance type: TCC (Figure 1); 3,4,40-trichlorocarbanilide; 
3-(4-Chlorophenyl)-1-(3,4-dichlorophenyl)urea). 
TCC is an antimicrobial agent used widely in various personal 
hygiene products including soaps, toothpaste and shampoo and 
is used in 100-1000 tonnes per annum. TCC is remarkably 
stable and resistant to biological and chemical treatments, so 
there is also a potential for exposure by ingestion of 
contaminated water and/or agricultural products exposed to 
TCC-containing sludge (Duleba et al 2011). Several studies 
have reported that serum concentrations of triclocarban in 
humans are in the nM range (from Wu et al. 2016).  
 
4. Human health hazard assessment 
4.10.3 Endocrine disruption 
4.10.3.1 General approach – human health 
4.10.3.2 In vitro information indicative of endocrine activity 
 
Wu et al. (2016)  
This study examined the effects of TCC on sodium/iodide symporter (NIS)-mediated iodide uptake 
and the expression of genes involved in thyroid hormone (TH) synthesis in rat thyroid follicular 
FRTL-5 cells (at concentrations from 0.01 to 1000 µM), and on the activity of thyroid peroxidase 
(TPO) using rat thyroid microsomes. TCC inhibited NIS-mediated iodide uptake in a concentration-
dependent manner at ranges below effects on cell viability. A decrease in the iodide uptake was also 
observed in the absence of sodium iodide (NaI) at non-cytotoxic concentrations. Kinetic studies 
showed that TCC is a non-competitive inhibitor of NIS. FRTL-5 cells were also used to measure the 
transcriptional expression of three genes involved in TH synthesis, Slc5a5, Tpo, and Tgo, as well as 
three thyroid transcription factor genes, Pax8, Foxe1, and Nkx2-1. No significant changes in the 
expression of any genes were observed for TCC. Furthermore, TCC inhibited the activity of TPO in a 
concentration-dependent manner, however with a low potency, i.e. IC50 of >300 μM. The 
observations that TCC inhibited NIS-mediated iodide uptake, but did not influence the transcriptional 
expression levels of Slc5a5, the mRNA that codes for NIS, suggest that TCC may affect NIS at the 
post-translational level. When FRTL-5 cells were incubated with TCC in the absence of NaI, 
inhibition of iodide uptake was observed at as low as 0.3 μM. This concentration was much lower 
than the IC50 value for iodide uptake (17.2 μM) when FRTL-5 cells were exposed to the TCC and 
NaI simultaneously, and this indicates that inhibition of iodide uptake by TCC is mediated primarily 
through regulating NIS at the post-translational level. Although TCC inhibited the TPO activity in a 
concentration-dependent manner, TPO seemed not a primary target of TCC, because the IC50 value 
for TPO activity inhibition (>300 μM) was higher than those for iodide uptake. In summary, TCC 
acted as non-competitive inhibitors of NIS and inhibited NIS-mediated iodide uptake in FRTL-5 cells. 
Compared to iodide uptake, TPO seemed not to be a primary target of TCC. 
Figure 1. 2D structure from 
PubChem  
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Study quality and assessment: TCC inhibited NIS-mediated iodide uptake in a concentration-
dependent manner has been shown at ranges below effects on cell viability. Kinetic studies showed 
that TCC is a non-competitive inhibitor of NIS. TCC inhibited the TPO activity in a concentration-
dependent manner, but compared to iodide uptake, TPO seemed not to be a primary target of TCC. 
Overall, the quality of the study is evaluated as high and the in vitro evidence for NIS inhibition is 
evaluated as strong.  
 
Kolšek et al. (2015)  
The effect of TCC on glucocorticoid receptor (GR) antagonistic activity was investigated using the 
MDA-kb2 cell line stably transfected with MMTV luciferase reporter gene. TCC at concentrations of 
2µM was shown to enhance hydrocortisone (HC) (500nM) induced luciferase activity to ~156% 
compared to control (DMSO 100%). The same effect was seen when investigating TCC androgen 
receptor (AR) antagonistic activity. 2 µM TCC enhanced dihydrotestosterone (DHT) induced signal 
to ~166% when co-administrated with 0.5 nM DHT. 
Study quality and assessment: The study is well-written although some details on methods are 
described in the results section. The chosen assays appear to be well performed, e.g. the tested 
concentrations of TCC were below cytotoxicity and each experiment was at least performed in 
duplicates. However, a study has shown that TCC stabilizes the luciferase enzyme, which may have 
confounded the read-outs from the AR reporter gene assay. The study is thus assessed to be of 
medium quality. This study provides weak evidence that TCC acts as a modulator of the GR and AR 
activity. 
 
Huang et al. (2014) 
TCC exerted estrogenic activity by inducing luciferase activity in an ER reporter gene assay, 
promoting the proliferation of human mammary carcinoma MCF-7 cells, up-regulating the expression 
of estrogen-inducible pS2 gene and down-regulating ERα expression at both mRNA and protein 
levels in the MCF-7 cells. Furthermore, TCC could alter the expression of multiple microRNAs (mir-
22, mir-206 and mir-193b) in the MCF-7 cells.   
 
Study quality and assessment: The study is well-described, all assays were performed in triplicates 
and included both positive and vehicle controls. However, more information on CAS-number would 
have been preferred. Cytotoxicity was not evaluated but most of the results including increased 
proliferation, increased luciferase activity, increased protein levels (of pS2) and upregulation of gene 
expression (of pS2) and microRNA expression levels indicate that cytotoxicity is not present at the 
concentration tested. Similar TCC concentrations were used in all assays and cytotoxicity is not 
considered an issue in this study. A study has shown that TCC stabilizes the luciferase enzyme which 
may have confounded the read-out on luciferase activity and the results from the ERα reporter gene 
assay has limited scientific value. The study is assessed to be of medium quality. The study provides 
moderate evidence of an estrogenic mode of action in vitro. 
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Tarnow et al. (2013)  
In a MDA-kb2 reporter cell line transfected with a stable MMTV.luciferase.neo reporter gene 
construct, 1µM1 TCC was shown to induce androgen-mediated amplification of luciferase-activity by 
~40%. 1µM of TCC was also shown to induce estrogen-mediated amplification of luciferase-activity 
by ~50% in HeLa9903 cells stably transfected with human estrogen receptor (ER)α and an estrogen 
responsive element (ERE) driven luciferase reporter gene. TCC did not affect the transcription of 
genes known to be regulated by androgen receptor (AR): specifically androgen-regulated gene protein (SARG), N-myc downstream regulated 1 (NDRG1) and sorbitol dehydrogenase (SORD). Also, no 
effect of TCC was seen on estrogen responsive genes in human mammary carcinoma MCF-7 cells co-
exposed to 17b-estradiol, Bisphenol A, butylparaben or genistein. The induced estrogen mediated 
enhancement of luciferase-activity was further investigated using an assay (E-screen), where 
estrogen-dependent cell proliferation is used as the endpoint. These findings show that treatment with 
E2 resulted in a dose-dependent increase in MCF-7 cell number, however addition of 1µM TCC was 
not able to further enhance estrogen-dependent cell proliferation, as was seen with the ~50% 
enhanced luciferase activity in HeLa9903 cells. Due to the conflicting results, the effect of TCC on 
firefly luciferase enzyme heat stability was examined using thermal shift. The thermal shift assay 
showed a stabilizing effect of TCC (above 5µM) on the luciferase enzyme, which was specifically 
enhanced in the presence of adenosine triphosphate (ATP) as enzymatic co-factor. The authors argue 
that in cellular assays the effective concentration is likely to be lower due to more physiological 
buffered conditions. Thus, these results point to the effects of TCC on ER and AR as being false 
positive due to a stabilizing effect of TCC on the luciferase enzyme. TCC showed a co-stimulatory 
effect on transcription of CYP1A1 and CYP1B1, which are classical target genes of the transcription 
factor aryl hydrocarbon receptor (AhR). The authors argue that TCC interfere with AhR, which are 
connected to ERα via complex regulatory crosstalk, and interference due to AhR-ER crosstalk may 
lead to adverse outcomes (reviewed in Tarnow et al. 2013). 
Study quality and assessment: The study is well described and the authors appear to be thorough in 
the methods used. Each assay was performed in triplicates, they include positive and negative 
controls, and they verified the presence and absence of relevant receptors (e.g. AR and ER) in the cell 
lines. As discussed above, TCC stabilizes the luciferase enzyme and this may have confounded the 
read-out on luciferase activity and the results from the AR reporter assay and the ER reporter gene 
assay have limited scientific value. Moreover, they did not test for cytotoxicity. Finally, more 
information on CAS number and purity of the substances would have been preferred. The study is 
assessed to be of medium quality. The study provides weak evidence of an endocrine disrupting mode 
of action of TCC. 
 
Duleba et al. (2011) 
Summary: Luciferase reporter plasmids containing probasin (probasin-luc) or three repeats of the 
androgen response element ligated to the luciferase reporter (ARE-luc) was transfected into LNCaP 
and C4-2B cells (human prostate cancer cell lines). The transfected cells were exposed to testosterone 
(T) (1nmol/L), dihydrotestosterone (DHT) (1nmol/L), TCC (1µmol/L) or a combinational treatment 
of TCC + T or TCC + DHT. Furthermore, the signal transduction independency via androgen receptor 
(AR) was tested using the AR inhibitor, biclutamide. T and DHT significantly increased luciferase 
activity in both LNCaP and C4-2B cells containing ARE-luc or probasin-luc. TCC alone had no effect 
on luciferase activity, however in combination with androgens, the luciferase activity was further 
                                                     
1 corresponds to the maximal levels realistically expected in human blood – stated by the authors 
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increased by 221% (probasin promotor, DHT) and 175% (ARE promoter, T) in LNCaP cells 
compared to androgen treatment alone. The same enhancement of luciferase activity was seen in C4-
2B cells where TCC + androgen co-treatment further enhanced luciferase activity by 25.9% (probasin 
promotor, DHT) and 38.5% (ARE promoter, T) compared to androgen treatment alone. Furthermore, 
the AR binding inhibitor, bicalutamide, significantly suppressed the enhanced effect of TCC and 
androgens down to levels comparable to when TCC was administrated alone.  
Study quality and assessment: The study is well-described and is assessed to be of high quality. 
However, a study has shown that TCC stabilizes the luciferase enzyme which may have confounded 
the effect. This study provides moderate evidence for amplification of androgen activity. 
 
Hinther et al. (2011)  
Summary: This study assessed the effects of TCC (10, 100 or 1000 nM), alone or in combination with 
triiodothyronine (T3) (10 nM), on thyroid hormone (TH) signaling and cellular stress using the 
cultured frog tadpole tail fin biopsy (C-fin) assay and the TH-responsive rat pituitary GH3 cell line. 
mRNA abundance of TH receptor β (TRβ), Rana larval keratin type I (RLKI), both indicating a TH 
response was measured in the C-fin assay. The TH-responsive gene transcripts encoding growth 
hormone (Gh), deiodinase I (Dio1), and prolactin (Prl) were measured in the GH3 cells. In the C-fin 
assay, TCC alone significantly decreased RLKI transcript levels (p =0.021) at the highest 
concentration (1000 nM) but did not affects TRβ transcript levels. In the presence of T3, TCC did not 
affect TRβ or RLKI steady-state transcript levels. In the GH3 cells, TCC (1000 nM), alone or in the 
presence of T3, significantly reduced the levels of TH-responsive gene transcripts: Gh, Dio1 and Plr.  
Study quality and assessment: This study has been criticized by Fort et al. (2011) and DeLeo et al. 
(2011) for inadequate/wrong citations and the applied method, respectively. DeLeo et al. (2011) 
further noted that since TCC induced down-regulation of RLKI, but did not alter TRβ, TCC should 
not necessarily be considered a disruptor of thyroid axis without further evidence. Overall, the quality 
of the study is evaluated as low and the evidence of TH MoA is evaluated as weak.  
 
Christen et al. (2010)  
Summary: MDA-kb2 cells were stably transfected with murine mammalian tumor virus (MMTV)-
luciferase. TCC was analyzed in concentration that was previously shown not to be cytotoxic. In the 
analysis of anti-androgenic activity the MDA-kb2 cells were co-exposed to dihydrotestosterone 
(DHT) and TCC (+ a solvent control (negative control) and DHT (positive control)). Luciferase 
activity was measured after 24 h of incubation. TCC showed cytotoxicity at concentrations higher 
than 5 µM. TCC showed no androgenic activity in itself, but potentiated the DHT response (0.5nM) 
up to 130% at 0.01-5 µM TCC. Addition of 10µM flutamide inhibited the induction of this response, 
thereby excluding that the potentiation is due to/originates from co-activation of the glucocorticoid 
receptor (GR) that can also stimulate the expression of luciferase by TCC.  
 
Study quality and assessment: The study is well-described and is assessed to be of high quality. 
However, a study has shown that TCC stabilizes the luciferase enzyme which may have confounded 
the effect. This study provides moderate evidence for amplification of androgen activity. 
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Chen et al. (2008)  
Summary: The androgen and/or anti-androgenic activity of TCC was investigated using human 
embryonic kidney 293 (2933Y) cells, which were transfected with PCDNA6-human androgen 
receptor (AR) and MMTV-Luc.neo plasmid containing a luciferase reporting gene. No cell 
cytotoxicity was detected for TCC when administrated alone or in combination with 0.125 nM 
testosterone (T). When administered alone TCC (1.0 µM) showed no effect on transcriptional 
luciferase activity, however in combination with T (0.125nM), TCC amplified the T-induced 
transcriptional activity by 45%. This amplifying effect was both time and dose dependent. Flutamide, 
a competitive inhibitor of androgen binding to the AR, suppressed this amplification effect of 1.0µM 
TCC at a flutamide concentration of 10uM. 
TCC was tested in a competitive binding assay at multiple concentrations up to 200 µM, but showed 
no competitive binding to the AR. Also, TCC did not activate cyclic adenosine monophosphate 
(cAMP)/ protein kinase A (PKA)-mediated luciferase activity or enhanced the signal transduction 
induced by human chorionic gonadotropin (hCG).   
The effect of TCC on AR protein expression was investigated by western blot analysis. MDA-kb2 and 
2933Y cells were treated for 48h with either 0.1 nM T, 1.0 µM TCC or a combination of T (0.1 nM) 
and TCC (1.0 µM). Subsequently, western blot analysis was conducted on cell lysates. Results show 
that treatment with T as well as T+TCC increased AR immunoreactive (AR-ir) protein in both cell 
lines compared to vehicle control. In the MDA-kb2 cells TCC + T resulted in more AR-ir protein 
compared to treatment with T alone. However, in 2933Y cells no statistical difference on AR-ir 
protein was observed between the T and T+TCC treatment. The authors state that this difference 
could be due to the inherent differences between the exogenous AR in the 2933Y cells and the 
endogenous AR MDA-kb2 cells. 
 
Study quality and assessment: The study is well-described and is assessed to be of high quality. 
However, a study has shown that TCC stabilizes the luciferase enzyme which may have confounded 
the results. This study provides moderate evidence for amplification of androgen activity in two 
different in vitro assays. 
 
Ahn et al. (2008)  
Summary: 1 µM TCC was shown to significantly enhance estradiol (E2) induced luciferase activity in 
recombinant human ovarian cells [BG1Luc4E2, ER-α-positive] containing estrogen receptor (ER)-
responsive firefly luciferase reporter gene plasmid, pGudLuc7ERE, when E2 was co-administrated at 
concentrations of 1-10 nM. Furthermore, TCC (1µM) enhanced testosterone dependent induction of 
AR-mediated luciferase gene activity in recombinant human cells [T47D-androg-responsive-element 
(ARE)] containing AR-responsive firefly luciferase reporter gene plasmid, pGudLuc7ARE, but only 
at testosterone concentrations of 10µM (the highest concentrations). TCC showed weak ER activity at 
concentrations of 1-10µM. 
 
Study quality and assessment: The study is well-described and is assessed to be of high quality. 
However, a study has shown that TCC stabilizes the luciferase enzyme which may have confounded 
the effect. This study provides moderate evidence for weak ER activity. 
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4.10.3.3 In vivo effects with regard to an endocrine mode of action  
 
Kennedy et al. (2015)  
Summary: This study (from the same group as Chen et al. 2008 and Duleba et al. 2011) investigated 
how exposure to TCC during early life affects the trajectory of fetal and/or neonatal survival and 
development. Sprague Dawley rats were provided control, 0.2% weight/weight (w/w), or 0.5% w/w 
TCC-supplemented chow through a series of 3 experiments that limited TCC exposure to critical 
growth periods: 1) gestation, 2) gestation and lactation, or 3) lactation only (cross-fostering). In the 
first experiment, the level of TCC was measured in serum and amniotic fluid of gestation day (GD) 19 
in dams fed from GD5-19 with either TCC-supplemented (n=5 in each group) or standard chow 
(n=4). They also assessed circulating hormone levels (E2, progesterone, T, triiodothyronine (T3), 
thyroxine (T4) and thyroid-stimulating hormone (TSH)), number of implantation sites, systemic 
(liver, kidney and adrenal) organ weights, and sex organ (ovary) weights and histology. The only 
observed effect from TCC exposure was a decreased T3 level in the 0.5% TCC group. In  the second 
experiment, the effect of in utero and lactational exposure to TCC on neonate survival was first 
examined by feeding dams either standard or TCC-supplemented chow from GD5 until weaning at 
postnatal day (PND) 21 (n=5 in each group). While pups born and raised by control rats survived 
beyond weaning, pups born and raised by TCC-treated dams did not survive beyond PND8. 
Histological examinations of mammary glands collected from the TCC-treated dams showed evidence 
of increased lobule separation by interstitial mature fat, increase in epithelial vacuolation with fat and 
thinning of epithelial height. To further investigate if the effect of TCC exposure on mammary tissue 
and reduced lactation was involved in the reduced neonatal survival a new study was performed. Here 
daily estimates of the size of milk band on pups were used as an indicator for the amount of milk 
consumed by pups. After PND3 a decrease in milk band size was observed in the pups born/raised by 
dams receiving 0.5%TCC compared to control pups born/raised by control dams. The concentration 
level of TCC in dam milk and serum from dams and pups was measured during lactation. 
Interestingly, the level of TCC in the milk was almost four times higher than serum levels of TCC in 
the dams. Finally, in the third experiment, the effect of TCC exposure during lactation on the survival 
of F1 female pups was investigated in a cross-fostering study. The results from this study show 
decreased survival and body weight as well as distended abdomen and diarrhea of pups raised by 
TCC-treated dams compared to pups raised by control dams, regardless of their in utero exposure. No 
effect of TCC was seen on anogenital distance (AGD), vaginal opening (VO) date, or first date of 
estrus after VO in any of the exposure scenarios. 
 
Study quality and assessment: The quality of the study is evaluated as low due to the low number of 
litters per group (N=3-5). Thus, the lack of effect of TCC on anogenital distance, vaginal opening 
(VO) date, or first date of estrus after VO as well as the observed decrease of T3 level do not provide 
evidence for absence or presence of adverse endocrine effects of TCC. 
  
Duleba et al. (2011)  
Summary: This study was an extension of the study by Chen et al. 2008. In this study the same group 
of researchers examined whether TCC induces effects on intact peripubertal male rats. Twenty-four 
intact male SD rats aged 48-52 days were randomly assigned into two groups with 12 rats in each 
group: a control group receiving normal standard diet, and a TCC group receiving 0.25% (2500 ppm, 
2500 mg/kg diet) TCC in the diet for 10 days. Rats receiving TCC in the diet had a significantly 
higher absolute and relative weight of all accessory sex organs except from the testes compared to 
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control rats. The relative weight of the seminal vesicle was increased by ~38%, ventral prostate by 
~25%. Levator ani-bulbocavernosus (LABC) muscle by ~126% and glands penis by ~29%. The 
absolute and relative liver weight was also significantly increased by ~14% and ~8%, respectively, 
and post-treatment body weight (BW) was non-significantly increased by ~5% when compared to the 
control group. This increased organ weight seen in TCC treated animals was also applicable for the 
seminal vesicle, LABC muscle and glands penis when looking at dry weight. The kidney also had a 
small but significantly increase in dry weight even though this significant increase was not seen in the 
other weight measures. Furthermore, the TCC group also had significantly higher protein and DNA 
content (mg/organ) of the ventral prostate, LABC muscle and glands penis compared to the control 
group. When looking at water content of the organs only the LABC muscle had a small but 
significantly increase in % water. No effects on serum T and luteinizing hormone (LH) levels were 
measured, and no visible abnormalities or histologically differences of accessory sex organs were 
observed between treated and control rats.    
 
This paper is included in the REACH registration dossier for Triclocarban 
 
Study quality and assessment: The study is well-described and used a sufficient number of males per 
group. The study included only two dose groups, which is a limitation with regards to assessment of 
dose-response relationship. The study is therefore evaluated to be of medium quality.  
The study provides strong evidence for endocrine activity, i.e. androgen activity, in intact peripubertal 
male rats. The marked effect on male reproductive organ weights, in the absence of significant effects 
on body weight, is suggestive of either cell hypertrophy or hyperplasia. Ventral prostate, LABC and 
glans penis had significantly increased protein and DNA content indicating that exposure to TCC 
resulted in increased number of cells per organ, i.e. hyperplasia. The lack of histological differences 
between accessory sex glands from treated and control rats suggest that the increased growth 
associated with TCC was proportional in the epithelium and surrounding parenchyma of each organ. 
Overall, this study is evaluated to provide moderate evidence for adverse reproductive toxicity effects 
of TCC.    
 
Chen et al. (2008)  
Summary: The potential amplification effect of TCC on androgen ligands was investigated in vivo 
using an established and widely used rat model (corresponding to the Hershberger assay) to 
investigate androgenic/anti-androgenic effects of substances on accessory sex tissue. Castrated 48-52 
days old male Sprague Dawley (SD) rats (n=12) were treated for 10 days with sc. injections of 
testosterone propionate (TP) (0.2 mg/kg bw), TCC (0.25% in the diet, corresponding to 2500 ppm or 
2500 mg/kg in the diet), and a combination of TP injections and TCC-supplemented diet. The control 
group received vehicle (sesame oil) and normal diet. There were no effects of the treatments on body 
weights. TP treatment alone significantly increased the weight of all accessory sex organs, except 
from glans penis, compared with the control group and with the group receiving TCC alone. Rats 
receiving only TCC showed no effect on weight of the seminal vesicles, Cowper’s gland, Levator ani-
bulbocavernosus (LABC) muscle and glans penis, however a slightly but significantly increased liver 
weight (~17%) was observed, as well as an increased ventral prostate weight (~47%), when compared 
to the control group. The co-treatment of TCC and TP showed an additional increase in the weight of 
all accessory sex organs (~78% for the seminal vesicles, ~67% for the ventral prostate, ~35% for the 
gland penis, ~65% for the Cowper’s gland and ~13% for the LABC muscle) when compared to the 
effect of TP treatment alone.  
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Study quality and assessment: The study is well-described, used an established rat model 
(corresponding to the Hershberger assay) and is evaluated to be of high quality. This study provides 
strong evidence for endocrine disruptive activity, i.e. amplification of androgen activity, in castrated 
rats. 
 
REACH registration dossier  
Summary: Two potentially relevant studies are mentioned. In the first study, Sprague-Dawley rats (10 
rats/sex/group) were dosed with 25% aqueous solution of TCC at 0, 500 or 1000 mg/kg bw by 
intubation 5 days per week for a thirty day period. Food consumption and weight gain were recorded 
weekly and observations were made for outward symptoms of toxicity such as reduced activity and 
non-grooming. At the end of the 30 day period, representative animals from each group were 
sacrificed. The viscera of the 1000 mg/kg bw and control groups were examined microscopically and 
saved for possible future examination. Macroscopic examination was made of mounted tissue from 
liver, kidneys, gonads, adrenals, brain, heart, and lungs. No effects of 1000 mg/kg bw was found on 
food consumption, growth data, and at the macroscopic tissue examination. 
 
Study quality and assessment: The quality of the study is evaluated as high with regards to the number 
of doses and animals per dose group. However, the endpoints included are not likely to be sensitive to 
endocrine disruption and especially the performance of only macroscopic examination of the gonads 
is of very limited value. Overall, the quality of the study is evaluated as low due to the limited 
endpoints included. The study does not provide evidence for absence or presence of adverse endocrine 
effects of TCC.  
 
The second study included in the robust study summary refers Duleba et al. 2011 (see above under the 
heading Duleba et al 2011).  
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4.10.3.4 Summary of the plausible link between adverse effects and endocrine mode of 
action  
 
A vast amount of in vitro studies indicate that when administered alone TCC show no estrogenic 
(Huang et al. 2014, Ahn et al. 2008, Tarnow et al. 2015) or androgenic (Christen et al.2010, Duleba et 
al. 2011, Ahn et al. 2008, Tarnow et al. 2015, Chen et al. 2008) activity in itself, when using 
luciferase activity as the indirect read out. When co-administered together with androgens (T or DHT) 
or estrogens (E2), TCC induced both androgen- and estrogen-mediated amplification of luciferase 
activity (Christen et al. 2010, Duleba et al. 2011, Ahn et al. 2008, Tarnow et al. 2015, Chen et al. 
2008). The androgen receptor (AR) inhibitors, flutamide and bicalutamide, significantly suppressed 
the enhanced effect of co-administered TCC and androgens to the levels comparable to control or 
when TCC was administrated alone (Chen et al. 2008, Christen et al. 2010, Duleba et al. 2011). The 
amplifying effect of TCC is supported by in vitro results on AR protein expression, where co-
exposure to TCC + T resulted in a higher expression of AR-ir protein compared to treatment with T 
alone (Chen et al. 2008). The TCC amplified estrogen-mediated activity from the luciferase activity 
assay could not be reproduced using the E-screen assay. In contrast another study found that TCC has 
estrogenic properties in concentrations ranging from 1x10-9-1x10-6M, and that co-treatment with an 
ER antagonist inhibited the effect of TCC. Furthermore, mRNA analysis using qPCR showed that two 
estrogen-responsive genes were upregulated (pS2) and downregulated (ERα), respectively, when 
exposed to TCC, which was confirmed when measuring the protein levels of pS2 and ERα. Studies on 
micro-RNAs (mir-22, mir-206 and mir-193b), which have recently been identified as potent 
regulators of ERα in the MCF-7 cells, showed that TCC (and E2) upregulates the expression of these.    
A study has shown that TCC stabilizes the luciferase enzyme. This stabilization may explain why 
estrogenic effects of TCC where seen in the luciferase assay, whereas no effect of TCC was observed 
in the E-screen or in levels of estrogenic responsive genes. The same confounding effect may explain 
why TCC with androgens amplified AR activity in the luciferase assay, and is supported by results 
showing that TCC does not affect transcription of AR regulated genes. TCC showed co-stimulatory 
effect on transcription of CYP1A1 and CYP1B1, which are classical target genes of the regulon2 of 
the aryl hydrocarbon receptor (AhR). This may indicate that TCC interferes with AhR and thereby 
indirectly affects ERα activity due to AhR-ER crosstalk.  
 
In conclusion, TCC show no estrogenic or androgenic activity in itself in the above mentioned in vitro 
studies (table 1). When co-administered together with androgens (T or DHT) or estrogens (E2), TCC 
have induced amplification of both androgen- and estrogen-mediated activity in many studies. 
However, a confounding effect due to TCC-induced stabilization of the luciferase enzyme may partly 
explain the activity in luciferase assay. Thus, the in vitro evidence for estrogenic and androgenic MoA 
of TCC is evaluated as moderate. 
 
In vivo studies have shown effects of TCC corresponding to the enhancing effects of androgen and 
estrogen induced activity seen in vitro (Duleba et al. 2011, Chen et al. 2008) (table 2). Investigations 
in castrated males and intact peripubertal rats show that in presence of androgens, either exogenous or 
endogenous, TCC further increases the weight of all accessory sex organs compared to the effect of 
androgen treatment alone (Chen et al. 2008) or control rats (Duleba et al. 2011). Thus, there is both 
data showing in vivo androgenic MoA of TCC as well as effects typically induced by androgens.  
                                                     
2 A regulon is a group of genes that are regulated as a unit, generally controlled by the same regulatory gene that 
expresses a protein acting as a repressor or activator. 
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The in vivo evidence for endocrine MoA is evaluated as strong and moderate evidence for adverse 
reproductive toxicity effects of TCC.    
 
There is a strong biologically plausible link between the adverse effects in peripubertal male rats and 
the enhancing effects of androgen and estrogen induced activity seen in vitro and especially the 
androgen MoA seen in vivo.  
 
There is in vitro evidence for thyroid disturbing MoA of TCC, especially inhibition of NIS. Only one 
in vivo study of low quality has investigated relevant endpoints for thyroid effects and found 
decreased triiodothyronine (T3) in the absence of effects on thyroxine (T4) or TSH. This does not 
provide in vivo evidence for thyroid effects of TCC. As the in vivo evidence is evaluated as 
absent/weak, TCC is not evaluated to fulfil the WHO-definition for being considered as an ED with a 
thyroid MoA. However, TCC is evaluated as suspected ED with a thyroid MoA based on the in vitro 
data. 
 
There are two studies on MoA related to effects on the thyroid axis. Indications of thyroid disruption 
have been reported by Hinther et al., 2011, but the study is evaluated to have low quality and the 
results appear unclear, i.e. provide only weak evidence. TCC inhibited NIS-mediated iodide uptake in 
a concentration-dependent manner has been shown at ranges below effects on cell viability (Wu et al. 
2016). The, the in vitro evidence for TH MoA manifested as NIS inhibition is considered strong. 
 
In conclusion, triclocarban meets the WHO-definition of an endocrine disruptor with an androgenic 
MoA.  
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Table 1. Overview of in vitro and in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of triclocarban 
Reference MoA Quality of study  Evidence for ED 
MoA 
In vitro In vivo 
Wu et al. 2016 TCC acted as non-competitive inhibitors of NIS and inhibited NIS-
mediated iodide uptake in FRTL-5 cells. Compared to iodide 
uptake, TPO seemed not to be a primary target of TCC. 
 High Strong 
Kolšek et al 
2015 
TCC was shown to enhance hydrocortisone (HC) (500nM) induced 
luciferase activity to ~156% compared to control (DMSO 100%). 
The same effect was seen when investigating TCC androgen 
receptor (AR) antagonistic activity. 2 µM TCC enhanced 
dihydrotestosterone (DHT) induced signal to ~166% when co-
administrated with 0.5 nM DHT. 
 Medium  Weak  
Huang et 
al.2014 
TCC exerted estrogenic activity by inducing luciferase activity in an 
ER reporter gene assay, promoting the proliferation of human 
mammary carcinoma MCF-7 cells, up-regulating the expression of 
estrogen-inducible pS2 gene and down-regulating ERα expression 
at both mRNA and protein levels in the MCF-7 cells 
 Medium Moderate 
Tarnow et al. 
2013 
TCC was shown to induce androgen-mediated amplification of 
luciferase-activity by ~40%. 
no effect of TCC was seen on estrogen responsive genes in human 
mammary carcinoma MCF-7 cells co-exposed to 17b-estradiol, 
Bisphenol A, butylparaben or genistein. The induced estrogen 
mediated enhancement of luciferase-activity was further 
investigated using an assay (E-screen), where estrogen-dependent 
 Medium Weak  
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Reference MoA Quality of study  Evidence for ED 
MoA 
In vitro In vivo 
cell proliferation is used as the endpoint. These findings show that 
treatment with E2 resulted in a dose-dependent increase in MCF-7 
cell number, however addition of 1µM TCC was not able to further 
enhance estrogen-dependent cell proliferation.  
 
Duleba et 
al.2011 
TCC alone had no effect on luciferase activity, however in 
combination with androgens, the luciferase activity was further 
increased by 221% (probasin promotor, DHT) and 175% (ARE 
promoter, T) in LNCaP cells compared to androgen treatment alone. 
The same enhancement of luciferase activity was seen in C4-2B 
cells where TCC + androgen co-treatment further enhanced 
luciferase activity by 25.9% (probasin promotor, DHT) and 38.5% 
(ARE promoter, T) compared to androgen treatment alone. 
Furthermore, the AR binding inhibitor, bicalutamide, significantly 
suppressed the enhanced effect of TCC and androgens down to 
levels comparable to when TCC was administrated alone. 
 High Moderate 
Hinther et 
al.2011 
In the C-fin assay, TCC alone significantly decreased RLKI 
transcript levels (p =0.021) at the highest concentration (1000 nM) 
but did not affects TRβ transcript levels. In the presence of T3, TCC 
did not affect TRβ or RLKI steady-state transcript levels. In the 
GH3 cells, TCC (1000 nM), alone or in the presence of T3, 
significantly reduced the levels of TH-responsive gene transcripts: 
Gh, Dio1 and Plr.  
 Low Weak 
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Reference MoA Quality of study  Evidence for ED 
MoA 
In vitro In vivo 
Christen et al. 
2010 
TCC showed no androgenic activity in itself, but potentiated the 
DHT response (0.5nM) up to 130% at 0.01-5 µM TCC. Addition of 
10µM flutamide inhibited the induction of this response, thereby 
excluding that the potentiation is due to/originates from co-
activation of the glucocorticoid receptor (GR) that can also 
stimulate the expression of luciferase by TCC.  
 High Moderate 
Chen et al. 
2008 
Treatment with T as well as T+TCC increased AR immunoreactive 
(AR-ir) protein in both cell lines compared to vehicle control. In the 
MDA-kb2 cells TCC + T resulted in more AR-ir protein compared 
to treatment with T alone. However, in 2933Y cells no statistical 
difference on AR-ir protein was observed between the T and 
T+TCC treatment. The authors state that this difference could be 
due to the inherent differences between the exogenous AR in the 
2933Y cells and the endogenous AR MDA-kb2 cells. 
 High Strong 
Ahn et al. 
2008 
TCC showed weak ER activity at concentrations of 1-10µM.  High Moderate 
Thyroid peroxidase (TPO), dihydrotestosterone (DHT), androgen receptor (AR), Rana larval keratin type I (RLKI), TH receptor β (TRβ), triiodothyronine (T3), testosterone (T), estrogen 
receptor (ER) 
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Table 2. Overview of potential endocrine-related adverse effects of triclocarban. 
Reference Species, n Adverse effects Quality of study  Evidence for adverse 
effects 
Kennedy et 
al. 2015 
Rats 
n = 3-5 
The lack of effect of TCC on anogenital distance, vaginal opening (VO) 
date, or first date of estrus after VO as well as the observed decrease of T3 
level do not provide evidence for absence or presence of adverse endocrine 
effects of TCC. 
Low None 
Duleba et 
al.2011 
Rats 
N=12/group 
The marked effect on male reproductive organ weights, in the absence of 
significant effects on body weight, is suggestive of either cell hypertrophy 
or hyperplasia. Ventral prostate, LABC and glans penis had significantly 
increased protein and DNA content indicating that exposure to TCC 
resulted in increased number of cells per organ, i.e. hyperplasia. The lack 
of histological differences between accessory sex glands from treated and 
control rats suggest that the increased growth associated with TCC was 
proportional in the epithelium and surrounding parenchyma of each organ. 
Medium Moderate 
 
  
58 
 
 
References 
 
Ahn, K. C., Zhao, B., Chen, J., Cherednichenko, G., Sanmarti, E., Denison, M. S., Lasley, B., Pessah, 
I. N., Kültz, D., Chang, D. P. Y., Gee, S. J. and Hammock, B. D. (2008) ‘In Vitro Biologic Activities 
of the Antimicrobials Triclocarban, Its Analogs, and Triclosan in Bioassay Screens: Receptor-Based 
Bioassay Screens’, Environmental Health Perspectives, 116(9), pp. 1203–1210. doi: 
10.1289/ehp.11200. 
 
Chen, J., Ahn, K. C., Gee, N. A., Ahmed, M. I., Duleba, A. J., Zhao, L., Gee, S. J., Hammock, B. D. 
and Lasley, B. L. (2008) ‘Triclocarban Enhances Testosterone Action: A New Type of Endocrine 
Disruptor?’, Endocrinology, 149(3), pp. 1173–1179. doi: 10.1210/en.2007-1057. 
 
Christen, V., Crettaz, P., Oberli-Schrämmli, A. and Fent, K. (2010) ‘Some flame retardants and the 
antimicrobials triclosan and triclocarban enhance the androgenic activity in vitro’, Chemosphere. 
Elsevier Ltd, 81(10), pp. 1245–1252. doi: 10.1016/j.chemosphere.2010.09.031. 
 
Duleba, A. J., Ahmed, M. I., Sun, M., Gao, A. C., Villanueva, J., Conley, A. J., Turgeon, J. L., 
Benirschke, K., Gee, N. A., Chen, J., Green, P. G. and Lasley, B. L. (2011) ‘Effects of Triclocarban 
on Intact Immature Male Rat: Augmentation of Androgen Action’, Reproductive Sciences, 18(2), pp. 
119–127. doi: 10.1177/1933719110382581. 
 
Hinther, A., Bromba, C. M., Wulff, J. E. and Helbing, C. C. (2011) ‘Effects of triclocarban, triclosan, 
and methyl triclosan on thyroid hormone action and stress in frog and mammalian culture systems’, 
Environmental Science and Technology, 45(12), pp. 5395–5402. doi: 10.1021/es1041942. 
 
Huang, H., Du, G., Zhang, W., Hu, J., Wu, D., Song, L., Xia, Y. and Wang, X. (2014) ‘The in Vitro 
estrogenic activities of triclosan and triclocarban’, Journal of Applied Toxicology, 34(9), pp. 1060–
1067. doi: 10.1002/jat.3012. 
 
Kennedy, R. C. M., Menn, F.-M., Healy, L., Fecteau, K. A., Hu, P., Bae, J., Gee, N. A., Lasley, B. L., 
Zhao, L. and Chen, J. (2015) ‘Early Life Triclocarban Exposure During Lactation Affects Neonate 
Rat Survival’, Reproductive Sciences, 22(1), pp. 75–89. doi: 10.1177/1933719114532844. 
 
Kolšek, K., Gobec, M., Mlinarič Raščan, I. and Sollner Dolenc, M. (2015) ‘Screening of bisphenol A, 
triclosan and paraben analogues as modulators of the glucocorticoid and androgen receptor activities’, 
Toxicology in Vitro, 29(1), pp. 8–15. doi: 10.1016/j.tiv.2014.08.009. 
 
REACH registration dossier : https://echa.europa.eu/da/registration-dossier/-/registered-
dossier/12075/2/3  (Link used in November 2017) 
 
Tarnow, P., Tralau, T., Hunecke, D. and Luch, A. (2013) ‘Effects of triclocarban on the transcription 
of estrogen, androgen and aryl hydrocarbon receptor responsive genes in human breast cancer cells’, 
Toxicology in Vitro. Elsevier Ltd, 27(5), pp. 1467–1475. doi: 10.1016/j.tiv.2013.03.003. 
 
Wu, Y., Beland, F. A. and Fang, J.-L. (2016) ‘Effect of triclosan, triclocarban, 2,2′,4,4′-
59 
 
tetrabromodiphenyl ether, and bisphenol A on the iodide uptake, thyroid peroxidase activity, and 
expression of genes involved in thyroid hormone synthesis’, Toxicology in Vitro. Elsevier B.V., 32, 
pp. 310–319. doi: 10.1016/j.tiv.2016.01.014. 
  
60 
 
Octamethylcyclotetrasiloxane (D4), CAS 
no. 556-67-2 
 
 
Synonyms: Cyclic dimethylsiloxane tetramer, OMCTS. 
Octamethylcyclotetrasiloxane (C8H24O4Si4 ) is a cyclic 
siloxane/ silicone with low molecular weight (Figure 1). D4 is 
used in the synthesis of larger silicone polymers and 
organosilicon as well as in consumer products such as cosmetics 
and personal care products, washing and cleaning products, 
polishes and wax blends. D4 is used in 100000-1000000 tonnes 
per annum. D4 is classified in ECHA as a substance suspected of 
damaging fertility or the unborn child (Repr. 2) and may cause 
long lasting harmful effects in aquatic life (Aquatic Chronic 4)).  
 
4. Human health hazard assessment 
4.10.3 Endocrine disruption 
4.10.3.1 General approach – human health 
4.10.3.2 In vitro information indicative of endocrine activity 
Lee et al. (2015)  
Summary: The oestrogenic activity of D4 was investigated in vivo and in vitro in the present study. 
The GH3 cell line (from rat pituitary) was exposed to D4 (1x10-5 M) or to 17β-estradiol (E2) (1x10-9 
M) for 1 day. Gene and protein expression levels of CaBP-9K, ERα, PR and CYP2B1 were measured 
in the cells. Simultaneous exposure to ICI 182-780 (ICI) was used to investigate if the effects on gene 
expression level were regulated by the ER mediated pathway.  
CaBP-9K gene expression was increased in GH3 cells exposed to E2 or D4. When cells were exposed 
to ICI 182-780 in combination with D4 or E2, the gene expression level of CaBP-9K was not affected. 
Protein expression of CaBP-9K was slightly increased by E2 and D4 but not when ICI was 
administered simultaneously. Similarly, PR gene- and protein expression levels were increased by D4 
and E2, an effect that was blocked by ICI. Conversely, gene-and protein expressions of ERα were 
downregulated by E2 and D4 and ICI blocked the effect. 
Study quality and assessment: The study is well described and thorough and it is assessed to be of 
high quality although no CAS-number or purity of the chemical is given. The study provides strong 
evidence of an estrogenic mode of action of D4. 
 
 
Figure 1. 2D structure from 
PubChem 
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Quinn et al. (2007a)  
Summary: The purpose of the study was to determine the estrogenic, progestagenic and androgenic 
activity of two cyclic siloxanes in vitro and in vivo. In the in vitro part of the study receptor binding 
experiments and luciferase reporter gene assays were performed for oestrogen receptor (ER)α, ERβ, 
progesterone receptor (PR)α or PRβ. Androgenic activity was investigated in an in vivo assay (see 
below). Weak binding of D4 to ERα (compared to diethylstilbestrol) was observed. D4 did not appear 
to bind to ERβ, PRα or PRβ. The ERα reporter gene assay showed activity at 10 µM of D4, whereas 
no activation of the PRβ reporter gene assay was observed for any of the tested doses of D4 (0.1-10 
µM). 
This paper is included in the REACH registration dossier for D4 on toxicity to reproduction. 
Study quality and assessment: The in vitro studies are well described, the tests are performed in 
triplicates and although it is not stated whether cytotoxicity is evaluated, the findings do not reflect 
results from cytotoxicity. The study is assessed to be of high quality. The study provides strong 
evidence of an estrogenic mode of action of D4 through binding and activation of ERα. 
 
He et al. (2003)  
Summary: The objective of this study was to characterise the estrogenic mode of action of D4 in vivo 
and to investigate the estrogenic mechanism of D4 in vitro. An oestrogen receptor (ER) binding assay 
using human ERα and ERβ receptors was performed. The siloxane D4 bound competitively to ERα 
but not to ERβ. 
Study quality and assessment: The study is well-described and appears to be well-performed. The 
study is assessed to be of high quality. The study provides strong evidence of an estrogenic mode of 
action and the in vivo data support this conclusion.  
 
4.10.3.3 In vivo effects with regard to an endocrine mode of action  
 
Jean and Plotzke (2017)  
Summary: This study presents data of a chronic toxicity and oncogenicity study of D4. In the 
oncogenicity part of the study, male and female rats (60/sex/group) were exposed to D4 (0, 10, 30, 
150 or 700 ppm) for 6 hours per day for 24 months in whole-body inhalation chambers. Organ 
weights were recorded and histologic examination of organs was performed. 
Uterine (absolute and relative to body weight) and testis weights (relative to body weight) were 
increased in animals in the 700 ppm group. An increased incidence of uterine cystic endometrial 
hyperplasia (from 19 % in controls to 50 % in treated females) was found in females exposed to 700 
ppm D4. Although few high-dose females had cervical squamous epithelial hyperplasia and/ or 
ovarian atrophy, the incidence of these changes (5 % and 6.7 %, respectively) was statistically 
significantly increased compared to controls (0 % and 1.7 %, respectively). The severity of the 
changes in uterus and ovaries were increased by the exposure, but no information on the statistical 
significance for these is given. Similarly, a modest but significant increase in the incidence of 
testicular interstitial cell hyperplasia was observed after 24 months of exposure in the two highest 
exposure groups (150 and 700 ppm). 
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Study quality and assessment: The study is well-described and assessed to be of high quality although 
it would have been preferred if the CAS-number of the substance had been given. The study provides 
moderate evidence of reproductive adverse effects.  
 
 
Jean et al. (2017)  
Summary: This study describes the effects of chronic exposure to 700 ppm of D4 on markers of 
reproductive senescence in female rats (49-50 weeks of age). The animals (50 per group) were 
exposed through whole-body inhalation from 11 to 24 months of age. Estrous cycle was monitored 
throughout the study and blood samples were collected monthly (for measurement of prolactin, 
progesterone, estradiol and corticosterone). At necropsy, blood samples were collected (FSH, 
estradiol and estradiol metabolites), organ weights were recorded (adrenal glands, pituitary glands, 
uterus, ovaries with oviducts and other non-endocrine related organs) and histopathology (of ovaries, 
uterus and vagina) was performed. Histological assessment of reproductive organs was also used to 
evaluate the estrous cycle and the types of corpora lutea and to record the number of atretic and 
healthy antral follicles and primordial follicles. 
Increased number or percent of estrogen-predominant days (proestrous and estrous) in the estrous 
cycle was found in D4 treated animals compared to controls. Progesterone levels were elevated in 
exposed rats 2-10 weeks after start of treatment and estradiol was reduced over the total study period 
after exposure start. As a consequence, lower estradiol:progesterone ratios compared to controls were 
found in D4 treated females. Corticosterone concentrations was increased in exposed animals during 
the almost the entire study period. Statistical analysis of histological changes was not performed, but a 
marked decrease was observed in the incidence of antral-size atretic follicles and an increase in 
severity was observed for vaginal mucification. 
Study quality and assessment: The study is well described and thorough. Although information on 
CAS-number and feed had been preferred, the study is assessed to be of high quality. The study 
provides strong evidence of an endocrine mode of action of D4 and moderate evidence for 
reproductive adverse effects.  
 
Lee et al. (2015)  
Summary: The oestrogenic activity of D4 was investigated in vivo and in vitro in the present study. A 
Uterotrophic assay in immature female rats (18 days old) dosed s.c. for 4 days (5/group) with ethinyl 
estradiol (EE) (3 µg/kg) or D4 (500 or 1000 mg/kg) was performed. 4 more groups of rats were co-
treated with the ERα inhibitor ICI 30 min before EE or D4 administration. Animals were killed 1 day 
after the last dosage. Livers were weighed and gene- and expression of CYP2B1/2 was measured. 
Gene and protein expression was measured in uteri from the Uterotrophic assay for evaluation of the 
expression levels of the estrogenic biomarkers CaBP-9K, ERα and PR. 
Relative liver weights were increased by D4 but not by EE. Gene expression of CYP2B1/2 was 
increased markedly compared to controls in the D4 dose-group in a dose-dependent manner and ICI 
did not change the effect significantly compared to D4. In contrast, CYP2B1/2 gene expression was 
decreased by EE and co-administration of ICI and EE decreased the gene expression additionally 
compared to EE alone. In the Uterotrophic assay, the positive control EE increased the relative uterus 
weight markedly. No effects on uterus weight were seen with administration of D4. Gene-and protein 
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expression of CaBP-9K, ERα and PR was measured in rat immature uterus. The gene expression 
levels of CaBP-9K were increased by EE and D4 and the effect was blocked by ICI. Protein 
expression of CaBP-9K was similarly induced by EE and D4 and the effect was inhibited by ICI. Both 
protein and gene expression levels were more elevated after EE exposure than with D4. Expression of 
PR mRNA was suppressed by EE and by the high dose of D4. Co-treatment of ICI further decreased 
PR gene expression levels in controls, in EE treated animals and in the low-dose D4 group. In the 
high-dose D4 exposure group ICI treatment increased PR levels compared to D4 alone. For ERα, gene 
expression was reduced by EE and D4, and simultaneous exposure to ICI reduced the expression level 
further for EE exposure and increased expression in the high D4-group compared to D4 alone.  
Study quality and assessment: The study is generally well described and the Uterotrophic assay 
followed the OECD guideline for this test. However in the in vivo part of the result section there seem 
to be a mistake in referring to E2 instead of EE and there is conflicting description of data compared 
to the depicted data in a figure (PR gene expression levels in uterus).  Moreover, no CAS-number or 
purity of the chemical is given. The study is assessed to be of medium quality. Data on the estrogenic 
mode of action of D4 are somewhat conflicting as some effects of D4 are similar to EE and the ERα 
inhibitor ICI block some of the effects of D4, but some effects are not comparable between EE and 
D4. Also, D4 induced no effect on uterus weight. The study provides weak evidence of an estrogenic 
mode of action of D4. 
 
Meeks et al. (2007)  
Summary: The aim of this study was to investigate which phases of the female reproductive cycle are 
affected by D4. A study design allowing investigation of the complete female reproductive cycle from 
pre-mating and throughout gestation was performed. Several different cohorts were performed in 
female rats exposed by whole-body vapour inhalation for 6 hours per day. In the first experiment, 
female rats were exposed to D4 (0, 70, 300, 500 or 700 ppm) from 28 days prior mating to GD19 
(n=24/ group) or for a shorter period covering the ovarian phase, the fertilisation phase or the 
implantation phase. In these experiments, females were exposed to 700 ppm of D4 from 31 days prior 
to mating to 3 days before mating (n=26 and 50 pregnant dams in controls and exposed groups, 
respectively), from 3 prior to mating until GD3 (n=28 and 19 pregnant dams in controls an exposed 
groups, respectively) or from GD2-GD5 (n=23 pregnant females/ group), respectively. In the second 
experiment with focus on the fertilisation and implantation phases, females were exposed during 1 
day only on days 1, 2, 3 or 4 prior to mating or daily either for 3 days prior to mating or from 3 days 
prior to mating until GD3 (n=11-40 pregnant dams). Necropsies were performed on GD20 in the first 
experiment and on GD8 in the second experiment. The body weight gain, number of corpora lutea 
(CLs) in ovaries, number of foetuses, early resorptions and implantation sites and weight of uterus, 
ovaries, thyroid gland, adrenal glands and brain were assessed in all the studies. 
Exposure concentrations were found to be very close to the targeted exposure levels, e.g. in the 700 
ppm group, mean exposure concentrations were found to range between 689 and 702 ppm in the 
different studies. Overall, the paper shows effects of D4 on female fertility. In the first experiment, 
effects on the investigated parameters were seen in the study with exposure to D4 during the 
fertilisation phase and in the study with exposure during the whole mating to gestation period. In the 
second study, decreased fertility was seen in females exposed at a time-point close to mating.  
In the females exposed from before mating and throughout gestation reduced body weight gain during 
gestation and increased weight of adrenal glands was seen in the highest exposure group. The number 
of CLs was reduced by D4 in the three highest exposure-groups, but only statistically significantly in 
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the 300 and 500 ppm groups and increased pre-implantation loss was seen in the two highest dose-
groups of 500 and 700 ppm. The number of viable foetuses was lower compared to controls as a result 
of lower numbers of CLs and the higher level of pre-implantation losses. The gravid uterine weight 
was reduced in the highest exposure group due to a lower number of viable foetuses. In the 
fertilisation phase, pregnant females exposed to 700 ppm of D4 had a lower body weight gain, a lower 
number of CLs and an increased percentage of pre-implantation loss. The number of implantation 
sites, the number of viable foetuses and the uterine weight were reduced. No effects were found in 
females exposed during the ovarian or the implantation phases. In the second study, a reduced number 
of pregnant dams were found among the confirmed mated females exposed to D4 1 day prior to 
mating. A decreased number of CLs, decreased uterine weight and an increased number of small 
implantation sites were seen in females exposed from 3 days before mating until GD 3. 
This paper is included in the REACH registration dossier for D4 on toxicity to reproduction. 
Study quality and assessment: The study is well-described and although the paper includes many sub-
studies with different exposure periods it is clear how it was done, what the results are and the link 
between the different results is well explained. The study is assessed to be of high quality even though 
no CAS-number of D4 is given. The study provides strong evidence of adverse effects on female 
fertility around ovulation and fertilisation. 
 
Quinn et al. (2007a)  
Summary: The purpose of the study was to determine the estrogenic, progestagenic and the 
androgenic activity of two cyclic siloxanes in vitro and in vivo. In the in vivo part of the study the rat 
Uterotrophic and Hershberger assays for investigation of the estrogenic and androgenic activity, 
respectively, were performed. In both assays exposure to D4 (700 ppm) was through whole-body 
inhalation, 16 hours/day. In the Uterotrophic assay, exposure in Wistar and Fisher 344 rats (n=6 
controls and 10 treated for each strain) lasted 3 days and in the Hershberger assay exposure of Fisher 
344 rats (n=10/group) lasted 10 days. 
In the Uterotrophic assay uterine (wet and blotted) weight was increased, uterus was fluid filled and 
had increased luminal and epithelial cell height in both strains tested. The anti-estrogenic effect was 
investigated, however the results are unclear. The D4 but not the ER antagonist ICI 182,789 
suppressed the ethinyl estradiol induced increase in uterine weight, indicating a weak anti-estrogenic 
activity of D4. The Hershberger assay showed no androgenic or anti-androgenic activity of D4. 
Study quality and assessment: The study is well described but the CAS-number of the substance and 
housing conditions are not described. The study is assessed to be of high quality. The study provides 
strong evidence of an estrogenic mode of action of D4 and weak evidence of an anti-estrogenic mode 
of action.  
 
Quinn et al. (2007b)  
Summary: The objective of the study was to investigate the effects of D4 on ovulation and on 
reproductive hormones, including luteinizing hormone. Two studies in female rats (13 weeks old) 
were performed with whole-body vapour inhalation exposure (generally 6 hours per day) to D4 at 700 
or 900 ppm for 3 days from the day of diestrous until proestrous. In the first study, called phase I 
(n=24, 22 and 27 for controls, 700 and 900 ppm, respectively), rats were euthanized on the day of 
proestrous. Blood was collected for hormone analysis (Follicle stimulating hormone (FSH), 17β-
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estradiol, estrone and progesterone). In the second study, called phase II (n=138 in total at study start), 
blood was collected at 2, 4, 6, 8 and 10 p.m. on the day of proestrous and the animals were euthanized 
on the day of oestrous. The serial blood samples from phase II were analysed for luteinizing hormone 
(LH) and prolactin levels. On the day of necropsy body weight and weight of uterus, ovaries and brain 
were assessed and the number of ova in the oviducts was counted in both studies/ phases. Step 
sections of ovaries from phase II were evaluated histologically for assessment of large follicles, new 
corpora lutea and atretic antral follicles for classification of ovulators and non-ovulators. Terminal 
blood samples were used for hormone analysis (FSH, estradiol, estrone and progesterone). 
Body weight was reduced in both treatment groups in phase I and in the 900 ppm group in phase II. 
The absolute ovary and relative ovary and uterus weights were reduced in the highest exposure group 
in phase II as well as the ovary relative to brain weight. More non-ovulating females were seen in the 
treatment groups (n=26, 12 and 10 ovulating females in controls, 700 ppm and 900 ppm groups, 
respectively compared to n=9, 19, 23 non-ovulating females in the controls, 700 ppm, 900 ppm 
groups, respectively). In general, plasma LH levels and the peak levels of LH were lower compared to 
controls, but the changes in LH peaks were related to the ovulatory status, i.e. lower mean levels of 
LH were related to a higher number of non-ovulators in the treatment groups. However, in ovulating 
females, prolactin levels were reduced at 2 p.m. in the 900 ppm group. In phase I and II, estrone 
hormone levels were increased in both treatment groups and in phase II, 17β-estradiol levels were 
elevated in both exposure groups, both in ovulating and in non-ovulating rats. The ratio between 
estrone and 17β- estradiol was reduced in the 900 ppm group in non-ovulating females. FSH was 
decreased in both treatment groups. In phase I, progesterone was increased in the highest exposure 
group on the day of proestrous. Histological assessment of phase II ovaries showed a tendency to 
increased number of large antral follicles, which correlated well with the increased estradiol levels. 
The number of ova found in the oviducts was reduced in the treated groups compared to controls, but 
not in the ovulating females. Overall, there were no signs of follicular toxicity, but D4 appeared to 
disrupt the LH surge and decreased the portion of ovulating females. 
This paper is included in the REACH registration dossier for D4 on toxicity to reproduction. 
Study quality and assessment: The study is well described and the interpretation of data and relations 
between the different observed effects are elucidated. The number of animals used per group in the 
phase II study is not stated, but the number of ovulators and non-ovulators in the different groups are 
listed in a figure. The study is assessed to be of high quality although no CAS-number of D4 is given. 
The study provides strong evidence of an endocrine mode of action of D4 and  strong evidence of 
adverse effects on female reproduction. However, disruption of the LH surge that probably lead to the 
observed effects may be a rodent species specific mode of action and thus the effects on ovulation 
may not be relevant to humans. 
 
Siddiqui et al. (2007)  
Summary: The aim of the study was to evaluate the effects of D4 on reproductive function in F0 and 
F1 animals and on survival, growth and development of the offspring. A two-generation toxicity study 
with whole-body vapour inhalation of 0, 70, 300, 500 or 700 ppm of D4 for 6 hours per day was 
performed in rats. Male and female rats (F0, 165 per sex, 44-45 days old) were exposed from 70 days 
before mating and until weaning of the pups (F1, n=23-27 litters per group). The F1 offspring were 
exposed in utero and through lactation and directly exposed from weaning throughout adulthood with 
at least 70 days of exposure prior to first mating. F1 offspring were mated twice delivering two litters 
(F2a and F2b, n= 17-29 and n=12-26 litters per group, respectively) and male offspring were mated a 
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third time with untreated females while males were still exposed. Exposure was interrupted for 5 days 
at the time of delivery from GD20 until PND4 for all pregnant female rats. 
General toxicity (food consumption, body weight gain and weight and histology of liver, kidney and 
lung) was assessed. Reproductive (e.g. mating and fertility index, number of implantation sites, pups 
born per litter etc.) and developmental parameters (e.g. sperm parameters, AGD and sexual 
maturation) were assessed.  
Food consumption in F0 males was reduced compared to controls in the 700 ppm group during weeks 
1-2 which was consistent with a reduced weight gain observed in these males at that time-point. 
Increased organ weights were seen in livers (absolute and relative weights in F0 and F1 males and 
females), kidneys (absolute and relative weights in F0 males and F1 females and relative weights in F1 
males) and pituitary glands (absolute weights in F1 females and relative weights in F0 males and F1 
females). Histologically, changes were seen in livers, kidneys and lungs. Hepatocytic hypertrophy 
was increased in F1 females in 500 and 700 ppm groups and in F1 males in the 700 ppm group. In the 
F1 males in the 700 ppm group, increased bile duct hyperplasia and bile pigment were observed. 
Tubular mineralisation was seen in the kidneys of F0 and F1 males in the 700 ppm group.  
Reproductive parameters were also affected. Female body weight gain was reduced during GD14-20 
in the 700 ppm group (F0 and F1), a change considered to be related to a decreased number of 
foetuses in the uterus, as a reduced number of pups were born in this group. The percentage of mated 
rats with successful delivery of litters was reduced and the gestation length was increased in F1 
offspring in the 700 ppm treatment group. The oestrous cycle length was increased in F1 females in 
the highest exposure-group. Most (8 out of 9) females with extended diestrous did not show evidence 
of mating and this led to decreased mating indices (number of successful matings out of number of 
animals used for mating) during the second mating in F1 animals. Histologically, the number of 
corpora lutea was decreased in F1 females and half of the females (15 out of 30) in the highest 
exposure group were anovulatory or had disturbed oestrous cycles. In males, no effects were seen on 
sperm parameters. The number of litters was reduced in the 700 ppm group for the first mating in the 
F1 generation and in the two highest dose-groups for the second mating. The number of live pups per 
litter was reduced in the 500 and 700 ppm groups in the F0 and F1 generations and the number of 
implantation sites was reduced in the 700 ppm group in F0 females. Pup survival on PND 0 was 
reduced in F2b pups from the 700 ppm group.  
This paper is included in the REACH registration dossier for D4 on toxicity to reproduction. 
Reduction of fertility indices of F1b males and females (second mating) in the 500 and 700 ppm 
groups is reported as statistically significant compared to control levels in the REACH dossier but not 
in the published paper. 
Study quality and assessment: The study was conducted according to EPA OPPTS Health Effects Test 
guideline (which is equivalent or similar to the OECD guideline 416). It looks like there is a mistake 
in table 1 showing data on reproductive and developmental parameters from F0, F1a, F1b and F1c 
animals. The table covers more than one page and it is probably data from F1b and F1c that are shown 
on page 2 and not data from F0 and F1a as stated in the first line of the table on page 2. Apart from this 
detail, the study is well-described and thorough and the study is assessed to be of high quality. The 
study provides strong evidence of adverse effects on female reproduction of rats exposed as adults and 
especially in utero and throughout lactation. However, the F1 females showed more signs of toxicity 
(increased organ weights and histological changes in livers indicating metabolising activity) compared 
to F0 females and this may explain why more marked effects on reproductive parameters such as 
67 
 
gestation length and oestrous cycle length were seen in the F1 females. Thus, the study provides 
moderate evidence of adverse effects on female reproduction that could be explained by an endocrine 
disrupting mode of action.  
 
 
He et al. (2003)  
Summary: The objective of this study was to characterise the estrogenic mode of action of D4 in vivo 
and in vitro. Several in vivo studies were performed and other siloxanes were also tested in the 
Uterotrophic assay. Female mice (6-7 weeks old, n=6/group) were dosed orally with 1000 mg/kg D4 
for 7 days and serum oestradiol was measured. Subsequently intact, sham operated and 
adrenalectomised (ADX) mice were dosed similarly as the previous study and serum oestradiol and 
corticosterone were measured. The siloxane D4 was tested in an Uterotrophic assay in ovariectomised 
female mice dosed orally to 1000 mg/kg/day D4 for 3 days (n=5/group). A uterine peroxidase assay 
was performed on uteri from the ovariectomised mice. A dose-response study was additionally 
performed for the Uterotrophic assay using 0, 1, 10, 50, 100, 250, 500 and 1000 mg/kg D4 for a 3-
days exposure period (n=5/group) in ovariectomised mice. To investigate if the effects on uterine 
weight were mediated through ER, two more studies were performed. The Uterotrophic assay was 
repeated in ovariectomised mice with pre-treatment with the ER antagonist ICI 182,780. Finally, ERα 
knockout mice (αERKO) and wild-type controls were ovariectomised (n=5) and used in an 
Uterotrophic assay with oral dosing of 1000mg/kg D4 for 3 days.  
Serum oestradiol was reduced by approximately 50 % by D4 exposure. In the ADX study serum 
oestradiol was reduced in intact, sham operated and ADX mice. Serum corticosterone was increased 
in intact and sham operated mice, whereas corticosterone was reduced in ADX mice. This suggested 
that the D4 induced decreased in oestradiol was independent of corticosterone levels and an 
association between stress-like elevated corticosterone levels and suppression of the hypothalamic-
pituitary-gonadal axis could be excluded. D4 induced increased uterine weight in the Uterotrophic 
assay and increased uterine peroxidase activity in ovariectomised rats. The dose-response study in the 
Uterotrophic assay showed effects at doses of 250mg/kg D4 and above. Pre-treatment with ICI 
182,780 blocked the D4-induced increase in uterine weight, indicating that the effects on uterus 
weight are ER-mediated. Additionally, the D4 induced increase in uterus weight was absent in 
exposed αERKO mice, suggesting that the effects on uterus weight were more specifically mediated 
through ERα.  
Study quality and assessment: Information of the CAS-number and purity of the compound would 
have been preferred, but otherwise the study is well-described although it is a complex study 
describing several smaller studies. The study is assessed to be of high quality. The study provides 
strong evidence of an estrogenic mode of action of D4.  
 
Burns-Nass et al. (2002)  
Summary: The objective of the study was to investigate the subchronic toxicity of D4 in a 3 months 
inhalation study. Male and female rats (approximately 10 weeks old) were exposed to 0, 35, 122, 488 
or 898 ppm for 6h/day, 5 days a week for 3 months (20/sex/group) to D4 by nose-only inhalation. A 
recovery study was performed with 10 rats per group exposed to 0 or 898 ppm as described previously 
for 3 months and with a following recovery period of 1 month. Blood was collected for hematologic 
and clinical chemistry, urine analysis was performed and organs were weighed, including liver, 
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spleen, heart, lung, thymus, ovaries, testes, kidneys, adrenals and brain. Histopathological assessment 
of a full set of organs was conducted. 
Changes in endocrine related endpoints were found. Testes weight was increased in the 488 ppm 
group but not at the highest dose, and the change was considered not to be exposure related. Ovary 
weight was decreased (by 38% compared to controls) in the highest exposure group. 
Histopathological evaluation of the ovaries showed an increased incidence of hypoactivity seen as a 
lack of active corpora lutea in the 898 ppm dose-group after a 3 months exposure period. Follicular 
development appeared normal. The morphological changes indicated a decreased ovulatory activity of 
the ovaries and the reduced ovary weight was most likely due to the lower number of corpora lutea. 
After the 1 month recovery period, the ovaries showed normal follicular development. Increased 
incidence and thickness of mucification of the vaginal mucosa was seen in the uterus in females 
exposed to 898ppm for 3 months.  
Study quality and assessment: The study is well-described and is assessed to be of high quality. The 
changes observed in female reproductive organs may be related to an endocrine mode of action of D4. 
The study provides strong evidence of adverse effects on ovaries which can be explained by an 
endocrine mode of action of D4. 
 
McKim et al. (2001)  
Summary: The objective was to investigate the estrogenic and anti-estrogenic activity of the cyclic D4 
and the linear siloxane hexamethyldisiloxane in an Uterotrophic assay. Immature female rats (12 pups 
per group) from two different strains were used in the study. Sprague-Dawley rats (18 days old) and 
Fisher-344 rats (21 days old) were dosed by oral gavage with 0, 10, 50, 100, 250 or 1000 mg/kg/day 
of D4 for 4 days. For evaluation of anti-estrogenic properties of D4, EE was co-administered with 
either D4 (500 mg/kg/day) or ICI 182-780 (positive control). The uterine weight was measured and 
the epithelial cell height in uterus was measured histologically (n=6 per group). Relative potency of 
the different chemicals tested (EE, diethylstilbestrol dipropionate and Coumestrol) was evaluated 
based on the effects on uterine weight. 
Female body weight was decreased in the highest D4 dose-group on day 21 (SD rats) or on days 23, 
24 and 25 (Fisher rats). Compared to the other compounds tested, D4 was the least potent in 
increasing uterine weight (absolute and relative). Higher doses of D4 were necessary to get the same 
increase in uterine weight compared with the weak estrogenic compound Coumestrol. Uterus weight 
was significantly increased by 250, 500 and 1000 mg/kg/day of D4. Co-administration of D4 with EE 
attenuated the effect of EE on uterine weight suggesting an anti-estrogenic effect of D4. The 
compound D4 was less effective in inhibiting the effect of EE on uterine weight compared to ICI. 
Uterine epithelial cell height was increased by EE and D4 in a dose-dependent manner. In conclusion, 
D4 appeared to have weak estrogenic and anti-estrogenic properties.  
Study quality and assessment: The study has some limitations as the number of litters is not 
mentioned, which means it is unclear if litter mates were used. Moreover, more details on housing 
conditions would have been preferred as well as the CAS-number of D4. The study is assessed to be 
of medium quality. The study provides strong evidence of a weak estrogenic mode of action of D4. 
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Hayden and Barlow (1972)  
Summary: The purpose of the study was to investigate the effects of a series of organosiloxanes in 
immature females rats and to establish structure-activity relationships. However D4 does not appear to 
have been investigated in this study 
 
REACH registration dossier  
 
Toxicity to reproduction:  
Key Experimental results and Supporting Experimental results 
Summary: The applicant reported data from 7 additional study reports. Data from two of these studies 
are published in Meeks et al. (2007) and Siddiqui et al. (2007) and these papers have already been 
included here. The other 5 studies are one-generation reproductive toxicity studies in male and/or 
female rats with inhalation exposure. The studies do not add significant value or new information on 
the endocrine mode of action or endocrine-related adverse effects of D4, except for a reversible 
increase in the weight of the thyroid gland in adult males. In general, the studies show decreased 
weight gain and food consumption in adult rats and adverse effects on reproduction (e.g. reduced 
mean litter size, reduced pup viability and reduced number of implantation sites). 
Study quality and assessment: The quality of the unpublished studies cannot be assessed based in the 
summaries available. The studies are performed under GLP with 20-22 animals per dose-group, but 
not all of them follow test guidelines. The studies provide strong evidence of adverse effects on 
reproduction based on reduced litter size, pup viability and number of implantation sites. 
 
Developmental toxicity/ teratogenicity:  
001 Key Experimental results 
Summary: The first key study in the REACH registration dossier with data on developmental toxicity 
is published as an abstract in The Toxicologist in 1994 (York and Schardein 1994). This publication 
was not possible to retrieve from PubMed or by a Google search (24/11-2017). In this study pregnant 
rats (n=30 per group) were exposed through whole-body inhalation to 100, 300 or 700 ppm D4 for 6 
hours per day for 4 weeks (GD6-15). A caesarean section was performed GD20 for assessment of 
developmental parameters. No effects were found on embryolethality, litter size, sex distribution and 
foetal body weight. Mean maternal food consumption was reduced as well as the body weight gain in 
the highest exposure group.  
Study quality and assessment:  
The study is performed under GLP with 30 females per dose-group and the study design was 
equivalent or similar to OECD Guideline 414 (Prenatal Developmental Toxicity Study) with some 
(unspecified) missing details. Overall the study seems to be of good quality, but as only a summary is 
available and details on data and methods are not given, the quality of the study cannot be assessed. 
The study provides no evidence of relevance for evaluating adverse effects related to endocrine mode 
of action.  
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002 Key Experimental results:  
Summary: The second key study in the REACH registration dossier for D4 with data on developmental 
toxicity was published in the same abstract in The Toxicologist in 1994 (York and Schardein 1994) as 
the data from the first key study on rats. The publication was not possible to retrieve from PubMed or 
by a Google search (24/11-2017). In this study 20 rabbits per group were exposed to D4 through 
whole-body inhalation of 0, 100, 300 or 500 ppm on GD6-18 or during different intervals in this 
gestational period. Decreased maternal food consumption was observed. No effects were found on 
mortality, malformations, developmental variations or body weight gain. Slight increase in 
postimplantation loss was seen but the levels were within historical control levels. No treatment-
related effects were found on the number of viable foetuses per dam, mean foetal body weight, foetal 
malformations or developmental variations. 
Study quality and assessment: The study is performed under GLP with 20 females per dose-group and 
the study design was equivalent or similar to OECD Guideline 414 (Prenatal Developmental Toxicity 
Study) with some (unspecified) missing details. Overall the study seems to be of good quality, but as 
only a summary is available and details on data and methods are not given, the quality of the study 
cannot be assessed. The study provides no evidence of relevance for evaluating adverse effects related 
to endocrine mode of action. 
 
Supporting Experimental results 
Summary: Several supporting experimental results are included in the REACH registration dossier of 
D4 on developmental toxicity and teratogenicity. Overall, the (3 GLP) studies showed decreased food 
consumption and reduced body weight gain in dams and 1 study showed increased abortions (from 
500 mg/kg) and increased post implantation loss (1000 mg/kg), but the reduced food consumption 
was considered responsible for these findings on reproduction. One study in rabbits showed decreased 
weight of gravid uterus and a reduced number of live foetuses (1000 mg/kg). 
Study quality and assessment: Three out of 5 studies were performed under GLP compliance with 6 
female rats or rabbits/ group and the study design was equivalent or similar to OECD Guideline 414 
(Prenatal Developmental Toxicity Study). Overall the studies seem to be of good quality, but as only 
summaries are available and details on data and methods are not given, the quality of the studies 
cannot be assessed. Two study summaries were retrieved from IUCLID and included in this part of 
the REACH registration dossier of D4 but very few information on those studies are available. They 
are not GLP compliant and no details on the doses or the number of animals used are given. In 
conclusion, the quality of the unpublished studies cannot be assessed based on the summaries 
available. The studies appears to provide strong evidence of maternal toxicity based on food 
consumption and body weight gain and weak evidence of reproductive adverse effects but no 
conclusion can be made on the relation to endocrine disruption. 
 
Toxicity to reproduction: other studies 
Summary: Fifteen additional studies on reproductive toxicity and in vitro studies on endocrine related 
activity are included in the REACH registration dossier for D4. Some of these refer to published 
papers already assessed here (Meeks et al. 2007, He et al. 2003, Quinn et al. 2007 and McKim et al 
2001). No significant additional data on fertility and reproduction are given on these studies in the 
REACH registration dossier compared to the published papers. The only supplemental information 
given in the REACH registration dossier for the published studies is reduced food consumption in 
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females with reduced weight gain. The remaining studies included supporting data published in the 
papers assessed above. In these studies, D4 had an estrogenic effect in MCF-7 cells and in the 
Uterotrophic assay, D4 exposure led to fewer ovulating female rats, attenuated the LH surges, 
decreased serum prolactin levels and in vitro studies showed a lack of receptor binding and receptor 
activation of PR. Some data appear to support the hypothesis that D4 may be a dopamine D2-receptor 
agonist. 
Study quality and assessment: Most of the studies are non-GLP studies and do not follow specific 
guidelines. The quality of the studies cannot be assessed based on the restricted information given in 
the summaries. The studies appear to provide strong evidence of an endocrine mode of action of D4 
on female reproductive system, including strong evidence of an estrogenic mode of action and strong 
evidence for adverse effects, although the mechanism behind reduced ovulations may be species 
specific.  
 
Repeated dose studies  
Summary: Overall, repeated dose toxicity studies with exposure to D4 through inhalation showed 
effects on the female reproductive tract. Several of the studies found decreased ovary weight, ovary 
atrophy/ hypoactivity and vaginal mucification. Additionally, increased uterus weight and endometrial 
epithelial hyperplasia was seen in a study after 24 months of D4 exposure. Some studies found 
increased weight of adrenal glands in females and vacuolation of zona fasciculate of the adrenal 
glands was shown. Effects were also observed in the male reproductive tract, more specifically the 
testes. One study showed increased testes weight without histopathological changes after 24 months 
of exposure while another study found testes tubular atrophy after exposure to D4 for 13 weeks. 
Study quality and assessment: The studies referred to above were all GLP compliant and followed a 
test guideline. In these studies 10 rats or more were used per group.   Overall the studies seem to be of 
good quality, but as only summaries are available and details on data and methods are not given, the 
quality of the studies cannot be assessed. The studies appear to provide strong evidence of 
reproductive adverse effects.  
 
Specific investigations: Other studies 
Summary: In vivo studies investigating effects of D4 on thyroid glands and on serum prolactin levels 
are included. One of the studies showed increased thyroid gland weights, hyperplasia and increased 
proliferation in thyroid glands after 6 or 13 days of exposure. No such effects were seen after 5 days 
of exposure. This suggests a proliferative effect of D4 on cells in the thyroid glands after continuous 
exposure. Other studies showed time-dependent effects on serum prolactin levels. No changes in 
prolactin levels were seen in any of the studies immediately after exposure. However, 18 hours after 
D4 exposure decreased prolactin levels were observed in one study whereas another study showed 
increased prolactin levels 4 and 8 hours after D4 exposure.  
Study quality and assessment: The studies are not performed under GLP compliance and do not 
follow any guidelines. The quality of the studies cannot be assessed based on the restricted 
information given in the summaries. The studies provide weak evidence of an endocrine mode of 
action of D4 based on effects on serum prolactin levels in vivo and hyperplasia in thyroid glands. 
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4.10.3.4 Summary of the plausible link between adverse effects and endocrine mode of 
action  
 
A large number of studies have found adverse effects on female reproductive organs and reproductive 
function in rodents (Table 2). Most studies were performed in adult rodents and only one study in the 
published literature investigated developmental effects (Siddiqui et al. 2007). The reproductive effects 
reported include reduced fertility, disturbed oestrous cycles, reduced ovulations, increased uterus 
weights with endometrial hyperplasia, vaginal mucification, reduced ovary weight and atrophy of 
ovaries. These effects could be related to an endocrine disrupting mode of action involving female 
reproductive hormones such as oestrogens, LH or FSH or a combination of these (OECD GD 106). 
No additional effects were found in offspring in the developmental study, but the effects appeared to 
be more marked than in adult females (Siddiqui et al. 2007). This could be due to more general 
toxicity in the offspring as evidenced by increased organ weights of liver, kidney and pituitary glands 
and histologically observed hypertrophy of hepatocytes, indicative of increased metabolising activity 
of the liver. The evidence of effects on reproductive function related to endocrine disruption observed 
in the developmental study is thus weak. Reproductive effects observed in adult animals in the other 
studies are more convincingly related to an endocrine disrupting mode of action and the studies 
provide strong evidence of adverse effects on female reproduction. 
One published paper and a study registered in the REACH registration dossier reported work that has 
been done to identify whether D4 could lead to changes in plasma LH levels and if the reduced 
ovulations and fertility observed in vivo could be related to such changes (Quinn et al. 2007b). Lower 
plasma LH peaks in non-ovulating females compared to controls was reported and it is very likely that 
the link between low LH peak levels and reduced ovulations can explain some of the effects observed 
on lower fertility in females (e.g. reduced litter size) and disturbed oestrous cycles (Siddiqui et al. 
2007; Meeks et al. 2007; Jean et al. 2017). However, disruption of the LH surge may be a species 
specific mode of action and thus the effects on ovulation may not be relevant to humans. 
In concordance with the observed adverse effects in females (e.g. uterus and vaginal changes), several 
in vivo and in vitro studies showed an estrogenic mode of action of D4, although some studies show 
conflicting data on the estrogenic effects in vivo (Table 1). Overall, in vitro studies showed binding to 
and activation of ERα and estrogenic effects at gene- and protein expression level in GH3 cells. 
Compared to the positive controls ethinyl estradiol and 17β-estradiol, D4 showed similar effects in 
vitro (i.e. gene- and protein expression of the estrogenic biomarker CaBP-9K and of ERα in pituitary 
GH3 cells) and in vivo (i.e. gene- and protein expression of the estrogenic biomarker CaBP-9K and of 
ERα in the uterus and increase in uterine epithelial cell height) and the effects were blocked by the 
anti-estrogenic (ERα inhibitor) substance ICI 182-780 both for the effects observed after exposure to 
D4 and the positive control (Lee et al. 20015; McKim et al. 2003). Other in vitro studies showed 
binding of D4 to ERα (but not ERβ) and activation of the ERα reporter gene assay (Quinn et al. 
2007a; He et al. 2003) and this was supported by estrogenic effects of D4 in MCF-7 cells reported in 
the REACH registration dossiers. 
Some conflicting data on in vivo estrogenic effects in the Uterotrophic assay have been reported. One 
study did not find effects of D4 on uterus weight in the assay (Lee et al. 2015), whereas other studies 
did (Quinn et al. 2007a; He et al. 2003; McKim et al. 2001). This could be explained by the 
administration route as D4 was dosed s.c. in the study by Lee et al. (2015) whereas first-pass 
metabolism was possible in two of the other studies, where exposure was conducted through oral 
gavage (HE et al. 2003; MicKim et al. 2001). Moreover, the studies that found increased uterus 
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weight in the Uterotrophic assay had a larger number of animals per group compared to the study 
performed by Lee et al. (2015). Supporting studies submitted by the applicant in the REACH 
registration dossier also showed an estrogenic effect of D4 in the Uterotrophic assay. The anti-
estrogenic compound, ICI 182-780, was shown to have an inhibiting effect on the increase in uterine 
weight after D4 exposure in the Uterotrophic assay, indicating an ER-mediated effects of D4 on the 
uterus (He et al. 2003). Conflicting data on estrogenic effects of D4 were also seen at the hormonal 
level in rat studies. Some studies showed reduced serum estradiol levels (Jean et al. 2017; He et al. 
2003), whereas another study showed increased estrone and 17β-estradiol levels in plasma (Quinn et 
al. 2007b). The lack of effect in the study by Jean et al. (2015) could be explained by the differences 
in dosing period. In the study by Jean et al (20017), exposure was conducted in aging females. In 
contrast, females in the Quinn et al. (2007b) study were in the reproductive stage (13 weeks old), and 
the data on hormone levels are evaluated to be more reliable in the study performed by Quinn and co-
workers (2007b). In summary, the weight of evidence of the available in vivo and in vitro studies 
point to an estrogenic mode of action of D4. Altogether, the published data provide strong evidence of 
estrogenic mode of action of D4 and strong evidence for adverse effects linked to anti-estrogenic 
mode of action of D4. 
In addition to the effects on female reproductive function and female reproductive organs, some 
studies reported adverse effects on male reproductive organs. Increased testis weight and histological 
changes of testis (i.e. testicular interstitial cell hyperplasia and testis tubular atrophy) were described 
in the REACH registration dossiers and in the published literature (Burns-Nass et al. 2002; Jean and 
Plotzke, 2017). However, studies on the androgenic or anti-androgenic mode of action of D4 are 
sparse. A Hershberger assay was performed in a single study but no signs of androgenic or anti-
androgenic activity of D4 were found (Quinn et al. 2007b). There is moderate evidence of adverse 
effects on male reproductive organs, but the mode of action behind the testicular effects is unclear. 
However, it could be speculated, that the estrogenic potential of D4 could play a role in the testis. 
Thus, there is weak evidence for a plausible link between the estrogenic mode of action of D4 and 
adverse effects on male reproductive organs. 
In addition to the above mentioned effects on reproductive organs, one mechanistic in vivo study 
reported in the REACH registration dossiers showed increased thyroid gland weights, thyroid 
hyperplasia and increased proliferation in thyroid glands. Based on this study there appear to be 
moderate evidence of a thyroid disrupting potential of D4, and more studies on these endpoints are 
necessary to conclude on this kind of endocrine disrupting capacity of D4. Thyroid hormones play a 
role in the regulation of prolactin and the effects observed on plasma prolactin levels (Quinn et al. 
2007b; REACH registration dossier) may be related to the thyroid gland effects reported in the 
REACH registration dossier. 
Summary and conclusions 
All in all there is strong evidence that D4 has adverse effects on the reproductive system as well as 
weak evidence of adverse effects on the thyroid gland. There is strong evidence for an estrogenic 
mode of action of D4, and strong evidence for adverse effects on female reproductive system that can 
be related to this estrogenic mode of actin of D4 together with an endocrine mode of action through 
LH. However, changes in LH levels may be species specific. Changes in LH levels are probably 
responsible for some of the adverse effects observed, but D4 also had a strong estrogenic activity and 
it is unclear which adverse effects can be linked to this mode of action alone. The male reproductive 
effects are likely related to an endocrine mode of action as well, but the few data available on 
androgen-related mode of action did not confirm an anti-androgenic mode of action of D4. It is 
possible that the estrogenic mode of action of D4 could be responsible for the testicular effects 
74 
 
observed. The mode of action behind the effects observed on thyroid glands cannot be determined 
based on the available data. 
In conclusion, D4 does meet the WHO definition of an endocrine disruptor with an estrogenic mode 
of action leading to adverse effects on the female reproductive system. 
 
Additional literature not included in the evaluation 
Reviews on D4 have been used to check for additional literature not found in our literature search 
(Dekant et al. 2017; Franzen et al. 2017). Both reviews referred to an abstract with in vitro data on 
ligand binding assays and reporter gene assay for progesterone receptors, but this abstract was not 
accessible (Jean et al. 2005). 
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Table 1. Overview of in vitro and in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of octamethylcyclotetrasiloxane (D4).  
Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
Jean et al. 
2017 
 Progesterone levels were elevated in exposed 
rats 2-10 weeks after start of treatment and 
estradiol was reduced over the total study 
period. As a consequence, lower 
estradiol:progesterone ratios compared to 
controls were found in D4 treated females. 
Corticosterone concentrations were increased 
in exposed animals during almost the entire 
study period. 
High Strong 
Lee et al. 2015  CaBP-9K gene expression was increased in 
GH3 cells exposed to E2 or D4. When cells 
were exposed to ICI 182-780 in 
combination with D4 or E2, the gene 
expression level of CaBP-9K was not 
affected. Protein expression of CaBP-9K 
was slightly increased by E2 and D4 but not 
when ICI was administered simultaneously. 
Similarly, PR gene- and protein expression 
levels were increased by D4 and E2, an 
effect that was blocked by ICI. Conversely, 
gene-and protein expressions of ERα were 
downregulated by E2 and D4 and ICI 
blocked the effect. 
In the Uterotrophic assay, no effects on uterus 
weight were seen with s.c. administration of 
D4. 
Gene- and protein expression levels of CaBP-
9K, an estrogenic biomarker, were increased in 
the uterus by EE and D4 and co-administration 
of ICI inhibited the effect. PR gene expression 
in the uterus was decreased by EE and the high 
D4 dose. ERα gene expression was reduced in 
the uterus by EE and D4. 
Gene expression of CYP2B1/2 in the livers 
was increased markedly compared to controls 
in the D4 dose-group in a dose-dependent 
manner.  
High Strong (in vitro)-
Weak (in vivo) 
Quinn et al. 
2007b  
 A decrease in plasma LH peak levels in female 
rats were related to the ovulatory status, i.e. 
lower mean levels of LH were related to a 
higher number of non-ovulators in the 
treatment groups. In ovulating females, 
prolactin levels were reduced. In the 900 ppm 
group. Plasma estrone and 17β-estradiol 
hormone levels were increased in both 
High Strong 
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Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
treatment groups (700 and 900 ppm). The ratio 
between estrone and 17β- estradiol was 
reduced in the 900 ppm group in non-ovulating 
females. FSH was decreased in both treatment 
groups. Progesterone was increased in the 
highest exposure group. 
Quinn et al. 
2007a 
Weak binding of D4 to ERα was observed. 
D4 did not bind to ERβ, PRα or PRβ. 
Activation of the ERα reporter gene assay 
was seen, whereas no activation of the PRβ 
reporter gene assay was observed for D4. 
 
In the Uterotrophic assay with inhalation 
exposure to D4, uterine weight was increased, 
uterus was fluid filled and had increased 
luminal and epithelial cell height in both 
strains tested. D4 but not ICI 182,789 showed 
weak anti-estrogenic activity. The Hershberger 
assay showed no androgenic or anti-
androgenic activity of D4. 
High Strong 
He et al. 2003  D4 bound competitively to ERα but not to 
ERβ in an ER binding assay. 
 
Serum oestradiol was reduced by 
approximately 50% by D4 exposure. In 
adrenalectomised (ADX) mice serum 
oestradiol was reduced with D4 exposure. D4 
exposure induced increased serum 
corticosterone in intact and sham operated 
mice, whereas corticosterone was reduced in 
ADX mice. D4 induced increased uterine 
weight in the Uterotrophic assay and increased 
uterine peroxidase activity. Pre-treatment with 
ICI 182,780 blocked the D4-induced increase 
in uterine weight, indicating that the effects on 
uterus weight are ER-mediated. Additionally, 
the D4 induced increase in uterus weight was 
absent in exposed αERKO mice.  
High 
 
Strong 
McKim et al. 
2001 
 Body weight was decreased in the highest D4 
dose-group. Uterus weight was significantly 
increased by 250, 500 and 1000 mg/kg/day of 
D4. Co-administration of D4 with EE 
Medium Strong 
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Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
attenuated the effect of EE on uterine weight 
suggesting an anti-estrogenic effect of D4. D4 
inhibited the effect of EE on uterine weight. 
Uterine epithelial cell height was increased by 
EE and D4 in a dose-dependent manner.  
REACH 
registration 
dosier, 
Toxicity to 
reproduction: 
other studies 
An estrogenic effect of D4 was found in 
MCF-7 cells. 
A lack of receptor binding and receptor 
activation of PR was found for D4. 
An estrogenic effect of D4 was found in the 
uterotrophic assay.  
Moreover, D4 attenuated the LH surges and 
decreased serum prolactin levels. 
Not assessable Appears to be strong 
REACH 
registration 
dossier, 
Specific 
investigations 
 Studies showed time-dependent effects on 
serum prolactin levels. No changes in prolactin 
levels were seen in any of the studies 
immediately after exposure. However, 18 
hours after D4 exposure decreased prolactin 
levels were observed in one study whereas 
another study showed increased prolactin 
levels 4 and 8 hours after D4 exposure. 
Not assessable Weak 
Ethinyl estradiol (EE); 17β-estradiol(E2), estrogen receptor (ER);  progesterone receptor (PR), luteinizing hormone (LH).  
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Table 2. Overview of potential endocrine-related adverse effects of octamethylcyclotetrasiloxane (D4). 
Reference Species, n Adverse effects Quality of study  Evidence for 
adverse effects 
Jean and 
Plotzke, 2017  
 
Rats, 
n=60/sex/group 
Uterine and testis weights were increased in animals in the 700 ppm 
group exposed through inhalation for 24 months. An increased incidence 
of uterine cystic endometrial hyperplasia was found in high-dose 
females. Small but statistically significantly increased incidence of 
cervical squamous epithelial hyperplasia and/ or ovarian atrophy was 
observed. Similarly, a modest but significant increase in the incidence of 
testicular interstitial cell hyperplasia was observed after 24 months of 
exposure to 150 and 700 ppm D4. 
 
High Moderate 
Jean et al. 
2017 
Rats, 
n=50/group 
Increased number or percent of estrogen-predominant days (proestrous 
and estrous) in the estrous cycle was found in D4 treated animals 
compared to controls. A marked decrease was observed in the incidence 
of antral-size atretic follicles and an increase in severity was observed 
for vaginal mucification. 
High Moderate 
Lee et al. 
2015 
Rats, 
n=5/group 
D4 but not ethinyl estradiol increased the relative liver weights in 
immature female rats after s.c. exposure for 4 days.  
Medium Weak 
Meeks et al. 
2007 
Rats, 
n=24/group or 
60/group 
Decreased fertility was observed in female rats exposed at a time-point 
close to mating and fertilisation or when the exposure period included 
this time-point.  
High Strong 
Siddiqui et al. 
2007 
Rats, n=23-27 
litters/ group in 
the first 
generation 
Reproductive parameters were adversely affected, e.g. reduced number 
of litters, reduced number of pups per litter and extended oestrous 
cycles.  
High Moderate 
Quinn et al. 
2007b 
Rats, n=22-27 
in phase I, 
n=31-35 in 
phase II 
Body weight was reduced in both treatment groups (700 and 900 ppm) 
in phase I and in the highest exposure group in phase II. The absolute 
ovary and relative ovary and uterus weights were reduced in the highest 
exposure group in phase II as well as the ovary relative to brain weight. 
More non-ovulating females were seen in the treatment groups. 
Histological assessment of ovaries showed a tendency to increased 
number of large antral follicles, which correlated well with the increased 
estradiol levels. The number of ova found in the oviducts was reduced in 
High  Strong 
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Reference Species, n Adverse effects Quality of study  Evidence for 
adverse effects 
the treated groups compared to controls, but not in the ovulating 
females. 
Burns-Nass et 
al. 2002 
Rats, 
n=20/group 
Ovary weight was decreased in the 898 ppm group and histopathological 
evaluation of the ovaries showed an increased incidence of hypoactivity 
in the 898 ppm dose-group after a 3 months exposure period. Increased 
incidence and thickness of mucification of the vaginal mucosa was seen 
in the uterus in females exposed to 898 ppm. Testes weight was 
increased in the 488 ppm group but not at the highest dose, and the 
change was considered not to be exposure related. 
High Strong 
REACH 
registration 
dossier, 
toxicity to 
reproduction 
Rats, n=20-22/ 
group 
The studies show decreased weight gain and food consumption in adult 
rats and adverse effects on reproduction (e.g. reduced mean litter size, 
reduced pup viability and reduced number of implantation sites). 
Not assessable Strong 
REACH 
registration 
dossier, 
developmental 
toxicity 
Rats, n=30 
females/group 
Maternal toxicity was observed as reduced food consumption and 
reduced body weight gain in the 700 ppm group. 
Not assessable None 
REACH 
registration 
dossier, 
developmental 
toxicity 
Rabbits, n=20/ 
group 
Decreased maternal food consumption was observed. Slight increase in 
postimplantation loss was seen but the levels were within historical 
control levels. 
Not assessable None 
REACH 
registration 
dossier, 
Repeated 
dose: 
inhalation 
Rats, n=10 or 
more/group 
Several of the studies found decreased ovary weight, ovary atrophy/ 
hypoactivity and vaginal mucification. Additionally, increased uterus 
weight and endometrial epithelial hyperplasia was seen in a study after 
24 months of D4 exposure. Some studies found increased weight of 
adrenal glands in females and vacuolation of zona fasciculate of the 
adrenal glands was shown. One study showed increased testes weight 
without histopathological changes after 24 months of exposure while 
another study found testes tubular atrophy after exposure to D4 for 13 
weeks 
Not assessable Strong 
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Reference Species, n Adverse effects Quality of study  Evidence for 
adverse effects 
REACH 
registration 
dossier, 
Specific 
investigations 
NA Increased thyroid gland weights, hyperplasia and increased proliferation 
in thyroid glands after 6 or 13 days of exposure. No such effects were 
seen after 5 days of exposure, suggesting a proliferative effect of D4 on 
cells in the thyroid glands after continuous exposure.  
Not assessable Weak 
NA: not applicable (e.g. if represents several studies) 
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Figure 1. 2D structure from 
https://www.huidziekten.nl/allergie/stoffen
/tricresyl-phosphate.htm  
Tris(methylphenyl)phosphate (TMPP), 
CAS no. 1330-78-5 
 
Synonyms: Tricresyl phosphate (TCP)  
TMPP is a mixture of the 3 isomers ortho-, metha-, 
and para cresols (Figure 1) and is used in the 
manufacturing of e.g. plastics, organophosphate flame 
retardants and solvents. TMPP is registered under 
REACH with a tonnage band of 1 000 - 10 000 tonnes 
per annum and is classified as Rep. 2 or self-
classification as Repr. 1B; H360: May damage fertility 
or the unborn child . It is used in a variety of products 
such as furniture, electronics, textiles etc., and has 
been detected in the environment and in humans. The 
ortho isomer of TMPP, known as tri-ortho-cresyl 
phosphate (TOCP), is the most toxic of the 3 isomers 
and have been identified to cause neurotoxicity in 
humans and susceptible animals. 
 
4. Human health hazard assessment 
4.10.3 Endocrine disruption 
4.10.3.1 General approach – human health 
4.10.3.2 In vitro information indicative of endocrine activity 
Reers et al. (2016)  
Summary: In the present study, the effects of 6 organophosphate flame retardants (OPFRs), including 
TMPP (CAS no. 1330-78-5, purity not reported), on androgen receptor (AR), estrogen receptor (ER) 
and aryl hydrocarbon receptor (AhR) agonism and antagonism in vitro were studied. AR-mediated 
gene expression was studied by exposing metastatic prostate cancer LNCaP cells to chemicals in 
doses between 0.01-20 µM and measuring mRNA and protein accumulation. Effects on ERα and AhR 
were studied in endometrial carcinoma cells (ECC-1 cells), at the same dose ranges. For both studies 
both the agonistic activity and the antagonistic activity (with positive controls: E2 for ER activity in 
ECC-1, TCDD (a dioxin) for AhR activity, and R1881 (synthetic androgen) for AR-activity in LNCaP 
cells). TMPP did not cause any effects on AR or ERα and AhR gene expression in the exposed 
LNCaP and ECC-1 cells, respectively, in both the agonistic and antagonistic mode. 
Study quality and assessment: The material and methods section is not explicit with missing 
information on the measured mRNA and proteins in the two cell lines, purity of the tested chemicals, 
cytotoxicity information. The results from the first part of the study are also not explicitly presented. 
Overall, the quality of this study is assessed to be low. The evidence for lack of ERα, AR or AhR 
agonism or antagonism is weak due to the low quality of the study.  
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Schang et al. (2016)  
Summary: In the present study, the effects of 7 OPFRs, including TMPP (CAS no. 1330-78-5, purity 
not reported), on MA-10 mouse Leydig tumor cells were compared to those of the brominated flame 
retardant BDE-47. First cell viability and cell count was assessed after exposing the MA-10 cells for 
48h with 0, 1, 2, 5, 10, 20, 50 and 100 µM TMPP. Next, cells were treated with 0, 10.1, 1 and 10 µM 
TMPP for 48 h followed by measuring the superoxide production. Similarly the production of 
progesterone was assessed, both with cells only exposed to TMPP for 48 h, or TMPP and 2h post-
treatment with dbcAMP (1 mM) or luteinizing hormone (LH) (100 ng/ml), and the progesterone 
production was normalized to cell number. Finally, the MA-10 cells were exposed to 10 µM TMPP 
for 48 h with or without 2 h post treatment with dbcAMP or LH, and the quantification of the 
following steroidogenesis related genes: Star, Tspo, Hsd3b, Lhcgr, Cyp11a1, Adcy3. Each test was 
run in 5-7 independent experiments. TMPP significantly decreased cell viability at concentrations of 
20 µM or above and reduced the cell number at all tested concentrations except at 2 µM. Superoxide 
and progesterone production was increased in the 10 µM dose, but no significant effects were seen on 
the gene expression on steroidogenic genes.  
Study quality and assessment: The study well-described and –designed and only information on the 
purity of TMPP is missing. Overall, the study is assessed to be of high quality. The study provides 
moderate evidence of a steroidogenic MoA due to increased progesterone production although the 
exact mechanisms underlying this effect were not identified. 
 
Bradley et al. (2015)  
Summary: The present study used chicken eggs to test TMPP (CAS no. 1330-78-5, ≥89.0% purity) for 
effects on chicken embryo neurodevelopment. On day 0 of incubation, eggs were injected into air cell 
with 50 µM TMPP in dimethyl sulfoxide (DMSO) in doses of 0 (n=15), 10, 100 or 1000 ng/g egg 
(n=20/dose group), or used as a non-injected control ((n=15). Incubation mortality, successful pipping 
and hatching were recorded. At day 7 through 9 post-hatching the chicks were tested in multiple 
behavioural tests such as open field, righting reflex, angled balance beam, gait analysis and wing flap 
reflex to assess their locomotor function, fear, desire for social reinstatement, motor reflexes, 
coordination, balance, and neuromuscular strength. At day 10 post-hatching, the chicks were 
euthanized and left cerebrum was used for cholinergic analyses, while cerebellum was used for 
histological evaluation of purkinje cell number.  
The two control groups, non-incubated and DMSO incubated did not show any differences and were 
combined into a single control group.  TMPP did not affect, survival or hatching, and no treatment 
effects were seen in the behavioural tests, except for a non-significant decreased righting reflex in the 
10 ng TMPP/g egg. On histology, a non-significant increase in the number of cerebellar purkinje cells 
were observed at the highest 1000 ng/g egg group.  
Study quality and assessment: Overall the study is well described and assessed to be of high quality. 
The study provides no evidence for ED MoAs and only very weak evidence for neurodevelopmental 
effects in chickens. 
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Crump et al. (2014)  
Summary: The present study used chicken eggs to test TMPP (CAS no. 1330-78-5, 93.1% purity) for 
effects on chicken embryo development. In total 110 fertilised chicken embryos were used; 20 for 
dimethyl sulfoxide (DMSO) control, 10 for 7.8 ng/g, 20 for 780 ng/g, 8600 ng/g, 43,700 ng/g and 
261,400 ng/g, respectively. Pipping success was calculated as the number of pippings by day 22 
divided by the number of total fertile eggs per treatment group. Time to pip was also recorded. At day 
22, embryos were euthanized and tarsus length, body mass and liver mass was assessed and liver 
somatic index (LSI = liver mass / body mass * 100) was calculated. Thyroid glands were harvested 
from the first 6-8 embryos and used for thyroxin (T4) measurement. The hepatic right lobe was 
removed and used for RNA extraction (n=8/treatment group) of CYP2H1, CYP3A37, deiodinase 1, 2 
and 3, insulin-like growth factor 1 (IGF1), liver basic fatty acid-binding protein (LFABP), 
transthyretin (TTR) and uridine 5’-diphospho-glucuronosyltransferase 9 (UGT1A9). Whole blood 
was collected for free T4, bile acid and genetic sex determination. Pipping success in TMPP treatment 
groups were unaffected but an increase in deformities was observed in the embryos in the highest 
dose group, including reduced tarsus length and increased LSI with discoloured livers. TMPP up-
regulated CYP2H1 and CYP3A37, UGT1A9 (not significant) and LFABP and downregulated TTR, 
as well as affected a number of other genes in the liver. T4 levels in plasma and thyroid glands were 
unaltered, but bile acid concentration in plasma was increased in the highest dose group. 
Study quality and assessment: The study is well-described and assessed to be of high quality. The 
study provides only very weak evidence of ED MoAs due to effects on TTR gene levels as well as 
enzymes that could regulate hormone turnover. 
 
Kojima et al. (2013)  
Summary: In the present study, the effects of 11 OPFRs, including TMPP (here one of the TMPP 
isomers tricresyl phosphate (TCP) with CAS no. 78-30-8, >98% purity), on the agonistic and 
antagonistic activity on human nuclear receptors were studied. A transiently transfected CHO-K1 
(Chinese hamster ovary cell line) cell-based transactivation assays were used for testing the agonistic 
and antagonistic activities of 1·10-7-3·10-5 M TCP on estrogen receptor (ER)α, ERß, androgen 
receptor (AR), glucocorticoid receptor (GR), retinoic acid receptor (RAR)α, retinoic X receptor 
(RXR)α and thyroid hormone receptor (TR)α and ß. Likewise, the simian kidney COS-7 cell-based 
reporter gene assay was used to test TPC’s activity against pregnane X receptor (PXR), peroxisome 
proliferator-activated receptor (PPAR) α and PPARγ. All assays were run in 3 independent 
experiments. TCP showed sight cytotoxicity in both the CHO-K1 and COS-7 cells at the highest 
concentration of 3·10-5 M. In the CHO-K1 cells, TCP was a weak ERα agonist, an anti-androgen 
against 5α-dihydrotestosterone (DHT)-induced AR activity, and antagonized hydrocortisone (HC)-
induced GR activity. No effects on ERß, RARα, RXRα, TRα and TRß activity were measured. I the 
COS-7 cells, TCP caused PXR agonism and slight PPARγ agonistic activity but no PPARα activity.  
Study quality and assessment: The description of the material and method section could be more 
detailed and include more information on the agonism and antagonism modes of the assays. Also, the 
exact doses are not reported but can be read from the figures. Overall, the study quality is assessed to 
medium. The study provides moderate evidence for multiple ED MoAs of TCP, including oestrogenic 
and anti-androgenic activity, as well as GR antagonism and PXR agonism. 
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Liu et al. (2012)  
Summary: The present study investigates the effects of 6 OPFRs, including TMPP (here TCP, CAS 
no. 1330-78-5, 90% purity), on steroidogenesis in H295R cells, estrogenicity or anti-estrogenicity in 
MVLN cells, and hormone levels and syntheses in zebrafish. Here only the experiments in the H295R 
and MVLN cells are presented. H295R cells were exposed to 0.0, 0.001, 0.01, 0.1,1, 10 and 100 mg/L 
TCP for 48 hrs. First cytotoxicity was assessed in the MTT bioassay, and the non-cytotoxic doses 
were further evaluated for effects on hormone production. Next, 0.0, 0.001, 0.01, 0.1, 1 and 10 mg/L 
TCP was tested for estrogen receptor (ER) binding as well as ER antagonism using 100 nM 17ß-
estradiol (E2) in the MVLN luciferase assay. Here also only doses below cytotoxicity were evaluated. 
All experiments were run in 3 replicates. 
TCP caused cytotoxicity at concentrations of ≥10 mg/L in both the H295R and MVLN cells. In the 
H295R cells, TCP increased E2 (≥0.01 mg/L) and testosterone (T, ≥0.1 mg/L) production, and 
resulted in an increased E2:T-ratio at 0.01 and 1 mg/L. TCP induced transcription of CYP11A1 (≥0.1 
mg/L), CYP11B2, CYP19A1 and HSD3ß2 at 1 mg/L, and down-regulated gene transcription of 
SULT1E1 and SULT 2A1 at 1 mg/L. In the MVLN cells TCP did not bind to ER but significantly and 
in a concentration-dependent manner reduced the binding of E2 to ER. 
Study quality and assessment: The study is well-described and thorough and assessed to be of high 
quality. It provides strong evidence of both a steroidogenic and anti-oestrogenic MoA of TCP in 
human cells lines. 
 
4.10.3.3 In vivo effects with regard to an endocrine mode of action  
Bolon et al. (1997)  
Summary: This is an additional study using ovaries from mice tested previously in the NTP 
Reproductive Assessment by Continuous Breeding (RACB) bioassays for 15 different chemicals, 
including TMPP (here TCP, CAS no. and purity not reported). The testing and reproductive outcomes 
of TCP in the RACB assay has been described in Chapin et al (1988) and summarised in an NTP 
RACB report. In the present study, the ovaries from the exposed and control animals were sectioned 
and the number of follicles at 3 different stages were counted. Up to five experienced technicians 
performed the follicle counts, and the variation between pairs of technicians ranged from 0-30%. 
Then the results of the follicle counts were compared with the reproductive outcomes from the RACB 
study.  
TCP has been shown to cause decreased fertility in both male and female mice (Chapin et al.1988), 
but no effects on the follicle counts at the tested TCP doses were seen in the present study. 
Study quality and assessment: The study is well-described, although the CAS no. and purity of the 
chemical is not stated. Also it should be noted that the large interobserver variation of up to 30% 
might have affected the results. Overall, the study is assessed to be of medium quality. No ovarian 
toxicity of TMPP was observed in the present study and this effect can therefore not explain the 
reduction in female fertility in mice seen after TMPP exposure. No other potential MoAs underlying 
the reduced female fertility were explored and the present study therefore does not provide any 
evidence of an ED MoA. 
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Latendresse et al. (1995)  
Summary: The study investigated the functional effects of TMPP (here TCP, CAS no. 1330-78-5, no 
purity reported) and butylated triphenyl phosphate (BTP) induced adrenal and ovarian tissue changes 
on hormone levels and oestrous cycle in intact, adult female rats. First, female rats were exposed to 
0.0 or 0.4 g/kg TCP by a single oral dose for 20 (n=9), 40 (n=6) or 60 days (n=3). Vaginal cytology 
was taken daily to study the effects of TCP on oestrous cycle. Next, female rats were exposed to 0.0 
or 0.4 g/kg TCP by a single oral dose for 20 days (n=12), and blood samples, ovaries and adrenal 
glands were used after killing the animals. Estradiol, androstenedione and corticosterone 
concentration in serum was analysed as was cholesterol, high-density lipoproteins (HDL), low-density 
lipoproteins (LDL), alanine transaminase, albumin and total protein. The TCP exposed rats had 
normal oestrous cycle. Histopathological changes in the adrenal glands and ovaries were seen and it 
was hypothesized that these changes could alter steroid hormone production and metabolism. 
Estradiol levels were elevated but no other effects were seen on hormone levels 
Study quality and assessment: Overall the study is thorough, however the purity of the tested 
compound is not clear and only a single dose of TMPP was tested. Based on this the quality of the 
study is assessed to be of medium quality. The study provides moderate evidence for effects on 
female estradiol production or metabolism but the exact MoA(s) behind the elevated estradiol levels is 
not elaborated. The evidence for female reproductive adverse effect are moderate due to the 
histopathological changes in the ovaries. It is hypothesized that these may result in altered steroid 
hormone production or metabolism. 
 
Latendresse et al. (1994a)  
Summary: The present study investigates the effect of TMPP (here TCP, CAS no. 1330-78-5, no 
purity reported) and butylated triphenyl phosphate (BTP) on rat testes, ovaries and adrenal glands. 
Sexually mature male and female rats were exposed to 0.0 or 0.4 g/kg TCP by a single oral dose for 
20, 40 or 60 days (n=3/sex/dose group). After the exposure period, the rats were sacrificed and 
ovaries, testes, epididymides and adrenal glands were excised and weighed and then undergoing 
different histological examinations. 
No macroscopic changes in the ovaries were seen but at the microscopic level the ratio of interstitial 
tissue to follicles and corpora lutea was increased and the ovarian interstitial cells from all TCP-
exposed female rats were larger than the control group. The weight of testes from the 60 days TCP 
exposed rats was decreased, and the seminiferous tubules showed altered morphology in all TCP-
exposed animals. The adrenal glands of both TCP-exposed female and male rats were enlarged and 
had morphological changes. Due to an editorial error in the manuscript in the form of a picture 
covering text, tables and figures the remainder of the results section cannot be evaluated here. 
Study quality and assessment: Apart from the editorial error, the study is well-described. There is only 
3 animals per group and only 1 dose of TMPP is tested, and the purity of TMPP is not reported. With 
these limitations the quality of the study is assessed to be medium. The study provides strong 
evidence of ovary and testicular toxicity as well as effects on the adrenal glands in rats, but it does not 
study the underlying MoAs and it is therefore not clear if the adverse effects are due to ED MoAs.  
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Latendresse et al. (1994b)  
Summary: The present study investigates the effect of TMPP (here TCP, CAS no. 1330-78-5, no 
purity reported) and butylated triphenyl phosphate (BTP) on female and male rat reproductive 
performance using a modified NTP continuous breeding protocol. First, sexually mature male and 
female rats were paired and exposed to 0.0 (n=40 pairs) or 0.4 g/kg TCP (n=20 pairs) by a single oral 
dose for 7 days pre-breeding, 63 days during breeding and 28 days post breeding. Body weight, 
fertility, litters/pair, live pups/litter, gender and mean weights of pups were registered. Next, the rats 
were used in an 8 days cross-mating study with either: control males x control females, TCP males x 
control females or TCP females x control males (n=20/pairs/group). Vaginal plug and smears for 
sperm as well as oestrous stage was assessed daily. Then all F0 animals were sacrificed and ovaries, 
testes, epididymides, vagina and uterus, liver and adrenal glands were excised and weighed. The body 
weights of all exposed rats were significantly decreased as was the number of litters/pair and live 
pups/litter. In the cross-mating study only the exposed males showed a reduced fertility with no litters 
produced. No effects on reproductive performance of the exposed females were seen. Both sexes had 
increased adrenal gland and liver weights. The treated males had lower testicular and epididymal 
weights, while the ovaries in the treated females had increased weights.  
Study quality and assessment: Overall the study is thorough, however the purity of the tested 
compound is not clear and only 1 dose of TMPP was tested. Based on this the quality of the study is 
assessed to be of medium quality. The study provides moderate evidence of male reproductive 
adverse effects of TMPP as well as testicular and ovarian toxicology but does not study the 
underlying MoAs and it is therefore not clear if the adverse effects are due to ED MoAs.  
 
Chapin et al. (1988)  
Summary: This study evaluates the effect of TMPP (here TCP, CAS no. 1330-78-5, purity 74.9%) on 
reproductive performance in mice and consists of 4 tasks: 1) a range finding 14-day study, 2) a 98-
days continuous breeding study, 3) a cross-mating study with F0 animals from 2), and 4) an offspring 
assessment of F1 animals.  In 1), adult mice were exposed to 0.0, 0.437, 0.875, 1.75, 3.5 or 7.0% 
TMPP via feed for 14 days (n= 8/sex/group), and based on signs of toxicity and mortality the doses 
for 2) were set. In 2), animals were put in to breeding pairs and exposed to 0.0 (40 breeding pairs), 
0.05, 0.01 or 0.2% TMP (corresponding to approximately 62.5, 125, and 250 mg/kg/day, 20 
pairs/dose group) via feed for 98 days. After the last litter was reared, the F0 animals were used in a 
cross-mating study, i.e. task 3, to determine the affected sex in the F0 animals. Three groups were 
formed: control males paired with control females, control males paired with 0.2% TMPP females, 
and control females paired with 0.2% TMPP males. Following this the F0 animals were necropsied. 
The last litters from the control, 0.5% and 0.1% TMPP groups in task 2) were used in task 4) to study 
the effects on the F1 animals. When the F1 animals were sexually mature they were paired with an 
opposite sex from the same dose group but another litter and kept until first delivery. In 1) Doses of 
1.75% or above resulted in general toxicity and increased mortality. In 2), the highest dose of 0.2% 
TMPP resulted in hind limb weakness and reduced postpartum weights in the females, and increased 
number of dead pups, as well as reduced litters/pair, and pub BW. In 3) the fertility of both males and 
females was affected. The sperm motility and concentration were decreased, and the number of 
abnormal sperm was increased. Atrophy was seen in the seminiferous tubules. In 4) there was a trend 
toward lower mating and fertility indexes, and the number of live pups/litter was decreased in the 
0.1% TMPP F1 pairs. Sperm motility was decreased and number of abnormal sperm increased in F1 
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males but the number of sperm s were unaffected. No histopathological changes in the reproductive 
organs were found.  
Study quality and assessment: Overall the study is thorough, but it is not clear how many animals that 
were used in 3) and 4). Also the exact ages of the animals used in 2) and 3) is not clear from the text 
but can in most cases be read from the tables. Based on this the quality of the study is assessed to be 
of medium quality. The study provides moderate-strong evidence of male and female reproductive 
adverse effects of TMPP as well as effects on offspring reproductive performance but does not study 
the underlying MoAs and it is therefore not clear if the adverse effects are due to ED MoAs.  
 
Carlton et al. (1987)  
Summary: The present study evaluates the reproductive toxicity of TCP. Male Long Evans rats 4-6 
weeks old were given 0, 100 or 200 mg/kg TCP (CAS no. and purity not reported) per day by oral 
gavage for 56 days prior to breeding and during the 10 days breeding period and were then killed and 
blood, the reproductive tract and sperm were examined (n=12/dose group). Female Long Evans rats 
age 4-6 weeks were treated with 0, 200, 400 mg/kg per day by oral gavage 14 days prior to breeding, 
during breeding, gestation and lactation until killed at postnatal day 21, where blood and the 
reproductive tract were examined (n=24/dose group). One male was mated with 2 females: 0 mg/kg 
males with 0 mg/kg females, 100 mg/kg males with 200 mg/kg females, and 200 mg/kg males with 
400 mg/kg females. Blood and hormone analyses were made on the litters at PD 21.  No clinical signs 
of toxicity were detected in the male and female F0 animals at all doses. The fertility rates of TCP 
exposed rats were remarkably reduced compared with the controls. The 200 mg/kg TCP exposed male 
rats showed adverse reproductive effects with reduced epididymis weights, necrosis and degeneration 
of seminiferous tubules, and reduced sperm concentration, motility and progressive movement, and 
increased abnormal morphology.  Histopathological alterations were found in the ovaries of 400 
mg/kg TCP exposed females. 
Study quality and assessment: Overall the study is thorough and well-described, although no 
information on the CAS no. and purity of TCP is reported. The study is assessed to be of medium 
quality. The study provides strong evidence of male and female reproductive adverse effects of TCP 
but does not study the underlying MoAs and it is therefore not clear if the adverse effects are due to 
ED MoAs.  
 
Somkuti et al. (1987a)  
Summary: A 14 day dose-range study was conducted on tris-o-cresyl phosphate (TOCP, the most 
toxic isomer of TMPP, 99% purity, no CAS. no. reported) followed by a 63 day sub-chronic study of 
TOCP and tris-p-cresyl phosphate (TPCP, less  toxic isomer of TMPP, 97% purity, no CAS. no. 
reported). In the 14 day study, adult male Fischer were exposed to 0, 100, 200, 400, 800 or 1600 
mg/kg TOCP for 14 days (n=8/dose group), and 2 animals/group were prepared for histopathology, 
and the remaining 6 animals were used for other assays. Next, a 63 day dose-response study was 
performed by exposing rats to 0, 10, 25, 50, 75 or 100 mg/kg TOCP or 100 mg/kg TPCP daily 
(n=10/group). Five animals from each dose group were used for histopathology of testes and 
epididymis, and the remaining 5 animals were used for other assays: activity of nonspecific testes 
esterase (NSE) and neurotoxic esterase (NTE) was measured in testes, sperm motility, density and 
morphology were assessed, interstitial testis fluid testosterone levels was measured. 
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In the 14-day study dose-dependent increase in mortality and cholinergic toxicity were seen in 
animals exposed to ≥ 200 mg/kg TOCP, and a decrease in sperm density and testicular histopathology 
were observed in all animals treated with TOCP. In the 63-day study, animals treated with ≥50 mg/kg 
TOCP showed decrease in weight gain and testis:body weight ratio as well as dose-dependent 
decreases in sperm motility and density and increase in abnormal sperm morphology. Histopathology 
in testes and epididymis were seen at doses ≥ 25 mg/kg TOCP, and TOCP also resulted in decreased 
NTE (≥50 mg/kg) and NSE (≥10 mg/kg) activity. In the TPCP group, only lower sperm density was 
observed.  
Study quality and assessment: Overall the study is thorough and well-described, however it is only the 
TOCP and TPCP isomers that are tested here. It is not always clear from the material and methods 
section, which analyses were performed in the 2 studies. Due to these shortcomings, the study is 
assessed to be of medium quality. The study provides strong evidence of testicular toxicity and male 
reproductive adverse effects of TOCP in rats but does not study the underlying MoAs and it is 
therefore not clear if the adverse effects are due to ED MoAs.  
 
Somkuti et al. (1987b)  
Summary: In the present study changes in rooster testis histopathology, biochemistry and sperm 
motility after tris-o-cresyl phosphate (TOCP, the most toxic isomer of TMPP, 99% purity, no CAS. 
no. reported) TOCP oral exposure was studied. Adult leghorn roosters were treated with corn oil 
(n=10), a single oral dose of 750 mg/kg TOCP and killed after 24 h or 18 days (n=3/group), or 100 
mg/kg daily TOCP for 18 days (n=10). Brain, plasma, and left testis were removed quickly after the 
animals were dead and brain acetylcholinesterase (AChE), testis nonspecific esterase (NSE), testis 
neurotoxic esterase (NTE), and plasma butyrylcholinesterase (BuChE) were measured. Sperm 
motility and density were assessed. No clinical signs of toxicity was observed in the single dose 750 
mg/kg 24h treatment group, but in the 750 mg/kg 18 days treatment group and the 100 mg/kg daily 18 
days treatment group, signs of neurotoxicity was observed. Sperm motility and density were 
remarkably reduced in the 100 mg/kg daily treated group and in this group 50% of the 10 roosters has 
disorganized seminiferous epithelium. Inhibition of testis NSE activity was reduced in the 750 mg/kg 
24 h treatment group, and the NTE activity was reduced in 750 mg/kg 24 h treatment group and the 
100 mg/kg daily 18 days treatment group.  
Study quality and assessment: Overall the study is thorough and well-described, however it is only the 
TOCP isomer that is tested here. The study is assessed to be of strong quality. The study provides 
moderate evidence of testicular toxicity and male reproductive adverse effects of TOCP in roosters 
but does not study the underlying MoAs and it is therefore not clear if the adverse effects are due to 
ED MoAs.  
 
Somkuti et al. (1987c)  
Summary: The aim of the present study was to characterize the time course of tris-o-cresyl phosphate 
(TOCP, the most toxic isomer of TMPP, 99% purity, no CAS. no. reported) induced testicular 
toxicity. Male Fisher 344 rats were exposed to 0 or 150 mg TOCP/kg for 3, 7, 10, 14 and 21 days 
daily. Body weights and clinical signs were noted during exposure. At the end of exposure, the 
animals were killed and trunk blood, brain and testes were sampled. A second group of 10 animals 
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were used in a recovery study and first treated for 21 days, 2 were killed, the rest were allowed 98 
days of recovery before they were killed and examined. 
No clinical signs of toxicity were observed in any animals, but a decrease in sperm number was seen 
after 10 days of exposure and sperm motility was reduced after 14 days exposure. The testis to body 
weight ratio was decreased in rats exposed for 21-days. The testis enzyme nonspecific esterase and 
neurotoxic esterase activities were reduced at all the time points. No effects on serum LH, FSH or 
testosterone levels were seen. In the recovery study, the sizes of testes in the TOCP treated groups 
were decreased and they were devoid of germinal cells indicating irreversible testicular toxicity of 
TOCP. 
Study quality and assessment: Overall the study is thorough and well-described, however it is only the 
TOCP isomer that is tested here. The study is assessed to be of strong quality. The study provides 
strong evidence of irreversible testicular toxicity and male reproductive adverse effects of TOCP in 
rats but does not study the underlying MoAs and it is therefore not clear if the adverse effects are due 
to ED MoAs.  
 
REACH dossier  Toxicity to reproduction:  
All applicant-reported data are from published studies that have already been included here. 
 
Developmental toxicity / teratogenicity: 
001 Key | Experimental results 
Summary: The applicant reported information originates from an unnamed study report from 2004 
and is from a Prenatal developmental toxicity study (EPA OPPT 870.3700). Briefly, adult male and 
female rats were mated, and females evident of mating were selected for further studies. They were 
then dosed daily by oral gavage with TCP (CAS no. reported in the dossier, purity not stated) from 
gestation day 10 to 19 with 0, 20, 100, 400 or 750 mg/kg/day and sacrificed on GD 20. Clinical signs 
of toxicity, body weights, fertility and gravid uterus weight were some of the endpoints reported. The 
foetuses were weighted and examined for malformations macroscopically and by histology. 
The pregnant dams showed salivation from 100 mg/kg, decreased body weight/ (gain) and lower 
gravid uterus weights from 400 mg/kg/day. The foetuses in all treatment groups had lower weight 
with a dose-related response. No malformations in relation to the doses were observed. 
Study quality and assessment: The study was performed under GLP and followed the EPA OPPT 
870.3700 guideline, but since this is only a summary of a study report an assessment of the quality is 
not possible. The study however does not provide any evidence for ED related MoAs or adverse 
effects. 
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4.10.3.4 Summary of the plausible link between adverse effects and endocrine mode of action  
Some ED MoAs for TMPP have been reported in both in vitro and in vitro studies (Table 1), 
including effects on steroidogenesis in vitro with increased oestrogen, progesterone and testosterone 
levels and up-regulation of enzymes involved in their production as well as down-regulation of 
enzymes important for their turn-over. The in vitro effects on steroidogenesis and oestrogen 
production might explain the increased oestrogen level measured in exposed adult female rats (Table 
2). PXR agonism, ERα agonism, anti-oestrogenicity and AR antagonism MoAs were found in vitro, 
however in a study from 2016 the ER and AR MoAs could not be confirmed. Overall, there is 
moderate evidence for ED MoA of TMPP, mainly with regards to effects on steroidogenesis. 
A number of studies in rats, mice and roosters, found adverse effects (Table 2) on male fertility with 
histopathological changes in testes and epididymides and evidence of adversely affected sperm 
parameters and altered activity of testicular esterases. Reduced sperm motility and increased number 
of sperms with abnormal morphology were also observed in rat F1 males exposed in utero to TMPP 
in a continuous mating study. Thus, there is strong evidence for adverse reproductive toxicity effects 
in adult males. There is a biologically plausible link between these male reproductive effects and ED 
MoA(s) of TMPP, especially effects on steroidogenesis leading to increased oestrogen levels. In 
female rats, histopathological changes in ovaries have been found with no to weak effects on their 
fertility. A single study in mice report effects on female fertility after TMPP exposure, but in a 
retrospective study examining the ovaries from these mice no effects were found in follicle counts. 
For both sexes, histopathological effects on adrenal glands in rats after TMPP exposure were 
observed, and these changes might result in modulation of the endocrine system leading to e.g. altered 
fertility. Weak evidence for adverse effects on the developing foetus have been found with effects on 
tarsus length and liver mass and gene expression in exposed chicken embryos and inconsistent 
deformities in rat foetuses. 
Overall, the evidence for ED MoA(s) is moderate and the evidence for adverse effects of TMPP is 
strong, and the link between the adverse effects on reproduction and gonads to ED MoAs is  evaluated 
as moderate. clear  
In conclusion, TMPP meet the WHO definition of an endocrine disruptor with adverse effects on male 
fertility linked to effects steroidogenesis leading to increased oestrogen levels.  
 
Additional literature not included in the evaluation 
NTP RACB summary (1997): This is a summary of the NTP Reproductive Assessment by 
Continuous Breeding testing of TMPP in mice that has been described in the paper by Chapin et al. 
(1988). 
Health Canada (2016): This is a draft screening assessment report that among others assess 
reproductive toxicity of TMPP and it uses references already included here. 
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Table 1. Overview of in vitro and in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of TMPP.  
Reference MoA Quality of 
study  
Evidence for 
ED MoA  
In vitro In vivo 
Reers et al. 
(2016) 
No ERα, AhR, or AR agonistic or antagonistic activity in 
two human cancer cells 
 Low Weak 
Shang et al. 
(2016)  
Effects on basal progesterone production in mouse Leydig 
tumor cells 
 High 
 
Moderate 
Bradley et al. 
(2015) 
 Effects on chicken embryo neurodevelopment: no effects 
on chick behaviour or neurochemistry after in ovo 
exposure to TMPP. Non-significant increase in purkinje 
cell number in cerebellum in the highest exposure group. 
High None-weak 
Crump et al. 
(2014) 
 Effects on chicken embryo development: the highest 
dose-level of TMPP resulted in deformities such as 
reduced tarsus length and increased liver mass, as well as 
altered liver gene expression with up-regulation of 
CYP2H1 and CYP3A37, UGT1A9 (not significant) and 
LFABP, and down-regulation of TTR 
High Weak 
Kojima et al. 
(2013)  
ERα and PXR agonism, AR antagonism and very weak 
PPARγ agonism. No effects on ERß, TRα, TRß, RARα, 
RXRα, and PPARα activities were measured 
 Medium Moderate 
Liu et al. 
(2012) 
Effects on steroidogenesis in H295R cells: increased T and 
E2 production, induction of CYP11A1, CYP11B2, 
CYP19A1 and HSD3ß2 and downregulation of SULT1E1 
and SULT2A1. Anti-oestrogenic in MVLN cells. 
 High Strong 
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Androgen receptor (AR), estrogen receptor (ER) α and ß, aryl hydrocarbon receptor (AhR), glucocorticoid receptor (GR), retinoic acid receptor (RAR)α, retinoic X receptor (RXR)α, thyroid 
hormone receptor (TR)α and ß, liver basic fatty acid-binding protein (LFABP), transthyretin (TTR) and uridine 5’-diphospho-glucuronosyltransferase 9 (UGT1A9), pregnane X receptor (PXR), 
peroxisome proliferator-activated receptor (PPAR) α and PPARγ 
 
Table 2. Overview of potential endocrine-related adverse effects of TMPP. 
Reference Species, n Adverse effects Quality of study Evidence for 
adverse effects 
Bolon et al 
(1997) 
Mice, ovaries from 
the Chapin et al 
(1988) study 
No effect on follicle counts was seen. Medium None 
Latendresse et 
al (1995) 
Rats, 3-12/group Histopathological effects on ovaries and adrenal glands and elevated serum estradiol 
levels were found in exposed adult female rats. 
Medium Moderate 
Latendresse et 
al (1994a) 
Rats, 3/sex/dose 
group 
Histopathological effects on ovaries and testes as well as adrenal glands from both 
sexes were found. 
Medium Moderate 
Latendresse et 
al (1994b) 
Rats, 
20/pairs/group 
Adverse effects on male fertility as well on ovarian and testes weights. Medium Strong 
Chapin et al 
(1988) 
Mice, 8-40 males 
and females/group 
Reduced fertility in both sexes was seen in the highest dose group. On necropsy 
reduced sperm motility and increased number of abnormal sperms were seen in both 
F0 and F1 males, with only a reduced number of sperms in the F0 males. 
Medium Moderate-
Strong 
Carlton et al. 
(1987)  
Rats, 12 males and 
24 females/ dose 
group 
Males (200 mg/kg): reduced sperm concentration, motility, progressive movement, 
and increased abnormal sperm morphology, reduced epididymis weight, and necrosis 
and degeneration of seminal vesicles. Females (400 mg/kg): reduced litter size, 
histopathological changes in the ovaries 
Medium 
 
Strong 
Somkuti et al. 
(1987a) 
Rats, 8 males (14-
days) or 10 males 
Reduced sperm motility and density and increased number of abnormal sperm in the 
50, 75 and 100 mg/kg groups. Histopathology in testes and epididymides were seen 
Medium Strong 
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Reference Species, n Adverse effects Quality of study Evidence for 
adverse effects 
(63 days)/ dose 
group 
in all treatment groups ≥ 25 mg/kg, and decreases in testicular esterases were also 
seen as a response to TOCP treatment 
 
Somkuti et al. 
(1987b) 
Roosters, 10 (100 
mg/kg/ day in 18 
days) or 3 (750 
mg/kg  and killed 
after 1 or 18 days) 
Reduced sperm density and motility, and disorganized seminiferous tubules in the 
100 mg/kg group, inhibited activity of 2 testicular esterases in the 750 mg/kg 1 d 
group  
High Moderate 
Somkuti et al. 
(1987c) 
Rats, 8 males/time 
point and 10 males 
in the recovery 
group 
Reduced sperm motility (≥14 days) and density (≥10 days), and reduced testis:BW 
ratio (≥21 days), inhibited activity of 2 testicular esterases (≥3 days), no effects of 
LH, FSH and testosterone in serum 
Recovery study: decreased testis size and absence of germinal cells after 98 days of 
recovery 
High Strong 
REACH 
dossier 
Rats, 25 
females/dose group 
Maternal toxicity and lower foetal weight was seen in the treatment groups. 
Inconsistent deformities in the foetuses were seen and these were most likely not 
related to the treatments 
High None 
Luteinizing hormone (LH), Follicle stimulating hormone (FSH)  
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2-(4-tert-butylbenzyl)propionaldehyde, 
CAS no. 80-54-6 
Synonyms: Lilial, Lily aldehyde, lysmeral, butyl methylpropional, butylphenylmethylpropional 
The substance 2-(4-tert-butylbenzyl)propionaldehyde (Lilial) 
(Figure 1) is an aromatic aldehyde used in the industry as an 
odor agent and for consumers it is used in air care products, 
cleaning and furnishing care products, laundry and dishwashing 
products, personal care products and plastic and rubber products  
This substance is used in 1 000 - 10 000 tonnes per annum. Lilial 
is classified in ECHA as a reproductive toxicant (Repr. 1B, May 
damage fertility or the unborn child). 
 
4. Human health hazard assessment 
4.10.3 Endocrine disruption 
4.10.3.1 General approach – human health 
4.10.3.2 In vitro information indicative of endocrine activity 
 
A.K.Charles and P.D.Darbre (2009)  
Summary: The focus of this study is to investigate the estrogenic activity of 
butylphenylmethylpropional (Lilial), benzyl salicylate and benzyl benzoate in MCF-7 human breast 
cancer cells in vitro. Only data for Lilial will be included in this summary. The estrogen-responsive 
MCF-7 cell line was used in different assays to test for the estrogenic activity of the substance. The 
study was performed in five parts as follows 1) Competitive binding assay to the oestrogen receptor 
(ER) of MCF-7 cytosol, 2) Competitive binding assay to human recombinant ERα and  ERβ, 3) Assay 
of stably transfected oestrogen-responsive reporter gene (ERE-CAT) in MCF-7 cells, was used to test 
the ability of the substance to regulate gene expression, 4) A cell proliferation experiment and 5) 
Real-time RT-PCR analysis of MCF-7 cells exposed to the substance for 24 hours. Overall the results 
from the study show that Lilial possess estrogenic activity in MCF-7 cells in vitro. In the ER binding 
assay , Lilial showed a maximal of 47% inhibition of 3H-oestradiol binding and in the recombinant 
ER binding assay, inhibition of 3H-oestradiol binding to ERα was greater compared to the binding of 
ERβ . Lilial induced CAT gene expression (maximal effect of 1.8-fold at 5 x 10-4 M Lilial)  although 
but the expression was not of the same magnitude as with 17β-estradiol (2-fold at 10-8 M). In the cell 
proliferation experiments Lilial exposure showed a dose-dependent increase in MCF7 cell growth . 
but not at the same magnitude as for 17β-estradiol exposure of the cells.  The effect on proliferation 
could be inhibited by the antiestrogenic fluvestrent (Faslodex, ICI182,780), suggesting that the 
induced cell proliferation was ER-mediated. Finally, expression levels of the oestrogen-regulated 
gene, pS2, were increased following 24 h exposure to Lilial. .  
This paper is included in the REACH registration dossier for 2-(4-tert-butylbenzyl)propionaldehyde 
on toxicity to reproduction, other studies 
Figure 1: 2D structure from PubChem  
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Study quality and assessment: The study is very well-written and thoroughly described with details on  
CAS number (80-54-6) and purity (≥ 95 %) for the  substance used. The assays were carried out in 
triplicates but cytotoxicity of the substance concentrations used was not evaluated. The findings on 
gene expression levels and cell proliferation could not be a result of cytotoxicity and the lack of such 
a test is therefore not assessed to be of importance for these assays. The results in the competitive 
binding assay in MCF-7 cells, however, could be mistaken for cytotoxicity. The quality is assessed to 
be high and based on results all pointing to an estrogenic activity of Lilial, it provides strong evidence 
for an estrogenic ED MoA of Lilial (butylphenylmethylpropional) although less potent than 17β-
oestradiol. 
 
REACH registration dossier,  
 
Toxicity to reproduction: 
Summary: The information from the “Toxicity to reproduction” section in the REACH registration 
dossier originates exclusively from unnamed study reports. Based on the available results a short 
summary is given here. One in vitro study was performed in rat Leydig cells with a range of 
concentrations of Lilial (doses: 33, 10, 3.3, 1, 0.33, 0.1, 0.033, 0.01, 0.0033, 0.001 μg/ml). No 
cytotoxic effect occurred for cells treated with Lilial at concentrations of 0-10 μg/ml. Lilial decreased 
testosterone levels at 10 μg/ml after stimulation with high concentrations of human Chorion 
Gonadotropin (hCG). 
Study quality and assessment: The quality of the study cannot be assessed based on the summary 
available in the REACH registration dossier. The results indicate that Lilial decreased testosterone 
levels after stimulation with hCGThe and provides weak-moderate evidence for an anti-androgen 
mode of action of Lilial.   
 
4.10.3.3 In vivo effects with regard to an endocrine mode of action  
 
No published studies were found. 
 
REACH registration dossier  
 
Toxicity to reproduction: 
Outline: The information from the “Toxicity to reproduction” section in the REACH registration 
dossier originates exclusively from unnamed study reports. Based on the available results a short 
summary of the reports has been added below.     
Summary: The remainder of the studies were conducted in vivo and the animals used include rats (10 
studies) mice (1 study), dogs (4 studies), rabbit (1 study) and monkeys (1study). All were exposed 
orally by feed or gavage and in four of the rat studies 14 - 35 animals were assigned to each dose 
group. For the rest of the studies the number of animals per dose group ranged between 2-10. Study 
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results from experiments with no observation on clinical signs and mortality, mainly include male 
endpoint data such as decreased mean fraction of motile sperm and mean head count in the cauda 
epididymis, histopathological findings (epididymis and testis) in dose group 30 mg/kg bw and a dose 
dependent moderate to severe diffuse (18/20 animals) and focal testicular (11/20 animals) 
degeneration in rats fed 1700 ppm Lilial. In another study (2006) conducted with rats a dose of Lilial 
and lysmerylic acid (50 mg/kg) resulted in slight to severe testicular atrophy after 24-96 h of exposure 
and after 14 days repeated exposure the atrophy of testis were accompanied by 100 % sperm 
immobility for both substances. These data are in line with data from a study done in 1987 where a 
dose of 50 mg/kg in 52 days produced decreased weight of testes (75 % of control after 24 days and 
60 % of control after 52 days) and a study from 1991 that showed moderate to marked atrophy of 
testes in rats after 5 days of exposure to 50 and 100 mg/kg bw/d. Histopathological findings of 
testicular tissue revealed loss of seminiferous epithelium in a study from 1986, again at 50 mg/kg 
bw/day. On female data, a few studies reported an increase in gestation length, decreased live-born 
pups and pups delivered at levels of 30 mg/kg bw/day and low offspring weight and other data 
presented includes endpoints on liver.   
Study quality and assessment: The quality of the studies cannot be assessed based on summaries 
available in the REACH registration dossier. In 4 out of 19 studies the name of the substance used 
were not given but it must be assumed that Lilial was the substance tested. Overall, the in vivo results 
provide a moderate evidence for male adverse effects on testes after exposure to Lilial. With regard to 
the  studies that investigated female endpoints, the results provide moderate evidence for adverse 
effect on female reproduction (increased duration on gestation, decreased number of pups born alive,  
number of pups delivered and reduced birth weight of offspring) after exposure to Lilial. 
 
Developmental toxicity / Teratogenicity: 
 
Outline: The name of the substance used was not given in this study. The study design followed 
OECD guideline 414  and was conducted under GLP. Rats were exposed orally by gavage, daily from 
gestation day 6-20 with 25 females per dose group. Results revealed a significant reduction in the 
mean uterus weight in high dose dams and increased occurrence in skeletal malformations. Overall, 
data did not contribute with results that are relevant to assess the endocrine disrupting effects of Lilial. 
 
Other studies: 
 
Outline: The following study from the “Toxicity to reproduction, other studies” section in the REACH 
registration dossier has already been included here (A.K.Charles and P.D.Darbre, 2009) and the 
summary of their data can be found under the section for in vitro studies. 
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Repeated dose toxicity – Dermal + Oral: 
Outline: The information from the “Repeated dose toxicity” section in the REACH registration 
dossier comes exclusively from unnamed study reports and in some of the studies the name of the 
substance used was not given but it must be assumed that Lilial was the substance tested.  Based on 
the available results a short summary of the reports has been added below.  
Summary:  
All studies are performed in vivo, only a few of them follow a guideline (e.g. OECD TG) and about 
half is conducted according to GLP. In 5 out of 13 studies the substance used was not named and no 
CAS number could be found. Animals used included mainly rats but mice, dogs, guinea pigs and 
monkeys were also represented. In the 7 rat studies 3-14 animals was applied to each dose group, in 
the 3 dog studies 2-3 dogs per dose were used, 5 per dose was included in the two studies with mice 
and guinea pigs and for the single monkey study 2 monkeys were applied per dose group. The key-
study reported that a dose of 50 mg/kg bw/day gave rise to disturbances in spermatogenesis and 
spermiogenesis, testicular increase in Sertoli cells, increased surface density in Leydig cells and 
decreased density of spermatozoa, nucleated cells and spermatoceles in the epididymis. In four 
studies, no treatment related changes were found but the rest of the studies showed data with male 
endpoints and significant findings was presented for decreased mean weight of testes and seminal 
vesicles at doses of 50 mg/kg although a note on general toxicity was mentioned (abnormal posture, 
decreased body temperature, emaciation and pilo-erection). Other data registered was related to liver 
(inflammation, fatty changes and white spots), kidney (reduced weight), heart (pericarditis) and lungs 
(emphysema).  
Study quality and assessment:  
The studies appear to be of low quality when taking into consideration that the number of animals per 
dose group were between 3-14 and in 5 out of13 studies no name or CAS number could be found for 
the substance used, but the quality of the studies cannot be assessed based on summaries available on 
REACH registration dossier. Overall the studies provided weak evidence for an ED effect of Lilial.  
 
4.10.3.4 Summary of the plausible link between adverse effects and endocrine mode of 
action  
 
To our knowledge one in vitro study (A.K.Charles and P.D.Darbre, 2009) addressing the estrogenic 
activity of 2-(4-tert-butylbenzyl)propionaldehyde (Lilial) is currently available. The study is of high 
quality and show that Lilial possess estrogenic activity in MCF-7 human breast cancer cells and it 
provides a strong evidence for an estrogenic mode of action of Lilial.  
The additional information from The REACH registration dossier comes exclusively from 
unpublished study reports and counts several in vivo studies looking at the adverse effect of  2-(4-tert-
butylbenzyl)propionaldehyde. Overall the studies appears provide weak to moderate evidence for 
adverse effects on male reproductive endpoints manifested as atrophy of testes, seminiferous toxicity 
and decreased motility of sperm. For adverse effects on female reproductive endpoints the studies 
included in the REACG registration dossier provide moderate evidence for adverse effects on 
reproduction (increased duration on gestation, decreased number of pups born alive, and number of 
pups delivered) after exposure to 2-(4-tert-butylbenzyl)propionaldehyde. 
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The evidence for a plausible link between the strong evidence for ED MoA (in vitro estrogenic 
activity) and the weak to moderate evidence for adverse effects on male reproductive endpoints is 
evaluate as moderate.   
In conclusion, 2-(4-tert-butylbenzyl)propionaldehyde does not meet the WHO definition of an 
endocrine disruptor, but fulfil the WHO definition of a potential endocrine disruptor. Also 2-(4-tert-
butylbenzyl)propionaldehyde fulfil the proposed Danish criteria for being a suspected ED.  
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Table 1. Overview of in vitro and in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of 2-(4-tert-butylbenzyl)propionaldehyde. 
Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
A.K.Charles 
and 
P.D.Darbre 
(2009)  
 
Over all the results from the study show that Lilial possess 
estrogenic activity in MCF7 human breast cancer cells in vitro. In 
the first part, Lilial showed a maximal of 47 % inhibition of 3H-
oestradiol binding at 3000000 fold molar and in part two, an 
inhibition of the binding of 3H-oestradiol to ERα and  ERβ was 
observed at 3000000-fold molar excess with a greater inhibition of  
ERα (27 %) compared to ERβ. The results from the third part 
showed that Lilial could induce CAT gene expression, with 
maximal effect by 5 x 10-4 M Lilial (1.8-fold) although the 
expression was not of the same magnitude as with 10-8 M 17β-
estradiol (2.0-fold in each case). For the cell proliferation 
experiments Lilial exposure showed a dose-dependent increase in 
MCF7 cell growth after 7 days with a 2.44 ± 0.06 doublings with 
10-4 M Lilial. Without any addition MCF7 cells gave an average 
number of doublings in 7 days of 1.84 ± 0.08 and with addition of 
10-8 M 17β-estradiol the value was 5.23 ± 0.05.  The proliferation 
effect could be inhibited by 10-7 M of the antiestrogen fluvestrent 
(Faslodex, ICI182,780), suggesting that the results measured in the 
experiment were ER-mediated. The cell density reached near 
confluence after 35 days with 10-4 M Lilial and for 10-8 M 17β-
estradiol it was seen after 14 days with. And finally for the last part 
following 7 days of estrogen deprivation, a 24 h exposure to Lilial 
showed that it could increase the expression of pS2mRNA using 
Real time RT-PCR. 
 High Strong 
Estrogen receptor α and β (ERα , ERβ) 
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Salicylic acid (SA), CAS no. 69-72-7 
 
Synonyms:  Salicylate, 2-hydroxybenzoic acid, keralyt, 
acetylsalicylic acid, methyl ester 
Salicylic acid (Figure 1) is a Beta hydroxyl acid obtained 
from the bark and wintergreen leaves of the white willow 
and encompass bacteriostatic, fungicidal and keratolytic 
effects. Salicylic acid (SA) is a colorless, crystalline 
organic carboxylic acid. The substance is used in many 
skin-care products for the treatment of acne, psoriasis, 
callouses, keratosis pilaris and warts and is produced 
and/or imported to EU in 10 000 - 100 000 tpa.  
For the studies in this summary, different substance 
modifications of the substance have been used as a 
substitute, e.g. Acetylsalicylic acid (Aspirin), sodium 
salicylate and methyl salicylate.  
Acetylsalicylic acid and methyl salicylate are the results of esterification of salicylic acid and 
hydrolysis of methyl salicylate produces sodium salicylate. The compounds are closely related and the 
following statement from WHO has been used as guidance for this summary: “All salicylic acid 
derivatives except combinations with corticosteroids (M01B) or opioids (N02AJ) are classified in 
N02BA - Salicylic acid and derivatives, as it is difficult to differentiate between the use of salicylates 
in rheumatic conditions and other therapeutic uses of salicylates.” (WHO 2017). 
                                                                                              
4. Human health hazard assessment 
4.10.3 Endocrine disruption 
4.10.3.1 General approach – human health 
4.10.3.2 In vitro information indicative of endocrine activity 
 
Mazaud-Guittot et al. (2013)  
Summary: The study aimed to investigate the effect of mild analgesics on testis morphology and 
endocrine function. Three different drugs were used (Paracetamol, Aspirin and Indomethacin) but 
only data concerning Aspirin will be included in this summary. Human fetal testis (n=62) from 
gestation week (GW) 7-12 were cultured with exposure to Aspirin at 10-4 to 10-7 M. Testicular 
hormone levels of testosterone and Insulin-like factor 3 were measured by Radioimmuno Assay (RIA) 
and Anti-Müllerian hormone (AMH), prostaglandin D2 and E2 (PGD2/PGE2) was assayed by ELISA. 
Testicular cells (germ and Sertoli cells) were counted using the semiautomatic counting CAST grid 
image analysis software and mesenchymal cells of the interstitial tissue were identified by COUP-TF 
II staining. For assessment of nuclear receptor-mediated agonist or antagonist activities of Aspirin a 
reporter cell line expressing androgen, estrogen and peroxisome proliferator-activated γ-receptors was 
used. The study results showed no change in testis morphology, cell count or number of interstitial 
Figure 1: 2D structure from PubChem  
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cells. Regarding testosterone production, Aspirin showed a significant dose-response relationship 
increasing the level in the youngest fetal testis (8-9.86 GW) but not in the older (10-12 GW) and when 
all ages were pooled, no significant effect was observed. The AMH production was strongly 
stimulated by Aspirin and the PGE2 was significantly inhibited. No significant effect was reported on 
the remaining parameters. 
Study quality and assessment: The study is well-described but no CAS number (no.) and purity was 
reported for the substance used. The study is assessed to be of high quality and provides strong 
evidence for an endocrine disrupting (ED) mode of action (MoA) from Aspirin exposure. 
 
Albert et al. (2013)  
Summary: This study investigates the endocrine disrupting properties of mild analgesics in the adult 
human testis. Three types of analgesics were used in parallel studies but this summary will only cover 
the Aspirin part. Tissue used for the study came from prostate cancer patients who had not received 
any hormone therapy and NCI-H295R steroid producing human cell line. Only testis displaying 
spermatogenesis (assessed by transillumination) was used. Orchiectomy was performed and testis was 
transported on ice and processed as followed. The testicular tissue were fragmented and cultured by 
the procedure of Testis Explants Assay (TEXAS) and the media contained 10-5 and 10-4 M of Aspirin 
(purity ˃ 99%). To determine the levels of hormones in the cultured media, Radioimmuno Assay was 
applied for the measurement of testosterone and insulin-like growth factor 3 (INSL3),  Enzyme-
Linked immunosorbent Assay was conducted to measure Inhibin B and for estimation of 
prostaglandins (PGD2 and PGE2) Enzyme Immunosorbent assay was applied. To evaluate gross 
morphology the testis explants were fixed in Bouin fixative, stained and examined under a light 
microscope. No change in the gross morphology of the testis was found. Measurements described in 
the following text include values after 24 h and 48 h of culturing. Testicular testosterone production 
was decreased but did not reach statistical significance. For the NCI-H295R cell line, exposure to 10-5 
and 10-4 M Aspirin significantly reduced testosterone level. A reduction was also seen in the levels of 
INSL3, PGD2, PGE2 and Inhibin B production by the adult human testes.   
Study quality and assessment: The study is well described and thorough although CAS no. of the 
substance used could not be found. It is assessed to be of high quality and since data only showed a 
significant value in NCI-H295R cell line the study provides moderate evidence for ED MoA by direct 
exposure to Aspirin. 
 
Abend et al. (1991)  
Summary: The aim of this study was to examine the feedback mechanism from T3 / T4 on TSH by 
looking at the role of type II 5’Deiodinase (5’D-II). The study was carried out in 3 parts of which only 
one part is relevant to this summary. A small in vitro investigation was conducted to look at the 
activity of 5´D-II and it was carried out using100 and 200 pM [125I]-T4 as substrates. To investigate if 
sodium salicylate could be a direct inhibitor of 5´D-II, an assay was done with aliquots of normal 
pituitary homogenates for activity in the presence of 0, 2 and 10 mM sodium salicylates. The results 
from the study showed that the administrated dose of Salicylate did not inhibit the 5`D-II enzyme 
activity directly.  
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Study quality and assessment: The study has some shortcomings – the number of pituitaries used is 
not given and the CAS no. and purity of the substance used could not be found. The study is assessed 
to be of medium quality and it did not provide any evidence for an ED MoA on the activity of 5’D-II.  
 
Larsen, P.R.  (1972)  
Summary: This study was conducted to clarify the effect of SA on the protein binding of the two 
thyroid hormones (T3 / T4) in human serum. The investigation was made up from several smaller 
studies. 
1- The effect of addition of sodium salicylate on the ultrafiltrable fraction of T4 (UFT4) and T3 
(UFT3) in vitro: Sodium salicylate was added in increasing amounts to pooled human serum. The 
concentrations of salicylate used were within the therapeutic (20-30 mg/100 ml) or toxic (60mg/100 
ml) range (with humans as a reference for therapeutic and toxic values). A progressive increase in 
both of UFT3 and UFT4 was seen after sodium salicylate exposure.. 
2- The effect of dilution of human serum containing salicylate on UFT3 and UFT4: Two samples of 
human sera, one control and one salicylate-enriched were progressively diluted and a simultaneously 
determination of UFT3 and UFT4 was conducted. The result revealed a progressive decrease in the 
effect of salicylate when diluted and for UFT3 it was significant at 1:2 dilutions. 
3- Comparison of the effect of sodium salicylate and barbital on the binding of T3 andT4 in human 
serum and to human serum albumin: Diluted serum or human serum albumin was used in this study 
and a final concentration of sodium salicylate was established at 15 mg/ml. The result showed an 
increase of UFT3 and UFT4 for both Salicylate and barbital. 
4- Effects of sodium salicylate on T3 / Thyroxin-binding-prealbumine (TBPA): For this study the 
ultrafiltration system and simultaneous labeling with T3-131I and T4-125I was used in the presence of 
1.3 x 10-6 M TBPA and the result showed that addition of salicylate (15 mg/100 ml) increased both 
the UFT3 and the UFT4.  
5- Effects of sodium salicylate on T3 and T4 binding to Thyroxine-binding-globulin (TBG): The 
binding was examined in an assay system described in an earlier study. The result showed that both 
T3 and T4 were displaced from TBG (thyroxine-binding-globulin) by sodium salicylate. 
Study quality and assessment: The text is written with addition of several references to earlier studies 
regarding descriptions of methods used and in the section with results it is a challenge to distinguish 
result from the study conducted from results obtained from other experiments. No report of CAS no. 
and purity of the substance  used could be found. The study quality is assessed to be medium but the 
evidence for a thyroid disrupting MoA of SA in vitro is strong.  
 
Hansen and Mogensen  (1964)   
Summary:  This study investigated the effect of sodium salicylate on the uptake of 131I-labelled 1-
triiodothyronine by human erythrocytes. For this part of the study, human venous blood was obtained 
from donor blood and 4 portions of erythrocytes (2 x washed + 2 x unwashed) were prepared for use 
in a scintillation counter. To all samples 131I-labelled 1-triiodothyronine was added in the process 
(concentrations kept below 0,1 μg/ml) and 25 % W/v salicylic acid solution were added in 
proximately calculated amounts. The result from the study showed that by adding sodium salicylate to 
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the blood samples an increase in the T3 uptake was seen in erythrocytes. An additional study was 
performed where erythrocytes were washed six times and then suspended in physiological saline 
solution (instead of plasma). No increase in the T3 uptake was observed under those conditions. 
According to the authors the effects observed are a result of the influence of salicylate on plasma 
proteins and not a direct effect on the erythrocytes. 
Study quality and assessment: The quality of the study is assessed to be medium. No information on 
CAS no and purity of the substance used was given and there is no report of any control group. The 
study provides no evidence for a thyroid disrupting MoA of sodium salicylate through binding of T3 
to erythrocytes in vitro.   
 
Wolff et al. (1961)  
Summary: The aim of the study was to investigate T4 displacement from serum proteins in human 
serum after addition of natrium salicylate. The study consists of 3 experimental parts where only two 
of them are relevant to this assay. Pooled normal human serum (one batch) obtained from Baxter 
Laboratory was used in all studies and butanol solutions of thyroxine were added. For the first 
experimental part natrium salicylate (3•10-3 M) was added to serum before measurement by reverse 
flow electrophoresis.  For the second part natrium salicylate (3•10-3M) was added to the (NH4)2CO3 
buffer (pH was adjusted after addition). The displacement was measured at 4 different T4-
concentrations 0.15 μg T4/ml (0,19 μM), 0.28 μg T4/ml (0.36 μM), 1.54 μg T4/ml (2.0 μM) and 2.08 
μg T4/ml (2.7 μM). The result from the first study showed that natrium salicylate tended to displace 
T4 from Thyroxine-binding pre-albumin (TBPA) onto thyroxine binding globulin (TBG). However, 
the result was more reproducible in the second part where natrium salicylate was added to the buffer. 
In this part it was possible to measure a significant displacement of T4 from TBPA to TBG at low T4-
concentrations and when the amounts of T4 was higher, TBG was saturated and then T4 was displaced 
and bound to albumin. 
Study quality and assessment: The study is well-described but regarding the substance used it is only 
mentioned that it is of reagent grade but no CAS no. was given. Overall the study is assessed to be of 
high quality and it provides strong evidence for a thyroid disrupting MoA of natrium salicylate. 
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4.10.3.3 In vivo effects with regard to an endocrine mode of action  
Kristensen et al. (2012)  
Summary: This study aimed at investigating effects of mild analgesics (paracetamol, indomethacin 
and Aspirin) on ex vivo rat fetal testis development. Only results relevant to Aspirin will be included 
in this summary. To examine the effects of the mild analgesic, Sprague-Dawley rat testis (gestation 
day 14.5) was used in a 3 day ex vivo organotypic culture system with exposure to Aspirin at doses of 
0, 1, 10 and 100 μM. Testosterone, Insulin-like factor 3 (Insl3) and prostaglandin D2 (PGD2) 
concentrations were determined in the medium at 24, 48 and 72 h by Coat-A-Count Total 
Testosterone Kit (testosterone), Enzyme-linked immune sorbent assay (Insl3) and Prostaglandin D2-
Mox EIA Kit (PGD2). Leydig cells were prepared and counted by systematic random sampling in a 
CAST-grid stereotactic system with a reference to an earlier study. For evaluation of gonocyte 
apoptosis in the testis, a TUNEL assay with the in Situ Cell Death Detection Kit was conducted and 
finally gross morphology of the seminiferous tubules was examined. The result from the study 
showed significantly decreased testosterone levels at all Aspirin concentrations, with 20 – 75 % 
compared to control and for PGD2 Aspirin led to a modest decrease in the production at all time-
points. No significant data was obtained for gross morphology, leydig cells number and rate of 
gonocyte apoptosis.  
Study quality and assessment: The study is well described and thorough all though there was no report 
of CAS number. and purity of the substance used. The study is assessed to be of high quality and it 
provides a strong evidence for an anti-androgenic ED MoA after Aspirin exposure.  
 
Kristensen et al. (2011)  
Summary: The study consisted of 3 parts (in vivo, ex vivo and epidemiology) and the in vivo part will 
be described here. This study had a focus on intrauterine exposure to mild analgesics as a risk factor 
for development of male reproductive disorders in rats. Pregnant rat dams were exposed to 
acetylsalicylic acid at doses of 150, 200 and 250 mg/kg/day from GD 13-21 with cesarean section 
conducted on GD 21. For dose-response analysis, anogenital distance (AGD) in male fetuses was 
analyzed by the calculated ADG index (AGDi) divided by the cube root of the body. Analysis of 
testosterone and the production by testes were performed by a method with a reference to an earlier 
study. The results showed reduced AGD compared to control but due to fetal growth retardation AGD 
was undetectable in a number of fetuses and statistical results are not presented. A significant 
reduction of testosterone by testes was measured. 
Study quality and assessment: The study is well described although no CAS number and purity of the 
substance used could be found but overall the quality is assessed to be high. In the article it is noted 
that no signs of general toxicity were observed (no liver toxicity, normal maternal body weight gain, 
litter size, live fetuses, resorption, implantation and sex ratio when compared with controls). Thus, the 
findings regarding testosterone and AGD provide strong evidence of an anti-androgenic MoA after 
Aspirin exposure. 
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Kristensen et al. (2011)  
Summary: The study consisted of 3 parts (in vivo, ex vivo and epidemiology) and the ex vivo part will 
be described here. This study had a focus on intrauterine exposure to mild analgesics as a risk factor 
for development of male reproductive disorders in rats. Testes from male rat fetuses (n=8) obtained by 
caesarean section on GD 14.5 were incubated with two testes in each experiment, for 3 days in a 
media with or without Aspirin at concentrations of 1 μM and 10 μM. The media concentration of 
prostaglandin D2 (PGD2) and testosterone were measured by Prostaglandin D2-Mox EIA kit after 24, 
48 and 72 h. The result from the study show a dose dependent reduction in testosterone and PGD2 
with a significant result for testosterone at 10 μM Aspirin at all time points and a significant result for 
PGD2 at 48 and 72 h.     
Study quality and assessment: The study is well-described although no information on CAS number 
and purity of the substance used could be found. The quality is assessed to be high and it provides 
strong evidence for an anti-androgenic MoA.  
 
Gupta et al. (2003)  
Summary: The aim of this study was to compare the developmental toxicity of Aspirin (CAS 50-78-2) 
in rats using selected dosing paradigms. To allow a direct comparison between the responses of 
Sprague-Dawley (SD) rats (in this study) and Wistar rats (from Kimmel et al.1971), the study design 
and dose levels were based on the work of Kimmel et al (1971). The study was conducted in two parts 
with a single dose study and a multiple dose study and in both cases, timed-mated SD rats were 
assigned.  In the first study (single dose) groups of 7 rats were orally exposed (by gavage) to 
acetylsalicylic acid (ASA) on gestation day 9 (0, 250, 500 or 625 mg/kg), 10 (0, 500, 625 or 750 
mg/kg) or 11 (0, 500, 750, 1000 mg/kg). In the second study (multiple doses) groups of 20 rats were 
orally (by gavage) treated with ASA from gestation day 6 to 17 at concentrations of 0, 50, 125 or 250 
mg/kg. On gestation day 21 all rats were killed, and fetuses were examined and following parameters 
were noted: numbers of corpora lutea, implantation sites, late and early resorptions, viable and dead 
fetuses, individual fetus weight, placenta weight and finally all fetuses were examined for external 
and visceral anomalies and developmental variations with focus on ventricular septal defects (VSD) 
and midline defects (MD). The results from the study showed a high concordance between Wistar and 
SD rats regarding developmental anomalies with the exception to hydrocephalus in Wistar rats and 
the VSD in the SD rats. Whether ASA was administrated as a single dose or during the organogenesis 
(GD 6-17), the malformations were similar. All registrations of malformations are presented in a table 
and only in the high dose-group are they statistically significant. Hypoplastic testes were seen in 2 out 
of 137 fetuses and only in the highest dose group and along with ectopic adrenals, ablepharia was 
only detectable in the multiple dose study and not in the single dose study. 
This paper is included in the REACH registration dossier for Salicylic acid on developmental toxicity 
/ Teratogenicity  
Study quality and assessment: The study is well-written and thoroughly described and contains details 
on both animal housing conditions and CAS number of the substance used and it is assessed to be of 
high quality. The results provide weak evidence for ED-related adverse effects after exposure to 
Aspirin 
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Conte et al. (1999)  
Summary: The aim of this study was to examine the effect of Aspirin on plasma testosterone, 
pregnenolone, progesterone, 17OH-progesterone, androstenedione, dehydroepiandrosterone and 17β-
estradiol in response to human chorionic gonadotropin (hCG). Healthy men (n=8) age 20-30 years 
was examined in a placebo-controlled, single-blinded study and to test the efficacy of Aspirin as a 
prostaglandin-blocker an additional study was conducted where seminal prostaglandin E2 (PGE2) 
were determined at the same doses and times used in the experimental protocol. All subjects received 
the same four treatments, separated by an interval of at least 1 month. 1) Placebo Aspirin + hCG, 2) 
Aspirin + hCG, and for control 3) Aspirin + placebo hCG, 4) placebo Aspirin + placebo hCG. 
Administration of 1 tablet (800 mg) Aspirin or placebo Aspirin was done orally two times a day for 7 
days  (i.e. 2 days before and 5 days after administration of hCG or placebo hCG). For the experiment 
5000 IU hCG was injected intramuscular (IM) and blood samples were collected after 2, 24, 48, 72 
and 96 h and in the same period, all participants were asked to collect semen specimens (by 
masturbation) for PGE2 measurements. Parameters measured by radioimmune assay were plasma 
testosterone, pregnenolone, progesterone, 17OH-progesteron, androstenedione, 
dehydroepiandrosterone, 17β-estradiol and PGE2. The study result showed that Aspirin significantly 
lowered the seminal level of PGE2 and significantly reduced the response of testosterone, 17 OH-
progesterone, androstenedione and dehydroepiandrosterone to hCG stimulation (assessed by the mean 
integrated area under the curve). No change was seen with regard to 17β-estradiol, pregnenolone and 
progesterone when hCG was administrated. 
Study quality and assessment: The study is well-described and thorough with the exception that CAS 
no and purity of the substance used was not given. The study is assessed to be of high quality and 
because of the significant results it provides strong evidence that the androgen response to hCG is 
inhibited by Aspirin treatment. 
 
Davis et al. (1996)  
Summary: This study has a two-fold purpose. One part investigates the effect on maternal 
reproduction in rats after oral exposure to salicylic acid. The other part looks at the structure-toxicity 
relationship between acetylsalicylic acid (ASA) and salicylic acid (SA) with respect to the effects 
measured in part one. Sprague-Dawley virgin female rats (n=105) at the age of 63 days was mated 
and the presence of a copulating plug marked gestation day 0. Randomly assigned animals were 
divided into dose groups receiving SA at the level of 0 mg/kg/day, 20 mg/kg/day, 80 mg/kg/day, and 
200 mg/kg/day. A single group received a dose of ASA at 260 mg/kg/day. All groups were exposed 
by oral gavage on day 15-21 during gestation and administration of the compound was conducted 
twice a day (one half morning / one half 6-8 h after). Parameters recorded from the dams were body 
weight (measured on day: 0, 6 and 15-21), duration of gestation, labor time (time between the first 
and last born) and gross examination of uterus and ovaries (post-mortem). Registrations from pups 
included examination for external abnormalities, number of viable/non-viable, sex determination and 
weight. The results of the study showed that the groups exposed to SA 200 mg/kg/day and ASA 260 
mg/kg/day had a delay in the onset of labor, an increase in labor time and a significantly increase in 
maternal perinatal mortality. Regarding the treatment-associated fetotoxicity only the group exposed 
to ASA 260 mg/kg/day showed a significant increase in stillborn pups and peripartum death. 
Additionally, ASA and SA were well-tolerated in all treatment groups No substantial potency 
difference between the salicylate congeners, ASA and SA could be established only the differences in 
toxicity profile were evident.      
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Study quality and assessment:  The study is well-described but no information about CAS no. and 
purity could be found regarding sodium salicylate and acetylsalicylic acid. Overall the quality of the 
study is assessed to be high and from the result found it provides a moderate evidence of adverse 
effect on maternal reproduction and fetotoxicity including prolongation of labor and gestation after 
SA exposure.  
 
Abend et al. (1991)  
Summary: The aim of this study was to examine the feedback mechanism from T3/T4 on TSH by 
looking at the role of type II 5’Deiodinase (5’D-II). The study was carried out in 3 parts of which only 
one part is relevant to this summary. Three groups of male Sprague-Dawley rats were exposed to 1) 
Intraperitoneal injection of 40 nM NaOH vehicle (control), 2) Intraperitoneal injection of  2 
μmol/100g 3-methyl-4’,6-dihydroxy-3’,5’-dibromo-flavone (EMD 21388) and 3) 30 mg/100 g 
sodium salicylate administrated by oral gavage. All rats were sacrificed 1 h after exposure by 
decapitation and trunk blood and pituitaries was collected. From serum, values of thyroid-stimulating 
hormone (TSH), total T4, total T3 and free T4 was measured by Radioimmunoassay (RIA) and the 
level of salicylates was determined by a modification of Trinder’s method with a reference to an 
earlier paper. The results from the study showed that administration of salicylates significantly 
decreased the serum total T4 concentration. 
Study quality and assessment: Although sodium salicylate was not the main focus of the study, the 
findings are relevant to this summary because a significant decrease in the serum total T4 
concentration was observed (value of free T4 is not given for salicylate). In general the article has a 
number of shortcomings for instance, the age and number of animals used is not given in the text, 
only body weight is mentioned and no information on CAS number and purity of the chemical used 
could be found. Overall the study is assessed to be of medium quality and it provides moderate 
evidence for a thyroid disrupting MoA after exposure to sodium salicylic acid.  
 
Overman and White (1983)  
Summary: The aim of this study was to compare the teratogenic effect of methyl salicylate in 
hamsters after oral and topical exposure. Virgin female hamsters were individually mated and the 
pregnant rats were grouped into either an oral or topical treatment group. For Oral exposure (by 
intubation) two dose levels were established at 0 mg/100 g bw (control) and 175 mg/100 g bw. For the 
topical application four groups were established at levels of 0 mg/100 g bw (control, shaved and 
treated with saline solution and washed after 2 h.), 0 mg(control, anesthetized with Nembutal and 
shaved), 350 mg/100 g bw (applied to a clipped area and washed after 2 h), 525 mg/100 g bw (applied 
to a clipped area and washed after 2 h). All exposures to methyl salicylate were conducted once at 7 
days and 9hours into the pregnancy and at day 9-12 all animals were sacrificed. To monitor if the 
topical and oral doses were received by the animals, blood samples were obtained on a regular basis 
by heart puncture under light ether anesthesia and centrifuged for spectrophotometrically reading and 
to a 50 μl blood sample, 1 ml of modified Trinder reagent was added which precipitates protein and 
gives a color if salicylate is present. To determine if salicylate also reached the embryos an assay was 
done with a pooled sample of fetuses (oral treatment group) and compared to maternal salicylate 
levels from blood samples taken at the same time (assayed by the same procedure). Morphological 
examinations of the embryos were done on day 9 of gestation. The study result showed similar 
embryo malformations in both treatment groups and included both the cranium and spina where 
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failure of closure involved the midbrain region. The monitoring result showed a higher plasma 
concentration and a faster peak of salicylate after oral exposure than after topical treatment and 
regarding the comparison of salicylate levels in fetus and mother, it showed that salicylate was 
reaching the fetus but in lower concentration.  
Study quality and assessment: The study is well-described but more information on housing 
conditions, CSA no. and purity of the substance used would have been preferred. The number of 
maternal animals used and the size of each litter are not given in the text or any table but the number 
of litters can be found in table 1. No statistics were conducted. Overall the study is assessed to be of 
medium quality. The study provides moderate evidence for developmental adverse effects on skeletal 
malformations after oral and topical exposure to methyl salicylate and no evidence for ED related 
adverse effects.  
 
Didolkar et al. (1980)  
Summary: This study examines the effect of Aspirin (acetylsalicylic acid) on spermatogenesis in rats. 
The study examined two age-groups of male albino rats (n=12), Norwegian strain. Group one: 
Immature male rats, age 21-24 days and Group two: Adult male rats of proven fertility - both groups 
received doses of Aspirin at 0 mg/100 g bw (control) and 5 mg/100 g bw by oral administration once 
daily for 30 days. All animals were killed 12-13 h after the last exposure and testis was excised, 
blotted and weighed. Samples from testis were collected for histology, assays for hyaluronidase, β-
glucuronidase and sorbitol dehydrogenase were conducted and testicular nucleic acids were extracted 
and estimated. The result from the study shows that Aspirin caused a significant (P ˂ 0.05) decrease 
in testicular weight in the group of immature rats. A decrease in the activity of testicular enzymes was 
observed for hyaluronidase and sorbitol dehydrogenase in both groups. Regarding spermatogenesis, 
for both groups, Aspirin caused an impairment of the later stages by a decrease in numbers of 
spermatids and morphologically it was registered that the nuclei of the pachytene spermatocytes were 
increased (statistically insignificant). 
Study quality and assessment:  
The study is well-described but assessed to be of medium quality due to the lack of information 
regarding CAS no. and purity of the substance used, and there is no information on general toxicity in 
the animals. The study provides strong evidence for adverse effects on spermatogenesis after Aspirin 
exposure.  
 
Balasubtamanian and Ramakrishnan (1979)  
Summary: The aim of the study was to investigate the effect of acetylsalicylic acid (Aspirin) 
individually and in combination of prostaglandins (PGs) on carbohydrate and thyroid metabolism in 
rats. An in vivo and an in vitro study were performed, but the in vitro part and parts of the in vivo 
study focused on glucose and glycogen and will not be included here. The following groups were 
established: Control (ad libitum feeding), control (pair-fed), Aspirin 30 mg/day for 6 weeks 
(Chronic), Aspirin 60 mg as single dose (acute group), PGF2α 100 μg intraperitoneal, PGE2 100 μg 
intraperitoneal (IP), Aspirin (60 mg, single dose)  + PGF2α, Aspirin (60 mg, single dose)  + PGE2 and 
a withdrawal group with 2 exposure-free weeks following exposure to 30 mg/day for 6 weeks. Aspirin 
was administered through the diet and the exposure to radioactive iodine (Na131I) and (U-14C) 
glucose (5 μCi) was administered by intraperitoneal injection. Parameters measured for the in vivo 
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part included %uptake of injected radioactive iodine in thyroid and serum protein-bound iodine. The 
result from the study showed a decrease in percentage uptake of injected Na131I and plasma protein-
bound iodine (PBI) by the thyroid gland in the groups exposed to Aspirin (acute and chronic) and 
Aspirin + PGs but no effect on the parameters was seen in the PGF2α and PGE2 groups. In the group 
where Aspirin was withdrawn from the diet the two parameters were restored to normal levels.  
Study quality and assessment: The description of the study has a number of shortcomings starting with 
the section of materials and methods where information regarding treatment, size of the groups, 
housing conditions and procedures for preparation and administrations of PG, radioactive iodine and 
IP injected glucose is referred to earlier studies. No report of CAS no. and purity could be found for 
the substance used. Based on the lack of information the study is assessed to be of low quality but it 
provides moderate evidence for a thyroid disrupting MoA of Aspirin  
 
Beall and Klein (1977)  
Summary: This study was designed to determine if maternal food restriction would enhance the 
teratogenic effects of salicylic acid. Charles River, CD rats were mated and day 0 of pregnancy was 
determined by sperm in vagina. From a group of 49 pregnant rats four groups of similar size were 
established and received I) Food Ad Libitum (control), II) Food Ad Libitum + 250 mg/kg 
acetylsalicylic acid adm. orally by gavage (0.5 ml/100 g bw) suspended with vehicle (2,5% aqueous 
Tween 80) from day 7-10 of pregnancy, III)  Restricted food (6 g/day) from day 6-15 after mating 
along with vehicle (control) and IV) Restricted food + 250 mg/kg acetylsalicylic acid administration 
orally by gavage (0.5 ml/100 g bw) from day 7-10 of pregnancy. Food consumption was measured on 
a daily basis, all rats were weighed every 3 days and on day 21 after mating all rats were killed. 
Parameters investigated included offspring abnormalities, number of live pups, sex, bw of the pups, 
litter size and resorption sites. For examination of skeletal defects two-thirds of the pups from each 
litter were fixed and stained with alizarin red and for soft tissue examination the rest were fixed in 
Bouin’s solution and examined by serial slicing. The result from the study showed statistical 
significant values for increase in resorption sites for group IV, reduced mean body weight of pups in 
group II and increase in developmental defects (rib abnormalities, craniorachischisis and umbilical 
hernia, eye defects) in both Aspirin-treated groups. The combination of food restriction and exposure 
to Aspirin increased the incident of abnormalities from 24.4 % in group II (=32 pups) to 66.3 % (=59 
pups) in group IV.     
Study quality and assessment: The study is well-described but more information on housing 
conditions and the age of the rats would have been preferred and there was no report of CAS no. and 
purity of the substance used. The study is assessed to be of medium quality and it provides a moderate 
evidence for developmental adverse skeletal and soft tissue effects induced by Aspirin. 
 
Wilson et al. (1977)  
Summary: This study investigates the embryo toxicity and comparative distribution of acetylsalicylic 
acid in pregnant rats and rhesus monkeys. For all animals, gestation day 0 was assigned when sperm 
was found in vaginal lavage. First, two studies on embryotoxicity were performed. In the rat study, a 
weight adjusted volume of acetylsalicylic acid (suspended in 0.3% aqueous solution of 
carboxymethyl-cellulose) was administrated orally (by gavage) twice a day on gestation day 9-12 at 
doses of 0 (control), 100, 150, 175 and 200 mg/kg (2-8 litters/dose gr.). Embryo removal was 
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conducted at 1, 2, 4, 8 or 17 h after last exposure on GD12 or they were allowed to continue their 
pregnangy and removed on GD20. Blood samples for preparation of plasma were taken by cardiac 
puncture under light ether anesthesia at 1, 2, 4, 8 and 17 h after exposure. For the pregnant monkeys 
(n=8) acetylsalicylic acid was administrated orally (by gavage) twice a day on gestation day 23-32 at 
doses of 100 and 150 mg/kg (no report of a control group). Blood sample for serum preparation was 
taken by venipuncture at day 4, 5 or 10 at1, 2, 4, 8 and 17 h after gavage. Hysterectomy was 
performed at same intervals after the last gavage. For both groups of animals, parameters measured 
were plasma binding, and concentration of salicylic acid in plasma, placenta and embryonic tissues 
and finally all fetuses were examined for external, visceral and skeletal abnormalities. Monkey 
embryos were additionally examined for heart beat. To compare the distribution of acetylsalicylic acid 
in rats and monkeys, an additional rat study was performed and similarly to the monkey study 100 
mg/kg was chosen as the low dose and 150 mg/kg was set as the high dose in this rat study. The study 
result from the rat part showed a significant effect on intrauterine death, growth and malformation 
(cardiac, brain and skeletal) at doses of 150 and 200 mg/kg. Maternal plasma concentration was 
significantly higher in non-pregnant than pregnant rats at 100 mg (2 and 17 h after dosing) and 150 
mg/kg (after 2 h) and the teratogenic (maternal) dose of 150 mg/kg  resulted in an embryo 
concentration greater than 60 μg/g maintained for minimum 16 h/day. In monkeys both exposure 
doses (100 and 150 mg/kg) resulted in a slight increase in intrauterine death and transitory growth 
retardation. Maternal plasma concentration was not consistent but showed a significant difference 
between non-pregnant and pregnant animals at 100 mg/kg with a significant higher concentration in 
non-pregnant at 2, 4 and 8 h after dosage. The mean embryo concentration never exceeded 36 μg/g in 
monkeys. When the two groups of animals were compared, the highest value of unbound salicylate 
was found in rat plasma. 
Study quality and assessment: Overall the study is well described although information on CAS 
number. and purity of substance used was not available and more information on housing conditions 
would have been preferred. The study is assessed to be of medium quality and since the exposure 
doses were well tolerated by the maternal animals at levels below 200 mg/kg the study provides high 
evidence for adverse effects on embryonic development, growth and survival in rats and moderate 
evidence for adverse effects on embryonic growth and survival in monkeys.  
 
Tuchmann-Duplessis et al. (1975)  
Summary: The aim of the study is to look at the effects of prenatal administration of acetylsalicylic 
acid (ASA) in rats. Two groups of pregnant rats (COBS CD Charles River) were established and 
randomly divided in two dose groups (n=16/group), 0 mg/kg/day and 200 mg/kg/day. ASA, 
suspended in 1% tragacanth gum, was administered by gastric intubation twice a day starting on day 
15 until the end of pregnancy. Registrations were made on gestation length, parturition time  and 
effects on offspring (stillborn and death). The results revealed a statistical significant difference 
between the two groups with a prolongation of pregnancy in treated dams. The parturition time was 
also prolonged and in the treated group 2 out of 16 dams died due to an extended period of 
contractions. No significant observations were registered regarding effect on offspring survival. The 
dams tolerated the treatment well with no mortality or change in behavior during exposure. 
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Study quality and assessment: 
The study is well-described although the purity of the tested substance is not reported and more 
information on housing conditions would have been preferred. Overall the study is assessed to be of 
medium quality and it provides strong evidence for adverse effects on gestation length and parturition.  
 
Larsen, P.R.  (1972)  
Summary: This study was conducted to clarify the effect of SA on the protein binding of the two 
thyroid hormones triiodothyronine (T3) and thyroxine (T4). An in vivo and an in vitro experiment was 
conducted. In the in vivo part of the study Aspirin was administrated to humans (n=2) for a period of 
8-10 days in quantities sufficient to obtain a serum salicylate level of 20-25 mg/100 ml. Three 
baseline determinations were obtained during a 6 day control period prior to the study. During the 
period of treatment samples of serum were collected every other day and the free T3 and free T4 was 
estimated by ultrafiltration (UF). The results from the study showed an immediate and persistent 
increase in the UFT3 and UFT4 in both humans. 
Study quality and assessment: The study is not described in a structured way and it contains several 
references to earlier studies for description of methods used. There was no report of batch number of 
the Aspirin used. The in vivo part is assessed to be of medium quality. Although only two subjects 
were assigned to the study, it provides moderate evidence for thyroid ED MoA after Aspirin exposure. 
 
Collins et al. (1971)  
Summary: The aim of this study was to investigate the effect of methyl salicylate on rat reproduction. 
The study included a main part and a supplemental study but due to a mixed-compound exposure in 
the supplemental study, the result was found to be non-relevant and only the main part will be 
included in this summary. Osborne-Mendel rats were divided in groups of 20 pair (litter mated) and 
fed methyl salicylate through the diet for 100 days prior to mating at the levels of 0, 500, 1500, 3000 
and 5000 ppm. Two litters, F1a and F1b were produced by F0 and on day 4 all litters were reduced to 
include maximum 10 pups per litter. At weaning F1b were pair-housed and mated (20 pairs per group). 
Same procedure was followed for the following generations. Parameters investigated were fertility 
index (number of litters cast/number of females exposed to mating), Litter size, number of live born, 
viability index (number of live-born/total number born), surviving from day 0-4, survival index 
(number alive at day 4/number born alive), number of progeny weaned at day 21, weight of weanlings 
and abnormalities by external examination. Autopsy and histopathological examination (liver and 
kidney) was only performed on the weanlings from the third generation. The results from the study 
revealed significant findings at dose levels of 3000 and 5000 ppm regarding a decrease in the average 
litter size, number of live-born progeny, number of survivors to day 4 and number of survivors to day 
21. The decrease in number of live-born appeared to be dose-related. At the lower dose levels only a 
non-significant decrease was observed. 
This paper is included in the REACH registration dossier for salicylic acid on toxicity to reproduction. 
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Study quality and assessment: The study has a number of shortcomings. For example, the details on 
diet preparations, the description of the 3 generation study and the reason for the choice of 
concentrations refers to earlier studies and is only roughly described in the text. No report of CAS 
number and purity of the substance used could be found. Overall the study is assessed to be of 
medium quality and it provides moderate evidence for reproductive adverse effect after exposure to 
methyl salicylate during pregnancy. 
 
Hansen and Mogensen (1964)   
Summary:  This study investigated the effect of sodium salicylate on the uptake of 131I-labelled 1-
triiodothyronine by human erythrocytes. Human patients (n=9) were given 1 g sodium salicylate three 
times a day for 4 days and serum concentrations of salicylic acid were measured). From a 20 ml 
venous blood sample, 4 portions of erythrocytes (2 x washed + 2 x unwashed) were prepared for use 
in a scintillation counter. To all samples 131I-labelled 1-triiodothyronine was added in the process 
(concentrations kept below 0.1 μg/ml). The study result showed an increase of triiodothyronine (T3) 
uptake in erythrocytes of patients given salicylate.  
Study quality and assessment: The the study is assessed to be of medium quality. No information on 
CAS number and purity of the substance used was given and there is no report of any control group. 
The evidence for a thyroid disrupting MoA is moderate. 
 
Warkany and Takacs (1959)  
Summary: The aim of the study was to conduct an experimental production of congenital 
malformations in rats by salicylate exposure. The study was composed of two experimental parts. In 
the first part 116 female rats were mated and the presence of sperm in vagina marked the first day of 
pregnancy. One single dose of 0.1-0.5 cc (cubic centimeter) methyl salicylate was administrated 
subcutaneously on gestation day (GD) 9, 10 or 11. In the second study 43 pregnant rats received a 
single dose of 60-180 mg sodium salicylate also administrated subcutaneously on gestation day 9, 10 
or 11. For control group, 105 females were used. The results obtained in the first part (methyl 
salicylate) showed a weight reduction in most of the pregnant females of 15-25 g after treatment, 26 
of the 116 dosed animals died and 47 had fetal resorbtions. The last 43 pregnant rats were sacrificed 
on gestation day 21 and 298 progeny were obtained. At examination 45 of the offspring were 
externally visible malformations and in the remaining 253 pups that appeared externally normal, 75 
showed skeletal abnormities. In the second study (sodium salicylate) 6 of the 43 rats died (all dosed 
more than 120 mg) and 24 had fetal resorbtions. The remaining 13 were sacrificed on GD 21 and 100 
progeny were obtained. At examination 15 were externally abnormal and in the group of 85 that was 
externally normal, 11 had skeletal abnormities. In both groups malformations that were encountered 
were eye defects, fascial clefts, hydrocephaly, exencephaly, gastroschisis and irregularities of the 
vertebrae and ribs. In the control group of 105 female rats, 59 produced a litter and 484 progeny were 
obtained. No externally malformations were observed with the exception of 3 which had “wavy ribs”   
Study quality and assessment: 
The study has a number of shortcomings starting with no information on CAS number or purity of the 
two substances used. More information on housing condition, and the allocation of rats into dose 
groups would have been preferred and from the information given in the article it seems that the doses 
given is administrated with no consideration to body weight. Moreover, all progeny were pooled for 
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each group and litter effects were not taken into account. All data is only described in the text and not 
presented in any tables and no statistical analysis was conducted. The study quality is assessed to be 
low and due to the number of dead dams and resorbtions it provides a weak evidence for adverse 
effect on fetal development.  
 
Epidemiology study 
 
Kristensen et al. (2011)  
Summary: This study consisted of 3 parts (in vivo, ex vivo and epidemiology) and the epidemiology 
part will be described here. The focus of the study was to evaluate maternal use of mild analgesics 
during pregnancy in relation to congenital cryptorchidism in humans. A prospective birth cohort study 
was conducted in collaboration between the university hospital of Copenhagen (Rigshospitalet and 
Hvidovre Hospital) and the Turku University Central Hospital in Finland with the use of a self-
administrated questionnaire (assessing the use of mild analgesic by indication, name, dosage, and 
gestational week of administration), completed by 2297 women from both countries and a computer-
assisted interview over the telephone (addressing the use of analgesic), where 491 of the Danish 
mothers participated. Following criteria were established to obtain a genetically well-defined 
population: both the parents and grandparents of the unborn child should have been born and raised in 
Finland or Denmark with a maximum residence abroad of 10 years for the grandparents and father 
and 3 years for the mother. A total of 2521 mothers entered the Danish part of the study and 1071 
boys were examined, of those 5 were excluded as dependent cases and 26 excluded due to missing 
data. From Finland a total of 2728 mothers participated were 1499 boys were examined and from that 
group 25 were excluded as dependent cases along with 4 due to missing data. The assessment of the 
testicular position in the newborns was performed by trained pediatricians. In the Danish part, 
findings in the self-administrated questionnaire indicated that many mothers strongly under-reported 
their use of analgesic unless they were specifically asked and for that reason only the results from the 
computer-assisted telephone interview were taken into account. The data from that part, showed that 
the use of mild analgesic was dose-dependently associated with congenital cryptorchidism and 
especially the use during the second trimester increased the risk - for acetylsalicylic acid data was 
reported to be significant. In the finish cohort the same association could not be identified, only a 
trend was seen in the second trimester. 
Study quality and assessment: The study is well-described and is assessed to be of high quality. The 
study provides strong evidence of adverse effects of acetylsalicylic acid on male sexual development 
leading to congenital chryptorchidism. 
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Other studies 
 
In addition to the above described studies a number of experiments have been conducted where the 
results are not directly related to an endocrine disrupting (ED) action but a possible contribution 
cannot be excluded. 
Schardein et al (1969) presented a study with focus on male/female fertility (rats), the teratogenic 
potential (rats and rabbits) and the effect of treatment in the perinatal and postnatal period (rats). It 
should be noted that treated animals in all groups showed moderate to severe reduction of weight 
gain. Skeletal malformations, reduced litter size and reduced viability of the pups were noted and for 
the dams treated with aspirin in large doses a (> 210 mg/kg) all pregnancies resulted in resorption of 
all fetuses.  
Cappon et al. (2003) conducted a study with focus on comparing the developmental toxicity of 
Aspirin (acetyl salicylic acid) in rabbits when it was administrated throughout organogenesis or 
during sensitive windows of development. A repeated dose study was conducted on GD 7-19 with 
doses of 125, 250 and 350 mg/kg and a single dose study was conducted on day 9, 10 or 11 with dose 
levels of 500, 750 or 1000 mg/kg. On GD 29 cesarean sections were performed and an examination of 
fetuses was done with focus on external, visceral and skeletal development but the results from the 
study showed no malformations associated with the exposure to Aspirin.  
Erikson (1970) investigated the role of dosage and the frequency of administrating on the prenatal 
effect in rats produced by salicylate. Late pregnancy effect in the fetuses included superficial liver and 
gastric hemorrhage and vessel abnormalities and increased death.  
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REACH Registration Dossier 
 
Toxicity to reproduction : 
Outline: 
Following studies and reviews from “Toxicity to reproduction” in the REACH registration dossier has 
already been included here (Collins et al.1971 and Chapin and Sloane 1997) and summaries of their 
data can be found under the section for in vivo studies or reviews. The applicant also reported data 
from several additional studies and study reports that were not possible to retrieve in a search 
conducted up to the 15/11-2017. Based on information available in the REACH registration Dossier a 
short summary of all the additional studies has been added below.  
Summary:  
The studies did not add significant value or new information to the ED MoA or endocrine-related 
adverse effects on salicylic acid. In general the studies show a dose-related decrease in the average 
litter size and pup weight, effects on offspring viability and some studies investigated the effect on 
male/female reproduction but without any significant findings. 
Study quality and assessment:  
The quality of the unavailable studies cannot be assessed based on summaries available on REACH 
registration dossier. They all report to have a minimum of 20 animals/ dose group and a few is 
performed under GLP and follow a guideline. In the experiments that observe some changes, half of 
them report that the findings were significant so in general the studies are assessed to provide a 
moderate evidence for adverse effect on reproduction. 
 
Developmental toxicity / Teratogenicity : 
Outline: 
Following studies and reviews from “Developmental toxicity / Teratogenicity” in the REACH 
registration dossier has already been included here (Cappon et al.2003, Gupta et al.2003, Eriksson et 
al.1971 and Shardein et al.1969) and summaries of their data can be found under the section of in 
vivo and in vitro studies. The applicant also reported data from several additional studies and study 
reports where some of them were available but did not provide any relevant data on ED endpoints and 
others were not possible to retrieve in a search conducted up to the 15/11-2017. Based on information 
available in the REACH registration Dossier a short summary of all the additional studies has been 
added below.  
Summary:  
Overall the studies did not add significant value or new information to ED MoA or endocrine-related 
adverse effects on salicylic acid. Most of the studies were conducted according to OECD guideline 
414 and the study design of the remaining studies did not appear to follow a guideline. In general the 
studies provided information on decreased litter size and neonatal body weight, increased labor time, 
increased resorptions, skeletal abnormalities (vertebral and costal bones), hydrocephalus, delayed 
ossification, internal abnormalities (kidney), subcutaneous, liver and gastric hemorrhage and a 
reduction in fetal liver glycogen. A few studies presented new data showing that increasing dietary 
zinc reduced the teratogenic effects of salicylate, but in patterns different to strain (Wistar or Sprague-
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Dawley) and from that suggesting that marginal zinc deficiency in certain pregnant women might 
increase the possibility of salicylate teratogenesis (Hackman et al.1984) but it was also concluded that 
Zinc deficiency did not cause any lesions detectable in fetal kidneys (Gossrau et al.1988). The new 
results presented do not contribute with results that are relevant for the ED MoA of Salicylic acid.  
Study quality and assessment:  
The quality of the studies cannot be assessed based on summaries available on REACH registration 
dossier but the largest part of the studies contained 15 animals or more per dose. Overall the 
additional part of the studies does not provide information relevant to the ED effect of Salicylic acid. 
 
Other studies: 
Outline: 
A large part of the studies presented under “Other studies” in the REACH registration dossier were 
not possible to retrieve in a search conducted until the 15th of November 2017 and studies with 
endpoints that were considered to be of non-endocrine disruptive character has not been included here 
(abnormality of tail, facial malformations, decreased heart beat and focus regarding mouse palatal)   
 
Repeated dose toxicity – Dermal + Oral: 
Outline: 
Overall the studies under “Repeated dose toxicity” in the REACH registration dossier, presents data 
that show an effect on the kidneys, liver, skin (dermal lesions) and bones (density and lesions). Data 
did not contribute with results that are relevant for the ED effect of Salicylic acid.  
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Reviews  
Reviews on SA have been evaluated in the search for additional relevant studies not found in the 
literature search (Kristensen et al. 2016; Lapczynski et al. 2007; Belsito et al. 2007; SCCNFP 2002; 
Chapin and Sloane 1997). One of the reviews is included in the REACH registration dossier for 
Salicylic acid on toxicity to reproduction (Chapin and Sloane 1997).   
  
4.10.3.4 Summary of the plausible link between adverse effects and endocrine mode of 
action  
 
The androgenic activity is also investigated in vitro and ex vivo and the studies showed decreased 
testosterone production after acetylsalicylic acid exposure in all cases except one. The three studies 
showing a decrease includes investigations in H295 cells (Albert et al.2013) and ex vivo rat fetal 
testicular tissue (Kristensen et al. 2012 and Kristensen et al. 2011).  However, ex vivo studies in 
human testis did not show clear reductions in testosterone production after acetylsalicylic acid 
exposure. One study showed a reduction in testosterone levels in adult testis but it did not reach 
statistical significance (Albert et al.2013) and another study  found results showing that Aspirin 
stimulated testosterone production in testis from gestation week 8-9 but no effects were seen in older 
fetal testis (Mazaud-Guittot et al. 2013). It is unclear whether the differences in effects on ex vivo 
testosterone levels are due to species differences or if there is a difference in either the methods used 
or the sensitivity of the testis at different time-points. Taken together, both the in vitro and the ex vivo 
data provide moderate evidence of an anti-androgenic mode of action of acetylsalicylic acid. The 
human studies available show that Aspirin significantly inhibit the androgen response to hCG 
stimulation in  humans (Conte et al. 1991) and a significant decrease in testicular weight together with 
a decrease in the activity of testicular enzymes and an impairment of the later stages in the 
spermatogenesis were found by (Didolkar et al.1980). The adverse effects observed in human testis 
are likely related to the anti-androgenic MoA of acetylsalicylic acid. When all results are taken into 
consideration the data provide moderate evidence for an anti-androgenic ED MoA and adverse effects 
after exposure to acetylsalicylic acid.  
The ED MoA of Salicylic acid has been investigated in several in vivo, ex vivo and in vitro studies 
(Table 1). Starting with the results from in vitro studies concerning the thyroid function, some of the 
studies found that exposure to salicylates increased the free fraction of T3 and T4 (Larsen et al.1972). 
Going further into details, other studies found that salicylate affects the binding capacity between T4 
and TBPA (Wolff et al.1961) and that T4 then is displaced to TBG (Wolff et al.1961). A similar 
action of salicylate on the binding of T3 to TBPA and TBG was shown (Larsen et al. 1972) and it 
appears that this leads to an increased binding to erythrocytes in vivo (Hansen and Mogensen, 1964). 
Available human studies provide results that back up the in vitro findings. A human study showed an 
increase in free T3 and T4 after Aspirin exposure and this was in line with their in vitro results (Larsen 
et al.1972). Furthermore, studies showed a decrease in total serum T4 concentration (Abend et al. 
1991) and increased uptake of T3 by erythrocytes after salicylate treatment in humans (Hansen and 
Mogensen, 1964). Together, both the in vitro and the human studies provide strong evidence of a 
thyroid disrupting mode of action of salicylates and when all data are taken together, they provide 
strong evidence of a thyroid disrupting MoA of salicylates. No studies investigated endpoints relevant 
for evaluation of adverse effects related to thyroid disruption were found (Table 2).   
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In conclusion, salicylates meet the WHO definition of an endocrine disruptor with anti-androgenic ED 
MoA leading to adverse effects.   
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Table 1. Overview of in vitro and in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of Salicylic acid (SA). 
Reference MoA Quality of 
study 
Evidence for 
ED MoA In Vitro In Vivo 
Albert et al 2013 The production of testosterone by human testis 
revealed a decreased level but did not reach 
statistical significance. In the NCI-H295R cell line, 
exposure to 10-5 and 10-4 M Aspirin significantly 
reduced testosterone production. A reduction was 
also seen in the levels of INSL3, PGD2, PGE2 and 
Inhibin B production.   
 High moderate 
Mazaud-Guittot 
et al. 2013 
 Aspirin showed a significant dose-response 
relationship by increasing the level of 
testosterone in the youngest fetal testis (8-9.86 
GW). Anti-Müllerian Hormone production 
was strongly stimulated.  
PGE2 was significantly inhibited 
High Strong 
Kristensen et al. 
2012 
 
 
 Decreased testosterone levels in rat fetal testis 
were found at all Aspirin concentrations. For 
PGD2 , Aspirin led to a modest decrease in the 
production at all time-points 
High Strong 
Kristensen et al. 
2011 
 The results showed reduced AGD compared to 
control but due to fetal growth retardation 
AGD was undetectable in a number of fetuses 
and statistical data are not presented. A 
significant reduction of testosterone was 
measured. 
High  Strong 
Kristensen et al. 
2011 
 
 
   Dose dependent reduction in testosterone and 
PGD2 production in rat fetal testis with a 
significant result for testosterone at 10 μM 
Aspirin at all time points and a significant 
result for PGD2  at 48 and 72 h. 
 
High Strong 
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Reference MoA Quality of 
study 
Evidence for 
ED MoA In Vitro In Vivo 
Conte et al. 1999  Aspirin significantly lowered the seminal level 
of PGE2 and significantly inhibited the 
androgen response of testosterone, 17 OH-
progesterone, androstenedione and 
dehydroepiandrosterone to hCG stimulation in 
humans. 
High Strong 
Abend et al 1991 The result did not provide evidence for the 
administrated doses of salicylates to directly inhibit 
enzyme activity. 
 Medium none 
Abend et al 1991  Administration of salicylates significantly 
decreased the serum total T4 concentration. 
Medium Moderate 
Balasubramanian 
and 
Ramakrishnan 
1979 
 Decreased percentage uptake of injected Na131I 
and plasma PBI by the thyroid gland in the 
groups exposed to Aspirin (acute and chronic) 
and Aspirin + PGs.  
  
Low Moderate 
Larsen et al. 
1972 
Five smaller studies all confirmed the endpoint that 
addition of salicylate to human sera caused an 
increased in free T3 and T4 
Increase in free T3 and T4 after administration 
of Aspirin to humans (n=2) 
medium In vitro – 
Strong 
In vivo – 
Moderate 
 
Hansen og 
mogensen 1964 
 
 
Increased uptake of 131labelled 1-triiodothyronine 
by human erythrocytes after addition of sodium 
salicylate to human donor blood.  
Increased uptake of 131labelled 1-
triiodothyronine by human erythrocytes in 
blood from humans exposed to sodium 
salicylate  
Medium Moderate 
 
 
Wolff et al.1961 At low T4 concentrations in human serum most of 
the T4 was displaced from TBPA onto TBG by 
addition of natrium salicylate. 
In the situation where T4 was present in higher 
amounts TBG became saturated and T4  was further 
displaced to albumin. 
 High Strong 
Insulin-like growth factor 3 (INSL3), Prostaglandin D2 (PGD2), Prostaglandin E2 (PGE2), anogenital distance (AGD), hCG, protein-bound iodine (PBI), triiodothyronine (T3), thyroxine (T4), 
thyroxine-binding pre-albumin (TBPA), thyroxine binding globulin (TBG). 
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Table 2. Overview of potential endocrine-related adverse effects of Salicylic acid (SA): 
Reference Species, n Adverse effects Quality of study  Evidence for 
adverse effects 
Gupta et al. 
2003 
Rats  The results from the study showed a high concordance between Wistar and 
SD rats regarding developmental anomalies with the exception to 
hydrocephalus in Wistar rats and the VSD in the SD rats. Whether 
acetylsalicylic acid was administrated as a single dose or during the 
organogenesis (GD 6-17), the malformations were similar. Hypo-plastic 
testes were seen in 2 out of 137 fetuses and only in the highest dose group 
High Weak 
 
Davis et al. 
1996 
Rats 
n=105 
 
The results of the study showed that the groups exposed to 200 mg/kg/day 
SA and 260 mg/kg/day ASA had a delay in the onset of labor, an increase 
in labor time and a significantly increase in maternal perinatal mortality. 
Regarding the treatment-associated fetotoxicity only the group exposed to 
ASA 260 mg/kg/day showed a significant increase in the number of 
stillborn pups and peripartum death. 
 
High 
 
Moderate 
Overman and 
white 1983 
Hamsters Failure of closure of the neural tube resulting in cranium bifidum and/or 
spina bifida 
 
Medium None 
Beall and 
Klein (1977) 
Rats 
n=49  
Increase in resorption sites for group IV, reduced mean body weight of 
pups in group II and increase in developmental defects (rib abnormalities, 
craniorachischisis and umbilical hernia, eye defects) in both Aspirin-
treated groups. The combination of food restriction and exposure to 
Aspirin increased the incident of abnormalities from 24.4% in group II 
(=32 pups) to 66,3% (=59 pups) in group IV.     
Medium Moderate 
Wilson et al. 
1977 
Rats (n=  4-
8) 
Monkeys 
(n=8) 
The study result from the rat part showed a significant effect on 
intrauterine death, growth and malformation (cardiac, brain and skeletal) 
at doses of 150 and 200 mg/kg and for the monkey part the results showed 
that both exposure doses (100 and 150 mg/kg) resulted in a slight increase 
in intrauterine death and transitory growth retardation. 
 
High Rat study :  
Strong 
 
Monkey study: 
Moderate 
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Reference Species, n Adverse effects Quality of study  Evidence for 
adverse effects 
Tuchmann-
Duplessis et 
al. (1975)  
 
Rats 
n=32 
 
The results revealed a statistical significant difference in the two groups 
with a prolongation of pregnancy for the treated dams. The parturition 
time was also observed to be prolonged and in the treated group 2/16 dams 
died due to extended period of contractions.  
Medium Strong 
Collins et al. 
1971 
Rats  
3.generations 
Significant findings was observed at dose levels of 3000 and 5000 ppm 
regarding a decrease in the average number of litter size, number of live-
born progeny, number of survivors to day 4 and number of survivors to 
day 21. The decrease in number of live-born appeared to be dose-related. 
At the lower dose levels only a non-significant decrease were observed. 
Medium Moderate 
Didolkar et al.  
1980 
Rats  
n= 24 
The result from the study shows that Aspirin caused a significant decrease 
in testicular weight in the group of immature rats. A decrease in the 
activity of testicular enzymes was observed for hyaluronidase and sorbitol 
dehydrogenase in both groups. Regarding spermatogenesis, for both 
groups, Aspirin caused an impairment of the later stages 
Medium Strong 
Warkany and 
Takacs 1959 
Rats 
n=159 
pregnant rats 
Abnormalities (external or skeletal) were observed in 146 out of 398 
progeny.  
Out of 159 maternal rats, 32 died and 71 resorbed their fetuses after 
exposure 
low weak 
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Fenitrothion, CAS no. 122-14-5 
 
Synonyms: Phenitrothion, Sumithion, Nitrophos, Metathion, 
Metathionine. 
Fenitrothion (C9H12NO5PS) (Figure 1) is an 
organophosphate insecticide and acaricide and the usage is 
assumed to be below 100 tonnes per annum. Fenitrothion 
oxon is the active metabolite. Fenitrothion is classified as 
very toxic to aquatic life with long lasting effects. 
 
4. Human health hazard assessment 
4.10.3 Endocrine disruption 
4.10.3.1 General approach – human health 
4.10.3.2 In vitro information indicative of endocrine activity 
Suzuki et al. (2013)  
Summary: The aim of the study was to identify an organophosphate target in male mouse testis and 
epididymis. The activity-based protein profiling (ABPP) approach was used. An in vitro screen of 
enzyme activity in testis exposed to fenitrothion oxon, the active metabolite of fenitrothion, was 
performed in addition to an in vivo study. Fenitrothion oxon inhibited the enzyme (fatty acid amide 
hydrolase) responsible for hydrolysing anandamide. 
Study quality and assessment: The in vitro part of the study is briefly described in conjunction with 
testicular enzyme activity analysis from the in vivo study. It is unclear how many testis samples were 
used to extract testicular membrane proteome for the in vitro study and whether they were from 
control animals. The study is assessed to be of medium quality. The study does not provide evidence 
of endocrine mode of action of fenitrothion. 
 
Okubo et al. (2004)  
Summary: The study investigated the estrogenic activity of 20 pesticides. Fenitrothion was tested in 
the estrogen receptor (ER)-dependent MCF-7 proliferation assay. In addition, the anti-estrogen 
activity of fenitrothion was investigated by testing for its ability to inhibit cell proliferation induced by 
17β-estradiol. Finally, affinity for human ERα and AR were also tested in a competition assay. 
Fenitrothion suppressed 17β-estradiol-mediated cell proliferation, indicating an anti-estrogenic effect 
at 100 to 1000 µM. Moreover, fenitrothion showed capacity to bind to AR. 
Study quality and assessment: The study is well described, triplicates were performed of each 
experiment and cytotoxicity was tested. The study is assessed to be of high quality. The study 
provides strong evidence of an anti-estrogenic mode of action of fenitrothion  
 
 
Figure 1. 2D structure from 
PubChem  
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Sohoni et al. (2001)  
Summary: The aim of this study was to investigate the oestrogenic, androgenic and anti-androgenic 
activity of fenitrothion and other organophosphate pesticides in in vivo and in vitro assays. An in vitro 
assay with yeasts stably transfected with human androgen receptors (hAR) and human oestrogen 
receptors (hER) and with a reporter gene was used to identify active ligands to androgen and 
oestrogen receptors. Fenitrothion produced a (androgen agonistic) dose-response curve similar to 
dihydrotestosterone, but fenitrothion was 6000 times less potent compared to dihydrotestosterone. 
Anti-androgenic activity was seen for fenitrothion with potency close to flutamide.  
Study quality and assessment: The overall purpose and methods are described but detailed 
information on exposure concentrations, incubation time, incubation temperature etc. is missing and 
more information on purity and CAS-number of the substance would be preferred. Moreover, the 
main text refers to figures that are missing in the paper. The study is assessed to be of low quality. 
The study provides moderate evidence of an endocrine disrupting mod of action of fenitrothion acting 
as an androgen receptor agonist and antagonist. 
 
Tamura et al. (2001)  
Summary: This study investigated the interaction of fenitrothion with the human androgen receptor. 
An in vitro assay, a Hershberger in vivo assay and neurotoxicity assessment were performed. 
Interaction with the androgen receptor (AR) was assessed in HepG2 human hepatoma cells 
transfected with human AR and AR-dependent luciferase reporter gene. The cells were exposed to 
several concentrations of fenitrothion (10-8-10-5 M) in the presence or absence of dihydrotestosterone 
(DHT). The activity was measured by luciferase activity determination and 3 replicates of the 
experiments were performed.   
Dihydrotestosterone-dependent AR activity was reduced by fenitrothion in a concentration-dependent 
manner. Higher concentrations of fenitrothion combined with DHT led to a parallel displacement of 
the DHT dose-response curve to the right with no depression of the maximal response. These results 
indicated that fenitrothion is a competitive AR antagonist. Moreover, the highest concentrations of 
fenitrothion showed slight AR agonist activity. 
Study quality and assessment: The study is well-described and assessed to be of high quality. The 
study provides strong evidence of an anti-androgenic mode of action of fenitrothion. 
 
 
Berger and Sultatos (1997)  
Summary: The aim of the study was to investigate if P450-dependent metabolism of the steroids17β-
estradiol and oestrone is affected be fenitrothion exposure. In vivo studies were performed to measure 
microsomal concentrations of cytochrome P450 (CYP450). Kinetic analysis was performed in vitro to 
characterise the mechanisms behind the inhibition of oestrogen hydroxylation by fenitrothion.  
Co-incubation of hepatic microsomes with fenitrothion and 17β-estradiol suggested competitive 
inhibition of metabolisation (2-hydroxylation) of 17β-estradiol by fenitrothion. Pre-incubation of the 
mouse hepatic microsomes with fenitrothion before addition of 17β-estradiol suggested inactivation of 
certain forms of CYP450. All in all the data indicate that fenitrothion is a mixed inhibitor of 2-
hydroxylation of 17β-estradiol, both serving as a substrate and an irreversible inhibitor of CYP450. 
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Study quality and assessment: The study has some limitations. Purity and CAS-number of the 
substance and information of the number of animals used for isolation of microsomes in the in vitro 
part of the study are not given. Detailed information on the microsomal tissue of origin and what 
(hepatic microsomes) was exposed to fenitrothion in the in vitro assay are not found in the main text 
but in the figure legend. However, the assays seem to be well performed, e.g. with 3-6 determinations. 
The study is assessed to be of medium quality. The study provides moderate evidence of an estrogenic 
mode of action of fenitrothion based on inhibiting effects on enzymatic activity on 17β-estradiol. 
 
 
Clos et al. (1994)  
Summary: The aim of this study was to investigate if fenitrothion was able to modify the testicular 
capacity to metabolize xenobiotics. Animal studies were conducted and an in vitro study was 
additionally performed to investigate whether a metabolic activation is necessary before loss of 
testicular cytochrome P-450. Testicular microsomal enzymes with and without NADPH were 
incubated with fenitrothion at different concentrations (50 µM-200 µM). 
Cytochrome P-450 was not affected by fenitrothion when NADPH was omitted from the testicular 
microsomal fraction, but a decrease of cytochrome P-450 was observed (at 100, 150 and 200 µM 
fenitrothion) when NADPH was added to the medium. Similar responses were observed in hepatic 
microsomal fraction. 
Study quality and assessment: The in vitro study is described under the results section and not in the 
methods. The method is briefly described, not mentioning details on incubation time and temperature 
or the medium used. The study is assessed to be of low quality. The in vitro part of the study does not 
provide data relevant for assessing an endocrine mode of action of fenitrothion.  
 
4.10.3.3 In vivo effects with regard to an endocrine mode of action  
Saber et al. (2016)  
Summary: The objective of the study was to investigate the protective effects of quercetin on 
testicular toxicity in rats induced by fenitrothion. Adult male rats (4-5 months old) were dosed by oral 
gavage (6/group) with fenitrothion (20 mg/kg/day), quercetin or a mixture of fenitrothion and 
quercetin for 70 days. Blood samples for hormone analysis (luteinizing hormone (LH) and 
testosterone) and testis samples (for gene expression and histopathology) were collected at necropsy. 
Semen quality (sperm motility, count and morphology) was assessed. Gene expression levels of 
steroidogenic genes and oxidative stress genes were measured. In the following only data on the 
fenitrothion treated animals will be described. 
All sperm parameters were affected by fenitrothion. Sperm count and motility were both decreased 
and the percentage of sperm abnormalities were increased in the fenitrothion treated group compared 
to controls. The serum testosterone and LH levels were reduced compared to controls. Expression of 
steroidogenic genes (3β-HSD6, 17β-HSD3 and Nr5A1) was down-regulated in testis of the treated 
rats as well as antioxidant gene expression levels. Histopathological assessment of testes revealed 
degenerative changes in the testis of treated rats (focal testicular degeneration, congestion, interstitial 
oedema, vacuolation of germinal epithelium, absence of spermatogenesis, focally necrotic 
seminiferous tubules, spermatid giant cells).  
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Study quality and assessment: The study is well-described, but CAS no is not mentioned. The 
substances is called “Fenithotrion 50% EC” and it is unclear whether that reflects the purity of the 
substance. Fenitrothion was dissolved in corn oil and it would therefore have been preferred that the 
control group had been dosed with corn oil rather than saline. The choice of using saline rather than 
corn oil is probably because quercetin was dissolved in saline. However, corn oil have been used as a 
control solution in many other published studies without giving rise to effects similar to the ones 
reported in this study. Moreover, identical effects as the ones reported in this study have been 
described in the literature for fenitrothion and it is therefore highly plausible that the findings 
observed in this study are related to the treatment with fenitrothion. The quality of the study is 
assessed to be of medium quality. The study provides strong evidence of adverse effects on male 
reproductive organs and strong evidence of an anti-androgenic mode of action of fenitrothion. 
 
Ito et al. (2014)  
Summary: The aim of the study is to investigate the association between fenitrothion spermatotoxicity 
and the endocannabinoid signalling system in male reproductive organs. It is hypothesized that testis 
toxicity is mediated through hydrolysing enzymes affecting substrates for the cannabinoid type-1 
receptor (CB1R). Adult male rats (9 weeks old, n=8-10) were exposed orally to 5 or 10 mg/kg/day of 
fenitrothion 4 days a week for 9 weeks. After euthanasia, blood samples were collected and testes and 
epididymides were dissected for sperm analysis (sperm count, motility and abnormalities) and sperm 
ATP levels were analysed.  In vitro assays for assessment of the enzymatic system hydrolysing 
substrates for CB1R were performed (i.e. analysis of the activity of the enzymes, the testicular 
proteome and the testicular substrate levels).  
Body weight was decreased in the highest exposure group and clinical signs of neurotoxicity were 
observed in the fenitrothion treated groups. Sperm motility and the proportion of normal sperm were 
reduced in the fenitrothion treated animals (5 and 10 mg/kg). The sperm ATP levels were diminished 
by fenitrothion and may explain the change in motility. Enzyme activity (fatty acid amide hydrolase) 
and the endocannabinoid levels (anandamide) were reduced. Significant linear regression was 
observed between enzyme activity (fatty acid amide hydrolase) and sperm motility and morphology. 
Study quality and assessment: Some of the methods used in the study are not described in the methods 
section or are described to a too limited extend in the results section. The administration route is 
poorly described (exposure is oral, but it is unknown whether it is through gavage, diet or other) and 
more information on the housing conditions and purity and CAS-number of the substance would have 
been preferred. The methods used for measuring plasma cholinesterase, are not described and 
inconclusive, preliminary data are included on histological assessment of testis although the methods 
are not described. The methods used for testosterone (plasma and testicular) and follicle stimulating 
hormone levels are insufficiently described. The results of those data are thus unreliable and are not 
included in the above summary or in the evaluation of the effects of fenitrothion. The methods used 
for the remaining endpoints are properly described and the study is assessed to of medium quality. 
The study provides strong evidence of adverse effects on spermatids (motility and morphology).The 
study provides moderate evidence of an enzyme-mediated spermatotoxic mode of action of 
fenitrothion, but it is unknown whether this can be related to an endocrine disrupting mode of action. 
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Suzuki et al. (2013)  
Summary: The aim of the study was to identify an organophosphate target in male mouse testis and 
epididymis. The activity-based protein profiling (ABPP) approach was used. Male mice (n= 6-7 per 
group) were exposed orally to 50 or 100 mg/kg/day of fenitrothion for 10 days. Testes and cauda 
epididymides were weighed and frozen. Testicular membrane proteome was analysed for enzyme 
activity and hydrolysis activity of enzyme substrates (anandaminde and mono-oleoylglycerol) was 
assayed in testes and cauda epididymides. Finally, testicular anandamide levels and brain 
acetylcholinesterase activity were measured. Enzymatic activity (of fatty acid amide hydrolase) in 
testes and cauda epididymides was decreased in both treatment groups compared to controls. Brain 
acetylcholinesterase activity was reduced. 
Study quality and assessment: The method used for measurement of brain acetylcholinesterase 
activity is briefly mentioned in a figure legend and is insufficiently described. The remaining methods 
are well described; however, information on the purity and CAS-number of the substance would have 
been preferred. The study is assessed to be of medium quality. The study provides weak evidence of 
adverse effects on male reproductive organs based decreased testicular enzyme activity in the absence 
of changes in testis and epididymis weights.  
 
Taib et al. (2013)  
Summary: The aim of the study was to determine the effects on sperm, testis and biochemical and 
oxidative stress markers in rat testes. Adult male rats (n= 10/group) were exposed to 20 mg/kg 
fenitrothion for 28 days (5 days a week) trough oral gavage. At necropsy, blood samples were 
collected for biochemical analysis, weight of testes and epididymides was recorded and sperm 
parameters (viability, concentration and morphology) were assessed. Testes were evaluated for 
histopathological changes in classical H&E slides and for ultrastructural changes with transmission 
electron microscopy. Weight gain was reduced in the treated rats. Relative testis weight was increased 
and both absolute and relative epididymis weights were decreased compared to controls. Sperm 
parameters were all affected and showed lower viability and density and abnormal morphology. In 
concordance with these results, testis histology showed degenerative changes (e.g. degeneration of 
germ cells and Leydig cells, disarrangement of spermatogonia and cellular debris in lumens of 
seminiferous tubules) and electron microscopy showed ultrastructural changes (lipid droplets, 
increased number and vacuolation of mitochondria and less condensation of chromatin in late 
spermatids).  
Study quality and assessment: The study is well-described, and thorough. However, more information 
on the CAS-number of the substance and on housing conditions of the animals would have been 
preferred. The study is assessed to be of medium quality. The study provides strong evidence of male 
reproductive adverse effects.  
 
Struve et al. (2007)  
Summary: The objective of the study was to investigate if prenatal exposure to fenitrothion affects the 
development of the sexually dimorphic nucleus of the medial preoptic area in the brain. Time-mated 
female rats (8-10 weeks old) were dosed daily by oral gavage from gestation day (GD) 12 until GD 21 
with 20 or 25 mg/kg/day of fenitrothion (n=5 controls and 6 dams/fenitrothion treatment group). 
Adult offspring were euthanized when females were 60-65 days old and when males were 96-105 
days old. At necropsy, body and brain weights were measured. Brains were assessed for the volume of 
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the nucleus of the medial preoptic area of the hypothalamus (SDN-POA). Other endpoints assessed 
are published in Turner et al 2002. Maternal toxicity was observed. The number of pups born alive 
was decreased in the 25 mg/kg treatment group and a single litter in this group was dead at birth. 
Moreover, signs of neurotoxicity were observed in dams at GD 19 in exposed dams. In controls, the 
SDN-POA volume was larger in males compared to females, as expected. In treated animals, the 
SDN-POA volume was increased whereas in females it was decreased compared to controls of the 
same sex.  
Study quality and assessment: The study is well described but stage of oestrous cycle of adult female 
pups is not assessed before necropsy. The quality of the study is assessed to be of medium quality. 
The study provides weak evidence of neurological adverse effects in pups after in utero exposure to 
fenitrothion.   
 
Okahashi et al. (2005)  
Summary: The aim of this study was to provide a comprehensive evaluation of the anti-androgenic 
activity of fenitrothion in the reproductive and endocrine systems. A one-generation toxicity study 
was performed with dietary exposure (0, 10, 20, 60 ppm) of the parental generation (12 males and 12 
females per group) from 10 days prior to mating until end of lactation and the pups (2 pups per sex 
per litter) were exposed from weaning until the age of 10 weeks. Body weight, food consumption and 
oestrous cycle were monitored in the female parental rats and reproductive parameters (e.g. fertility, 
gestation period and live pups per litter) were recorded. Age and body weight at preputial separation 
and vaginal opening was recorded in the offspring. Moreover, the anogenital distance (AGD, on 
postnatal day (PND) 0, 21 and 35) and nipple retention (on PND 12 and 49) was recorded in the 
offspring. Parental animals were euthanized at weaning of the pups, implantation sites were counted 
and several organs were weighed (including adrenals, ovaries, uterus, testis, epididymides, levator 
ani-bulbocavernosus muscles and glans penis) and organs were evaluated histologically (pituitary 
gland, thyroid glands, uterus, ovaries, testes, epididymides, prostate and seminal vesicle). In the 
ovaries, the number of follicles and corpora lutea was recorded and cholinesterase activity was 
analysed in the brains. Selected F1 animals were euthanized on PND 70 and the remaining pups were 
euthanized PND21 and uterus was weighed. On PND 70 organs weights and microscopic analysis was 
performed as for the parental generation. Sperm analysis (sperm count, motility and morphology) was 
performed in parental and F1 males. The intake of fenitrothion was higher during lactation (1.32, 2.68 
and 7.75 mg/kg/day for the three dose-group, respectively) compared to pregnant and non-pregnant 
non-lactating animals (0.62-0.87, 1.22-1.82, 3.75-5.58, respectively). No effects on reproductive 
parameters or on reproductive organs were found in the parental generation and no effects in any of 
the evaluated endpoints in the offspring showed effects of exposure to fenitrothion during 
development.  
Study quality and assessment: The study is well described and is assessed to be of high quality. 
However, it should be noted that the purity of fenitrothion used in this study was low (94.60%) 
compared to the other studies assessed here (most above 99%). No signs of adverse effects were 
observed on reproduction or development. The study provides especially data to determine the anti-
androgen activity of fenitrothion, but no effects were found of fenitrothion on these endpoints. Based 
on this study, the evidence of adverse effects related to an anti-androgenic mode of action of 
fenitrothion is weak. Similarly, the evidence of adverse effects related to an estrogenic mode of action 
of fenitrothion is weak based on endpoints assessed in female adults.  
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Turner et al. (2002)  
Summary: The aim of the study was to investigate the androgenic activity of fenitrothion on male 
sexual development. An animal study (rats) with in utero exposure to fenitrothion by oral gavage 
from gestation day (GD) 12 to 21 was conducted in two blocks. In the first block time-mated dams 
were exposed to 0, 5, 10 or 15 mg/kg/ day (6 controls and 7 per treated group). In the second block, 
the dams were treated with 0, 20 or 25 mg/kg/day (5 controls and 6 per treated group). The dams were 
assessed for neurobehavioral effects in an abbreviated functional observational battery (e.g. tremors, 
muscle tone and acoustic response). In the offspring, anogenital distance (AGD) was measured and 
nipple retention, vaginal opening, preputial separation, cryptorchidism and hypospadias were 
recorded. Maternal body and organ (liver, kidney and uterus) weights were recorded at necropsy on 
postnatal day (PND) 21. Female and male offspring were euthanized on PND 60-65 and PND 96-105, 
respectively. Body and organ (liver, kidneys, adrenal glands, brain, ovaries, uterus, testes, 
epididymides, seminal vesicles with coagulating glands, vas deferentia, prostate and levator-ani 
bulbocavernosus muscles) weights from offspring were recorded. Some organs (testes, epididymides, 
prostate, liver, kidney and adrenal glands) were fixed and evaluated histopathologically. Dams from 
the two highest dose-groups exhibited signs of maternal toxicity (decreased weight gain) and adverse 
clinical signs of cholinergic stress (effects on gait, open-field tremors and acoustic response) and the 
severity of the clinical signs increased with subsequent days of dosing. However, no effects were 
observed on gestation length or the number of implantations. Effects were seen on the number of live 
pups per litter (in the 25 mg/kg dose-group) as a results of post-implantation loss. Decreased AGD (on 
PND1) and increased nipple retention was observed in the male offspring in the 25 mg/kg dose-group. 
In the female offspring, decreased liver and kidney weights were found in the 5 and 15 mg/kg dose-
groups, respectively. However, these changes were not considered dose-related as no changes in 
organ weights were found in the higher exposure groups.   
Study quality and assessment: The study is well described including much relevant information on 
housing conditions, rationale for choice of doses and methods used for e.g. measurement of AGD. 
However, the CAS-number of fenitrothion is not given and the stage of oestrous cycle at necropsy of 
sexually mature female offspring was not recorded. This may have led to a higher variation in female 
reproductive organ weights and histological morphology thus potential effects may not be detected 
and the relevance of the data is limited. The study is assessed to be of medium quality and provides 
strong evidence of anti-androgenic mode of action of fenitrothion. 
 
Sohoni et al. (2001)  
Summary: The aim of this study was to investigate the oestrogenic, androgenic and anti-androgenic 
activity of fenitrothion and other organophosphate pesticides in in vivo and in vitro assays. A 
prepubertal assay in young male rats (35-36 days old, 10 per group) exposed orally to fenitrothion for 
20 days was performed in two blocks. Diethylstilbestrol (DES) was used as a positive control. At 
termination the day after the last dose, body weight was recorded and liver, epididymides, seminal 
vesicle and prostate were weighed. A Hershberger assay was performed in castrated male rats (6 
weeks old, 5 per group) dosed orally with fenitrothion daily for 10 days. Testosterone propionate 
(subcutaneous injection) was used as an androgenic and flutamide as an antiandrogenic positive 
control. At termination, one day after the last dose, body weight was recorded and liver, kidneys, 
cowper’s glands, levator ani muscle, seminal vesicle and prostate were weighed. Finally, an 
uterotrophic assay was performed in immature mice dosed subcutaneously for 3 days with 
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fenitrothion. At termination, uterus was weighed (blotted and dry weight). Decreased body weight 
was observed in peripubertal male rats exposed to fenitrothion or DES. Weights of prostate and 
seminal vesicles were decreased in both fenitrothion and DES treated rats, but the effect of 
fenitrothion was only significant in the first block. Liver weight was decreased in both fenitrothion 
dose-groups in both blocks but not in DES treated animals. No effects of fenitrothion were observed 
in the Hershberger or uterotrophic assays. 
Study quality and assessment: The paper is easily read and understandable due to fluent English and 
one of the strengths of the study is the use of positive controls/ reference compounds in all the assays. 
However, the study has some limitations given that the main text refers to figures that are missing in 
the paper and description of housing conditions and the exact age and strain of the immature female 
mice used in the uterotrophic assay are not given. There is no rationale why different vehicles 
(hydroxypropyl methoxycellulose (HPMC) and arachis oil) are used in the different experiments. The 
study is assessed to be of medium quality. The study provides weak evidence of an anti-androgenic 
mode of action of fenitrothion. 
 
Tamura et al. (2001)  
Summary: This study investigated the interaction of fenitrothion with the human androgen receptor. 
An in vitro assay, a Hershberger in vivo assay and neurotoxicity assessment were performed. The 
Hershberger assay was performed in 7 weeks old castrated male rats (n=8 per group) dosed by oral 
gavage with 0, 15 or 30 mg/kg fenitrothion concurrently with subcutaneous administration of 
testosterone propionate. Flutamide (50 mg/kg/day) was used as an anti-androgenic positive control. At 
necropsy, organs (including the reproductive organs: prostate, glans penis, seminal vesicle with 
coagulating gland, levator ani-bulbocavernosus muscles) were weighed. Serum testosterone was 
measured. 
Body weight in the high-dose animals and weight gain in the two highest exposure groups were 
decreased after 7 days of treatment. Weights of ventral prostate, seminal vesicle and levator ani-
bulbocavernosus muscles were reduced after fenitrothion treatment (in 15 and 30 mg/kg dose-groups).  
Study quality and assessment: The study is well-described and assessed to be of high quality. The 
study provides strong evidence of adverse effects of fenitrothion on male reproductive organs. 
 
Ashby and Lefevre (2000)  
Summary: The aim of the study was to add data to the database for the peripubertal male rat assay, to 
determine the optimal exposure period to the agents and to assess the relative sensitivity of changes in 
reproductive organ weights and delays in preputial separation. Several test protocols were performed, 
but only one smaller study with focus on the influence of initial body weight on final organ weight 
and the day of preputial separation included exposure to fenitrothion. Immature male rats 35-36 days 
old (approximately 10/group) were dosed by oral gavage with 5 or 15 mg/kg fenitrothion for 20 
consecutive days. The body weight at study start, the day of preputial separation and body weight at 
preputial separation and at 55 days of age were recorded. 
Decreased body weight at 55 days of age but no delay in preputial separation was found for 
fenitrothion. 
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Study quality and assessment: The experiment with fenitrothion is briefly described and information 
on number of animals and dosing interval is described in a table summarizing the data. Information on 
housing conditions is missing and the CAS-number and purity of the chemical are not given. The 
study is assessed to be of medium quality. The study showed no effect on preputial separation and 
does thus not provide evidence of adverse effects on male reproductive development. 
 
 
Sunami et al. (2000)  
Summary: The aim of the study was to evaluate the reliability and feasibility of the 5-day Hershberger 
assay in young mature male rats and to investigate if fenitrothion has an androgen receptor (AR)-
mediated mechanism using this assay. The androgenic and anti-androgenic activity of fenitrothion 
was assessed in the Hershberger assay. Castrated male rats (10 weeks of age, 6 per group) were dosed 
by oral gavage to 0.75, 1.5 or 3 mg/kg/day for 5 days to evaluate the androgenic activity of 
fenitrothion. A similar experiment where the rats were treated with testosterone propionate was used 
to determine the antiandrogenic activity of fenitrothion. Serum androgen levels were measured and 
organs (ventral prostate, seminal vesicles with coagulating gland and levator ani-bulbocavernosus 
muscles) were weighed. Other effects of toxicity were additionally evaluated, such as body weight 
gain, liver weights and cholinesterase activity in the brain. 
No effects on reproductive organ weights were observed for either of the two experiments with 
fenitrothion, with or without treatment with testosterone propionate. The results suggest that 
fenitrothion does not have an AR-mediated mechanism in vivo. 
Study quality and assessment: The study is well-described and the study is assessed to be of high 
quality although the CAS-number of fenitrothion is not given. The study showed no effects 
demonstrating an androgenic or anti-androgenic mode of action of fenitrothion and thus the study 
provides no evidence for endocrine disrupting mode of action of fenitrothion. 
 
Berger and Sultatos (1997)  
Summary: The aim of the study was to investigate if P450-dependent metabolism of the steroids 17β-
estradiol and estrone is affected be fenitrothion exposure. Several experiments were performed using 
intraperitoneal injection of fenitrothion in male mice. In an acute toxicity test animals were killed 4 
hours after exposure to 0, 7, 15, 30, 70 or 500 mg/kg fenitrothion (n=4-5 per group). Time course 
studies were also performed dosing the mice with 70 mg/kg fenitrothion and isolating microsomes 
from livers 0, 4, 8, 16 and 24 hours after dosing. Concentration of hepatic microsomes was measured. 
Effects on microsomal activity were seen at doses below those giving rise to clinical neurological 
signs (symptoms of cholinergic crisis observed at 500 mg/kg). A decrease in the capacity to 2- and 4-
hydroxylate 17β-estradiol was observed in the mouse hepatic microsomes after exposure to 
fenitrothion, based on increased production of 2-OHE2 and 4-OHE2 from 7 mg/kg fenitrothion and 
more. In contrast, 16α-hydroxylation was increased by fenitrothion exposure based on increased 16α-
OHE1 production (from 7 mg/kg and above) and increased estriol production (from 30 mg/kg and 
above). The maximal effects on microsomal activity were seen at 4 and 8 hours after dosing in the 
time course studies with attenuation of the effect later on. In the case of 2-OHE2, production was 
subsequently increased compared to controls 24 hours post-treatment.  
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Study quality and assessment: The study has some limitations. Purity and CAS-number of the 
substance are not given and no information on housing conditions is described besides the name of the 
feed. Additionally, it is not described if a section of the liver or the whole organ is used for isolation 
of hepatic microsomes. They refer to other articles without a brief description of the method on how 
the microsomes were isolated from the livers. Details on the number of animals used and the 
microsomal tissue of origin are not described in the main text but can be found in the figure legends. 
In contrast, the incubation procedures and methods used for microsomal protein measurement are well 
described. The study is assessed to be of medium quality. The study provides moderate evidence of an 
estrogenic mode of action of fenitrothion based on effects on the enzymatic products from CYP450-
dependent hydroxylation of estradiol in the hepatic microsomes. 
 
 
Berlinska and Sitarek (1997)  
Summary: Fenitrothion was dosed daily by oral gavage to female rats from gestation day 6-15 (3, 15, 
30 and 45 mg/kg. Some dams were found dead in the two highest dose-groups. Several findings were 
found in dams in the 30 mg/kg dose-group including but not restricted to decreased weight gain, early 
resorptions and postimplantation losses were found in the 30 mg/kg group as well as fetal effects 
including deleyed ossification, enlarged cerebral ventricles and decreased fetal body weight and 
length. In the 15mg/kg dose-group, maternal toxicity was observed as decreased liver weight and fetal 
toxicity was observed as enlarged cerebral ventricles.  
Study quality and assessment: The article is in polish but an English abstract was available. The 
quality of the study is not assessable based on the abstract only. The study provides strong evidence of 
adverse effects on female reproduction and foetal development based on changes such as early 
resorptions, delayed ossification and decreased foetal body weight. However, the relation to an 
endocrine mode of action is weak. 
 
Clos et al. (1994)  
Summary: The aim of this study was to investigate if fenitrothion was able to modify the testicular 
capacity to metabolize xenobiotics. Male rats were exposed orally to fenitrothion in an acute (single 
dose of 165 mg/kg), a subacute (55 mg/kg for 3 days) or a chronic (5.5 mg/kg for 30 days) study. The 
testicular microsomal system (CYP-450, cytochrome b5 and NADPH cytochrome c reductase 
activity) and plasma testosterone levels were determined. The effects on the microsomal system were 
compared to the microsomal system in the liver. Moreover, plasma testosterone levels were measured. 
Acute and subacute exposure to fenitrothion inhibited testicular cytochrome P-450 (around 50% 
compared to controls). Decreased CYP-450 concentration was also seen in livers of rats after acute or 
subacute exposure. Plasma testosterone levels were markedly decreased after acute and subacute 
exposure but not after chronic exposure to fenitrothion. 
Study quality and assessment: The study has some limitations. The exact number of animals used is 
not given, but based on the table summarizing the results on microsomal enzymes, an estimation of 8 
animals per group can be made (each value is a mean of 4 samples, each sample consisting of pooled 
tissue from 2 rats). Moreover, very few details on housing conditions are described and it is not clear 
whether the control group was dosed with the vehicle, corn oil, or not. The study is assessed to be of 
low quality. The study provides strong evidence of an anti-androgenic mode of action of fenitrothion.  
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Holmes and Boag (1990)  
Summary: The aims of the study were (i) to gather information useful for interpretation of results 
from field studies and (ii) to determine the usefulness of an automated system for collection of 
behavioural data in evaluating neurobehavioral effects. Behavioural and reproductive effects were 
evaluated in zebra finches exposed orally (catheter down the oesophagus to the crop) to fenitrothion 
(0, 1.04 or 3.80 mg/kg, n=16 pairs per group). The birds were fasted 10-12 hours before treatment and 
10-15 minutes after dosing. Pairs were assessed for their breeding success, distributed among the 
groups and united the day before treatment. Reproductive parameters (number of eggs, nestlings and 
fledglings) were monitored and activity (perch hopping) was recorded. 
Effects were observed on activity levels but not on reproduction.  
Study quality and assessment: The study has some limitations that may affect the sensitivity of 
endocrine related endpoints on reproduction. The feed given to the birds included alfalfa sprouts and 
soy bean oil was used as vehicle in controls, both of which contain phytoestrogens. Control animals 
were thus exposed to estrogenic substances and this may potentially mask possible effects on these 
endpoints. Moreover, more information on housing conditions and CAS-number would have been 
preferred. The study is assessed to be of low quality. The study showed no effects on reproductive 
parameters and does thus not provide evidence of adverse effects on reproductive function. 
 
Lehotzky et al. (1988)  
Summary: The aim of the study was to investigate the prenatal effects of fenitrothion. Mated female 
rats (6 per group) were dosed by oral gavage from gestation day 7-15 with 0, 5, 10 or 15 mg/kg 
Sumithion (50% fenitrothion) fenitrothion per day. The number of pups per litter was recorded and 
the day of eye- and ear opening was recorded. Ten males from each dose-group were used in a battery 
of behavioural tests. The animals were tested on days 26, 36 and 104 post-partum. 
Treated animals had reduced horizontal activity in the highest exposure-group on day 104. On days 26 
and 104, the highest exposure group performed worse than the other groups in the motor coordination 
test (rotorod). The two highest exposure-groups showed more conditioned responses and shorter 
latencies compared to controls during the first days of testing in the conditioned escape test. Also, the 
two highest treatment groups spent more time in the social interaction test compared to controls. 
Study quality and assessment: The study is well described, but the substance used for the study 
contained 50% fenitrothion, which is a much lower concentration/ purity compared to the substances 
used in other studies. It is not stated what the other half of the substance is consisting of. The study is 
assessed to be of medium quality. The study provides strong evidence for behavioural effects of 
fenitrothion. However, the relation to an endocrine mode of action is weak. 
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Draft Assessment Report  
In the draft assessment report for fenitrothion, 6 reproductive toxicity studies are included. One of 
these studies is described above (Sunami et al. 2000), but the remaining studies were not possible to 
retrieve from PubMed or a Google search (05/12-2017, 15:51 GMT+1) (Hoberman 1990; Morseth 
1987; Morseth 1986a; Morseth 1986b; Kohda et al. 1975). According to the draft assessment report, 
these studies count a multigeneration study in rats, 3 developmental toxicity studies in rats and rabbits 
and a dominant lethal assay in mice. In general, the studies showed reduced body weight in dams and 
offspring. Neither evidence of foetotoxicity nor any evidence of impaired reproductive performance 
was recorded. Reduced lactation indices were reported in a study with rats exposed to 120 ppm 
(corresponding to 7.4 mg/kg/day) and abortions were observed in another study with rabbits exposed 
to 30 mg/kg/day which was considered related to maternal toxicity. It is stated in the summary that the 
multigeneration and developmental toxicity and long-term studies do not reveal findings suggestive of 
an endocrine disrupting mode of action of fenitrothion. 
Study quality and assessment: The quality of the studies cannot be assessed based on the summaries 
available in the draft assessment report. The additional studies included in the draft assessment report 
not already assessed above do not add significant data on endocrine disrupting adverse effects or on 
an endocrine mode of action of fenitrothion. 
 
4.10.3.4 Summary of the plausible link between adverse effects and endocrine mode of 
action  
 
Several studies showed effects indicating an androgenic and/or anti-androgenic mode of action of 
fenitrothion (Table 1). In vitro studies either found that fenitrothion has the capacity to bind androgen 
receptors (AR) or that it acts as an androgen giving rise to dose-response curves similar to 
dihydrotestosterone in the assays suggestive of an androgenic mode of action (Okubo et al. 2004; 
Sohoni et al. 2001). Some studies suggest that fenitrothion may additionally have anti-androgenic 
activity similar to flutamide or act as a competitive AR antagonist (Sohoni et al. 2001; Tamura et al. 
2001). Overall, the studies provide moderate evidence of an androgenic and anti-androgenic mode of 
action of fenitrothion in vitro. 
One study has investigated the anti-androgenic mode of action of fenitrothion in vivo and the data 
support the findings from the in vitro studies. Decreased serum testosterone levels and down-
regulation of testicular steroidogenic genes were found (Saber et al. 2016). A Hershberger assay was 
performed in three studies but they found conflicting results although two of the studies used the same 
dose of fenitrothion (15 mg/kg). One study found no effects of fenitrothion (Sohoni et al. 2001) 
whereas another study found reduced male reproductive organ weights (Tamura et al. 2001). This 
could be explained by a larger group size (n=8 versus n=5/group) and the use of a lower dose of 
dihydrotestosterone (0.05 mg/day versus 0.12 mg/day in the latter study. The third study tested low 
levels of fenitrothion (up to 3 mg/kg) in the Hershberger assay compared to the two other studies 
(Sunami et al. 2000). Based on these studies, there is strong evidence of an anti-androgenic mode of 
action of fenitrothion in vivo.  
In contrast to the few studies on in vivo mode of action, there are several animal studies showing 
adverse effects on male reproductive organs, male reproductive development, plasma testosterone 
levels and on sperm parameters, all suggesting an anti-androgenic mode of action of fenitrothion 
(Table 2). Decreased sperm count, sperm motility and sperm abnormalities were observed in adult 
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male rats, a finding retrieved in different laboratories (Saber et al. 2016; Ito et al. 2014; Taib et al. 
2013). One study investigated plasma testosterone levels and found a reduction after fenitrothion 
treatment (Clos et al. 1994). Decreased seminal vesicle weight and increased weight of testis with 
degenerative changes has been reported (Taib et al. 2013) although other studies did not see such 
effects (Suzuki et al. 2013; Okahashi et al. 2005). The absence of effects in the latter studies may be 
due to differences in species (mice versus rats), fewer animals per group (6-7/group versus 10/group) 
and lower doses (60 ppm corresponding to 7.75 mg/kg during the highest exposure period versus 20 
mg/kg). Finally, effects on male development such as decreased anogenital distance and increased 
nipple retention in male offspring exposed in utero (Turner et al. 2001) are known to be related to an 
anti-androgenic mode of action and support the previous findings in in vitro and in vivo studies 
suggesting an anti-androgenic mode of action of fenitrothion. All in all, the in vivo studies provide 
strong evidence of adverse effects that can be related to an endocrine disrupting mode of action of 
fenitrothion and there is a strong link to and anti-androgenic mode of action. 
The mechanisms related to the effects observed on sperm motility and morphology have been 
investigated in a study (Ito et al. 2014) and they found decreased sperm ATP levels, reduced enzyme 
activity (fatty acid amide hydrolase) and the lower endocannabinoid levels (anandamide) in treated 
animals. A correlation between the enzyme activity and sperm motility and morphology was found. 
Another study supported the findings on activity of this enzyme in vivo and in vitro (Suzuki et al. 
2013) and these changes appear to be linked to the observed effects on motility and morphology (Ito 
et al. 2014) and low ATP levels may explain the effects on sperm motility, but it is unclear whether 
these mechanisms could be activated through endocrine disruption. Aside from this, other in vivo 
adverse effects were found to be consistent with an anti-androgenic mode of action and agree with the 
findings in vitro and in vivo an anti-androgenic mode of action of fenitrothion. There is strong 
evidence of a link between the adverse effects observed in vivo and the mode of action found in vitro 
and in vivo studies. 
The estrogenic effects have been investigated to a lesser extent compared to the anti-androgenic 
activity of fenitrothion (Tables 1 and 2). Two in vitro studies suggest an anti-estrogenic mode of 
action of fenitrothion in MCF-7 cells (Okubo et al. 2004) and a competitive inhibition of the 
metabolisation of 17β-oestradiol (Berger and Sultatos 1997). However, these effects may be mediated 
through another pathway than through estrogen receptor (ER), as binding to the human ER was not 
demonstrated (Sohoni et al. 2001). There is weak evidence that fenitrothion has an anti-estrogenic 
mode of action in vitro. 
A mode of action of fenitrothion involving oestrogen levels is supported by in vivo studies showing 
decreased cytochrome P450 activity and ability to hydroxylate 17β-oestradiol in hepatic and testicular 
microsomes after fenitrothion exposure (Clos et al. 1994; Berger and Sultatos 1997). In the 
uterotrophic assay, no effects were observed indicating that fenitrothion does not act as an oestrogenic 
agonist (Sohoni et al. 2001). There is thus weak evidence for an anti-estrogenic mode of action of 
fenitrothion in vivo. 
In vivo studies did, however, not show adverse effects supportive of an anti-estrogenic mode of action 
of fenitrothion. No in vivo studies showed effects on weight or histopathology of female reproductive 
organs after adult or in utero exposure to fenitrothion (Okahashi et al. 2005; Turner et al. 2002). There 
is weak evidence of adverse effects of fenitrothion on female reproduction in vivo. All in all, the 
available in vitro and in vivo data suggest that fenitrothion may have an anti-androgenic mode of 
action but more studies focused on oestrogen sensitive endpoints are necessary to elucidate this 
further. 
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Thyroid disrupting effects of fenitrothion has not been investigated. However, a single study with 
exposure during gestation showed behavioural changes in male rat offspring. Female offspring were 
not tested and it is not known whether the behavioural changes are sex-specific. The behavioural 
changes could be related to the endocrine disrupting modes of action described above or it may be 
related to thyroid disruption. Based on the few available data on behaviour, it is not possible to 
determine whether it is related to endocrine disruption or not. 
 
Summary and conclusions 
In vitro and in vivo studies demonstrate that fenitrothion has an anti-androgenic mode of action. This 
was shown both on the receptor level (binds to AR), blood hormone level (testosterone) and at gene 
expression level in testis (steroidogenic genes) and in vivo adverse effects (effects on male 
reproductive organs and male development) suggestive of an anti-androgenic mode of action 
supported these findings. There are less data supporting an androgenic mode of action of fenitrothion. 
The available data suggest that fenitrothion may have anti-estrogenic mode of action, but more in vivo 
studies with focus on oestrogen sensitive endpoints are necessary to determine if fenitrothion gives 
rise to adverse effects related to such a mode of action. 
There is strong evidence of an anti-androgenic mode of action of fenitrothion leading to adverse 
effects on male reproductive organs and male development. In conclusion, fenitrothion fulfil the 
WHO definition of an endocrine disruptor. 
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Table 1. Overview of in vitro and in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of fenitrothion.  
Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
Saber et al. 
2016 
 The serum testosterone and luteinizing 
hormone (LH) levels were reduced. 
Expression of steroidogenic genes was down-
regulated in testis of the treated rats. 
Medium Strong 
Ito et al. 2014  Fatty acid amide hydrolase activity and 
anandamide levels were reduced. Significant 
linear regression was observed between fatty 
acid amide hydrolase activity and sperm 
motility and morphology. 
Medium Weak 
Suzuki et al. 
2013 
Fenitrothion oxon (active metabolite of 
fenitrothion) inhibited the enzyme 
responsible for hydrolysing anandaminde. 
Enzymatic activity (of fatty acid amide 
hydrolase) in testes and cauda epididymides 
was decreased in both treatment groups 
compared to controls. 
Medium None 
Okubo et al. 
2004 
Fenitrothion suppressed 17β-estradiol-
mediated cell proliferation in MCF-7 cells, 
indicating an antiestrogenic effect of the 
pesticide. Moreover, fenitrothion showed 
capacity to bind to AR. 
 High Moderate  
Sohoni et al. 
2001 
Fenitrothion produced a (androgenic) 
dose-response curve similar to 
dihydrotestosterone in yeast cells with 
integrated AR, but fenitrothion was 6000 
times less potent compared to 
dihydrotestosterone. Anti-androgenic 
activity was seen for fenitrothion with 
potency close to flutamide. 
No effects of fenitrothion were observed in 
the Hershberger or uterotrophic assays. 
Low (in vitro)-
Medium (in vivo) 
Moderate (in vitro)-
Weak (in vivo) 
Tamura et al. 
2001 
Dihydrotestosterone-dependent AR 
activity was reduced by fenitrothion in a 
concentration-dependent manner. Higher 
concentrations of fenitrothion combined 
with DHT led to a parallel displacement of 
In a Hershberger assay (n=8 per group), body 
weight in the high-dose animals and weight 
gain in the two highest exposure groups were 
decreased after 7 days of treatment. Weights 
of ventral prostate, seminal vesicle and 
High Strong (in vitro) – 
Moderate (in vivo) 
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Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
the DHT dose-response curve to the right 
with no depression of the maximal 
response. These results indicated that 
fenitrothion is a competitive AR 
antagonist. 
levator ani-bulbocavernosus muscles were 
reduced after fenitrothion treatment. 
Sunami et al. 
2000 
 No effects of fenitrothion were observed on 
reproductive organ weights in the 
Hershberger assay with or without co-
administration of testosterone propionate.  
High Weak 
Berger and 
Sultatos 1997 
Co-incubation of hepatic microsomes with 
fenitrothion and 17β-estradiol suggested 
competitive inhibition of metabolisation of 
17β-estradiol. Pre-incubation of the 
hepatic microsomes with fenitrothion 
before addition of 17β-estradiol suggested 
inactivation of certain forms of CYP450. 
 
A decrease in the capacity to (2- and 4-) 
hydroxylate 17β-estradiol was observed in 
the mouse hepatic microsomes after exposure 
to fenitrothion from 7 mg/kg and above. In 
contrast, 16α-hydroxylation was increased by 
fenitrothion exposure (from 7 mg/kg and 
above). The maximal effects on microsomal 
activity were seen at 4 and 8 hours after 
dosing and the effects were attenuated later 
on. In the case of 2-OHE2, production was 
subsequently increased compared to controls 
24 hours post-treatment. 
Medium Moderate 
Clos et al. 
1994 
Cytochrome P-450 was not affected by 
fenitrothion when NADPH was omitted 
from the testicular microsomal fraction, 
but a decrease of cytochrome P-450 was 
observed (at 100, 150 and 200 µM 
fenitrothion) when NADPH was added to 
the medium. Similar responses were 
observed in hepatic microsomal fraction. 
Acute (165 mg/kg) and subacute (55 mg/kg) 
exposure to fenitrothion inhibited testicular 
cytochrome P-450. Decreased CYP-450 
concentration was also seen in livers of rats 
after acute or subacute exposure. Plasma 
testosterone levels were markedly decreased 
after acute and subacute exposure but not 
after chronic (5.5 mg/kg) exposure to 
fenitrothion. 
Low Strong 
Androgen receptor (AR), dihydrotestosterone (DHT). luteinizing hormone (LH) 
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Table 2. Overview of potential endocrine-related adverse effects of Fenitrothion. 
Reference Species, n Adverse effects Quality of study  Evidence for 
adverse effects 
Saber et al. 
2016 
Rats, 
n=6/group 
Adult male rats treated with Fenitrothion for 70 days showed decreased 
sperm count and motility and the percentage of sperm abnormalities were 
increased. Histopathological assessment of testes revealed degenerative 
changes in the testis of treated rats.  
Medium Strong  
Ito et al. 2014 Rats, n=  
8-10/group 
Body weight was decreased in adult males in the highest exposure group 
and clinical signs of neurotoxicity were observed in the fenitrothion treated 
groups. Sperm motility and the proportion of normal sperm were reduced 
in the fenitrothion treated animals (5 and 10 mg/kg). The sperm ATP levels 
were diminished by fenitrothion. Enzyme activity (fatty acid amide 
hydrolase) and the endocannabinoid levels (anandamide) were reduced by 
fenitrothion. 
Medium Strong 
Suzuki et al. 
2013 
Mice, n=  
6-7/group 
No effects on male reproductive organ weights were found. Brain 
acetylcholinesterase activity was reduced. 
 
Medium Weak 
Taib et al. 
2013 
Rats, 
n=10/group 
Weight gain was reduced in the treated adult male rats. Relative testis 
weight was increased and both absolute and relative epididymis weights 
were decreased compared to controls. Sperm parameters showed lower 
viability and density and abnormal morphology. Testis histology showed 
degenerative changes and electron microscopy showed ultrastructural 
changes of testes.  
Medium Strong 
Struve et al. 
2007 
Rats, n=5 
controls and 
6 dams/ 
treatment 
group 
In offspring exposed in utero, the volume of the nucleus of the medial 
preoptic area of the hypothalamus was increased whereas in females it was 
decreased compared to controls of the same sex.  
Medium Weak 
Okahashi et 
al. 2005 
Rats, 
n=2 pups/ 
sex/ litter, 
10-12 
litters/ 
group 
No effects on reproductive parameters or on reproductive organs were 
found in the parental generation and no effects in any of the evaluated 
endpoints in the offspring showed effects of exposure to fenitrothion 
during development.  
High Weak 
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Reference Species, n Adverse effects Quality of study  Evidence for 
adverse effects 
Turner et al. 
2002 
Rats,  
n=5-7 
dams/group 
Decreased AGD and increased nipple retention was observed in the male 
offspring in the 25 mg/kg dose-group.  
Medium Strong 
Sohoni et al. 
2001 
Rats, 
n=10/group 
Weights of prostate and seminal vesicles were decreased in fenitrothion 
treated rats, but the effect of fenitrothion was only significant in the first 
block. 
Medium Weak 
Ashby and 
Lefevre 2000 
Rats, 
n=10/group 
Decreased body weight at 55 days of age but no delay in preputial 
separation was found in young male rats  
Medium None 
Sunami et al. 
2000 
Rats,  
n= 6/group 
No effects of fenitrothion were observed on reproductive organ weights in 
the Hershberger assay with or without co-administration of testosterone 
propionate. The results suggest that fenitrothion does not have an AR-
mediated mechanism in vivo. 
High Weak 
Berlinska and 
Sitarek 1997 
Rats, 
n=unknown 
Fetal toxicity was observed as enlarged cerebral ventricles. No effects were 
observed in the lower dose-groups (3 mg/kg). 
Not assessable Weak 
Clos et al. 
1994 
Rats, 
n=probably 
8/group 
Plasma testosterone levels were markedly decreased after acute and 
subacute (high doses) exposure but not after chronic (lower dose) exposure 
to fenitrothion. 
Low Strong 
Holmes and 
Boag 1990 
Finches, n= 
16 pairs per 
group  
Effects were observed on activity levels in adults but not on reproduction.  
 
Low None 
Lehotzky et 
al. 1988 
Rats, 
n=6/group 
The male offspring exposed in utero had reduced horizontal activity in the 
highest exposure-group on day 104. On days 26 and 104, the highest 
exposure group performed worse than the other groups in the motor 
coordination test (rotorod). The two highest exposure-groups showed more 
conditioned responses and shorter latencies compared to controls during 
the first days of testing in the conditioned escape test. Also, the two highest 
treatment groups spent more time in the social interaction test compared to 
controls. 
Medium Strong 
Anogenital distance (AGD) 
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Bifenthrin, CAS no. 82657-04-3 
 
Synonyms: Cyclopropanecarboxylic acid, (2-methyl-3-phenylphenyl)methyl (1R,3R)-3-[(Z)-2-
chloro-3,3,3-trifluoroprop-1-enyl]-2,2-dimethylcyclopropane-1-carboxylate (IUPAC Name) 
Bifenthrin is a pyrethroid insecticide. Bifenthrin has 3 sites of isomerism and can therefore exist as 8 
potential enantiomers. Each of the four pairs of enantiomers is present as racemic mixture. The cis-Z 
isomers are the predominant species comprising minimum 98% total Bifenthrin (Figure 1) ((ECHA 
2011). In 2012, it was decided in EU that biocidal products 
with bifenthrin of product type 18, insecticides, acaricides 
and products to control other arthropods shall no longer be 
placed on the market with effect from 1 May 2013 because 
of an unacceptable risk for the aquatic compartment. 
The decision was based on a RAC opinion proposing 
harmonised classification and labelling at Community level 
of bifenthrin (ECHA 2011). Bifenthrin was evaluated in the 
US EPA EDSP Tier 1 screening assays. The results of these 
assays are described under “other information used” 
 
5. Environmental hazard assessment 
5.6.2 Endocrine Disruption 
5.6.2.1 General approach – environment 
The peer reviewed literature was investigated by use of Web of Science including all databases. 
Search terms included bifenthrin + endocrine, bifenthrin + fish, bifenthrin + amphibian, bifenthrin + 
vitellogenin. A google search including the search terms bifenthrin + endocrine, bifenthrin + fish, 
bifenthrin + amphibians and bifenthrin + vitellogenin were also performed and revealed the US EPA 
EDSP tier 1 screens of which the amphibian metamorphosis assay (AMA) and the fish short term 
reproduction assay (FSTRA) are discussed. Studies solely investigating effects of bifenthrin in 
invertebrates were not taken into account due to lack of endocrine specific endpoints. Studies using 
mixtures of chemicals where the effects could not be directly related to bifenthrin were also not taken 
into account. A summary of the EDSP tier 1 screens including in vitro screens and mammalian 
screens are included. Also, abstracts from relevant mammalian tests published at Toxnet are included. 
 
  
 
Figure 1. 2D structure from PubChem  
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5.6.2.2 In vitro information indicative of endocrine activity. 
 
Beside the study below, in vitro information is included when such assays were conducted in 
combination with in vivo environmental assays. An overview of the in vitro assays can be seen in 
Table 2.  
 
Zhao et al. (2014)  
Summary: The authors tested the effects of bifenthrin enantiomers on human trophoblast cells (JEG-3 
cell line) in vitro. Biomarkers included cell viability, hormone secretion, and steroidogenesis gene 
expression. The interactions of BF enantiomers with the estrogen receptor were predicted. The study 
showed that progesterone and human chorionic gonadotropin secretion were induced below cytotoxic 
levels. Also, gene expression of the progesterone receptor was increased significantly. An 
upregulation of gene-expression of GNRHI, GNRHRI, CYP17 and CYP19 was seen – especially for 
the S-BF enantiomer which generally affected the endocrine markers more than R-BF. This difference 
in effect was also shown by molecular docking of enantiomer ER binding affinity.  
Study quality and assessment: The study is well described and evaluated to be of high quality. The 
link between the gene-expression data, molecular docking and progesterone secretion to the 
estrogenic pathway is highly plausible. 
 
5.6.2.3 In vivo effects with regard to an endocrine mode of action  
Bertotto et al. (2017)  
Summary: In this study, the authors investigated the hypothesis that BF impairs dopaminergic (DA) 
and estrogenic regulation in fish and this was tested in both embryonic and one-month old juvenile 
zebrafish (Danio rerio) with exposure to measured concentrations of 0.34 and 3.1 μg/L BF for 96 
hours. Effects on the estrogenic pathways were investigated by analysis of gene expression (qRT-
PCR) of estrogen receptor α (ERα), ERβ1, ERβ2, LHβ, FSHβ, vitellogenin (VTG), cytochrome P450 
cyp19a1a and cyp19a1b. Effects on the dopaminergic pathways were investigated by gene expression 
of tyrosine hydroxylase (TH), dopamine receptor 1 (DR1) and 2A (DR2A) and dopamine active 
transporter (DAT). Levels of E2 were measured by ELISA. Dopamine and its metabolites 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) concentrations were measured 
by LC-MS/MS. For embryonic exposure, 20 viable embryos (3 hpf) were placed in 10 ml of the 
working solution. Treatments consisted of vehicle control (0.1%EtOH), 0.15 μg/L BF, and 1.5 μg/L. 
For qPCR assays, each replicate pool consisted of 20 embryos with 5 to 12 replicate pools per 
treatment. For the E2 ELISA assay, each replicate pool consisted of 80 embryos (20 embryos per petri 
dish) with 6 to 7 replicate pool per treatment. For measurements of DA and its metabolites, 200 
embryos (20 embryos per petri dish) were used for each replicate pool, with 3 to 4 replicate pool per 
treatment group. Water was sampled before and after exposure to determine measured values of BF. 
For juvenile exposure, fish were transferred to glass beakers at 30 dpf. Juveniles were exposed to 
vehicle control, 0.15 and 1.5 μg/L BF nominal concentrations, for 96 hours. No significant difference 
was identified in hatch per day, morphological deformities or survival in embryos or juveniles 
compared with controls in both zebrafish stages. Significant decreases of TH (31 fold) and DR1 (33 
fold) transcripts, and HVA levels as well as ratios of HVA/DA and HVA+DOPAC/DA in zebrafish 
embryos were observed after BF treatment. Significant 2-fold and 4.5-fold increases in the expression 
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of ERβ1 were observed in juveniles exposed to 0.15 μg/L and 1.5 μg/L BF respectively. A significant 
increase in the DOPAC/DA ratio was also noted. E2 decreased significantly in a dose-dependent 
relationship in the embryonic exposures and a trend toward increasing E2 was seen in the juvenile 
exposure. These results show a possible anti-estrogenic effect of BF in embryos, and estrogenicity in 
juveniles. 
Study quality and assessment: The study is very detailed and is assessed to be of high quality. The 
results on the dopaminergic pathway of BF exposure are quite clear because of more than 30-fold 
decreases in gene transcription of key genes but the link to the estrogenic effects are unclear although 
plausible. The effects on the estrogenic pathway in embryos and juveniles are well established and of 
medium-high plausibility. In this study, there are no endocrine specific adverse endpoints so the link 
to adversity is weak. 
 
Decourten & Brander (2017)  
Summary: In this study, the authors investigated the effects of 1 ng/l BF exposure (measured 
concentration, 0.89 ng/l) at either 22  °C or 28 °C in a multigenerational study with inland silverside 
(Menidia beryllina). Parents (P) were exposed for 14 days prior to the initiation of spawning trials. 
Embryos in the F1 generation were exposed to EDCs until 21-days post hatch (dph), reared to 
adulthood (~35 days) in clean water at elevated temperatures, and spawned. F2 juveniles were not 
exposed to BF. Five replicates of 10-13 were used for F0. For the spawning assays, 8–15 adult fish 
(depending on exposure mortality) for the F0 generation and 9–18 fish for the F1 generation were 
used. F1 sex ratios were significantly influenced by elevated temperature but not by BF alone. The 
authors observed fewer viable offspring (larvae) at 22 °C and increased developmental deformities in 
the F1 and F2 generations, with a greater impact on F2 juveniles caused by BF exposure. Also, fewer 
eggs were produced by F1 at 22 °C. 
Study quality and assessment: The study is very detailed and is assessed to be of medium-high quality 
all though the authors only used one BF exposure group and the exposure concentration of 0.89 ng/l 
bifenthrin is very low. Also, the exposure to 1 ng/l EE2 did not affect sex ratio at 22 ⁰C. It is not 
discussed if the phenotypic sex in the inland silverside is reversible and if the 35-day depuration 
period could affect the sex ratio result. Beside sex ratio, no endocrine specific endpoints were 
investigated so the potential adverse effects on fecundity cannot be directly linked to ED effects of 
BF. The link to e.g. anti-estrogen and anti-androgen effects of BF and its metabolites is weak.  
 
Li et al. (2017) 
Summary: In this study, the effect of BF on the testicular development in the marine rockfish 
Sebastiscus marmoratus was investigated after 50 days of exposure. Three concentrations of BF (1, 
10 & 100 ng/L) as well as a solvent control group (4 µl/l acetonitrile) were tested with groups sizes of 
25 fish per concentration. Endpoints and biomarkers included GSI (gonadosomatic index), T and E2 
hormone levels and caspase 3 activity in testes, CYP19A & B gene expression, histological 
examination of testes and cell apoptosis in testes (TUNEL assay). BF from 1 ng/l caused a change in 
the percentage of spermatocytes, spermatogonia, and sperm with an increase in both spermatocytes 
and spermatogonia while the percentage of sperm cells decreased (n=3). The levels of T and E2 
decreased from 10 and 1 ng/l BF respectively (n=6). CYP19A gene expression levels decreased in 
both brain and testes whereas CYP19B expression increased in both organs. The marker for apoptosis; 
Caspase-3 activity increased in a dose dependent manner with significance from 10 ng/l BF and this 
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apoptotic effect was confirmed in the TUNEL assay from 1 ng/L BF. The concentrations of BF were 
quantified in the liver of 4 fish per group.   
Study quality and assessment: The study is assessed to be of medium-high quality. The study 
investigated the effect of chronic (50 days) exposure of BF to adult male S. marmoratus. The study 
design and biomarker examination is clearly described: Fish were randomly sampled from two 
replicates of 25 fish for the different biomarkers. Only 3-6 fish per exposure group were though used 
to investigate single endpoints. The link between decreased E2 and Cyp19A is strong but decreased T 
is not linked to decreased CYP19A. The apoptotic effects cannot be directly linked to an endocrine 
mechanism. Decreased sperm cell number were based on only 3 fish per group but could be 
moderately linked to decreased T. 
 
Brander et al. (2016)  
Summary: The effects of BF were investigated in two separate experiments with the euryhaline fish 
Menidia beryllina: A 14-day exposure of juvenile inland silverside M. beryllina and a 21-day 
reproduction study with adult silverside. Also, a 96-h acute toxicity range finding study were 
performed to determine BF LC50. The main objective of the studies was to assess the molecular and 
physiological responses of BF with focus on ED-related effects. The authors evaluated responses of 
juvenile fish exposed to BF using a specific microarray, quantitative real-time polymerase chain 
reaction (qPCR) on 26 ED-related genes, and a specific ELISA to the egg-coat protein choriogenin. 
The approach was to get information on mechanisms of toxicity and linked changes at higher 
biological levels of organization. Test concentrations in the juvenile experiment were 0.5, 5 and 50 
ng/L BF. The effects on reproduction were investigated in a 21-day adult assay exposed to 0.5 ng/l 
BF. Several thousand genes were investigated in the microarray and a number of estrogen-related 
genes were downregulated – especially at 0.5 ng/l. The ELISA on the choriogenin showed a dose 
related decrease. The reproduction was significant reduced (less fertilized eggs per female) at 0.5 ng/l 
BF. All experiments were conducted with 4 replicates of 10 fish per concentration and controls. The 
experiments were semi-static with 80% daily renewal of water. Chemical analysis of BF 
concentrations in the test water were conducted at the beginning of the experiment and the measured 
concentrations were <0.6 ng/l (detection limit), 14.6 ng/l and 62.9 ng/l. 
Study quality and assessment: The study is very detailed and is assessed to be of high quality. The 
authors link the different effects to an anti-estrogenic effect of BF and an estrogenic effect of the 
metabolite 4-hydroxy BF dependent on the test concentration. Estrogenic effects were dominant at the 
low concentration of 0.5 ng/L whereas anti-estrogenic effects were more dominant at the higher 
concentrations which the authors hypothesise is caused by enzyme saturation. The decrease in the 
choriogenin is probably endocrine mediated whereas the decreased reproductive capacity could or 
could not be endocrine mediated. The link between the altered gene expressions of estrogen related 
genes and the decrease in choriogenin is moderate. The link to the reproductive decrease is also 
moderate because this endpoint is not endocrine specific. 
 
Crago & Schlenk (2015)  
Summary: The effects of BF (unknown mix of R-Cis-BF and S-Cis BF) on the dopaminergic pathway 
and E2 levels were investigated in juvenile rainbow trout (Oncorhynchus mykiss) for 96 h and 14 
days in a semi-static system with 50% water exchange daily. Stock solutions of BF were analysed but 
BF was not measured in test tanks. A reference to previous measurements of BF in a similar 
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experiment in the same laboratory was given (Forsgren et al., 2013). The authors measured changes in 
plasma E2 and hepatic VTG mRNA expression as well as in dopaminergic pathway genes (TH, 
DR2A, and GNRH2) in the brain of juvenile rainbow trout. For the 96 h exposure, 9 tank replicates of 
1 fish were used per concentration and for the 2 weeks exposure, 7 replicate tanks of 1 fish per 
concentration were used. Fish were exposed to either dechlorinated tap water with <0.01% ethanol as 
solvent, 0.15 µg/l BF or 1.5 µg/l BF. Neither weight change nor mortality was observed in any of the 
experiments. After both 96 h and 2 weeks exposure there was a trend of increase in plasma E2 and 
after 2 weeks also a significant concentration-dependent 2.3 fold increase in the relative expression of 
VTG mRNA was observed in fish exposed to 1.5 µg/l BF. For the dopaminergic pathway, after 96 h 
exposure, there was a 3.5 fold increase in the relative expression of TH mRNA in fish exposed to 1.5 
µg/l BF. After 2 weeks exposure, TH transcripts were only identified in the control but not in the BF 
groups. There was no difference between TH expression in controls at 96 hand 2 weeks. A massive 
426-fold decrease in the relative expression of DR2A was observed in the 1.5 µg/l BF group after 96 
h. This was followed up by a 269-fold decrease in DR2A expression after 2 weeks exposure to 1.5 
µg/l BF.     
Study quality and assessment: The study is very detailed and is assessed to be of high quality. The 
authors suggest that the effects of BF on the estrogenic pathways in rainbow trout are partly caused by 
modulation of the dopaminergic pathways by BF where the present results indicate that the BF affects 
negatively the dopamine pathway and thereby decreases the dopaminergic inhibiting of GnRH2. In 
this study, there are no endocrine specific adverse endpoints so the link to adversity is weak but link 
to BF effect on dopaminergic and estrogenic pathways are moderate. 
 
Crago et al. (2015)  
Summary: In a larger study design where mixtures of pesticides and alkylphenols was tested, the 
authors also tested the effect of 1 and 5 ng/l BF on the VTG-gene expression in adult male fathead 
minnow (Pimephales promelas). The fish were exposed for 7 days with 3 replicates of 3 fish per 
exposure concentration. No mortality was observed during the experiment and. Nominal 
concentrations were used, based on measured stock solutions and a daily 50% water exchange was 
performed. No statistical difference between BF exposure and control values of VTG-mRNA 
expression was observed in this study.    
Study quality and assessment: The study is very detailed and is assessed to be of high quality. The 
lack of change in VTG-gene expression is different from other studies but it should be taken into 
account that the results are based on 3 fish in three replicates only. No link to endocrine effects by BF 
exposure in this study.  
 
Weston et al. (2015) 
Summary: in this study, juvenile rainbow trout (Oncorhynchus mykiss) or chinook salmon 
(Oncorhynchus tshawytscha) were exposed for 5 days for river water including up to 14.6 ng/l BF for 
the rainbow trout exposure and 7.8 ng/l for the chinook exposure. Seven replicates of 1 rainbow trout 
or 7 replicates of 6 chinook salmon were used. No effect on VTG or steroid hormone levels were seen 
(11-KT, T, E2). 
Study quality and assessment: All though the study is well described and the quality is evaluated 
moderate (low N), the exposure system with river water and variating BF concentrations make it 
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difficult to judge in relation to ED effects of BF. The number of fish per exposure is quite low (7x1 
for rainbow trout and 7 pooled replicates of 6 fish for Chinook salmon. The BF is also not described 
in terms of enantiomer composition so is not possible to link effects and lack of effects to BF. 
 
Brander et al. (2012)  
Summary: The authors evaluated the in vivo concentration-dependent ability of BF (1, 10, 100 ng/L) 
and permethrin to induce choriogenin (an estrogen-responsive protein) in inland silverside Menidia 
beryllina. The choriogenin in vivo response (quantified by specific ELISA) were then compared with 
an estrogen receptor responsive in vitro assay—chemical activated luciferase gene expression 
(CALUX) using a human ovarian carcinoma (BG-1) cell line. The study was 14-d static aqueous 
exposure (with daily water renewal) using 65- to 70-d-old juvenile fish. Four replicates of 10 fish 
were used except an EE2 control with two replicates. All three BF concentrations caused significant 
induction of choriogenin compared to methanol control (0.01%). This result indicates, according to 
the authors that BF is estrogenic at the low ng/l level and 1 ng/l BF was a more potent inducer of 
choriogenin than 1 ng/l EE2.  Estrogenic effects were dominant at the low concentration of 1 ng/l 
whereas anti-estrogenic effects were more dominant at the higher concentrations. This could be 
caused by difference in estrogenicity between the parent BF and metabolite(s) which was also 
demonstrated by the results of the CALUX assay. 
Study quality and assessment: The study is detailed and assessed to be of high quality. BF 
concentrations were measured analytically and had recoveries within 80-110% of nominal values. 
Overall the experiments indicate that BF is estrogenic in vivo but anti-estrogenic in the BG-1 cell line. 
This is probably caused by an estrogenic metabolite that does not occur in the in vitro assay. The link 
between estrogen agonism at low BF concentrations and increased choriogenin concentrations is high. 
The link between BF estrogen antagonism and the CALUX assay is moderate. 
 
DeGroot & Brander (2014)  
Summary: In this study, it was investigated whether the in vivo estrogenic effects of bifenthrin (BF) 
could be caused by the metabolite 4-hydroxy BF because BF is documented to be anti-estrogenic in 
vitro, (ER-CALUX assay). Juvenile (60 DPH) Inland silverside (Menidia beryllina) were exposed for 
7 days (semi-static) to 10 ng/l BF, 10 ng/l 4-hydroxy BF and 10 ng/l BF + 25 µg/l piperonyl butoxide 
(PBO, a P450 inhibitor). Five replicates of 8 fish were used for all concentrations. The study revealed 
that 4-hydroxy BF caused significantly higher estrogen-mediated choriogenin protein levels than 
BF/PBO-exposed fish. Choriogenin was quantified by use of a M. beryllina specific ELISA. Exposure 
with BF alone was between these groups and not significantly different from either. The authors 
suggest that the metabolites are the main contributors to BF in vivo estrogenicity. 
Study quality and assessment: the study is precise and well-written and assessed to be of high quality. 
The links between estrogen agonism of 4-hydroxy BF and increased choriogenin concentrations is 
high. The suggestion that it is metabolization of BF to 4-hydroxy BF that causes the in vivo 
estrogenicity is well documented by the data on inhibition of the estrogenic effect with the P-450 
inhibitor PBO and the link is high. 
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Forsgren et al. (2013)  
Summary: In this study, Juvenile male and female steelhead (Oncorhynchus mykiss) were exposed to 
bifenthrin (BF) for two weeks (0.1 & 1.5 µg/l) in either freshwater or 8 or 16 ppt saltwater at semi-
static conditions with water renewal every 48 h. N per replicate was 5 but the number of replicates 
were not given. For male fish, BF did not affect Plasma 11-KT and E2 levels in freshwater or 
saltwater. GSI was reduced in freshwater but not in saltwater. Testicular tissue was also unaffected. T 
plasma levels were not affected by BF exposure except at 8 ppt saltwater where it was reduced. For 
females, BF exposure in freshwater caused significant increase in Plasma E2 levels and ovarian 
follicle diameter whereas saltwater acclimated fish exposed to the same concentrations of BF had 
significantly reduced E2 levels and smaller follicles as well as ovarian follicles undergoing atresia. 
Plasma 11-KT levels in female fish in freshwater were not significantly different. Plasma 11-KT was 
significantly elevated in fish treated with 1.5 µg/L BF in 8ppt whereas both BF treatments 
significantly elevated 11-KT in 16ppt with no difference observed between the treatments. BF 
treatment in freshwater significantly reduced plasma T levels. There was no significant difference in T 
levels in fish in 8ppt treated with BF. Fish treated with BF at 16 ppt had significantly lower plasma T 
levels. 
Study quality and assessment: Overall, the study is not very well described: The fish mortality and the 
number of test replicates are not described. A total of 148 fish were used for GSI analysis and with 9 
treatment in total it could be estimated that 4 replicates were used per exposure concentration 
including about 20% mortality but this is speculative. The measured concentrations of BF varied 
highly from nominal and were generally 20-50% of nominal. Therefore, the study is assessed to be of 
low to moderate quality. Opposite effects on hormones and gonads of BF exposure dependent on the 
salinity of the test water and fish sex make the linking between BF exposure and effects difficult.  
 
Riar et al. (2013) 
Summary: the authors exposed two strains of the salmonid Oncorhynchus mykiss (rainbow trout and 
steelhead) acclimated to freshwater and 8 g/L and 17 g/L salinity to 0.1 and 1.5 µg/l BF (99.1% 
purity, Z-cis-bifenthrin isomer mixture) for 14 days. For each exposure concentration 3 replicate tanks 
of 5 fish were used. The exposure system was semi-static with change of water every 2 days. Potential 
biotransformation of BF was measured in liver microsomes. The authors inform that the NADPH-
dependent biotransformation of BF was lower in rainbow trout than in rat supersomes and human 
microsomes. Significant mortality was observed for freshwater acclimated rainbow trout exposed to 
1.5 µg/l BF (1.07 ug/L measured). Beside some non-endocrine related endpoints, plasma VTG and 
plasma steroid hormones (11-KT, T and E2) were measured. No significant effects were seen in VTG 
levels in any exposure. Also 11-KT and T were not changing. The only significant change was an 
increase in plasma E2 levels for steelhead acclimated to freshwater.  
Study quality and assessment: The study is detailed and well described and the quality is high. The 
authors suggest that the lack of biotransformation of BF to the more estrogenic metabolite 4-hydroxy 
BF could explain the lack of VTG induction in the present study. The ratio between the 1R-Cis BF 
and 1S-Cis BF was not known. The amount of the 1S-Cis enantiomer is important because other 
studies have shown that this enantiomer of BF is up to several orders of magnitude more ED potent 
than the 1R-Cis enantiomer. This study does not provide a link between observed effects and 
endocrine specific mechanisms. 
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Tu et al. (2016) 
Summary: In this study, embryonic zebrafish (blastula stage) were exposed semi-statically to 1, 3 and 
10 μg/L of bifenthrin (BF) or λ-cyhalothrin (λ-CH) until 72 h post fertilization with daily water 
renewal. Embryos were exposed to BF in 1 L beakers with 500 mL of exposure solution and 500 
embryos. Three replicates per control and test concentration were used. The following biomarkers and 
endpoints were investigated: Body condition, bioaccumulation, thyroid hormone levels and 
transcription of related genes along the HPT axis. After exposure, 430 larvae from each replicate were 
collected and divided into three groups: 30 for RNA extraction, 100 for BF analysis, and 2x150 for 
the Thyroid assay. The deviations between measured and nominal concentrations were 18 to 31.7% at 
T0 and 43 to 51% at T24. Body weight was not affected by BF exposure groups and no BF-related 
mortality or malformations occurred. BF markedly accumulated in the larvae up to 538 ng/g. BF 
caused a decrease in thyroxine (T4) and an increase in triiodothyronine (T3) levels. Most of the HPT 
axis-related genes (including CRH, TSHβ, TTR, UGT1ab, Pax8, Dio2 and TRα) were significantly 
upregulated in the presence of BF. Molecular docking analyses revealed that at the atomic level, BF 
binds to thyroid hormone receptor (TRα) protein. 
Study quality and assessment: The study is detailed and well described. The gene-expression data are 
based on pooled fish with N=3 and some of the effects on the expression on single genes could be a 
little overinterpreted. Overall the study is assessed to be of moderate to high quality. Looking at the 
effects on all genes related to the thyroid axis in combination with the molecular docking model, the 
link between BF exposure and HPT-interference is moderate to high.  
 
Schlenk et al. (2012)  
Summary: In this study, Evaluation of estrogenic activity of BF (1 and 5 ng/L) and other chemicals 
was characterized by in vitro bioassays using rainbow trout hepatocytes (Oncorhynchus mykiss) and 
in vivo studies with Japanese medaka (Oryzias latipes). Adult male Japanese medaka were held in 1 L 
glass jars (3 fish per jar in three replicates per treatment) under static conditions for 7 days. 
Biotransformation of BF to estrogenic metabolites was not observed in liver microsomes. Also, no 
VTG-gene expression or protein induction were observed when hepatocytes or male medaka were 
exposed to BF at 1 ng/L or 5 ng/L. 
Study quality and assessment: The study is well described. The number of fish per replicate is low 
(N=3) and the pooling of replicate fish before VTG protein analysis is generally not recommended 
because it removes inter-replicate variability and decreases the power of the assay. The BF 
concentration in the in vivo and in vitro studies were 98 ± 4% of nominal concentrations (no further 
details) which is surprisingly close to nominal concentrations compared to other studies. The study is 
assessed to be of medium to high quality. There was no link to endocrine effects of BF at the tested 
concentrations. Of 1 and 5 ng/L. 
 
Beggel et al. (2011)  
Summary: This study investigated sublethal effects of BF (ref. std. grade 99% purity, 97% Cis-
isomer) on larval fathead minnow (Pimephales promelas) exposed for 24 h to 0.09, 0.18, 0.31 or 0.46 
µg/l BF (0.07, 0.14, 0.24, or 0.35 µg/l measured concentrations). Fish were sampled after 24 h, 48 h 
(24 h recovery) and 7 days (6 days recovery) with 30 fish (10 per replicate) per timepoint. 
Transcriptomic responses were assessed by RT-QPCR and combined with individual effects on 
swimming performance of the larvae. Each treatment consisted of 9 replicate 600 mL Pyrex beakers 
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containing 250 mL test solution and 10 fish larvae. Swimming performance was tested by touching 
the tail fin to trigger escape responses for the duration of 1 min. The distance travelled by the fish was 
recorded and used as a measure for swimming performance. Significant transcriptomic responses 
were observed at 0.07 µg/l BF (lowest observed effect concentration, LOEC) but mostly followed a 
biphasic rather than a linear dose–response with increasing concentration. By PCA (Principle 
Component Analysis) Genes were clustered in: (A) detoxification, general stress response, (B) 
neuromuscular function, energy and (C) endocrine function. Transcript patterns for genes involved in 
detoxification, neuromuscular function and energy metabolism were linked to an impairment of 
swimming performance at ≥0.14 µg/L. With increasing treatment concentration, a significant down-
regulation was observed for genes coding for cyp3a, aspartoacylase, and creatine kinase. 
Metallothionein was up-regulated. The description of VTG-gene regulation is unclear because it is 
written that BF induced a significant down-regulation of vitellogenin gene expression (7-8 fold) after 
24 and 48 h but no difference after 6 days recovery. But it is also written that: The egg yolk precursor 
vtg, a well-known biomarker of exposure to estrogenic compounds, was significantly up-regulated 
and later that: During a 6-day recovery period, down-regulation of vitellogenin was observed at 
lowest exposure concentrations. Based on the data it seems correct that a down regulation of VTG-
gene expression was seen after 24 h and 48 h and no effect was seen after 6 d recovery 
Study quality and assessment: The study is detailed and generally well described but the description 
of VTG-gene regulation is unclear as discussed above. The study is assessed to be of medium quality. 
The short exposure period of 24 h is a limitation in assessing the link between the gene responses to 
BF and the effect on swimming behaviour. Endocrine gene responses can though not be linked 
directly to behaviour and is therefore weak.  
 
Wang et al. (2010)  
Summary: In this study, the estrogenic potential of specific enantiomers of three pyrethroid pesticides 
including 1R-Cis-BF and 1S-Cis-BF were investigated in vitro in a yeast assay with human ERα 
responsive β-galactosidase induction. Beside the yeast assay, a program for ligand docking (Autodock 
1.4.5) was employed to dock pyrethroid enantiomers including Cis-BF into the ER-α site. Pyrethroid 
enantiomers were separated by a HPLC-procedure before use in the yeast assay and complete 
resolution was obtained for Cis-BF by this method. The relative induction efficiency (RIE) defined as 
the ratio of maximal enzymatic activity of samples to that of E2 (E2 set to 100) was 64.9 for 1S-Cis-
BF and 0.11 for 1R-Cis-BF. The EC50 for 1S-Cis-BF was 10-7.1 mol/l compared to 10-10.1 mol/l for E2. 
The EC50 for 1R-Cis-BF could not be determined due to low activity. The docking results show that 
hydrogen bonds were found in 1S-cis-BF but not 1R-cis-BF and hydrophobic interactions with the 
glycine amino acid No 512 in ERα could be the reason for the difference in affinity of R and S-Cis-
BF. 
Study quality and assessment: The study is detailed and well described and is assessed to be of high 
quality. The yeast assay show clear estrogenic action of the BF enantiomer 1S-Cis-BF via ERα-
interaction. Both enantiomers were inducing β-galactosidase in the yeast assay but 1S-Cis BF was 
much more potent than 1R-Cis-BF The difference is argued to be caused by different binding affinity 
to ERα. The link between an estrogenic mechanism of the enantiomers and yeast cell β-galactosidase 
induction in vitro is highly plausible. 
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Jin et al (2009). 
 In this study, among several non-endocrine endpoints, zebrafish embryo–larvae were exposed to BF 
and Vtg-1 mRNA levels were measured using reverse transcription real-time PCR in pools of 7 larvae 
in three replicates.  Results showed that, at the only exposure level of 150 µg/l, the Vtg-1 gene was 
clearly induced in larval zebrafish exposed to BF for 72 h, approximately 5.7-fold relative to the 
negative control. The effect increased further after 96 h exposure.  
Study quality and assessment: The study is well described and is assessed to be of medium quality in 
relation to the endocrine effect because the concentration of BF is quite high in the Vtg-1 gene study 
(150 µg/l BF) and caused different other effects as malformations, increased hatching rates and 
increased swimming rates. The induction of the VTG gene is though plausibly linked to an estrogenic 
mechanism of BF. 
 
Wang et al. (2007)  
Summary: In this study, the estrogenic potential and uptake of the 1R and 1S-Cis enantiomers of BF 
were investigated in vitro in the human MCF-7 cell proliferation assay and in vivo in a 10-day semi-
static exposure of adult male Japanese medaka (Oryzias latipes) to 10 ng/l BF. Significant differences 
in estrogenic potential were observed between the two enantiomers in the MCF-7 cell proliferation 
assay where the 1S-Cis BF was the more potent inducer of maximum cell proliferation (at 10-9 mol/l 
compared to 10-8 mol/l for 1R-Cis BF and 10-9 mol/l for E2).  The difference could be due to different 
metabolization of the enantiomers. The cell proliferation caused by BF enantiomers could effectively 
be blocked by ICI 182,780 indicating a direct ER-interference. In the medaka experiment, VTG was 
induced by both enantiomers but the response to 1S-cis-BF was about 123 times greater than that to 
the R enantiomer (N=5). This was not caused by a difference in uptake because the uptake of 1R-Cis 
BF was higher in both liver and other tissue.   
Study quality and assessment: The study is detailed and well described and is assessed to be of high 
quality. The MCF-7 assay show clear estrogenic action via ER-interference because the effect was 
blocked by ICI 182,780. Both enantiomers induced VTG above control levels with 1S-Cis BF being 
more than 100 times as potent as 1R-Cis BF. This difference is argued to be caused by different steric 
accessibility for enzymes. E.g. hydroxylation via a cytochrome P450 monooxygenase mediated 
conversion to more estrogenic potent metabolites. The link between an estrogenic mechanism of the 
enantiomers and MCF-7 cell proliferation in vitro and VTG induction in vivo is highly plausible.  
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Additional information used: 
US EPA Tier 1 EDSP (Endocrine Disrupter Screening Program). 
BF was included in the Tier 1 screening program with the screening assays shown in Table 1 
 
Table 1. US EPA Tier 1 screening assays for bifenthrin.
   
The Amphibian metamorphosis assay (AMA) and the fish short term reproduction assay (FSTRA) 
will be discussed in more details below: 
AMA: The AMA (OECD 231) protocol was followed. Exposure concentrations were 13.3, 50.6 & 
235 ng/l BF. Biological Endpoints: Day 7: NF stage (Nieuwkoop & Faber), wet weight, SVL (snout-
vent-length), HLL (hind-limp-length), normalized HLL. Day 21: NF stage, wet weight, SVL, HLL, 
normalized HLL, thyroid histopathology. There were significant differences between the negative and 
solvent control groups in growth parameters, which showed a consistent pattern of promotion in the 
solvent control relative to the negative control. BF significantly delayed (p<0.05) median NF 
developmental stage at 21 days in the high treatment group (median NF=57) relative to the solvent 
control (median NF=58.5). No effect in relation to negative control. Day 21 HLL (Hind Limp Length) 
and normalized HLL were significantly decreased (p<0.05) by 22.1 and 18.7%, respectively, in the 
high treatment group relative to the solvent control. Mild to moderate thyroid gland atrophy was noted 
in the high treatment group (9/20) relative to the negative control (4/15) and solvent control (4/20). 
These effects were evaluated by the US EPA to be inconsistent with a direct, thyroid-related delay and 
may be more reflective of treatment-related growth inhibition because no effects were seen on the 
incidence of follicular cell hypertrophy or hyperplasia, which are expected to be more commonly 
affected in the presence of a thyroid related developmental delay. Due to lack of detailed knowledge 
to the AMA effects interpretation, it is difficult for the authors of the present document to challenge 
this conclusion. Our opinion is though, that a lack of thyroid interference by BF in amphibians cannot 
be concluded by the present study alone. 
FSTRA: The 21-day assay (comparable to OECD 229) was performed with fathead minnows 
(Pimephales promelas) under flow-through conditions with 6-month old fish in 20 spawning groups 
0f 2 males and 4 females. Fish were exposed to BF (93.6% purity) at mean measured concentrations 
of 0, DMF <20 μL/L), 17, 75, and 402 ng BF/l. There was a 100% male mortality in the high dose and 
erratic swimming in the females but with no significant mortality in females. There were statistically 
significant effects on fecundity in females, with a 60% increase at the mid concentration and a 74% 
reduction at the high concentration. No statistically significant reductions (p>0.05) in fertilization 
success were seen. There was an increase of 51% in female GSI at the high concentration. There was 
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a significant increase in oocyte atresia in 13/15 female in the high treatment group (compared to 4/15 
fish in the negative control). There were no other statistically significant differences between severity 
scores or gonadal stages in treated groups compared to the negative or solvent controls for females. 
No effect on Plasma VTG were seen but a trend toward increasing VTG in female fish was seen at the 
highest test concentration (P=0.087).  
The reason for the gender specific mortality was not discussed. This could be of interest in relation to 
ED-effects. There are no clear links between effects and endocrine mechanisms because VTG and 
secondary sex characteristics were not affected. Changes in fecundity could be endocrine mediated 
but also caused by other mechanisms. 
A summary copied from the EDSP Weight of Evidence (WoE) Conclusions on the Tier 1 Screening 
Assays for the List 1 Chemicals (https://www.epa.gov/endocrine-disruption/endocrine-disruptor-
screening-program-tier-1-screening-determinations-and) is inserted below and sum up the WoE for 
BF in relation to interaction of BF with the EA&T pathways as evaluated by US EPA:  
 Executive Summary: 
“The Endocrine Disruptor Screening Programs (EDSP) Tier 1 assay battery is designed to provide 
the necessary empirical data to evaluate the potential of chemicals to interact with the estrogen (E), 
androgen (A) or thyroid (T) signaling pathways. This interaction includes agonism and antagonism at 
the estrogen and androgen receptors, altered steroidogenesis, as well as hypothalamic-pituitary-
gonadal (HPG) and hypothalamic-pituitary thyroid (HPT) perturbations. In addition to the available 
Tier 1 data, other scientifically relevant information (OSRI), including general toxicity data and open 
literature studies of sufficient quality were considered in this weight of evidence (WoE) assessment. In 
determining whether bifenthrin interacts with E, A, or T hormone pathways, the number and type of 
effects induced, the magnitude and pattern of responses observed across studies, taxa, and sexes were 
considered. Additionally, the conditions under which effects occur were considered, in particular, 
whether or not endocrine-related responses occurred at dose(s) that also resulted in general systemic 
toxicity or overt toxicity. 
On June 11, 2014, the EDSP Tier 1 Assay Weight of Evidence Review Committee (T1WoERC) of the 
Office of Pesticide Programs (OPP) and the Office of Science Coordination and Policy (OSCP) 
conducted a weight-of-evidence (WoE) analysis of the potential interaction of bifenthrin with the E, A 
or T hormone pathways. The T1WoERC conclusions from the WoE evaluation in this report are 
presented by pathway (E, A and then T) beginning with the results of the Tier 1 in vitro assays 
followed by in vivo mammalian and wildlife results, then the results of the cited OSRI for mammalian 
and wildlife studies (40 CFR Part 158 and literature).  
Bifenthrin is a member of the synthetic pyrethroid class of insecticide having similar toxicity profiles 
that elicit neurotoxic behaviors in laboratory animals. This assessment includes studies conducted 
with two enantiomers: 1S-cis-bifenthrin and 1R-cis-bifenthrin. For the estrogen pathway, bifenthrin 
was negative in the Tier 1 in vitro assays [estrogen receptor (ER) binding, ER transactivation assay 
(ERTA), steroidogenesis and aromatase assays]. Although, potential estrogenic and/or anti-
estrogenic activity were reported in several non- Guideline in vitro assays, these positive in vitro 
responses were not supported by the in vivo assays. The Tier 1 uterotrophic assay was negative and, 
in the female pubertal rat assay, there were no treatment-related estrogen-related effects observed in 
the absence of overt toxicity. Furthermore, in the fish short-term reproduction assay (FSTRA), all 
effects in females occurred in the presence of overt toxicity. In the mammalian Part 158 studies, the 
only estrogen-related effect in the absence of overt toxicity was a slight (9%) decrease in absolute 
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ovarian weight in the two-generation rat reproduction study. In the avian reproduction studies, the 
only effect observed was an increase in number of cracked eggs, but no differences in mean egg 
weight or egg shell thickness or other reproductive parameter. Therefore, there is a lack of 
convincing evidence for potential interaction with the estrogen pathway. For the androgen pathway, 
bifenthrin was negative in the Tier 1 in vitro AR binding and steroidogenesis assays. Additionally, the 
Tier 1 Hershberger assay was negative. In a nonguideline Hershberger assay submitted as OSRI, 
while decreases in AST weights were reported, chemical purity and numerical AST data were not 
reported. No treatment-related effects were observed in the male pubertal rat study, in the absence of 
overt toxicity. No androgen specific effects were observed in the FSTRA, in the absence of overt 
toxicity, or in the Part 158 wildlife studies. As such, there is no convincing evidence for potential 
interaction with the androgen pathway.  
Based on mammalian Tier 1 assays and the OSRI mammalian studies, bifenthrin does not appear to 
affect the thyroid or the HPT axis. Developmental findings in the amphibian metamorphosis assay 
(AMA) included decreased developmental stage and normalized hind limb length at Day 21 (test 
termination), concurrent with effects on growth (decreased snout-vent length and body weight). 
Treatment-related differences in thyroid gross pathology and histopathology analysed statistically by 
the study authors indicated a slight trend (p = 0.11) towards mild gland atrophy in the high treatment 
group relative to the negative control group with a decrease in maximum follicle size (p=0.024). 
Although findings of thyroid gland atrophy are identified in the AMA guideline as diagnostic criteria, 
the differences between control and treated tadpoles in this study were slight. Moreover, no effects 
were seen on the incidence of follicular cell hypertrophy or hyperplasia, which are expected to be 
more commonly affected in the presence of a thyroid related developmental delay. Overall, the 
thyroid and developmental findings in the AMA with bifenthrin are inconsistent with a direct, thyroid-
related delay and may be more reflective of treatment-related growth inhibition. In both the female 
and male pubertal rat assays, no treatment-related effects were noted for thyroid weight or 
histopathology. Serum thyroxine (T4) concentration was decreased only in the low-dose groups of 
both sexes (↓16%), with an increase in thyroid stimulating hormone (TSH) concentration occurring 
only in the high-dose males and which was associated with overt toxicity. Furthermore, there were no 
effects on thyroid weight or histopathology.  
Based on weight of evidence considerations, mammalian EDSP Tier 2 testing is not recommended for 
bifenthrin since there was no convincing evidence of potential interaction with the estrogen, androgen 
or thyroid pathways.”  
 
Comment to the summary: The summary describe that the assessment includes studies conducted 
with two enantiomers: 1S-cis-bifenthrin and 1R-cis-bifenthrin but considering the DER (Data 
Evaluation Record) the bifenthrin description is: Technical bifenthrin of 93.6% purity and the 
proportion of the 1S and 1R-Cis enantiomers is not referred. This is important because the studies by 
Wang et al. (2007 & 2010) show a more than 100-fold difference in estrogenic potency between these 
two enantiomers with 1S-Cis bifenthrin as the more potent. The WoE considerations by the US EPA 
turns out not to recommend further testing of bifenthrin because of lack of convincing evidence of 
interaction with EA&T pathways. This is based on that most ED related effects occurred at 
concentrations where also signs of overt toxicity existed. The authors of the present document do not 
agree that ED effects occurring in combination with overt toxicity should not be considered. Such ED 
effects should be evaluated case by case and the plausible mechanism behind the effect should be 
discussed.   
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Mammalian tests as summarized from Toxnet (https://toxnet.nlm.nih.gov/cgi-
bin/sis/search/a?dbs+hsdb:@term+@DOCNO+6568) : 
“Developmental or Reproductive Toxicity/ The commercial bifenthrin (BF) contains two cis 
isomers. In the present study, a dose of 15mg/kg of 1R-cis-BF or 1S-cis-BF was orally 
administered for 3 weeks to female mice before or during pregnancy. Then, the expression of 
steroidogenesis related genes which were considered as effective biomarkers of endocrine 
disruption were analyzed in the male offspring. Maternal exposure to 1S-cis-BF during 
pregnancy significantly reduced the mRNA levels of peripheral benzodiazepine receptor 
(PBR) and steroidogenic acute regulatory protein (StAR) in the testes of 3- or 6-week old 
male offspring. In addition, a significant decrease of cytochrome P450 17alpha-
hydroxysteroid dehydrogenase (P450-17alpha) was also observed in the testes of 6-week old 
male offspring when dams were treated with 1S-cis-BF during pregnancy but not before 
pregnancy. Moreover, the scavenger receptor class B type 1 (SRB1) and cytochrome P450 
cholesterol side-chain cleavage enzyme (P450scc) decreased significantly in the testes of 6-
week old male offspring when dams were treated with 1S-cis-BF during and before 
pregnancy. Thus, oral administration of the maternal mice to cis-BF for 3 weeks, particularly 
during pregnancy, resulted in endocrine disruption in the male offspring, with the 1S-cis-BF 
causing more significant alterations than the 1R-cis-BF form. 
[Jin Y et al; Reprod Toxicol 42: 156-63 (2013)] **PEER REVIEWED** PubMed Abstract 
 
/ENDOCRINE MODULATION/ /The objective was/ to study the potential endocrine 
disrupting effects of bifenthrin (BIF) by using uterotrophic assay and Hershberger assay. In 
uterotrophic assay, 60 female SD rats were randomly divided into 6 groups, 10 rats per 
group. Rats in bifenthrin-treated groups were given different doses of bifenthrin (1.47, 4.41 
and 13.23 mg/kg BW by gavage for 3 consecutive days). Rats in negative control groups were 
given corn oil by gavage. Rats in ethinyl estradiol (EE) oral positive control groups were 
given EE 1.0 ug/kg BW by gavage. Rats in EE injected positive groups were given 0.6 ug/kg 
BW EE by subcutaneously injection while given corn oil by gavage. At necropsy, the wet and 
blotted uteri were weighed. The relative uteri weights were calculated, and the histology of 
uteri was observed. In Hershberger assay, 60 castrated male SD rats were randomly divided 
into 6 groups, with 10 rats in each group. Rats in BIF-treated groups were given different 
doses of BIF (1.4, 4.2 and 12.6 mg/kg BW) by gavage. Flutamide (3.0 mg/kg BW) were given 
to animals in the positive control group by gavage. Rats in the negative control group and 
testosterone propionate group were given corn oil by gavage for 10 consecutive days. Rats in 
all groups except the negative control group were also treated with testosterone propionate 
(TP, 0.2 mg/kg BW) by subcutaneous injection. At necropsy, ventral prostate (VP), seminal 
vesicle plus fluids and coagulating glands (SVCG), levator ani-bulbocavernosus muscle 
(LABC), paired Cowper's glands (COW) and the glands penis (GP), liver, kidneys, adrenals 
were weighed. Serum triiodothyronine (T3) and thyroxine (T4) were determined. In 
uterotrophic assay, compared with the negative control group, the mean relative wet weight 
and relative blotted weight of uterine were increased significantly in the female rats given by 
BIF at 13.23 mg/kg BW for 3 days (P < 0.05). BIF resulted in a significant increase of 
epithelial cell heights of uteri at 4.41 and 13.23 mg/kg BW, as compared with control group. 
In Hershberger assay, compared with the TP group, mean absolute weight and relative 
weight of VP and LABC in BIF high dose group were significant decreased. Moreover, total 
T3 and T4 level were decreased also (P < 0.05). ... 
[Tan Y et al; Wei Sheng Yan Jiu 41 (3): 399-404 (2012)] **PEER REVIEWED** PubMed Abstract 
 
ENDOCRINE MODULATION/ Bifenthrin (BF), as a chiral pyrethroid, is widely used to 
control field and household pests in China. At present, the commercial BF is a mixed 
compound containing cis isomers (cis-BF) including two enantiomers of 1R-cis-BF and 1S-
cis-BF. In the present study, the two individual cis-BF enantiomers were separated by a 
preparative supercritical fluid chromatography. Then, four week-old adolescent male ICR 
mice were orally administered 1R-cis-BF and 1S-cis-BF separately daily for 3 weeks at doses 
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of 0, 7.5 and 15 mg/kg/day, respectively. Results showed that the transcription status of some 
genes involved in cholesterol synthesis and transport as well as testosterone (T) synthesis in 
the testes were influenced by cis-BF enantiomers. Especially, we observed that the 
transcription status of key genes on the pathway of T synthesis including cytochrome P450 
cholesterol side-chain cleavage enzyme (P450scc) and cytochrome P450 17alpha-
hydroxysteroid dehydrogenase (P45017alpha)) were selectively altered in the testis of mice 
when treated with 1S-cis-BF, suggesting that it is the possible reason to explain why the 
lower serum T concentration in 1S-cis-BF treated group. Taken together, it concluded that 
both of the cis-BF enantiomers have the endocrine disruption activities, while 1S-cis-BF was 
higher than 1R-cis-BF in mice when exposed during the puberty. The data was helpful to 
understand the toxicity of cis-BF in mammals under enantiomeric level. 
[Jin Y et al; Environ Toxicol 30 (7): 746-54 (2015)] **PEER REVIEWED** PubMed Abstract” 
 
 
 
5.6.2.4 Summary of the plausible link between adverse effects and endocrine mode of 
action 
There is strong evidence from in vitro and in vivo studies that especially the 1S-Cis bifenthrin 
enantiomer is estrogenic and/or anti-estrogenic (summarized in Table 2). In a yeast assay with human 
ERα responsive β-galactosidase induction, the relative induction efficiency (RIE) defined as the ratio 
of maximal enzymatic activity of samples to that of E2 (E2 set to 100) was 64.9 for 1S-Cis-BF and 
0.11 for 1R-Cis-BF. In another in vitro study with human MCF-7 cells, 1R-Cis-BF and 1S-Cis-BF 
were tested. Maximum cell proliferation was at 10-9 mol/l for 1S-Cis BF compared to 10-8 mol/l for 
1R-Cis BF and 10-9 mol/l for E2. In this study, ER-interference of bifenthrin enantiomers was 
confirmed by cell proliferation blockage by ICI 182,780. In an in vivo study, estrogenic effects were 
dominant at the low concentration of 1 ng/l where the estrogen responsive protein choriogenin was 
significantly induced, whereas anti-estrogenic effects were more dominant at the higher 
concentrations. This could be caused by difference in estrogenicity between the parent bifenthrin and 
metabolite(s). Anti-estrogenicity was demonstrated with the CALUX assay using a human ovarian 
carcinoma (BG-1) cell line. Several studies show that BF negatively affects the dopaminergic 
pathway and this could be a part of the estrogenic response of BF because GNRH2 is normally 
negatively regulated by dopamine.  
The mammalian studies referred from Toxnet are not evaluated for quality in this document but it 
should be noticed that these studies also indicate that the 1S-Cis BF enantiomer is the more potent 
enantiomer in relation to the estrogenic pathway. 
The link from the mechanistic effects described above to effects seen on adverse endpoints like 
fecundity and other reproductive parameters described in the evaluated studies is difficult to establish 
because of lack of endocrine specificity of these endpoints.  
The challenge with the interpretation of results from most of the evaluated studies is that the 
enantiomer composition of the bifenthrin used in the studies was not given and mostly a technical 
bifenthrin solution was used. Several studies reported that bifenthrin did not affect endocrine 
biomarkers like vitellogenin and in one study also fish sex ratio but these studies did not report the 
enantiomer composition of bifenthrin. Examples of this are the US EPA tier 1 EDSP screens (e.g. 
AMA and FSTRA) where a technical bifenthrin of 93.6% purity was used without further information 
on enantiomer composition.   
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The link from endocrine mode of action of BF and population relevant adverse effects is weak to 
moderate because the adverse effects seen on fish fecundity in three studies are not endocrine specific 
(summarized in Table 3). The effects do though occur at levels below 1 ng/l in two fish species, and 
overt toxicity is not expected at such concentrations in the affected fish species. The only study that 
was investigating phenotypic sex ratio did not see any effect after 21 day exposure and a 35 day 
depuration period. In this study, it was not discussed if estrogenic induced phenotypic sex change in 
the inland silverside is reversible and if the 35-day depuration period could affect the sex ratio result.  
The evidence from the referred studies do not support that technical bifenthrin is an endocrine 
disrupter according to the IPCS/WHO definition but there is a high concern that the 1S-Cis 
enantiomer is an ED and that the metabolite 4-hydroxy bifenthrin is an ED.   
  
5.6.2.5 Environmental relevance   
Effects related to the estrogenic pathway in fish were reported at concentrations in the low ng/l BF 
area and are clearly within concentrations measured in the aquatic environment. Reduced T and E2 
levels were seen between 1 and 10 ng/l. Decreased fecundity was seen below exposure levels of 1 ng/l 
in two studies and effects on the oestrogen responsive protein choriogenin was also seen in two 
studies at these environmental relevant concentrations. It should also be considered that the major 
metabolite of BF in the environment has been reported to be 4-hydroxy BF which was shown in one 
study to be more estrogenic potent than BF.  
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Table 2. Overview of potential endocrine MoA effects of Bifenthrin. 
Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
Decourten & 
Brander 
(2017)  
 
 Sex ratio study in a multigenerational study with inland 
silverside (Menidia beryllina). Five replicates of 9-18 fish 
were used for F1. Parents F0 were exposed for 14 days, F1 
from egg to 21 dph and reared for 35 days in clean water. F2 
not exposed. One exposure concentration of 0.89 ng/l BF at 
two temperatures (22 ⁰C or 28 ⁰C)   ntrol 1 ng/l 
EE2. No effect on sex ratio of BF in F1. No effect of EE2 at 
22 ⁰C         
↓ in F1 and F2. Deformities ↑ in F1 and F2 
Medium-High 
 
Weak 
Li et al. 
(2017) 
 Testicular development in the marine rockfish Sebastiscus 
marmoratus, 50 days of exposure (n=3-6) to 1, 10 or 100 
ng/l BF.  
Number of spermatocytes and spermatogonia ↑. Percentage 
of sperm cells ↓ 
CYP19A gene expression levels decreased in both brain and 
testes whereas CYP19B expression increased in both organs 
Reduced T and 17β-E2 levels in the testes compared to the 
control. The levels of T were significantly reduced in the 10 
and 100 ng/L groups, and that of E2 were significantly 
reduced in the all BF treated groups 
The apoptosis marker Caspase-3 activity increased from 10 
ng/l BF (confirmed by Tunnel assay. 
Medium-high Moderate-strong 
Bertotto et al 
(2017) 
 Dopaminergic and estrogenic regulation investigated in 
zebrafish embryos and juveniles (96 h exposure). Tyrosine 
Hydroxylase ↓ (31 fold) and Dopamin Receptor 1 ↓ (33 
fold). ERβ1 ↑ in juveniles (0.15 and 1.5 μg/L). E2 ↓ in 
embryos (trend in juveniles). 
High Moderate-Strong 
Brander et al. 
(2016) 
Effects on steroidogenesis in the 
H295R cell line: ↑ progesterone,  ↓ 
testosterone, aldosterone and cortisol at 
sub-cytoxic concentrations 
A 14-day exposure of juvenile inland silverside M. beryllina 
(0.5, 5 and 50 ng/l) and a 21-day reproduction study (0.5 ng/l 
BF). All studies with 4 replicates of 10 fish per 
concentration. Estrogen related genes downregulated at 0.5 
ng/l (microarray data). Choriogenin ↓ (dose related).  
Reproduction ↓ at 0.5 ng/l. 
 
High Moderate-Strong 
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Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
Tu et al. 
(2016) 
 Embryonic zebrafish exposed semi-statically to 1, 3 and 10 
μg/l BF. Three replicates of 500 embryos. T4 ↑, T3↓.  
CRH, TSHβ, TTR, UGT1ab, Pax8, Dio2 and TRα ↑ 
Molecular docking show BF binding to TRα. 
 
Medium-high Moderate 
Crago et al. 
(2015) 
 VTG-gene expression in adult male fathead minnow 
(Pimephales promelas). Exposure for 7 days with 3 
replicates of 3 fish to 1 and 5 ng/l BF. No effect on VTG 
 
High Low 
Crago & 
Schlenk 
(2015) 
 Dopaminergic and estrogenic pathway and E2 investigated in 
juvenile rainbow trout (Oncorhynchus mykiss) for 96 h and 
14 days. VTG mRNA ↑ (1.5 µg/l). Tyrosine Hydroxylase 
mRNA ↑ (1.5 µg/l). DR2A ↓ (426-fold after 96 h and 269-
fold after 2 weeks exposure to 1.5 µg/l) 
 
High Moderate 
Weston et al. 
(2015) 
 Exposure of juvenile rainbow trout and chinook salmon to 
river water with up to 14.6 ng/l BF for 5 days. No effect on 
VTG or steroid hormone levels was seen (11-KT, T, E2). 
 
Medium Low 
Degroot & 
Brander 
(2014) 
 Juvenile (60 DPH) Inland silverside (Menidia beryllina) 
exposed for 7 days (semi-static) to 10 ng/l BF, 10 ng/l 4-
hydroxy BF and 10 ng/l BF + 25 µg/l piperonyl butoxide 
(PBO, a P450 inhibitor). Five replicates of 8 fish were used 
for all concentrations. Choriogenin ↑ after exposure to 10 
ng/l of the metabolite 4-hydroxy BF. P-450 inhibitor PBO 
removed effect. 
High Strong 
Zhao et al. 
(2014) 
BF enantiomers were tested on human 
trophoblast cells (JEG-3 cell line) in 
vitro. Progesterone and human 
chorionic gonadotropin secretion ↑ 
Progesterone receptor ↑  
Gene-expression of GNRHI, GNRHRI, 
CYP17 and CYP19 ↑  
S-BF more potent than R-BF 
(confirmed by molecular docking of 
enantiomer ER binding affinity) 
 High Strong 
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Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
Riar et al. 
(2013) 
 Oncorhynchus mykiss (rainbow trout and steelhead) 
acclimated to freshwater and 8 g/L and 17 g/L salinity 
exposed to 0.1 and 1.5 µg/l BF (99.1% purity, Z-cis-
bifenthrin isomer mixture) for 14 days. Biotransformation of 
BF – low. No effect on plasma VTG and plasma steroid 
hormones (11-KT, T and E2) except E2 ↑ in freshwater 
acclimated steelhead. 
High low 
Forsgren et al. 
(2013) 
 Juvenile male and female steelhead (Oncorhynchus mykiss) 
were exposed for two weeks (0.1 & 1.5 µg/l) in either 
freshwater or 8 or 16 ppt saltwater. Plasma E2 levels and 
ovarian follicle diameter ↑ in females in freshwater. whereas 
saltwater acclimated females exposed to the same 
concentrations of BF had significantly reduced E2 levels and 
smaller follicles as well as ovarian follicles undergoing 
atresia. No effect on 11-KT and E2 plasma levels in males. 
Low-medium moderate 
Brander et al. 
(2012) 
Estrogen receptor responsive in vitro 
assay—chemical activated luciferase 
gene expression (CALUX) using a 
human ovarian carcinoma (BG-1) cell 
line. BF was anti-estrogenic in the BG-
1 cell line. 
Inland silverside Menidia beryllina (65-70 dph) exposed for 
14 days (1, 10, 100 ng/L). Four replicates of 10 fish. 
Choriogenin quantified by specific ELISA. Choriogenin ↑ at 
all doses. Highest effect at 1 ng/l. Probably metabolite that is 
estrogenic. 
High Strong 
Schlenk et al. 
(2012) 
In vitro bioassays using rainbow trout 
hepatocytes. No VTG-mRNA 
induction after 1 and 5 ng/l BF 
exposure.  
in vivo studies with Japanese medaka (Oryzias latipes). 
Adult male Japanese medaka (3 fish per tank in three 
replicates per treatment) for 7 days and 1 or 5 ng/l BF. No 
VTG induction 
Biotransformation of BF to estrogenic metabolites was not 
observed in medaka liver microsomes. 
Medium low 
Beggel et al. 
(2011) 
 Larval fathead minnow exposed for 24 h to 70 or 140 ng/l 
BF. VTG gene expression was down regulated after 24 and 
48 h but no difference after 6 d recovery. 
Medium Low-moderate 
Wang et al. 
(2010) 
Yeast assay with human ERα 
responsive β-galactosidase induction. 
The Z-Cis BF enantiomers 1R-Cis-BF 
and 1S-Cis-BF was tested. The relative 
induction efficiency (RIE) defined as 
the ratio of maximal enzymatic activity 
 High Strong 
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Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
of samples to that of E2 (E2 set to 100) 
was 64.9 for 1S-Cis-BF and 0.11 for 
1R-Cis-BF. The EC50 for 1S-Cis-BF 
was 10-7.1 mol/l compared to 10-10.1 
mol/l for E2. The EC50 for 1R-Cis-BF 
could not be determined due to low 
activity. 
Jin et al. 
(2009) 
 zebrafish embryo–larvae were exposed to BF (150 µg/l) and 
Vtg-1 mRNA levels were measured using reverse 
transcription real-time PCR in pools of 7 larvae in three 
replicates. VTG1-gene expression ↑ but concentration of BF 
high 
Medium Moderate-strong 
Wang et al. 
(2007) 
Human MCF-7 cell proliferation assay. 
The Z-Cis BF enantiomers 1R-Cis-BF 
and 1S-Cis-BF was tested. maximum 
cell proliferation was 10-9 mol/l for 1S-
Cis BF compared to 10-8 mol/l for 1R-
Cis BF and 10-9 mol/l for E2. ER-
interference was blocked by ICI 
182,780 
10-day semi-static exposure of adult male Japanese medaka 
(Oryzias latipes) to 10 ng/l BF. VTG was induced by both 
enantiomers but the response to 1S-cis-BF was about 123 
times greater than that to the R enantiomer (N=5). This was 
not caused by a difference in uptake because the uptake of 
1R-Cis BF was higher in both liver and other tissue 
High Strong 
US EDSP tier 
1 FSTRA 
(TG 229) 
 The 21-day assay (comparable to OECD 229) was performed 
with fathead minnows (Pimephales promelas) under flow-
through conditions with 6-month old fish in 20 spawning 
groups 0f 2 males and 4 females. Fish were exposed to BF 
(93.6% purity) at mean measured concentrations of 0, DMF 
<20 μL/L), 17, 75, and 402 ng BF/l. There was a 100% male 
mortality in the high dose and erratic swimming in the 
females but with no significant mortality in females. There 
were statistically significant effects on fecundity in females, 
with a 60% increase at the mid concentration and a 74% 
reduction at the high concentration. No statistically 
significant reductions (p>0.05) in fertilization success were 
seen. There was an increase of 51% in female GSI at the 
high concentration. There was a significant increase in 
oocyte atresia in 13/15 female in the high treatment group 
(compared to 4/15 fish in the negative control). There were 
High low 
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Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
no other statistically significant differences between severity 
scores or gonadal stages in treated groups compared to the 
negative or solvent controls for females. No effect on Plasma 
VTG were seen but a trend toward increasing VTG in female 
fish was seen at the highest test concentration (P=0.087). 
US EDSP tier 
1 AMA (TG 
231) (OCSPP 
Guideline 
890.1100) 
 The AMA (OECD 231) protocol was followed. Exposure 
concentrations were 13.3, 50.6 & 235 ng/l BF. Biological 
Endpoints: Day 7: NF stage (Nieuwkoop & Faber), wet 
weight, SVL (snout-vent-length), HLL (hind-limp-length), 
normalized HLL. Day 21: NF stage, wet weight, SVL, HLL, 
normalized HLL, thyroid histopathology 
There were significant differences between the negative and 
solvent control groups in growth parameters, which showed 
a consistent pattern of promotion in the solvent control 
relative to the negative control. 
BF significantly delayed (p<0.05) median NF developmental 
stage at 21 days in the high treatment group (median NF=57) 
relative to the solvent control (median NF=58.5). No effect 
in relation to negative control.  
Day 21 HLL (Hind Limp Length) and normalized HLL were 
significantly decreased (p<0.05) by 22.1 and 18.7%, 
respectively, in the high treatment group relative to the 
solvent control 
Mild to moderate thyroid gland atrophy was noted in the 
high treatment group (9/20) relative to the negative control 
(4/15) and solvent control (4/20) 
High Low-moderate 
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Table 3. Overview of potential endocrine-related adverse effects of bifenthrin in fish. 
Reference Species, n Adverse effects Quality of study Evidence for 
adverse effects 
Decourten & 
Brander 
(2017)  
Inland 
silverside  
In vivo effect on reproduction including decreased fecundity  high moderate 
Brander et al. 
(2016) 
Inland 
silverside 
In vivo effect on reproduction including decreased fecundity  high moderate 
USEPA, EDSP 
Tier 1 FSTRA 
Fathead 
minnow 
In vivo effect on reproduction including increased and decreased fecundity   high Low-moderate 
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Di-n-pentylphthalate (DPP), CAS no.131-18-0 
 
Synonyms: Dipentyl phthalate (DPeP), Diamyl phthalate, Amyl phthalate, Amoil, di-n-Amyl 
phthalate 
Di-n-pentyl phthalate (C16 H26 O4) is a phthalate ester used as a 
plasticizer (Figure 1). Since no registration dossiers in REACH 
on DPP are available, it is assumed that it is produced and/or 
imported to EU in tonnages less than 100 tpa. In EU 
(classification) the substance is classified as Rep. Cat. 1B (H360: 
May damage fertility or the unborn child) and as hazardous to the 
environment/ acute hazard category 1 (H400: very toxic to 
aquatic life).  
 
4. Human health hazard assessment 
4.10.3 Endocrine disruption 
4.10.3.1 General approach – human health 
4.10.3.2 In vitro information indicative of endocrine activity 
Yuan et al. (2012)  
Summary: In this study, 14 phthalates were tested for their inhibitory action on human and rat 
testicular 3β-hydroxysteroid dehydrogenase (3β-HSD) and 17β-hydroxysteroid dehydrogenase 
3enzymes (17β-HSD3) (with exposure to 1mM phthalate) and their activity was compared with their 
structure. The inhibitory effect of a range of concentrations of the phthalate (10-7-10-3 M) was tested 
on the microsomal enzymes prepared from human and rat testis. The enzymes are important in 
testosterone synthesis in Leydig cells. The enzyme 3β-HSD catalyses conversion of pregnenolone to 
progesterone and 17β-HSD3 catalyses conversion of androstenedione to testosterone.  
Activity of 3β-HSD was reduced by more than 50% in both rat and human testis and 17β-HSD3 was 
also reduced in rat and human testis by DPP. Altogether, the results demonstrated that phthalates with 
ethanol moieties consisting of 1-2 or 7-8 carbon atoms had no effects on the enzyme activities. 
Study quality and assessment: The study is assessed to be of high quality and the study provides 
moderate evidence of an endocrine mode of action of DPP on testosterone synthesis. 
 
Christen et al. (2010)  
Summary: In this study in vitro androgen receptor reporter gene assays for androgenic and anti-
androgenic activity was performed. Partial inhibition curves were observed for DPP whereas no 
notable androgenic activity was seen at the concentrations tested (3.3, 67 and 334 µM DPP). 
Study quality and assessment: The study is well described, included triplicates of the assays, included 
controls and tested concentrations of DPP below cytotoxic levels. This study is assessed to be of high 
quality. The study provides strong evidence for anti-androgenic mode of action of DPP in vitro. 
Figure 1: 2D structure from 
PubChem 
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Creasy et al. (1988)  
Summary: The effects of mono-n-pentyl phthalate (MPP) on Sertoli cell ultrastructure and germ cells 
in vitro was investigated and compared with the effects of DPP on these cell types in vivo. Sertoli and 
germ cell cultures from Sprague-Dawley rat testis was exposed to MPP at 0, 100, 200, 500 or 1000 
µM for 3 or 24 hours. Cell morphology was examined under transmission electron microscope and 
scanning electron microscope and evaluation of the distribution of actin filaments was performed on 
the cultured cells.  
Sertoli cells in vitro changed in shape and developed microprocesses between Sertoli cells and germ 
cells after MPP exposure (200-1000 µM). Reorganization of actin filaments was seen in vitro after 
MPP exposure (500-1000 µM), a change that correlated well with changes in Sertoli cell shape in vivo 
after DPP exposure. Rarefaction of Sertoli cell cytoplasm in vivo correlated with mitochondrial 
hypertrophy in vitro.  
Study quality and assessment: The study is old and the in vivo part of the study is relatively 
superficially described. The in vitro part of the study is described in more details than the in vivo part, 
yet some information on the number of samples and replicates used per group and assessment of 
cytotoxicity is not described. The in vitro part of the study is assessed to be of low quality. The data 
provide weak evidence that MPP can lead to adverse effects on the testicular Sertoli cells. 
 
4.10.3.3 In vivo effects with regard to an endocrine mode of action  
Gray Jr et al. (2016)  
Summary: The aims of this study were to (1) determine the reductions necessary in testosterone 
production, testicular testosterone levels and foetal rat plasma testosterone to induce reproductive 
malformations and (2) determine the reduction in foetal testosterone necessary to induce postnatal 
adverse effects in the offspring. In this paper two animal studies are described with exposure to DPP 
by oral gavage of time-mated rats (0, 11, 33, 100, 300 mg/kg/day). In the foetal experiment dams 
were dosed GD14-18 and animals were euthanized on GD18 (n=7-9 litters per group). Testes and 
blood samples from foetuses were collected and endpoints for assessment of maternal toxicity was 
recorded (maternal weight gain, number of resorptions, live foetuses etc.). Testis weight was recorded 
(n=up to 3 males from 5-6 litters/group), foetal testosterone levels in plasma and testis was measured, 
the descent of testis was evaluated, the ex vivo testosterone production in testis and gene expression of 
foetal testes was investigated. In the postnatal experiment, dams (n=5 litters per group) were dosed 
GD 8-18 and necropsy of the offspring was performed when they were 120 days old. Age and weight 
at sexual maturation of male and female offspring were recorded. At necropsy of female offspring, 
gross malformations and weights of pituitary, uterus, ovaries, kidneys and livers were recorded. In 
male offspring gross malformations, length or gubernacular cord and weight of glans penis, seminal 
vesicle, ventral prostate, testis, epididymis, levator ani-bulbocavernosus muscles, Cowper’s glands, 
kidney and liver were assessed. Testis and epididymis were processed for histopathology and male 
and female skulls were processed for morphometric analysis. 
Assessment of maternal toxicity in the postnatal study showed decreased maternal weight gain and 
lower pup survival in the highest exposure group (300 mg/kg/day). In the foetal study, delayed testis 
descent (1 and 13 male pups with undescended testis out of 14 and 13 examined males from the 100 
and 300 mg/kg dose-groups, respectively), decreased foetal testis weight (at 300 mg/kg/day) and 
decreased testosterone levels in plasma and testis (at 33-300 mg/kg/day) and decreased ex vivo 
testicular testosterone production (at 33-300 mg/kg/day) was found. Decreased male anogenital 
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distance (AGD) and nipple retention was observed in offspring from the two highest exposure groups 
in the postnatal experiment (2 out of 14 and 9 out of 13 examined males from each 4 litters, in 100 
and 300 mg/kg/day, for nipple retention respectively).  Malformations of adult male reproductive 
organs were seen in high numbers in the highest exposure group (50% of examined animals or more; 
n=13 males examined from 4 litters in the highest exposure group compared to n=30 males examined 
from 5 litters in controls). The malformations observed were hypospadias, agenesis of vas deferens, 
agenesis or abnormal seminal vesicle, abnormal testis, agenesis of epididymis, agenesis or elongated 
gubernaculums and undescended testis. Few males (n=2) had small ventral prostates in the highest 
exposure group. Weights of reproductive organs (seminal vesicle, epididymis, testes, ventral prostate, 
levator ani-bulbocavernosus muscles, Cowper’s glands and glans penis) were decreased in 120 days 
old offspring. Decreased body weight and liver weight were found in adult males. Altogether, this 
study shows that DPP disrupts foetal testicular endocrine function and induces malformations in 
reproductive organs of male rats. 
Study quality and assessment:  The study is well-described and thorough. The number of test and 
control samples (i.e., n=5-9 litters) is adequate for showing clear effects and the study design is 
relevant. The study is assessed to be of high quality. The study provides strong evidence for an 
endocrine mode of action on testosterone steroidogenesis. Moreover, the study provides strong 
evidence for irreversible adverse effects on male reproductive system such as malformations of male 
reproductive organs, decreased weight of male reproductive organs, decreased AGD and nipple 
retention in males.  
 
Beverly et al. (2014)  
Summary: The objective of the study was to test two hypotheses: (1) that Simvastatin exposure in 
utero leads to lower foetal testicular testosterone production without changes in the expression of 
genes involved in cholesterol and androgen synthesis and transport; (2) that Simvastatin and DPP in a 
mixture reduces testosterone levels in an additive manner as they may have different modes of action. 
Two animal studies were performed, and one of the studies investigated the effects of DPP. In this 
study, pregnant rat dams were exposed by oral gavage on GD 14-18 to 50 mg/kg/day of DPP (3-4 
dams/group) and euthanized GD 18. Samples from dams included blood (for clinical chemistry, e.g. 
cholesterol, creatinine and bilirubin), weights and gene expression of liver, adrenals and ovaries and 
histopathology of livers. Samples from offspring included blood (for clinical chemistry), testis for ex 
vivo foetal testicular testosterone production and gene expression of adrenals and testis. 
Ex vivo foetal testicular testosterone production was measured on GD 18 and was found to be 
decreased. Genes involved in cholesterol transport and synthesis, sex differentiation and 
steroidogenesis were downregulated in the foetal testis.  
Study quality and assessment: The study is well-described with few uncertainties on duration of 
dosing. The number of test and control samples (i.e., n=3-4 litters) is adequate based on power 
analysis. The study is assessed to be of high quality. The study provides strong evidence for an 
endocrine mode of action on testosterone steroidogenesis. 
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Hannas et al. (2012)  
Summary: This study had three objectives. Firstly, to determine if phthalates with an anti-androgenic 
mode of action act through similar mechanisms on the gene expression level, secondly, to determine if 
the potency for the individual phthalates to reduce testosterone production correlates with their 
potency to reduce gene expression. Third, test a model prediction of the ability of a mixture of 9 
phthalates to reduce gene expression. Several phthalates were tested in this study (DPP, diisobutyl, 
dihexyl, diheptyl, diisononyl and diisodecyl phthalate) for effects in testis after gestational exposure 
and evaluation of the relative potency of the tested phthalates. Pregnant rat dams were exposed by oral 
gavage GD 14-18. Animals exposed to DPP were dosed with 0, 11, 22, 100 or 300 mg/kg/day. A gene 
array screen on testis from GD18 foetuses was performed for DPP and downregulation was found for 
several genes involved in steroid synthesis (in testis and adrenals), steroid regulation and steroid 
transport. DPP was found to be more potent in downregulation of steroid-related genes than the other 
phthalates tested. This was in good coherence with the high potency of DPP to decrease testosterone 
production and inducing malformations in the reproductive tract postnatally, as reported in a previous 
study (Hannas et al. 2011). The data demonstrated that the effects of phthalates on gene expression of 
androgen-related genes were linked to the reduced testosterone production.  
Study quality and assessment: The study is well-described and thorough. The number of test and 
control samples (one testis from every male foetus in a litter were pooled; n=3-4 litters per group) is 
adequate. The study is assessed to be of high quality. The study provides moderate evidence for an 
endocrine mode of action on testosterone steroidogenesis, but when these effects at gene expression 
level are taken together with data on testosterone synthesis reported in the previous study by Hannas 
et al. (Hannas et al. 2012), these data provide strong evidence for an anti-androgenic mode of action 
of DPP. 
 
Hannas et al. (2011)  
Summary: The objective was to establish comprehensive dose-response and potency data on foetal 
and postnatal male reproductive endpoints for DPP. Four different in vivo experiments are described. 
In the first experiment pregnant rat dams were exposed to a single dose of 500 mg/kg DPP on GD 17 
(6 dams per group). In the second study, pregnant rat dams were exposed orally to a single dose of 0, 
300, 600, 900 or 1200 mg/kg DPP on GD 17 (3 dams per group). In these two first studies ex vivo 
testicular testosterone production in foetuses GD 17 was measured in testis dissected 5-6 hours after 
maternal exposure. In the third study pregnant rat dams were dosed by oral gavage to 0, 11, 33, 100, 
300 mg/kg/day of DPP from GD 14-18 (3 dams per group). Gene expression (of StAR, insl3 and 
Cyp11a) and testosterone production on GD 18 were assessed in this 5-days repeated-dose study. In 
the final study on postnatal development pregnant rat dams were dosed by gavage to 0, 11, 33, 100, 
300 mg/kg/day of DPP from GD 8-18 (5 dams per group). AGD and NR were evaluated in the last 
study.  Foetal testicular testosterone production was decreased in a dose-related manner and in 5-days 
repeated-dose study the gene expression levels of the androgen synthesis related genes StAR and 
Cyp11a and of insl3 were decreased (from 100 mg/kg/day). Decreased AGD (at 100mg/kg/day or 
more) and increased NR (at 300 mg/kg/day) was found in male offspring exposed to DPP for 10 days 
in utero.  
Study quality and assessment: The study is well-described and thorough, although few details on the 
number of exposed dams in the first study are missing. The study is assessed to be of high quality. 
The study provides strong evidence for an endocrine mode of action on testicular testosterone 
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steroidogenesis. The study also provides strong evidence for endocrine-related adverse effects on 
male sexual differentiation. 
 
Howdeshell et al. (2008)  
Summary: The aim was to provide dose-response information on the effects of several phthalates on 
foetal testosterone production and to investigate if the data could be used to predict effects of a 
mixture of phthalates on testosterone production. Time-mated rat dams were dosed by oral gavage 
from GD8-18 with 0, 25, 50, 100, 200, 300, 600 or 900 mg/kg/day of DPP. At study start the number 
of mated dams was 2-6 per dose-group. On GD18, there were 5, 5, 4, 6, 4, 2, 1 and 2 pregnant dams, 
respectively. DPP reduced maternal body weight gain GD8-18 at 300, 600 and 900 mg/kg/day and in 
these dose-groups 100% foetal mortality (resorptions/implantations) was seen. Testosterone 
production measured in ex vivo testis from foetuses exposed to DPP during gestation (GD 8-18) was 
reduced at 100 and 200 mg/kg/day. The study showed inhibition of foetal testosterone production 
Study quality and assessment: This study is well described and includes necessary information such as 
compound, dosing period and number of animals. The study is assessed to be of high quality. The data 
provide strong evidence on an anti-androgenic mode of action of DPP on foetal testosterone 
production. 
 
Hild et al. (2007)  
Summary: This study evaluates the time course of acute ultrastructural changes occurring in Sertoli 
and germ cells after a single dose of CDB-4022 with DPP as a positive control. Four adult male rats 
per group were exposed orally to a single dose of 0 or 2200 mg/kg DPP and killed after 0, 3, 6, 9, 12, 
18 or 24 h after dosing. Controls were killed after 0 or 24 h after dosing. Testes were examined 
morphologically under light microscope and ultrastructurally in a transmission electron microscope.  
Degenerative changes in Sertoli cells, spermatocytes and spermatids were seen after DPP exposure. 
Spermatogonia appeared unaffected. 
Study quality and assessment: The present study is well described and included important information 
such as animal number, life stage of animals and time point at euthanasia, although more details on 
CAS-number, exact age of the animals and housing conditions would be preferred. The study is 
assessed to be of moderate quality. The data from the study provides strong evidence of adverse 
effects on testes at the cellular level but does not study the underlying modes of action and it is 
therefore not clear if the adverse effects are due to an endocrine mode of action. 
 
Liu et al. (2005)  
Summary: The aim of the study was to identify genes involved in the development of testicular 
dysgenesis. A selection of phthalates known to affect male reproductive development after in utero 
exposure was used to induce such changes, including DPP. A range of phthalates known not to affect 
male reproductive development was used as negative controls. Time-mated rat dams (10 controls and 
5 per exposed group) were dosed by oral gavage from GD 12-19 to 500 mg/kg/day DPP. Caesarean 
section of foetuses was performed on GD 19, where AGD was measured and testes were used for 
gene expression analysis (testis from 1 foetus per litter per group was used for microarray analysis. 
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For RT-QPCR, 1 testis per litter from 6 litters in the control group and 1 testis per litter from 3 litters 
in the treated group were used). Immunohistochemistry of testes from control and DBP exposed 
foetuses was performed.  
Male foetuses exposed to DPP in utero had reduced AGD compared to controls on GD19. Gene 
expression levels in GD19 foetal testes exposed to DPP in utero was changed for genes involved in 
regulating steroidogenesis and insulin signalling (e.g. downregulation of Luteinizing 
hormone/choriogonadotropin receptor (Lhcgr), Low-density lipoprotein receptor (Ldlr) and Insulin 
induced gene (Insig1)). The phthalates appeared to target Sertoli cells and gonocytes and the 
interaction between the two. 
Study quality and assessment: The study is well described and important information on sample sized, 
exposure period and age at tissue sampling are described. Although no CAS-number for DPP is 
mentioned, the study is assessed to be of high quality. The data provide strong evidence of adverse 
effects on male AGD. The changes in gene expression levels of genes involved in steroidogenesis 
provide moderate evidence of a mode of action of DPP on steroidogenesis.  
 
Hild et al. (2001)  
Summary: In this study, the testicular cell types affected by CDB-4022 were determined. DPP was 
used as a known Sertoli cell toxicant and estradiol-3-benzoate was used as a positive control of germ 
dell apoptosis. To study the acute effects on testicular germ cell apoptosis and Sertoli cell function 
and testicular morphology, fertile male rats were exposed to a single oral dose of DPP (2200 mg/kg, 3 
per group) and killed after 3, 6 or 12 hours after dosing. A second study was performed to investigate 
the acute effects on Sertoli cell function in prepubertal male rats (10 per group) dosed orally with a 
single dose of 2200 mg/kg DPP and euthanized 24 or 48 hours after dosing. An indicator of the 
seminiferous tubule fluid (STF) was assessed. Serum inhibin B and epididymal androgen binding 
protein (ABP) content were assessed in the two studies to evaluate Sertoli cell function. A third study 
was performed to determine the effects on Leydig cell function and fertility but only exposure to 
CDB-4022 was investigated. 
In the first study (in adult males), an increased percentage of seminiferous tubules with a higher 
number of apoptotic germ cells (early spermatocytes and spermatogonia) per tubule compared to 
controls was seen. Morphologically, vacuolization of Sertoli cells and detachment of germ cells was 
observed. Serum inhibin B was decreased. In the second study (in prepubertal males), STF secretion 
(by Sertoli cells) was suppressed and serum inhibin B levels and epididymal ABP were decreased. 
The data indicate that DPP interferes with early stages of spermatogenesis by inducing apoptosis of 
early stages of germ cells via disruption of Sertoli cell structure and function. 
Study quality and assessment: The study is well-described, but more details on housing conditions, 
age of adult males, CAS-number and purity of DPP would be preferred. The study is assessed to be of 
moderate quality. The data show decreased Sertoli cell function, disrupted Sertoli cell morphology 
and apoptosis of germ cells. The study provides strong evidence of adverse effects on testis function 
and morphology in adult males and decreased function of Sertoli cells in prepubertal male rats after 
exposure to DPP. 
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Jones et al. (1993)  
Summary: The aim of this study was to investigate phthalate toxicity on Leydig cells structure and 
functionality. Four different phthalates, including DPP, were investigated in vivo and their 
monoesters, including MPP, were investigated in vitro. Adult (6-8 weeks old) male rats were exposed 
to DPP by daily oral gavage for 2 days (n=3/group). Rats were euthanized 24h after the last dose. Rats 
were killed and both testes from each rat were used for pathological and ultrastructural examination. 
In vitro tests on isolated Leydig cells from 10 male rats were performed to measure the effects of 
MPP on testosterone production.  
Exposure to DPP showed rarefaction and vacuolization of Sertoli cells, necrosis of germ cells and 
shedding of spermatocytes and spermatids. No changes were seen in Leydig cell morphology or 
ultrastructure and in vitro secretion of testosterone from Leydig cells was not affected by MPP.  
Study quality and assessment: Although the study is old, some important information on number and 
age of animals and viability of cultured cells in vitro is provided. No information on CAS-number or 
purity is provided and more details on housing of animals would be preferred. The quality of this 
study is assessed to be of moderate quality. The data provide strong evidence on adverse effects of 
DPP on the structure of testicular tubular cells (Sertoli cells and spermatogonia) but not on Leydig 
cells in vivo. The study provides moderate evidence that the mode of action of DPP behind the effects 
on testosterone production is not through the metabolite MPP on Leydig cell function.  
 
Granholm et al. (1992)  
Summary: The testicular inflammatory reaction after DPP exposure and correlation with 
morphological inflammatory changes in the testes was investigated in rats and mice in this study. Rat 
testis weight and morphology were also assessed. Male rats (40 days old) were dosed by oral gavage 
to 2.2 g/kg DPP. Rats were killed after 0, 3, 6, 9, 12, 18 or 24 hours after dosing. Control animals 
were killed 0 or 24 h after dosing.  
No changes were seen in testis weight but histological examination showed slight morphological 
changes in Sertoli cells with rarefaction of the basal cytoplasm. 
Study quality and assessment: The present study is poorly described and it is not always readily 
obvious whether data are assessed from mice or rats. The study is old and there is missing information 
on CAS-no, number of animals used per treatment groups and animal housing conditions. The study is 
assessed to be of low quality. The reported data provide weak evidence for adverse effects of DPP on 
male testis.  
 
Heindel et al. (1989)  
Summary: The reproductive toxicity of three phthalates was investigated in this study, where a 
continuous breeding protocol was followed. The reproductive effects of DPP were investigated in a 
breeding study and in a cross-over breeding study. In the breeding study, 40 control pairs and 20 
pairs/treatment group was used. Male and female mice (11 weeks old) were exposed to 0, 0.5, 1.25 or 
2.5% DPP in the feed for 7 days prior mating. The breeding pairs were evaluated for clinical signs, 
body weight, fertility (based on the number of pairs producing litters), number of litters per pair, live 
pups per litter, proportion of pups born alive, sex of live pups, pup body weight and food and water 
consumption. In the 1-week cross-over breeding study, exposed mice (20 pairs/group) were paired 
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with control mice of the opposite sex to determine the sex affected by DPP. Mice were exposed to 0 
or 2.5% DPP in the food during the whole period after mating. Decreased fertility was seen in the 
breeding study in the 0.5% treatment group; fewer litters/pair, fewer live pups per litter and fewer 
pups born alive were seen. Breeding pairs exposed to higher levels of DPP were infertile. In the cross-
over breeding study, both male and female mice were infertile after treatment with 2.5% DPP. 
Decreased body weight was seen for male and female mice and decreased absolute and relative organ 
weights were found for testis, epididymis, seminal vesicles and kidneys. Epididymal sperm count was 
decreased to a non-detectable level. Prostate weight was comparable to controls and liver weight was 
increased (absolute and relative). Histopathological changes were seen in testis, where degeneration 
of seminiferous tubules and interstitial cell hyperplasia was seen. In epididymis, accumulation of fluid 
and degenerated cells was seen. No effects were seen on oestrous cycle length and no 
histopathological changes were found in female reproductive organs (ovaries, oviduct, uterus and 
vagina). Infertility induced by DPP on mating mice was shown to be related to effects in both the 
male and the female mice, although no morphological or weight-related changes were found in the 
reproductive organs of exposed female mice. Several changes in male reproductive organs were 
found.  
Study quality and assessment: Although the study is old and the study protocol is complicated, it is 
well-described and includes important information such as number and age of animals. More 
information on housing conditions and CAS-number would have been preferred. A large number of 
animals per group were used. The study is assessed to be of high quality. This study provides strong 
evidence on adverse effects on reproductive organs and fertility of mice exposed to DPP. 
 
Creasy et al. (1988)  
Summary: The effects of MPP on Sertoli cell ultrastructure and germ cells in vitro was investigated 
and compared with the effects of DPP on these cell types in vivo. An in vivo study with 3 adult (28 
days old) male rats per group exposed orally to a single dose of 2.2 g/kg DPP were killed 1, 3, 6, 12 or 
24 hours after dosing. Morphology of Sertoli- and germ cells was evaluated under transmission 
electron microscopy and compared with the findings from the in vitro tests with MPP. 
Generally seen, Sertoli cell shape resulted in direct apposition of germ cells 6 hours after dosing and 
necrotic germ cells 24 hours after dosing. Interstitial neutrophil infiltrates were apparent after 12 
hours of dosing. Rarefaction of Sertoli cell cytoplasm in vivo correlated with mitochondrial 
hypertrophy in vitro and changes in Sertoli cell shape in vivo after DPP exposure correlated well with 
Sertoli cell shape and actin filament organisation changes seen in vitro after MPP exposure.  
Study quality and assessment: The study is old and the in vivo part of the study is relatively 
superficially described. The most important information such as age and number of animals used, the 
doses and timing of termination is described, but no details on housing conditions, source of the 
animals or whether one or two testes per animal was used for the assessment of testicular changes was 
described. The in vivo part of the study is assessed to be of low quality. The data provide moderate 
evidence that DPP can lead to adverse effects on the testicular Sertoli cells. 
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Lindström et al. (1988)  
Summary: The relationship between spermatogenesis and serum levels of androgen binding protein 
were investigated in this study by testing if testicular effects are reflected by altered serum levels of 
androgen binding protein. This was performed in two animal studies with single dose-exposure to 
DPP at 0, 0.25, 1 or 2g/kg by oral gavage. In the first study, 10 adult Fisher 344 rats per group 
(approximately 6 weeks of age) were killed 2 days after exposure or each week for 10 weeks. At 
necropsy, body weight and weight of testis, epididymis, prostate, seminal vesicle, liver and kidney 
were assessed. Epididymal sperm density and morphology were measured and histological 
morphology of testis and epididymis was evaluated. Serum androgen binding protein was measured.  
In the second study (20 males per group), male fertility after DPP exposure was evaluated by testing 
their ability to impregnate female rats and assessment of the number of live pups and preimplantation 
loss. After fertility assessment, the males were killed 14, 18 and 30 weeks after dosing (5 controls and 
5 high-dose males at each time-point) to assess testicular recovery histologically.  
In the first study Lindström and co-workers found effects on body weight and male reproductive 
organs. Lower body weight in the two highest dose-groups was seen during the first week after 
dosing. Testicular weight and epididymal weight were lower than controls in the 1 and 2g/kg dose-
groups and remained below controls for all 10 weeks they were studied. Sperm density was lower 
than controls in all dose-groups and sperm morphology was abnormal in the highest dose-group. 
Histological evaluation of testis showed effects on germ cells and intertubular spaces. Liver weights 
were increased 2 days after dosing but returned to control levels after 2 weeks. In the second study, 
fewer fertile males were found in the high-dose group compared to controls; they had less ability to 
impregnate female rats, there was an increased number of preimplantation losses after mating and an 
increased number of dead pups. Finally, 30 weeks after dosing no signs of recovery of the testicular 
damage was seen.   
Study quality and assessment: Although this is an old study much important information is included 
such as purity of the chemical, rat strain, details on housing conditions and number of animals for 
each study performed and for the endpoints assessed. However, more information on CAS-number 
would be preferred. The study is assessed to be of moderate quality. The data from the present study 
provide strong evidence for adverse effects on testis in adult males after exposure to a single dose of 
DPP without obvious recovery at the cellular level 30 days after exposure.  
 
Creasy et al. (1987)  
Summary: The study investigates the effects of 2.2 g/kg DPP on sexually mature rat testis at different 
time-points after oral exposure. Two control and three exposed animals (15 weeks of age) were killed 
3, 6, 12, 18, 24 or 48 h after dosing and testis were examined under light microscope, electron 
microscope and transmission electron microscope.  
Creasy and co-workers found stage-specific changes in the testicular tubules (morphologically 
observed as vacuolization and closure of the lumen, increased affinity for stain and vacuolization of 
tail cytoplasm of elongating spermatids and necrosis of spermatocytes) and degeneration of Sertoli 
cells. Interstitial inflammatory infiltrate was seen 12 hours after dosing or later. The changes appeared 
to be reversible.  
Study quality and assessment: Although this is an old study, it is well described and includes much 
important information such as number of animals used, age of animals at study start and detailed 
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descriptions of the changes observed. Few control animals were included (2 control rats per 
experiment) and no CAS number or purity was stated for the chemical. All in all the study is assessed 
to be of moderate quality. This study provides strong evidence for testicular adverse effects in 
sexually immature rats in the case of continuous exposure. 
 
Gray and Gangolli (1986)  
Summary: This paper investigates some features of testicular effects of some phthalates in rats, 
including effects on Sertoli cells, and effects of phthalate monoesters on testicular germ cell cultures. 
Some investigations, such as the effects on reproductive organs with co-administration of 
gonadotropins or the effects of metabolites on testicular cell cultures of Sertoli cells and germ cells 
were performed on other phthalates but not on DPP or the metabolites of DPP. 
Tubular atrophy was seen in testes from 15 weeks old males 24 hours after exposure to 2200 
mg/kg/day DPP, but was less severe and developed slower than in immature rats. A single dose of 
2200 mg/kg DPP in immature 4-5 weeks old rats (5 per group) showed a complete or close to 
complete depression of androgen binding protein (ABP) and fluid in rete testis, respectively. The 
lower single dose of 440 mg/kg DPP decreased fluid and ABP, but not 220 mg/kg. In older rats 10 
weeks of age, the highest dose (2200 mg/kg) also decreased fluid and ABP, but not in the same 
dramatic extent as in the younger rats (reduced to 60% of control values). Repeated dosing of 220 
mg/kg for 3 days did not change fluid or ABP production significantly. Mono-n-pentyl phthalate 
(MPP) was shown to cross the blood-testis barrier in very little amounts (levels in rete testis was 5% 
of plasma levels 25 minutes after phthalate administration, n=3 controls and 2 dosed with MPP). MPP 
administered i.v. for 4 days showed histological testicular changes characteristic of phthalate changes 
at 50 mg/kg/day but not at 25 mg/kg/day. 
Study quality and assessment: The methods used in the study are described in an unstructured way 
and are confusing. Dosing levels, duration of dosing and number and age of animals used is not 
described in the methods section and the number of animals is not accessible, if the data are not 
presented in a table (e.g. for the data on testicular atrophy in males exposed to DPP). The methods 
used for cell culture are poorly or hardly described. It is unclear whether some of the data described 
are from the present study or are a description of findings from a previously published study. The 
study is assessed to be of low quality. The data provide weak evidence of adverse effects of DPP on 
male reproductive tract.  
 
Creasy et al. (1983)  
Summary: The study was performed to identify the primary site of DPP damage and follow the 
development of the lesion. Moreover, the study aimed at providing indications of the functional 
integrity of the affected Sertoli cells. Single dose studies and repeated dose studies on DPP are 
described with focus on testicular effects in sexually immature male Sprague-Dawley rats (3-4 weeks 
of age). Necropsies of rats were performed 1, 3, 6 or 24 hours after a single dose of 2.2 g/kg DPP or 
after 3, 4 or 5 days of daily dosing of 2.2 g/kg DPP. One control animal and 3 exposed animals were 
used for each experiment.  
Early degenerative vacuolization of Sertoli cells 3 to 6 hours after oral dosing was seen. After 2-4 
days of repeated dosing, degeneration of spermatocytes and spermatids as well as depletion of 
spermatogonia and germinal cells was seen. 
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Study quality and assessment: Although this is an old study, it is well described and includes much 
important information such as purity of the chemical, age of animals at study start and at necropsy and 
number of animals used. Few control animals were included (1 control rat per experiment) and no 
CAS-number was stated for the chemical. All in all the study is assessed to be of moderate quality.  
This study provides moderate evidence for testicular adverse effects in sexually immature rats.   
 
Foster et al. (1983)  
Summary: Steroidogenic enzyme activity was measured in testis and livers from male rats (4 weeks 
old) exposed orally to DPP or diethyl phthalate daily or as a single dose. Male rats were dosed with a 
single dose of 7.2 mmol/kg of DPP and killed 0, 1, 3, 6 or 24 h after dosing. Other male rats were 
dosed daily with 7.2 mmol/kg/day of DPP and killed after 2, 3 or 4 days. Microsomes and cytochrome 
P450 from testes and livers were extracted. Single doses of DPP decreased enzyme activity of 17-α-
hydroxylase and 17-20 lyase in testes. Repeated dosing of DPP for 2 or 4 days increased the activity 
of 17-β-dehydrogenase in testicular microsomes. 17-α-hydroxylase, 17-20 lyase and 17-β-
dehydrogenase are enzymes involved in conversion of progesterone to testosterone. Cytochrome P450 
in testes was also decreased by DPP. 
Study quality and assessment: The present study is old and there is missing information on CAS-
number, number of animals used per treatment groups and animal housing conditions. The study is 
assessed to be of weak quality. The reported data provide moderate evidence for an endocrine mode 
of action of DPP through action on the steroidogenic enzymes in testes. 
 
Foster et al. (1982)  
Summary: The aim of this study was to determine the localization of zinc in the normal testis and in 
testis exposed to DPP until reaching atrophy of testis. Single dose and repeated dose studies of 2.2 
g/kg DPP by oral gavage in male rats were described by Foster et al (1982). In the single-dose 
experiments, 3 controls and 3 exposed animals were killed at 0, 1, 3, 6 or 24 h after dosing. In the 
repeated-dose studies, 3 controls and 3 exposed animals were killed after 2, 3 or 4 days of daily 
exposure. The weight of testis, prostate and seminal vesicle was measured and a significant decrease 
in testis weight was found. Morphology of testes was assessed and vacuolization of Sertoli cells and 
necrosis of spermatids and spermatocytes was found. Analysis of zinc deposits in testicular cells 
indicated that the testicular damage may be associated to zinc depletion. 
Study quality and assessment: Although this is an old study, it is well described and includes much 
important information such as purity of the chemical, weight of animals at study start and number of 
animals used. The relative organ weights were reported as % of controls and the life stage (sexually 
mature or immature) of the animals is unclear. The study is assessed to be of moderate quality. This 
study provides strong evidence of testicular adverse effects. The data indicate a relation to zinc 
depletion which may be affect gonadotropins and androgen production in testis, but it is not clear if 
the adverse effects are due to an endocrine mode of action. 
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Foster et al. (1980)  
Summary: This study was performed to compare the testicular effects of some phthalates with their 
effects on zinc excretion in the rat. Young adult male rats (70-90 g, 12/group) were exposed to 7.2 
mmol/kg/day (2.1 g/kg/day) of DPP by oral intubation for 4 days. Body weight gain, food intake, 
testis weight, histological testicular morphology and zinc levels in urine, faeces, testis, liver and 
kidney were assessed. Relative testis weight was decreased (data on absolute weight is neither shown 
nor mentioned) and histological evaluation of testis showed atrophy of seminiferous tubules with loss 
of spermatocytes and spermatids. Urinary excretion of zinc-65 was increased. Zinc content in testis 
was decreased whereas the content in liver and kidney was increased. The animals showing testicular 
atrophy also had increased urinary excretion of zinc and a putative link between low zinc levels in 
testis and testicular atrophy was established.  
Study quality and assessment: Although no CAS-number or information on housing conditions is 
provided in this early study, other important information is given, such as number and weight of 
animals used, dose level and method and duration of dosing. Therefore the study is assessed to be of 
moderate quality. The data from the present study provide strong evidence of testicular adverse effects 
of DPP. Moreover, the study provides some evidence of a mode of action of DPP involving zinc, but 
it is not clear if the adverse effects are due to an endocrine disrupting mode of action. Therefore the 
study is assessed to provide weak evidence of an endocrine-related mode of action of DPP.  
 
4.10.3.4 Summary of the plausible link between adverse effects and endocrine mode of 
action  
 
Several in vivo studies investigating the endocrine mode of action of DPP showed an anti-androgenic 
mode of action of DPP (Table 1). Many studies showed decreased testosterone levels in foetuses 
either in plasma, testis or ex vivo testicular testosterone production (Gray et al. 2016; Beverly et al. 
2014; Hannas et al. 2011; Howdeshell et al. 2008). Genes involved in steroid synthesis, regulation or 
transport have also been shown to be downregulated by DPP exposure (Hannas et al. 2012; Hannas et 
al. 2011; Liu et al. 2005). Finally, microsomal enzymes involved in steroid synthesis were affected by 
DPP exposure in vivo and in vitro (Yuan et al. 2012; Foster et al. 1983). Other in vitro studies 
investigating the endocrine mode of action of DPP and the monoester mono-n-pentyl phthalate (MPP) 
showed weak signs of anti-androgenic activity of DPP and no effects of MPP on testosterone 
production in Leydig cells (Christen et al. 2010; Jones et al. 1993). Some studies investigating zinc 
excretion and deposition in testis showed that low zinc levels may be involved in DPP related testis 
damage (Foster et al. 1982; Foster et al. 1980). Altogether, several rodent studies have demonstrated 
strong evidence of an anti-androgenic mode of action of DPP in vivo.  
DPP is classified as a reproductive toxicant and adverse effects on the reproductive system in rodents 
that may be related to an endocrine disrupting mode of action have been shown in a large number of 
in vivo studies (Table 2). Effects on the male reproductive system that are known to be able to be 
induced via endocrine disrupting modes of action have been reported, e.g. decreased male AGD, 
increased nipple retention in males, decreased number of spermatocytes (decreased sperm count), 
malformations of male reproductive organs (hypospadias, malformations of vas deferens, epididymis 
and gubernacular cord), decreased weight of male reproductive organs in adulthood, decreased foetal 
testis weight and delayed descent of testis. Other changes in the male reproductive system were also 
seen although it is not clear if the adverse effects are due to an endocrine mode of action. The changes 
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include degenerative changes of testicular Sertoli cells and degeneration or loss of spermatocytes 
(Hild et al. 2007; Hild et al. 2001; Jones et al. 1993; Granholm et al. 1992; Creasy et al. 1988; Creasy 
et al. 1987; Creasy et al. 1983; Foster et al. 1982; Foster et al. 1980). 
Effects of DPP were also seen on female fertility without effects on weights of female reproductive 
organs (Heindel et al. 1989), but the modes of action are unclear. All in all the evidence for adverse 
effects of DPP in males is strong but the evidence for adverse effects in the female reproductive 
system is moderate. 
 
Summary and conclusions 
Overall, several rodent studies have shown adverse effects on the male reproductive system and male 
reproductive development. Many of the effects observed are generally known to be androgen 
dependent and changes such as decreased AGD and increased nipple retention in males is associated 
with an anti-androgenic mode of action and low androgen levels. Studies on the endocrine-related 
modes of action of DPP showed effects on steroid production at several levels including 
downregulation of steroid-related genes, reduced activity of enzymes involved in steroid synthesis and 
decreased levels of testosterone in plasma and testis. The adverse effects observed for DPP can be 
attributed to an anti-androgenic mode of action, and it is highly biologically plausible, that there is a 
link between the decreased testosterone synthesis found for DPP and the adverse effects observed on 
male reproductive organs and male reproductive development. The evidence for an endocrine mode of 
action of DPP is strong, the evidence for adverse effects on male reproductive system is strong and 
there is strong evidence for a causal link. In conclusion, DPP meets the WHO definition of an 
endocrine disruptor. 
 
Additional literature not included in the evaluation 
Reviews on DPP have been used to check for additional literature not found in our literature search 
(Gangolli et al. 1982; Gray et al. 1982; NTP 1985).  
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Table 1. Overview of in vitro and in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of di-n-pentylphthalate (DPP)  
Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
Gray et al. 
2016 
 Decreased testosterone levels in plasma, testis 
and ex vivo testicular testosterone production. 
High Strong 
Beverly et al. 
2014 
 Decreased ex vivo testicular testosterone 
production. 
Medium Strong 
Hannas et al. 
2012 
 Downregulation of several genes in GD18 
testis involved in steroid synthesis, steroid 
regulation and steroid transport.  
High Moderate 
Yuan et al. 
2012 
Reduced activity of microsomal enzymes 
related to testicular testosterone synthesis. 
 High Moderate 
Hannas et al. 
2011 
 Decreased ex vivo testicular testosterone 
production in a dose-related manner in testis 
GD 17 and 18 and downregulation of gene 
expression levels of androgen synthesis genes 
StAR and cyp11a and of insl3 in testis GD 
18. 
High Strong 
Christen et al. 
2010 
Androgen receptor reporter gene assay: 
Partial inhibition curves (anti-androgenic 
activity) were observed for DPP. No 
notable androgenic activity was seen. 
 High Moderate 
Howdeshell et 
al. 2008 
 Reduced testosterone production in ex vivo 
foetal testis exposed to DPP during foetal 
development (GD 8-18). 
 
High  Strong 
Liu et al. 2005  Gene expression levels in GD 19 foetal testes 
was changed for genes involved in regulating 
steroidogenesis and insulin signaling. DPP 
appeared to target Sertoli cells and gonocytes 
and the interaction between the two. 
High Moderate 
 
Jones et al. 
1993 
Secretion of testosterone from cultured 
Leydig cells was not affected by MPP. 
 Medium Moderate 
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Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
Creasy et al. 
1988 
An in vitro study on effects of MPP on 
Sertoli cells showed changes in Sertoli cell 
shape, development of microprocesses 
between Sertoli cells and germ cells and 
reorganization of actin filaments. 
 Low Weak 
Foster et al. 
1983 
 
 
 Single doses of DPP decreased microsomal 
enzyme activity involved in testosterone 
synthesis in testes. Repeated dosing of DPP 
for 2 or 4 days increased the activity the 
enzymes. Cytochrome P450 in testes was also 
decreased by DPP. 
Low Moderate 
Foster et al. 
1982 
 Analysis of zinc deposits in testicular cells 
indicated that the testicular damage may be 
associated to zinc depletion. 
Medium Weak 
Foster et al. 
1980 
 Animals showing testicular atrophy had 
increased urinary excretion of zinc and 
decreased zinc levels in testis.  
Medium Weak 
MPP: Mono-n-pentyl phthalate, the monoester of DPP, gestation day (GD) 
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Table 2. Overview of potential endocrine-related adverse effects of di-n-pentylphthalate (DPP) 
Reference Species, n Adverse effects Quality of study  Evidence for 
adverse effects 
Gray Jr et al 
2016 
Rats,  
n=5 litters/ 
group 
Decreased male AGD PND2, malformations of male reproductive organs 
in adult offspring (hypospadias, malformations of vas deferens, 
epididymis and gubernacular cord), decreased weight of reproductive 
organs in adult offspring. Decreased foetal testis weight and delayed testis 
descent GD 18. 
Medium Strong 
Hannas et al. 
2011a 
Rats, n=5 
dams/group 
Decreased male AGD PND2 and increased male NR PND13. High Strong 
Hild et al. 
2007 
Rats, n=4/ 
group 
Degenerative changes in Sertoli cells, spermatocytes and spermatids were 
seen after DPP exposure. Spermatogonia appeared unaffected. 
High Strong 
Liu et al 2005 Rats; n=10 
control dams 
and n=5 
exposed 
dams 
AGD in GD 19 foetuses was decreased after DPP exposure GD12-19. High Strong 
Hild et al. 
2001 
Rats, n= 3 
adults/group 
and 10 
prepubertal / 
group 
An increased % of seminiferous tubules with a higher number of 
apoptotic germ cells per tubule compared to controls was seen. 
Morphologically, vacuolization of Sertoli cells and detachment of germ 
cells was observed. Serum inhibin B was decreased. In the second study 
(in prepubertal males), STF secretion (by Sertoli cells) was suppressed 
and serum inhibin B levels and epididymal ABP were decreased.  
Medium Strong 
Jones et al. 
1993 
Rats; 
n=3/group 
Rarefaction and vacuolization of Sertoli cells, necrosis of germ cells and 
shedding of spermatocytes and spermatids after DPP exposure. No 
changes were seen in Leydig cell morphology or ultrastructure after DPP 
exposure. 
Medium Strong 
Granholm et 
al. 1992 
Rats, n=not 
described. 
No changes were seen in rat testis weight but histological examination 
showed slight morphological changes in Sertoli cells with rarefaction of 
the basal cytoplasm. 
Low Weak 
Heindel et al. 
1989 
Mice; study 
A: n=40 
control and 
20 treated 
Fewer litters/pair, fewer live pups per litter and fewer pups born alive 
were seen in the 0.5% treatment group. Breeding pairs exposed to higher 
levels of DPP (1.25 or 2.5%) were infertile. In the cross-over breeding 
study, both male and female mice were infertile after treatment with 2.5% 
High Strong for males, 
moderate for 
females 
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Reference Species, n Adverse effects Quality of study  Evidence for 
adverse effects 
breeding 
pairs/group; 
study B: 
n=20 cross-
over breeding 
pairs/group;  
DPP. Decreased body weight was seen for male and female mice and 
decreased absolute and relative organ weights were found for testis, 
epididymis and seminal vesicles. Epididymal sperm count was decreased 
to a non-detectable level. Prostate weight was comparable to controls and 
liver weight was increased (absolute and relative). Histopathological 
changes were seen in testis, where degeneration of seminiferous tubules 
and interstitial cell hyperplasia was seen. In epididymis, accumulation of 
fluid and degenerated cells was seen. No effects were seen on estrous 
cycle length and no histopathological changes were found in female 
reproductive organs. 
Creasy et al. 
1988 
Rats; 
n=3/group 
Changes in Sertoli cell shape and rarefaction of the cytoplasm was seen 
after DPP exposure.  
Low Moderate 
Lindström et 
al. 1988 
Rats, n=10/ 
group, n=20 
in fertility 
study, n=5 in 
recovery 
study 
Study on reproductive organs: lower body weight in the two highest dose-
groups (1 and 2 g/kg) was seen during the first week after dosing. 
Testicular weight and epididymal weight were lower than controls in the 
1 and 2g/kg dose-groups and remained below controls for all 10 weeks 
they were studied. Sperm density was lower than controls in all dose-
groups. Sperm morphology was abnormal in the highest dose-group. 
Histological assessment of testis showed effects on germ cells and 
intertubular spaces. Liver weights were increased 2 days after dosing but 
returned to control levels after 2 weeks. Prostate and seminal vesicle 
weights were never different from controls. 
Fertility study: less fertile males were found in the high-dose group 
compared to controls – they had less ability to impregnate female rats, 
there was an increased number of preimplantation losses after mating and 
an increased number of dead pups. 
Recovery study: no signs of recovery on germinal epithelium were seen 
30 weeks after dosing. 
 
Low-medium Strong 
Creasy et al. 
1987 
Rats, n= 2 
control and 3 
exposed 
Stage-specific changes in the testicular tubules and degeneration of 
Sertoli cells. The changes appeared to be reversible. 
 
 
Medium Strong 
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Reference Species, n Adverse effects Quality of study  Evidence for 
adverse effects 
Gray and 
Gangolli 1986 
Rats, n= 
5/group 
unless 
otherwise 
mentioned  
Testicular tubular atrophy (in 15 weeks old males) 24 hours after 
exposure to 2200 mg/kg/day DPP, but was less severe and developed 
slower than in immature rats. A single dose of 2200 mg/kg DPP in 
immature 4-5 weeks old rats showed a complete or close to complete 
depression of ABP and fluid in rete testis, respectively. 440 mg/kg DPP 
decreased fluid and ABP. In rats 10 weeks of age, the highest dose (2200 
mg/kg) also decreased fluid and ABP, but not in the same dramatic extent 
as in the younger rats. Repeated dosing of 220 mg/kg for 3 days did not 
change fluid or ABP production significantly. Mono-n-pentyl phthalate 
(MPP) was shown to cross the blood-testis barrier in very little amounts 
(n=3 controls and 2 dosed with MPP). MPP administered i.v. for 4 days 
showed histological testicular changes characteristic of phthalate changes 
at 50 mg/kg/day but not at 25 mg/kg/day 
Low Weak 
Creasy et al. 
1983 
Rats, n=1 
control and 3 
exposed/ 
time-point 
Degenerative vacuolization of Sertoli cells 3 to 6 hours after oral dosing. 
Degeneration of spermatocytes and spermatids as well as depletion of 
spermatogonia and germinal cells was seen with repeated dosing. 
Medium Moderate 
Foster et al. 
1982 
Rats, 
n=3/group 
Vacuolization of Sertoli cells and necrosis of spermatids and 
spermatocytes was found.  
Medium Strong 
Foster et al. 
1980 
Rats, 
n=12/group 
Relative testis weight was decreased and histological evaluation of testis 
showed atrophy of seminiferous tubules with loss of spermatocytes and 
spermatids. 
Medium Strong 
ABP: androgen binding protein. AGD: ano-genital distance. GD: gestation day. PND: postnatal day. STF: Seminiferous tubule fluid, MPP: Mono-n-pentyl phthalate, the 
monoester of DPP. 
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Figure 1. 2D structure from PubChem  
Bisphenol AF (BPAF), CAS no.1478-61-1 
 
Synonyms: 4,4´-(Hexafluoroisopropylidene)diphenol 
BPAF is a fluorinated organic diphenol and a structural 
analog to Bisphenol A in which the two methyl groups are 
replaced with trifluoromethyl groups (Figure 1). BPAF has 
broad applications and is for example used as cross-linking 
reagent in the production of fluoropolymers and 
fluoroelastomers and as a monomer in production of many 
polymers. Since no registration dossiers on BPAF are 
available, it is assumed that it is produced and/or imported 
to EU in tonnages less than 100 tpa. BPAF has been 
detected in different environmental samples and in samples 
from humans. At present there is a lack of toxicological 
information on BPAF and is therefore currently undergoing 
extensive evaluations for in vivo toxicity by the National 
Toxicology Program, USA. 
 
4. Human health hazard assessment 
4.10.3 Endocrine disruption 
4.10.3.1 General approach – human health 
4.10.3.2 In vitro information indicative of endocrine activity 
Lei et al. (2017)  
Summary: In this study, the effects of BPAF (>98% purity, CAS no. 1478-61-1) (and other 
bisphenols) on cell viability, DNA and plasma membrane damage, intracellular reactive oxygen 
species (ROS) formation, and Ca(2+) levels of MCF-7 cells were evaluated. Cell viability of MCF-7 
cells was measured using the cell counting kit-8 (CCK-8) assay with BPAF concentrations ranging 
from 0.01-100 μM for 24 h. Lactate Dehydrogenase (LDH) release was assessed to indicate the 
plasma membrane damage in MCF-7 cells, and for this BPAF was tested at concentrations from 1-100 
μM for 24 h. DNA damage was measured by alkaline single cell gel electrophoresis, i.e. the Comet 
assay, and BPAF was tested in concentrations from 1-50 μM for 24 h. The production of ROS was 
measured after cells were exposed for 24 h to concentrations of BPAF from 0.01-50 μM. Calcium 
levels were measured after 24 h exposure to 0.00001–10 μM BPAF. At the same time, the estrogenic 
and thyroidal hormone receptor-mediated potentials (i.e., ERα and TRα activity) of BPAF were 
evaluated using the two-hybrid yeast bioassay with 10-12 dilutions (in triplicate). 
The results showed that BPAF significantly increased cell viability in MCF-7 cells at low 
concentrations (0.01-1 μM), but caused a significant decrease in cell viability at higher exposure 
concentrations (25-100 μM). BPAF increased LDH activity (25, 50 and 100 μM, i.e. at cytotoxicity 
levels), and caused increased DNA-damage (10, 25 and 50 μM) in MCF-7 cells. BPAF also resulted 
in a concentration-dependent increase in both ROS production (0.01-25 μM, i.e. below cytotoxicity) 
and intracellular Ca(2+) levels (0.0001-10 µM). The two-hybrid yeast bioassay showed that BPAF is 
an estrogen receptor α (ERα) (EC50 = 5.3 µM) and thyroidal hormone receptor α (TRα) (EC50 = 1.4 
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µM) agonist. Overall the results from the present study showed that BPAF exert cell biological 
effects, estrogenic and thyroidal effect with greater potency than BPA.  
Study quality and assessment: In general, the study is well-described although the material and 
methods section does not specify the exact tested concentrations. This can instead be read from the 
graphs, and a large concentration range from 0.0001-100µM of BPAF was tested. The quality of the 
study is assessed to be strong. The study provides strong evidence for endocrine MoAs, i.e. ERα and 
TRα agonist, of BPAF as well as other biological/toxicological effects on MCF-7 cells. 
 
Liang et al. (2017)  
Summary: This study developed and validated an automated multi-parametric high-content analysis 
(HCA) using the mouse C18-4 spermatogonial cell line as a model. The validated HCA, including 
nuclear morphology, DNA content, cell cycle progression, DNA synthesis, cytoskeleton integrity, and 
DNA damage responses, was applied to characterize and compare the potential testicular toxicities of 
various concentrations of BPA and 3 analogous including BPAF (98% purity, CAS no. not reported) 
BPAF was tested at0, 0.1, 1, 5, 10, 25 (≤ cytotoxicity level) µM (read from the relevant figures:) with 
exposure time of24, 48 and 72 h (3 replicates in 3 separate experiments). Cell viability was 
determined by measuring the capacity of cells to take up neutral red (BPAF doses: 0, 25, 50, 75 and 
100 µM, time: 24-72 h, 5 replicates in 2 separate experiments)The results revealed that BPAF 
exhibited higher cytotoxicity on spermatogonial cells compared with BPA and BPS at 25, 50, 75 and 
100 µM, both after 24 and 48 h exposure. BPAF significantly reduced cell viability in a time and 
dose-dependent manner, and cytotoxicity started at the lowest tested concentration of 25 µM for 24 h. 
Moreover, BPAF induced dose- (5-25 µM) and time-dependent (24-72 h) alterations in nuclear 
morphology, cell cycle, DNA damage responses, and perturbation of the cytoskeleton of the 
spermatogonial cells. 
Study quality and assessment: The study is well-described and is assessed to be of high quality. This 
study provides strong evidence for BPAF spermatogonial toxicity in vitro, however the MoAs for the 
alterations in spermatogonial cell morphology and potential testicular toxicity are not studied and a 
link to endocrine MoAs can therefore not be made. 
 
Conley et al. (2016)  
Summary: In this study, the T47D-KBluc estrogen receptor transcriptional assay (ERTA) was used to 
evaluate the estrogen receptor α (ERα)-mediated activity in vitro of BPAF (97% purity, CAS. no. 
1478-61-1) and other bisphenols, as well as and 17α-ethinyl estradiol (EE2) 17β-estradiol (E2). BPAF 
was run on individual plates over a range of doses separated at half-log intervals for 24 h. Each plate 
included 4 technical replicates per dose group and each chemical was tested across 6 biological 
replicates. Cell viability was assessed before the cells were lysed and luciferase activity measured. 
It was found that BPAF activates ERα but at a relatively low potency when compared to the reference 
compounds EE2 and E2. The main aims of the study were to evaluate how information from this in 
vitro assay can be used to predict results in the in vivo Uterotrophic assay and to explore the 
challenges and limitations of such extrapolations. The in vivo Uterotrophic assay and results on BPAF 
from this study is summarized in section 4.10.3.3.  
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Study quality and assessment: The study is well-designed and -described. The exact test 
concentrations of BPAF in ERTA are not specified but according to Figure 2 in the paper the tested 
concentrations range from 1∙10-10 to 1∙10-10 M (i.e., ~0.1-100 µM). Also, the cytotoxicity results are 
not reported. Overall, the study is assessed to be of moderate quality. This study provides a strong 
evidence for an estrogenic MoA of BPAF in vitro. 
 
Feng et al. (2016)  
Summary: In the present study, the H295R cell line was used as a model to compare the cell toxicity 
and effects on steroid hormone synthesis by four bisphenols: BPA, BPS, BPF, and BPAF (99% 
purity, CAS no. is reported as B0945, which is instead a product number). First, the viability of 
H295R cells exposed to 10-500 µM BPAF for 24 h, 48 h, and 72 h was measured using the cell 
counting kit-8 (CCK-8) assay. Next, BPAF was tested at sub-cytotoxic concentrations (0, 0.1, 1, 10, 
30, and 50 µM, 3 replicates of each exposure) for 48 h followed by quantification of hormone levels 
and gene expression. 
The LC50 values at 72 h exposure indicated that the rank order of cytotoxicity of the tested chemicals 
was BPAF > BPA > BPS > BPF. The results demonstrated that all the tested BPA analogues were 
capable of altering steroidogenesis in H295R cells. More specifically, BPAF showed significant 
increase in progesterone (10, 30 and 50 µM) and significant reductions in testosterone and aldosterone 
(1, 10, 30 and 50 µM) and cortisol (10, 30 and 50 µM) (Figure 2).  
Gene expression was significantly reduced for FDX1 (50 µM), CYP17A1 (1, 10, 30 and 50 µ), 
CYP11B2 (10, 30 and 50 µM), CYP11B1 and HSD3B2 (30 and 50 µM) in H295R cells. The 
inhibitory effects of BPAF on hormone production were probably mediated through the down-
regulation of these steroidogenic genes. 
Study quality and assessment: The study is well-described and investigates effects of BPAF on both 
hormone levels and enzyme expression. The OECD TG 456 was not applied or mentioned in the 
paper. Overall, the study is assessed to be of high quality. The links between altered expression of 
steroidogenic enzymes and hormone levels after BPAF exposure are discussed and can generally 
explain the lower testosterone level in the cells. Overall, the study provides strong evidence of 
endocrine MoA of BPAF on steroidogenesis. 
Figure 2. Overview of the steroidogenesis and the effect of 50 µM BPAF exposure (from Feng et al 2016)  
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Nakano et al. (2016)  
Summary: The aim of this study was to analyse the effects of BPA and BPAF (purity and CAS no. not 
reported) exposure on oocyte maturation in vitro. Mice oocytes were cultured in the presence of 
different concentrations of BPA or BPAF (0, 2, 20, 50 and 100 μg/ml, 3 replicates/dose group) for 18 
h (i.e., the time required to complete an oocyte maturation in mice) to determine the concentration-
dependent effects on nucleus maturation rate. Next, oocytes were exposed to 2 μg/ml BPA or BPAF 
and cultured for 6, 9, 12, 15 or 18 h (3 replicates/group) in order to study the effects on the cell cycle 
delay during maturation. To clarify if BPAF and BPA affect oocyte progression into metaphase II, 
oocytes were exposed to 50 μg/ml BPA or BPAF for 18 or 21 h or for 12 h followed by 9 h in control 
medium (dimethyl sulphoxide (DMSO)) (3 replicates/group). Finally, oocytes cultured in the presence 
of 50 μg/ml BPA or BPAF for 21 h (3 replicates/group) were tested for the localization of α-tubulin 
and MAD2, a spindle assembly checkpoint (SAC) protein, using immunofluorescence to study effects 
on the spindle and SAC.  
The first study showed that both BPA and BPAF at concentrations of 50 and 100 μg/ml significantly 
inhibited oocyte maturation, with BPAF treatment causing the most potent decrease in the number of 
oocytes reaching maturity. Oocyte exposure to 2 μg/ml BPA or BPAF did not suppress meiotic 
progression at 18 h, but when analysing effects of this exposure level at different exposure times, i.e. 
6, 9, 12, 15 and 18 h, it was found that oocyte maturation rate was significantly delayed for BPAF at 
both 12 and 15 h. To determine whether the meiotic inhibition seen at the 50 and 100 μg/ml exposure 
to BPAF and BPA was due to arrest or delay, the oocytes were exposed for 21 h, and it was seen that 
BPAF arrested maturation while BPA caused a delay. After 12 h of culture in 50 μg/ml BPAF or 
BPA, oocytes were transferred to control medium for 9 h to explore if the effects on maturation were 
reversible, and only 63.3% oocytes treated with BPAF progressed to metaphase II (MII). Exposure to 
BPAF (50 μg/ml) resulted in spindle abnormalities but not in MAD2 re-localisation. 
Study quality and assessment: Overall, the study is thorough; however, the study has some minor 
limitations in its description such as not reporting the chemical’s purity, a cytotoxicity evaluation and 
it is not always clear how and why the specific work was performed. The study is therefore assessed 
to be of moderate quality. This study provides moderate evidence for effects on oocyte maturation in 
vitro after BPAF exposure. 
 
Ruan et al. (2015)  
Summary: In this study, 8 bisphenols (BPs) were identified in sewage sludge collected from 
wastewater treatment plants in 15 cities in China. The estrogenic potencies of the 8 BPs, including 
BPAF (98% purity, CAS no. not reported) and BPA, and the estrogenic activities of sludge samples 
were evaluated using a bioluminescence yeast estrogen screen (BLYES) assay. Cytotoxicity was 
determined by the LIVE/DEAD ® Yeast Viability Kit. BPAF was tested in doses from approximately 
50 nM to 4∙105 nM (read from Figure 2b) with 4 replicates per dose group. 
All 8 BPs exhibited estrogenic activity in the BLYES assay, and BPAF had the highest activity and 
showed significant bioluminescence induction when the concentration was between 100 and 5∙103 
nM. Furthermore, all 15 sludge samples elicited considerable estrogenic activity in the BLYES assay. 
Study quality and assessment: The study is well-described although the number of experimental 
replicates and tested doses are not specifically given in the material and methods section but can be 
found in e.g. figures. Cytotoxicity was measured but only results for TBBPA and the sludge extracts 
are given, and from this it seems that the chemicals were only tested for estrogenic activity at 
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concentrations below their cytotoxic levels. Due to these few shortcomings, the study is assessed to be 
of moderate quality. The study provides moderate evidence for an endocrine MoA, i.e. estrogenic 
activity, of BPs, and reports that BPAF had a higher estrogenic potency than the remainder tested BPs 
including BPA.  
 
Li et al. (2014) 
Summary: In the present study, the effect and mechanism of BPAF-induced endogenous transcription 
was investigated in human breast cancer cells. After 24h in vitro BPAF (purity and CAS no. not 
reported) exposure to estrogen receptor α (ERα)-positive T47D and MCF7 cells (0, 1 nM, 10 nM, 100 
nM, 1 µM and 10 µM), and ERα-negative MDA-MB-231 cells (0, 100 nM, 1 µM and 10 µM) (3 
replicates per dose group), real-time PCR was performed to evaluate the dose-dependent effect of 
BPAF on endogenous transcription of 3 estrogenic responsive genes: trefoil factor 1 (TFF1/pS2), 
growth regulation by estrogen in breast cancer 1 (GREB1) and cathepsin D (CTSD). Time-dependent 
effects (1, 2, 4, 8, 24, 48 and 72 h exposure duration) of 1 µM BPAF on estrogenic responsive gene 
transcription in T47D and MCF-7 cells were also performed. To explain the mechanism of BPAF-
induced endogenous transcription (1 µM for 24 h), gene-silencing with small interfering RNA 
(siRNA) against ERα, ERβ and G protein-coupled estrogen receptor 1 (GPER) was used in T47D and 
MCF7 cells. In addition, the inhibition of BPAF-induced (1 µM for 24h) ER activity was studied 
using ICI 182780 (1 µM, ERα and ERβ antagonist) in the ERα-positive T47D and MCF7 cells. The 
ERα-negative MDA-MB-231 cells were transfected with an adenovirus overexpressing ERα, exposed 
to BPAF and followed by gene expression quantification of TFF1, GREB1 and CTSD.  
In both the T47D and MCF7 cells, BPAF (100 nM –10 µM) significantly induced transcription of the 
3 oestrogen responsive genes TFF1, GREB1 and CTSD in a dose-dependent manner. BPAF did not 
induce TFF1, GREB1 and CTSD mRNA expression in the ERα-negative MDA-MB-231 cells. A 
BPAF dose of 1 µM over a time course of 1-72h, showed altered gene expression of TFF1, GREB1 
and CTSD in both T47D and MCF-7 cells after 4h of exposure. Gene-silencing of ERα, ERβ and 
GPER by siRNA revealed that BPAF-induced endogenous transcription was dependent on ERα and 
GPER, implying that both genomic and non-genomic estrogenic pathways might be involved in the 
endogenous transcription induced by BPAF. ERα-mediated gene transcription was confirmed by 
inhibition of ER activity using ICI 182780 in theT47D and MCF7 cells as well as in MDA-MB-231 
cells overexpressing ERα. Moreover, the Src tyrosine kinase inhibitor, PP2, and the two MEK 
inhibitors, PD98059 and U0126, were used to elucidate the rapid non-genomic activation of 
Src/MEK/ERK1/2 cascade on endogenous transcription. It was shown that BPAF-induced 
transcription could be significantly blocked by PP2, PD98059, and U0126, suggesting activation of 
ERK1/2 was also required to regulate endogenous transcription. Taken together, these results indicate 
that BPAF-induced endogenous transcription of oestrogen responsive genes is mediated through both 
genomic and non-genomic pathways involving the ERα and ERK1/2 activation in human breast 
cancer cells. 
Study quality and assessment: Overall the study is thorough, but the material and method section does 
not report the doses of BPAF exposure used in the study or the purity and CAS no. of BPAF. The 
doses can, however, be read from Figure 1. Furthermore, no results from cytotoxicity studies are 
given. Due to these shortcomings the study is assessed to be of moderate quality. The study provides 
strong evidence for two estrogenic MoAs of BPAF, i.e. activation of ERα and GPER.  
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Li et al. (2013)  
Summary: The study examines the estrogenic receptor (ER) α and ERβ agonistic activity of 12 EDCs, 
including BPAF (purity and CAS no. not reported). First, HepG2 and HeLa cells were used to 
determine the estrogen responsive element (ERE)-mediated estrogenic transcriptional activity of ERα 
and ERβ via the luciferase reporter assay using the 2 luciferase reporters, 3xERE and pS2ERE. Next, 
Ishikawa cells stably expressing ERα were used to determine changes in selected endogenous ER 
target gene expression by real time PCR. All experiments were repeated at least 3 times, and BPAF 
was tested at 100 nM for 18 h in all experiments. 
BPAF (100 nM for 18 h) strongly induced ERα 3xERE and pS2ERE in both HepG2 and Hela cells, 
and in the HepG2 cells it also induced ERβ 3xERE and pS2ERE responses.  
BPAF (100 nM for 18 h) significantly induced endogenous ERα target genes (PR, pS2, GREB1, 
SPUVE, WISP2, and SDF-1) in the Ishikawa/ERα cells. 
Study quality and assessment: The study is well-designed and thorough. Only one concentration (100 
nM) of the EDCs, including BPAF, was tested but it was tested in multiple assays for similar effects 
and overall the results were in agreement. No cytotoxic levels are reported. Based on this the study is 
assessed to be of moderate quality. This study provides strong MoA evidence of BPAF as an ERα 
agonist and a potential ERβ agonist.  
 
Teng et al. (2013)  
Summary: One aim of this study was to investigate the molecular mechanisms of how BPA, BPAF 
(purity not reported, CAS no. 1478-61-1) and BPS may affect estrogen receptor α (ERα) and 
androgen receptor (AR). For this transient transfection experiments with full-length ERα and or AR 
and their corresponding response elements were performed. In the AR functional assay, monkey 
kidney CV1 (AR negative) cells were bulk transfected with pSG5-AR, MMTV-luciferase (reporter 
gene to measure the transcriptional activity of AR) and Renilla-Luc. The assay was run in both 
agonist mode, i.e. 24h incubation with test compound with increasing concentrations (10-8-10-4 M), 
and antagonist mode, i.e. incubation with the AR agonist R1881 (5·10-10 M) and increasing 
concentrations of the test compound.  For the ERα functional assay, CV-1 (ERα negative) or HepG2 
cells were bulk transfected with pRST7-ERa, 3X-ERE-TATA-luc (reporter gene to measure the 
transcriptional activity of ERα), and Renilla –Luc. The assay were carried out as described for AR 
except E2 (2 · 10-10 M) was used in the antagonist mode assay. Each assay consisted of triplicate 
samples and the experiment was repeated 2–3 times.  
The study confirmed that BPA and BPAF act both as ERα agonists and AR antagonists, and a 
competition experiment indicated that the AR antagonism was due to competitive antagonism. 
Study quality and assessment: Overall the study is thorough and well-described, but the material and 
method section does not report the purity of the tested chemicals and the doses of BPAF exposure are 
not explicitly stated. Also, no information on cytotoxicity /cell viability is reported. The figures and 
figure text does not always report the results in the optimal format. Based on this the study is assessed 
to be of moderate quality. The study provides strong MoA evidence of BPAF being an ERα agonist 
and a competitive AR antagonist.  
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Delfosse et al. (2012)  
Summary: The study examined how BPA, BPAF and bisphenol C (BPC) bind and activate estrogen 
receptor  (ER) α and ERβ and how this mechanistically differs from that of 17β-estradiol (E2). First, 
the bisphenols ERα transcriptional activity and cell proliferation effect was examined using human 
breast cancer ERα-positive MCF-7 reporter cells (MELN cell line). Next, the effect of bisphenols on 
ERs transcriptional activity was tested by using HeLa reporter cells stably expressing human ERα and 
ERβ (HELN ERα and ERβ lines), allowing for  a direct comparison of the effect of compounds on the 
two ERs in similar cellular context. A competitive binding assays with [3H]E2 was also performed to 
confirm observations from the previous experiments. The relative contributions of the ER 
transcriptional activation factors (AF-1 and AF-2) responsible for the ER activities were examined 
using HELN cells stably transfected with ERs deleted of their N-terminal AF-1 region. Next, it was 
examined if an altered cellular response could be observed due to AF-1 deletion by using the HELN 
ER cell line whose proliferation is known to decrease in response to E2 treatment. Each chemical was 
tested in HELN cells transfected with full ERα or AF-1 deleted ERα. The capacity of bisphenols to 
induce co-activator recruitment to ERα AF-2 was studied next by measuring the interaction of 
fluorescein-labelled SRC-1 (co-activator) with the ERα-LBD (ligand binding domain, containing AF-
2). The effect of bisphenol on H12 (helix 12) active conformation stability was also studies, with and 
without addition of the co-activator SRC-1. Finally, to gain a better structural insight to the binding 
mode of bisphenols to ERs, the Y537S mutant ERα-LBD was crystallized in complex with each 
compound. 
In the MELN assay, BPAF (and BPA and BPC) exerted a partial potency on luciferase reporter 
activity (~80% compared to E2) but was a full ERα agonist on cell proliferation. In the HELN assays, 
BPAF (and BPA and BPC) was activating ERα with a 60-70% potency of E2. BPAF also exerted 
~60% potency on ERβ. This indicates that BPAF is an ER agonist and a partial ER antagonist in the 
presence of E2. The competitive binding assays confirmed that BPAF binds to both ERs. The deletion 
of AF-1 strongly reduced the bisphenol-induced transcriptional activity of both ERα and ERβ while 
no effects was seen on E2 ER activity. The cell response was also in agreement with this, as all 
bisphenols inhibited proliferation of HELN ER cells, but showed only very weak proliferative 
inhibition in the HELN AF-1 deleted cells. Overall, this indicates that the ER activity of bisphenols 
relies mainly on the AF-1 while the ER activity of E2 is independent of the AF-1 region. While E2 
enhanced the binding affinity between the co-activator SRC-1 and the ERα-LBD and the ER 
antagonist 4-hydroxytamoxifen decreased the affinity, the bisphenols showed a weaker effect on the 
co-activator binding. The mobility of H12 was higher in the presence of bisphenols compared to E2 
strongly stabilized H12 in the active conformation. Addition of SRC-1 resulted in a dose-dependent 
increase in H12 stability with BPA and BPAF treatment. When crystalized with BPA or BPAF the 
ERα-LBD displayed an active conformation with H12 capping the ligand binding pocket (LBP) and 
the SRC-1 bound to the AF-2 surface. BPAF displayed two orientations in the two subunits of the ER 
dimer; and agonist and antagonist positioning, indicating a regulatory crosstalk between the subunits. 
Together, these experiments show that bisphenols can be considered as selective ER modulators 
(SERMs) that relies mainly on the AF-1 and are dependent on the cellular contents such as available 
amounts of co-activators.  
Study quality and assessment: The study is very thorough and well-described although the doses in 
the different studies are not clear from the text but only appears in the figures. Overall, the study is 
assessed to be of high quality. It provides a strong MoA evidence for BPAFs interaction with ERs and 
detailed information on the molecular mechanisms behind this interaction. 
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Li et al. (2012)  
Summary: In this study three human cell lines (Ishikawa, HeLa, and HepG2) representing three cell 
types were used to evaluate the dose- and cell-specific mechanistic actions of BPA, BPAF, and 
Zearaleone (Zea) on estrogen receptor (ER) α and ERβ. To evaluate estrogen response element 
(ERE)-mediated transcriptional activity of ERα and ERβ, the promoter activation in Ishikawa, HeLa, 
and HepG2 cells was examined using a luciferase reporter assay system at BPAF doses of 0, 1, 10, 
100, or 1,000 nM. Similarly the antagonistic effects of BPAF were examined by treating the cells with 
1 or 10 nM BPAF, with or without 10 nM E2 co-treatment. The specific effects of BPAF (100 nM) on 
ERα functionality was analysed using wild-type (WT) ERα and specific ERα mutations in the 
following domains: H1 (ERE-mediated activation, no tethered-mediated activation), AA (tethered 
AA-mediated activation, no ERE-mediated activation), E1 (activation factor-1 (AF-1) inactive), and 
AF-2 (activation factor-2 (AF-2) inactive). Next, the role of co-activators on BPAF (100 nM) on 
ERE-mediated ERα activation was studied by co-treating the cells with the co-activators SRC2 or 
p300. To examine the phosphorylation events in the rapid ER action responses to BPAF, Ishiwaka 
cells transfected with a vector control or wild type (WT)-ERα were used. First the expression of ERα 
and the ER ERE-mediated activation was confirmed in the Ishiwaka/ERα cells. Then western blot was 
performed to identify phosphor-p44/42 MAPK and other kinases in the vector and ERα cells, 
respectively. Then the effect of 2 kinase inhibitors, PD 98059 (MAPK inhibitor) and PP2 (src family 
tyrosine kinase inhibitor), on BPAF-mediated expression of the ER target gene Progesterone receptor 
(PR) in Ishiwaka/ERα cells was examined. Finally, ERα-dependent responses to BPAF was examined 
by detecting endogenous gene expression of PR, and 3 other ER target genes in Ishiwaka/ERα cells 
using real time PCR. 
For ERα, BPAF showed weak ERE-mediated estrogenic activity at low concentrations (≤10 nM) and 
strong activation at the higher concentration (1,000 nM) in the Ishikawa cells. The HeLa cells were 
less sensitive, while the HepG2 were highly responsive. For ERβ, BPAF resulted in only a weak 
response in the Ishikawa and HepG2 cells, while the responses in the HeLa cells to 100 and 1000 nM 
BPAF were similar to E2. In the antagonistic mode, BPAF did not antagonize E2 ERα activation in 
any of the cell lines, but ERβ activation by E2 was reduced by BPAF (1 and 10 nM) in HeLa cells 
only. The functionality studies demonstrate that BPAF can activate ERE-mediated transcription via 
AF-2 in Ishiwaka cells. No activity was measured in the AA- or AF-2-ERα mutants, indicating that 
BPAF do not mediate tethered or AF-1 activation of ERα. It was also found that both co-activators, 
SRC-2 and p300, resulted in an enhanced BPAF-induced ERα activity. Regarding the effect on the 
rapid ER action response, it was found that BPAF could activate both the p44/42 MAPK pathway and 
the tyrosine kinase src pathways. BPAF also induced gene expression of the ERα target genes PR and 
GREB1. Together, these results indicate that BPAF can function as an ER agonist and antagonist, and 
activates ERα by ERE-mediated activation via the AF-2 function or via a non-genomic rapid-action 
response. The estrogenic activity of BPAF depended on the cell type and content. 
Study quality and assessment: The study is thorough and well-described. No information on 
cytotoxicity of the tested compounds in the individual cell lines is reported. Based on this missing 
information, the study is assessed to be of moderate quality. The study provides strong evidence for 
BPAFs estrogenic MoA as well as detailed information on the specific functionalities on ER 
activation. 
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Sui et al. (2012)  
Summary: In the study it was investigated whether BPA and selected analogues, including BPAF, 
bind to and activate human PXR (hPXR) and mouse PXR (mPXR). HepG2 cells were transfected 
with full-length hPXR together with CYP3A4-luc reporter or full-length mPXR together with 
(CYP3A2)3-luc reporter and CMX–β-galactosidase control plasmid and treated with BPAF (0, 5, 10 
and 20 µM for 24 h, read from Figure 4). Structural requirements of BPA analogues that activate 
hPXR were deduced by docking studies to tethered PXR, linker, SRC-1 (steroid receptor coactivator 
1). BPAF was found to be an hPXR agonist (< BPA) and caused a dose-dependent activation, but it 
did not affect mPXR activity. The replacement of the CH3 by CF3 in BPAF helped BPAF retain a 
partial agonist activity relative to BPA. 
Study quality and assessment: BPAF was only included in part of the studies reported and the 
cytotoxicity of BPAF in HepG2 is not reported. Overall the quality of the study is assessed to be 
moderate, and the study provides moderate evidence for a PXR agonist MoA of BPAF. PXR agonism 
may alter the expression of enzymes and transporters relevant for endogenous hormones and thereby 
indirectly result in ED.  
 
Bermudez et al. (2010)  
Summary: The present study characterize the individual dose-response curves of estradiol-17β (E2), 
BPA, TBBPA, and BPAF (CAS no. 1478-61-1, 100% purity) on oestrogen-dependent luciferase 
expression in T47D-KBluc cells and determine how binary and ternary mixtures of E2 with BPAF 
and/or BPA interact with ERs. T47D-KBluc cells that naturally expresses ERα and ERβ were 
transfected with a triplet estrogen-response element (ERE) promoter-luciferase reporter gene 
construct, and exposed to E2, BPA or BPAF at multiple concentrations (1pM to 1 µM, read from 
Figure 1). BPAF was also tested in a binary mixture with E2 and a ternary mixture with E2 and BPA. 
BPAF caused a dose-dependent increase in oestrogen activity in the T47D-KBluc cells and was 
significantly more potent than BPA. Both the binary mixtures of E2 with BPAF and the ternary 
mixture of E2, BPA, and BPAF behaved in an additive manner experimentally, and at a concentration 
of 10 pM E2 the system reached saturation and additional BPAF did not produce an increase in 
activity. 
Study quality and assessment: The study is well-described, although cytotoxicity results for TBBPA 
are only given. From this it seems that all the chemicals were only tested for estrogenic activity at 
concentrations below their cytotoxic levels. Overall, the study is assessed to be of moderate quality, 
and it provides moderate evidence for an estrogenic MoA of BPAF. 
 
Matsushima et al. (2010)  
Summary: The aim of the study was to determine the relative preference of BPAF (CAS no. 1478-61-
1, 99% purity) for estrogen receptor (ER)α and ERβ and the BPA target receptor estrogen related 
receptor γ (ERRγ), and to clarify structural characteristics of receptors that influence BPAF binding. 
First the receptor-binding activities of BPAF (doses: 10-12 to 10-5 M, read from Figure 2) relative to 
radio-labelled 17β-estradiol (E2) (5 nM) to ERα or ERβ ligand binding domain (LBD), or radio-
labelled BPA (5 nM) to ERRγ LBD were measured with each assay run in duplicate and repeated at 
least 5 times. Next, functional luciferase reporter gene assays were performed to assess BPAF (doses: 
10-12 to 10-5 M, read from Figure 3) receptor activation in HeLa cells transfected with the receptor and 
a reporter gene. To measure the antagonistic activity of BPAF on ERβ, 4 concentrations (0.01, 0.1, 1, 
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and 10 µM) of BPAF was tested against 10-12 to 10-5 M E2. Similarly, 2 concentrations of E2 (10 or 
100 nM) were tested against increasing levels of BPAF (10-12 to 10-5 M)  
BPAF strongly (>BPA) and selectively binds to ERs over ERRγ. Furthermore, BPAF receptor-
binding activity was 3 times stronger for ERβ than for ERα. When examined using the functional 
luciferase reporter gene assays, BPAF was a full agonist for ERα in a dose-dependent manner at con-
centrations of 10–10 to 10–5 M. In contrast, it was almost completely inactive in stimulating the basal 
constitutive activity of ERβ. When tested in ERβ antagonist mode, BPAF acted as a distinct and 
strong antagonist against the ERβ activity of E2. 
Study quality and assessment: The study is thorough and well-described although the exact doses 
tested are not explicitly given in the material and methods and no cytotoxicity studies in the applied 
HeLa cells are reported. Due to such shortcomings, the study is assessed to be of moderate quality. 
The study provides strong evidence for an estrogenic MoA with ERα agonism and ERβ antagonism. 
 
Kitamura et al. (2005)  
Summary: The potential endocrine-disrupting activities of BPA and 19 related compounds, including 
BPAF (CAS no. and purity not reported) were comparatively examined by means of different in vitro 
and in vivo reporter assays. First BPAF was tested for estrogen receptor (ER) activity in the ERE-
luciferase reporter assay in MCF-7 cells (doses tested: 10-4 – 10-9 M) as well as for ER antagonism of 
17β-estradiol (E2) activity. Similarly BPAF was tested for AR agonism and antagonism (i.e. 
inhibition of dihydrotestosterone (DHT) activity) in transfected NIH3T3 cells (mouse fibroblast cell 
line). The induction of growth hormone production in GH3 cells after BPAF exposure was also 
examined as was the inhibition of triiodothyronine (T3) induced hormone production the cells.  
BPAF exhibited strong estrogenic activity from 10-7 to 10-4 M in the MCF-7 cells. No androgenic 
activity was observed for BPAF, but BPAF was instead showing anti-androgenic activity on DHT in 
the NIH3T3 cells. BPAF did not induce or inhibit the thyroid hormone-dependent production of 
growth hormone by GH3 cells. 
Study quality and assessment: The study is well-described and although cytotoxicity is not directly 
reported for each cell line, renilla luciferase activity in the transfected cells was used to control for 
cytotoxic effects. Overall, the study is assessed to be of moderate quality and provides strong 
evidence for estrogenic and anti-androgenic MoAs of BPAF. 
 
Hasimoto et al. (2001)  
Summary: In this study, the estrogenic activities of 13 BPA analogues, including BPAF (here called 
BP3, CAS no. not reported, 97% purity), in three in vitro bioassays are examined. BPAF was tested in 
concentrations from 10-7 to 10-3 M in both the yeast two-hybrid system (YES) and in a competitive 
ER-binding fluorescent polarization assay, and 10-9 to 10-4 M in MCF-7 cells (including proliferation 
called the E-screen), respectively. BPAF showed cytotoxicity at 10-4 M in the E-screen (according to 
the discussion section). 
In the YES assay, BPAF showed a dose-dependent increase in estrogenic activity in the absence of 
S9, and the activity was enhanced with the addition of S9. BPAF could effectively displace the 
fluorescent non-steroid probe from the ER-FES complex form a concentration of 10-6 M and above. In 
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the E-screen, BPAF significantly increased the cell proliferation from concentrations of 10-7 M and 
above, except at the highest concentration 10-4 (i.e. cytotoxic dose). Overall, the estrogenic activity of 
BPAF/BP3 was stronger than that of BPA.  
Study quality and assessment: In general the material and methods description is very short and 
inadequately described and cytotoxicity studies are not explicitly reported. The study can confirm the 
results in three independent, orthogonal assays, and also includes the effect on activity of metabolism 
(rat liver S9) in the YES assay. The number of biological and technical replicates are not given, and 
no p-values or other statistics are reported in text or figures. Overall, the study quality is assessed to 
be moderate. The study provides moderate evidence of BPAF having an estrogenic MoA. 
 
Perez et al. (1998)  
Summary: In this study BPAF (here called MM7, CAS no. not reported, ≥97% purity) and other 
bisphenols were tested in the E-screen, which measures proliferation of MCF-7 cells, at doses from 
10-8 to 10-5 M. The synthesis and secretion of 2 cell type-specific, oestrogen-responsive proteins, 
progesterone receptor (PgR) and pS2, were also measured in exposed MCF-7 cells. Finally, the 
relative binding affinity of BPAF at multiple doses (10-12 to 10-4 M) was measured in a competitive 
binding assay using cytosol from immature rat uteri incubated with radio-labelled 17β-estradiol (E2). 
BPAF resulted in an increased MCF-7 cell proliferation as well as increased PgR and pS2 levels. 
BPAF showed high relative binding affinity to ER in the competitive binding assay. 
Study quality and assessment: The study does not report the CAS no. of the tested chemicals or any 
statistical significant results in the related figures. Also, cytotoxicity levels for the MCF-7 cells are not 
reported. Overall, the study quality is assessed to be of moderate quality, and the study provides 
moderate evidence of an estrogenic MoA of BPAF in vitro. 
 
The following four additional in vitro studies on BPAF were found when looking into the included 
literature: Kanai et al. (2001), Rivas et al. (2002), Yamasaki et al. (2003b), and Laws et al. (2006). 
These were not further evaluated as the abstracts indicate that all four studies support an in vitro 
oestrogenic MoA already adequately covered by the included studies, i.e. they do not provide new 
information. 
 
4.10.3.3 In vivo effects with regard to an endocrine mode of action  
Foster et al. (2017) (poster abstract and poster) 
Summary: The poster describes a NTP modified one-generation study (MOG) of BPAF. Four groups 
of 20 time-mated dams were exposed to 0, 338, 1125 or 3750 pmm BPAF in the diet from gestation 
day (GD) 6 until weaning. 
Significant delay in male puberty and advancement in female puberty was observed. Ten males at 
3750 ppm did not achieve puberty assessed as Balano-Preputial Separation by PND 98. Two cohorts 
of offspring were mated and litter size was assessed on GD 21 or after birth. Both cohorts failed to 
produce any offspring at the highest dose of 3750 ppm in the diet and litters size was significantly 
decreased at 1125 ppm. 
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Study quality and assessment: Only very limited information is available in the abstract, but more 
information are available in form of a poster print. Optimally, the evaluation should be based on a 
study report or a paper. However, the NTP MOG study design is very similar to OECD TG 443, the 
group performing the BPAF study are very experienced and relevant results regarding the effects and 
dose levels are shown in the poster. Thus, the study is assessed to be of high quality and provides 
strong evidence of adverse effect on female and male reproduction. The effects observed are 
consistent with an oestrogenic mode of action. 
 
Conley et al (2016) 
Summary: This study evaluated the effect of oral exposure to BPAF (CAS no. 1478-61-1, 97% purity) 
(and other oestrogens) in the Uterotrophic in vivo assay, which is largely estrogen receptor (ER)-α-
mediated. BPAF was given daily by oral gavage to adult ovariectomised female rats (age ~81 days) 
(n=3-6/group, 3-8 dose groups: 3-300 mg/kg/d (read from figure 2)) for 4 consecutive days. The rats 
were assessed for overt toxicity and euthanized 3 h after the final dose. Trunk blood was collected and 
uterine tissue excised and weighted with luminal fluid (wet), and after being drained for fluid 
(blotted). The fluid weight was estimated as the mass difference between wet and blotted. No general 
toxicity was observed at the tested BPAF concentrations, but BPAF caused a dose-related increase in 
uterus weight (wet, blotted and fluid) as well as histopathological changes (increased epithelial and 
glandular height). These results were used to evaluate the in vitro T47D-KBluc oestrogen receptor 
transactivation reporter assay’s potential to accurately predict in vivo effects. T47D-KBluc is also 
mainly ERα-mediated, and as described in section 4.10.3.2, the same study found that BPA is an ER-α 
agonist in vitro. Extrapolation of the in vitro results on BPAF could predict the EC50 of in vivo 
results within the 95% confidence interval of the observed EC50.  
Study quality and assessment: The study is well-designed and described and is assessed to be of high 
quality. Together with the results from the in vitro ERα activation study, this study provides strong 
evidence of an estrogenic MoA of BPAF. 
 
Li et al. (2016) 
Summary: Sixty male and 60 female 8-week old Sprague-Dawley rats were acclimated 1 week before 
pairing. The females were exposed to 100 (n=30) or 0 (control group: n=30) mg BPAF/kg/day (CAS 
no. 1478-61-1, 97% purity) by oral gavage from gestational day (GD) 3-19. On the day of birth (i.e., 
postnatal day (PD) 0), cross-fostering took place between treated and control litters, and cross-
fostered mother rats were given 0 or 100 mg BPAF/kg/day, respectively, from PD 3-19. This resulted 
in four test groups: unexposed control (CC), pups exposed prenatally (TC), pups exposed postnatally 
(CT), and pups exposed both prenatally and postnatally (TT) (n=6/group according to text in figures). 
All animals were euthanized at PD 23, where blood was collected, and testes and epididymis excised 
and weighed. BPAF and hormones were measured in the blood and testes, and gene and protein 
expression was done in the testes.  
The absolute and relative weights of the testis and the absolute weights of the epididymis of the 
exposed male pups (TT, TC and CT) on PD 23 showed no differences compared with the CC group. 
HPLC-MS/MS analysis showed that BPAF was transferred via cord blood and breast milk and bio-
accumulated in the testes of the offspring. Pups exposed to BPAF both pre- and postnatally (TT) 
showed a significant increase in serum and testis testosterone levels compared with that of the control 
pups (CC), while all pups exposed to BPAF (prenatally and/or postnatally: TT, CT and TC) showed a 
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significant decrease in serum and testis inhibin B levels compared to unexposed offspring (CC). 
Compared with the CC group, RNA-sequencing revealed that 279 genes were significantly 
differentially expressed in the testes of pups exposed to BPAF both pre- and postnatally (TT). 
Specifically, mRNA levels of steroidogenic acute regulatory protein (StAR), estrogen receptor (ER)α, 
and androgen receptor (AR) in the TT group were increased compared to the CC group. The testes 
protein levels P450scc and StAR, both involved in steroidogenesis, were increased in the TC and TT 
groups, and the testes protein levels of AR were significantly increased in the TT and CT groups. 
Together the decreased inhibin B and increased testosterone levels in the testes indicated that Sertoli 
and Leydig cell functions were both disturbed by gestational and lactational BPAF exposure, and 
these results were in agreement with the altered levels of genes and proteins involved in testosterone 
synthesis. The transcriptomic analyses also showed that BPAF alters the expression of genes involved 
in progression of meiosis and DNA recombination, indicating that BPAF has deleterious effects on 
meiotic progression and germ cell development during critical stages of differentiation.  
Study quality and assessment: In general, the study is well-described and thorough, although more 
information on the housing conditions would have been preferred. Overall, the study quality is 
assessed to be high. The study provides strong evidence of a steroidogenic ED MoA of BPAF, and the 
link between the mechanistic information from the RNA seq/protein level analysis and the effects on 
testosterone level is strong. 
 
Feng et al. (2012) 
Summary: The aim of this study was to determine whether BPAF exposure produces adverse effects 
on testosterone production and to further elucidate the mechanism of BPAF toxicity in testes. Seven 
week old Sprague-Dawley (SD) male rats were acclimated for 1 week before exposure by oral gavage 
to BPAF (CAS no. is reported as B0945, which is instead a product number , 99% purity) for 14 days 
at doses of: 0, 2, 10, 50 and 200 mg/kg/d (n=6/group). Rats were weighed daily during the exposure 
and euthanized 24 h after the last exposure. Total cholesterol, follicle-stimulating hormone (FSH), 
luteinizing hormone (LH), and testosterone were measured in serum. BPAF concentration and the 
gene expression of SR-B1, StAR, P450scc, 3β-HSD, CYP17α, 17-beta-hydroxysteroid dehydrogenase 
(17β-HSD),  luteinizing hormone receptor (LHR), androgen receptor (AR), estrogen receptor (ER)-α, 
ER-β, HMG CoA reductase (HMGR), sterol regulatory element binding protein 1c (SREBP-1c), 
inhibin B, and Mullerian inhibiting substance MIS in the testes were quantified. Protein content in the 
testes was also determined. The body weights of the 50 and 200 mg/kg/d groups were decreased, the 
absolute testis weight was unchanged in the BPAF treatment groups compared to the control group. 
An increased relative testis weight was observed in the 200 mg/kg group. The BPAF concentration in 
the testes was found to increase with increasing doses of BPAF. Total cholesterol levels in serum 
were decreased in rats given a dose of 50 and 200 mg/kg/d. A significantly reduced serum 
testosterone level was observed in the 200 mg/kg group only, while increases in LH was seen in the 
50 and 200 mg/kg groups, and FSH increased in the 10, 50 and 200 mg/kg groups. The 200 mg/kg 
BPAF exposure resulted in significant declines in the expression of genes involved in cholesterol 
biosynthesis (SREBP-1c), transport (SR-B1, StAR), and steroid biosynthesis (P450scc, 17β-HSD). 
Similarly, the testicular mRNA levels of inhibin B, ERα and LHR also decreased in rats given a 
dosage of 200 mg/kg/d BPAF. Protein expression of SR-B1, StAR, and P450scc in testes was also 
significantly reduced in the 200 mg/kg/d BPAF group. Together, these data demonstrate that BPAF 
has the potential to impair the pituitary–gonadal function at different levels by increasing LH and FSH 
concentrations and decreasing testosterone levels in serum, and that the BPAF-induced inhibition of 
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testosterone production primarily resulted from the alteration of genes and proteins in the testosterone 
biosynthesis pathway. 
 
Study quality and assessment: The study is well-described and the sample size of n=6 is large enough, 
at least to show effects at the highest doses. Therefore, the study is assessed to be high quality. The 
study provides strong evidence of a steroidogenic ED MoA of BPAF, and the link between the 
mechanistic information from the RNA seq/protein level analysis and the effects on testosterone level 
is strong. 
 
Akahori et al. (2008)  
Summary: The overall aim of the study was to explore the relationship between in vitro estrogen 
receptor (ER)α binding and the in vivo Uterotrophic assays for 65 chemicals spanning a variety of 
chemicals classes. BPAF (CAS no. 1478-61-1, >95% purity) (and 64 other chemicals) was tested in a 
recombinant human ER-α-LBD binding assay and in the immature rat Uterotrophic in vivo assay 
using 20 day old immature female Cr:CD (SD) IGS rats. Tree doses were given (exact doses not 
specified) by s.c. injections for 3 consecutive days, alone or in co-administration with ethinyl estradiol 
(0.6 µg/kg/day) for anti-estrogenic assay mode. BPAF was a hERα-LBD binder in vitro, and showed 
both estrogenic and anti-estrogenic activity in vivo.  
Study quality and assessment: The description of the study has multiple shortcomings for examples 
are the exact doses not reported just as the results for the individual chemicals, including BPAF, are 
not given. The study is based on this assessed to be of low quality. The study provides moderate 
evidence of both an estrogenic and anti-estrogenic MoA of BPAF. The study does discuss the effects 
of ADME on extrapolation and since the chemicals are administered s.c. the effect of first-pass 
metabolism is minimal.  
 
Yamasaki et al. (2003)  
Summary: In this study 18 chemicals, including BPAF (CAS no. 1478-61-1, 98.8% purity), were 
tested in the immature rat Uterotrophic assay and Hershberger assay (under GLP guidelines) to assess 
the relationship between the results of the two assays. The selected chemicals were all positive in the 
reporter gene assay for estrogen receptor  (ER)α activity and on the list of suspected endocrine 
disruptors published by the EU. In the immature rat Uterotrophic assay, 19 day old immature Crj:CD 
(SD) female rats were s.c. injected with BPAF at doses of 0, 8, 40 and 100 mg/kg/day (read from table 
4) (n=6/group) for 3 consecutive days.  To assess potential anti-estrogenic effects, some rats were co-
administered with subcutaneous administration of ethynyl estradiol (EE, dose: 0.6 µg/kg/day). Uteri 
were weighted with (wet) and without (blotted) intraluminal fluid. In the Hershberger assay, 56 
postnatal  day old castrated male Brl Han: WIST rats were administered with BPAF by oral gavage at 
doses of 0, 50, 200 and 400 mg/kg/day (read from table 5) (n=6/ group) for 10 consecutive days. 
Again to assess the potential anti-androgenic effects, some rats were co-administered with 
testosterone propionate (TP, dose: 0.2 mg/kg/day) by subcutaneous injection. Ventral prostate, seminal 
vesicle, bulbocavernosus/levator ani muscle (BC/LA), glans penis and Cowper’s gland were weighed, 
and general toxic signs were registered.  
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In the Uterotrophic assay, BPAF alone caused a significant, dose-dependent increase in uterine weight 
at all doses, and significantly decreased the uterine weight in the group given EE + 40 mg/kg/day 
BPAF when compared to the vehicle + EE group. In the Hershberger assay, the 600 mg/kg/day dose 
caused toxic signs, including death, and the maximum dose was therefore reduced to 400 mg/kg/day. 
Decreased spontaneous locomotor activity was decreased in the 200 and 600 mg/kg group with and 
without testosterone propionate (TP). The BC/LA weight was decreased and the glans penis weight 
increased in the 400 mg/kg/day group. In the groups co-exposed to TP, increases in seminal vesicle 
(50 and 400 mg/kg/day), glans penis (50 and 400 mg/kg/day) and Cowper’s gland (400 mg/kg/day) 
weights were seen. 
Study quality and assessment: The study is well-described and assessed to be of high quality. The 
study provides moderate evidence of both an estrogenic and anti-estrogenic MoA of BPAF. The 
effects in the Hersberger assay were less consequent.  
 
4.10.3.4 Summary of the plausible link between adverse effects and endocrine mode of 
action  
 
There is strong evidence from in vitro and in vivo studies for both an estrogenic and anti-estrogenic 
MoA of BPAF (Table 1). The in vitro studies have shown that BPAF is an ERα agonist, an ERß 
antagonist and G-protein coupled ER (GPER) agonist, and that these effects depend on the cell type 
and doses. In Uterotrophic assays using both intact immature female rats and adult ovariectomised 
rats, BPAF caused an increase in urine weight when it was run in agonist mode, while the uterine 
weight declined when PBAF was tested in the antagonistic mode with co-administration of EE. The 
effects on uterus weight in this assay are known to be primarily ERα-mediated, and although the 
alterations in uterine weights are not regarded as an adverse effect as such but a MoA, the results 
provide weak evidence for adverse female reproductive effects. A single study has also reported 
delayed oocyte maturation in exposed rats but the underlying MoAs were not explored and therefore 
no conclusion regarding a link to an ED MoA can be made. 
Studies have shown an anti-androgenic activity of BPAF in vitro and weak effects in the in vivo 
Hershberger assay, which uses alterations in accessory organ weights as endpoints for (anti)androgen 
effects. In addition, effects on steroidogenic enzymes in vitro and in vivo (in testis at both gene and 
protein level) have been identified, and this may explain the altered serum testosterone levels found in 
the BPAF exposed male rats. The effects on serum testosterone depended on the life stage with 
increased testosterone levels in foetal and prepubertal male rats exposed via cord blood or milk, and 
decreased testosterone levels in adult male rats. The effect on testosterone levels and antiandrogenic 
effects in the Hershberger assay in male rats provides weak evidence for adverse male reproductive 
effects. A single study found that BPAF caused spermatogonial toxicity in vitro but they did not study 
this effect’s link to an ED MoA.  
A new in vivo study using the NTP modified one-generation study (MOG) has shown marked delay in 
male puberty, advancement in female puberty and clear effects on fertility of offspring exposed to 
BPAF during development (Table 2). The study results are not published in a study report or paper 
yet, but are available as poster print and poster abstract. The NTP MOG study design is very similar 
to OECD TG 443, the group performing the BPAF study are very experienced, and relevant results 
regarding the effects and dose levels are shown in the poster. Thus, the study is assessed to be of high 
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quality and provides strong evidence of adverse effect on female and male reproduction. The effects 
observed are consistent with an oestrogenic MoA. 
In addition to its oestrogenic, anti-androgenic and steroidogenic MoA, BPAF has also been shown to 
activate TRα and act as a human PXR agonist in vitro. BPAF may through PXR activation alter the 
turnover of multiple hormones. 
The total evidence for adverse effects of BPAF is strong (Table 2), the evidence for an estrogenic 
MoA of BPAF is strong (Table 1) and the evidence for a plausible link between the MoA and adverse 
effects is also strong.  
In conclusion, BPAF meet the WHO definition of an endocrine disruptor. 
 
Additional literature not included in the evaluation 
ANSES report (2013): the report on BPA and 8 structural analogous including BPAF concluded that 
at the present time, i.e. 2013, there were not enough toxicological data available on BPAF to make a 
comprehensive toxicological evaluation. More toxicological studies on BPAF have been published 
since the ANSES report was published in 2013 (see above). Both the ANSES report and previous 
studies have shown that most BPA analogous including BPAF share common mechanistic properties 
such as estrogenic activity.  
NTP NIEHS (2008): This document is a chemical information profile for BPAF and summarises 
results from other studies on BPAF that have been included in the above. 
Kemikalieinspektionen (2017): This is a report in Swedish that summarises the available 
information on 39 bisphenols including BPAF to assess them in a risk perspective, and includes many 
of the references included here. 
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Table 1. Overview of in vitro and in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of BPAF.  
Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
Lei et al. (2017)  ERα and TRα activity as well as other 
biological/toxicological effects in MCF-7 cells 
 High Strong 
Liang et al. (2017) Spermatogonial toxicity in the mouse C18-4 
spermatogonial cell line, but no link to any ED 
MoAs studied 
 High 
 
Weak 
Conley et al. (2016) ERα-mediated activity in the T47D-KBluc 
estrogen receptor transcriptional assay 
Uterotrophic study in adult ovariectomised 
female rats (n=3-6/dose group), oral: dose-
dependent ↑ uterus weight and histological 
changes 
Medium-high Strong 
Feng et al. (2016)  Effects on steroidogenesis in the H295R cell 
line: ↑ progesterone,  ↓ testosterone, 
aldosterone and cortisol at sub-cytotoxic 
concentrations 
 High Strong 
Li et al. (2016)  Cross-sectional study in immature male rats 
(n=6/group): serum and testes testosterone ↑ and 
inhibin B levels ↓ in male infants exposed pre-
and/or postnatally plus effects on testes gene and 
protein expression (where n=3-4/group), 
including increased expression of AR, ERα and 
StAR, P450scc. Together indicating effects on 
steroidogenesis. 
High Strong 
Nakona et al. 
(2016)  
Delayed mice oocyte maturation, but no link 
to any ED MoAs studied 
 Medium Weak 
Ruan et al. (2015) Estrogenic activity in the bioluminescence 
yeast estrogen screen (BLYES) assay 
 Medium Moderate 
Li et al. (2014) Estrogenic through activation of ERα and 
GPER in human breast cancer T47D and 
MCF7 cells 
 Medium Strong 
Li et al. (2013) ERα agonism and potential ERβ agonism in 
HepG2, HeLa and Ishikawa/ERα cells 
 
 Medium Strong 
Teng et al. (2013) ERα agonism and a competitive AR 
antagonism in transfected monkey kidney 
CV1 cells 
 Medium Strong 
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Reference MoA Quality of study  Evidence for ED 
 Delfosse et al. 
(2012) 
ERα and ERβ activity on MCF7 and HeLa 
cells, and mechanism studies on the 
interaction with ERα 
 High Strong 
Feng et al. (2012)  Study in adult male rat (n=6/group): ↑testis/BW 
ratio, serum total cholesterol and testosterone ↓, 
and LH and FSH ↑, plus testis gene expression of 
StAR, P450scc, 17ß-HSD, SREBP-1c, ERα, 
LHR, Inhibin B and SR-B1 ↓. Testes protein 
levels of StAR, P450scc and SR-B1 ↓. Together 
indicating effects on steroidogenesis. 
High Strong 
Li et al. (2012) Estrogenic activity in Ishikawa, HeLa, and 
HepG2 cells, and functionality studies of the 
ER activation 
 Medium Strong 
Sui et al. (2012) Human PXR agonism in transfected HepG2 
cells, an indirect potential ED MoA 
 Medium Moderate 
Bermudez et al. 
(2010) 
Oestrogen activity in T47D-KBluc cells, and 
caused estrogenic additivity in a binary (with 
E2) and a ternary (with E2 and BPA) mixture 
until system saturation 
 Medium Moderate 
Matsushima et al. 
(2010) 
ER-LBD binding in a cell-free assay as well as 
ERα agonism and ERβ antagonism in 
transfected HeLa cells 
 Medium Strong 
Akahora et al. 
(2008) 
Active for hERα-LBD binding Uterotrophic study in immature female rats 
(n=6/dose group), s.c.: ↑ uterus weight in 
estrogenic mode and ↓ uterine weight in the EE 
co-administered anti-estrogenic mode 
Low Moderate 
Kitamura et al. 
(2005) 
Estrogenic potential in MCF-7 cells and anti-
androgenic activity in NIH3T3 cells 
 Medium Strong 
Yamasaki et al. 
(2003) 
 Uterotrophic study in immature female rats 
(n=6/dose group), s.c.: ↑ uterus weight in 
estrogenic mode and ↓ uterine weight in the EE 
co-administered anti-estrogenic mode 
High Moderate 
Hershberger study in adult castrated male rat 
(n=6/dose group), oral: ↓ BC/LA weight in 
androgenic mode and ↑ seminal vesicle, glans 
penis and Cowper’s gland weights in the TP co-
administered anti-androgenic mode 
High Weak 
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Reference MoA Quality of study  Evidence for ED 
 Hasimoto et al. 
(2001) 
Estrogenic activity in the YES assay with and 
without S9, as well as in a displacement assay 
and the E-screen (MCF-7 cell proliferation 
assay) 
 Medium Moderate 
Perez et al. (1998) Estrogenic in the E-screen and increases levels 
of the estrogen-responsive proteins, 
progesterone receptor and pS2, in the MCF-7 
cells. The reported relative binding affinity to 
ER is high.  
 Medium Moderate 
estrogen receptor α (ERα), thyroidal hormone receptor α (TRα), steroidogenic acute regulatory protein (StAR), androgen receptor (AR), bioluminescence yeast estrogen screen (BLYES), G 
protein-coupled estrogen receptor 1 (GPER), ligand binding domain (LBD), ethynyl estradiol (EE), follicle-stimulating hormone (FSH), luteinizing hormone (LH), luteinizing hormone receptor 
(LHR), sterol regulatory element binding protein 1c (SREBP-1c), bulbocavernosus/levator ani muscle (BC/LA), testosterone propionate (TP), yeast two-hybrid system (YES) 
 
 
Table 2. Overview of potential endocrine-related adverse effects of BPAF. 
Reference Species, n Adverse effects Quality of study Evidence for 
adverse effects 
Foster et al. 
(2017) 
Rats, ~20/ 
group 
In vivo study using the NTP modified one-generation study: marked delay in male 
puberty, advancement in female puberty and clear effects on fertility of offspring 
exposed to BPAF during development. The effects observed are consistent with an 
oestrogenic MoA. 
High Strong 
National toxicology program (NTP),  
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5. Environmental hazard assessment 
5.6.2 Endocrine Disruption 
5.6.2.1 General approach – environment 
 
The peer-reviewed literature was investigated by use of Web of Science including all databases. The 
search terms were: bpaf + endocrin*, bisphenol af + endocrin*, bisphenol-af + endocrin*, 
(Hexafluoroisopropylidene)diphenol + endocrin*, 1478-61-1 OR 1478-611 OR 147861-1 OR 
1478611 + endocrin*, bisphenol af + endocrin*, bisphenol-af + endocrin, bpaf + endocrin* 
A google search with the search terms bpaf + endocrin*, bisphenol-af + endocrin*, bisphenol af + 
endocrin* was also performed, but without relevant hits. Literature describing mammalian studies and 
in vitro studies based solely on mammalian cell lines was excluded because it is covered in the 
toxicological hazard assessment.  
 
5.6.2.2 In vitro information indicative of endocrine activity  
 
The results from in vitro studies are mentioned under in vivo studies because the in vitro studies were 
always performed in combination with in vivo studies, except for one study (Fic et al. 2014). 
Fic et al. (2014)  
Summary: The (anti)estrogenic and (anti)androgenic properties of BPA and BPA analogs including 
BPAF (CAS no. 1478-61-1, 97% purity) were investigated in the XenoScreen XL YES and YAS 
assays, which are commercial and modified versions of the original YES and YAS assays.1  
BPAF and its metabolite BPAF-M were tested first in eight concentrations (BPAF: 300 µM to 30 pM 
and BPAF-M: 30 µM to 30 pM) and thereafter in a narrower concentration range to determine EC50 
(at least two independent additional experiments in duplicate). BPAF demonstrated agonistic 
estrogenic activity with an EC50 of 0.39 µM. BPAF is less potent than E2 (EC50: 0.0002 µM) but 
more potent than BPA (EC50: 3.60 µM). An anti-androgenic activity of BPAF was also demonstrated 
by inhibition of the AR in co-treatment with the anti-androgen flutamide. BPAF-M did not 
demonstrate any observable activity in any of the four assays. 
Study quality and assessment: The paper is detailed and well written, and the results are in agreement 
with previous studies using the original YES/YAS assay. The study is assessed to be of high quality. 
It is shown that BPAF has both estrogenic (agonistic ER-binding) and anti-androgenic properties 
(antagonistic AR-binding) and thereby the MoA for BPAF involves receptor binding, but the MoA is 
not linked to any physiological effects. The evidence for an ED MoA is considered as strong. 
1 Yeast cells transfected with the human ERα or ARα and estrogen responsive elements (EREs) linked 
to a reporter gene (lacZ).  
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5.6.2.3 In vivo effects with regard to an endocrine mode of action  
 
Moreman et al. (2017) 
Summary: The toxicity and teratogenic effects of the bisphenols BPA, BPS, BPF and BPAF (>97% 
purity, CAS no. 1478-61-1) in zebrafish embryo/larvae were investigated, and also their estrogenic 
mechanisms were assessed in estrogen-responsive transgenic zebrafish larvae (ERE-TG). The toxicity 
and developmental deformities were determined after 96 hours (0-96 hpf) and the following BPAF 
concentrations were tested: 0.5, 0.75, 1.0 and 2.0 mg/L (n = 20 larvae in three replicates per 
treatment). Assessment of the estrogenic response by GFP induction was determined at 120 hpf (0-
120 hpf) and at the following concentrations: 0.001, 0.01 and 0.1 mg/L (n = 20 larvae in three 
replicates per treatment). Co-exposure with the estrogen receptor antagonist ICI 182,780 was 
performed to investigate a possible ER-mediated MoA. The exposures were semi-static and ethanol 
(0.01%) was used as a solvent. The experimental setups used to determine toxicity/morphological 
abnormalities followed the OECD guideline for Fish Embryo Acute Toxicity Test (TG 236). The 
chemical concentrations were measured by LC-MS. 
BPAF was the most potent bisphenol for toxic and developmental effects (BPAF was 6-7 times more 
potent than BPA for hatching rate and mortality); the LC50 (96 hpf) for BPAF was 1.6 mg/L, the 
EC50 for hatching success (72 hpf) was 0.92 mg/L, and cardiac edema occurred at 1 mg/L. Generally 
for all bisphenols, toxic and developmental effects occurred at concentrations several orders of 
magnitude higher than concentrations measured in the environment (the environmental concentrations 
of BPAF are generally in the range of ng/L). 
BPAF was also the most potent bisphenol in the ERE-TG zebrafish larvae: GFP induction was 
observed in the heart at 0.01 mg/L and in the liver and tail region at 0.1 mg/L. By exposure of each 
single bisphenol chemical in combination with the estrogen receptor antagonist ICI 182,780, the 
induction of GFP expression in all tissues was completely removed, which clearly demonstrates that 
the responses are mediated by an ER-pathway. BPAF is more estrogenic than the other investigated 
BPs including BPA. 
Study quality and assessment: The paper is very well written, and the experimental setup, including 
group size, replicates and quantification of exposure concentrations, is solid and well described. 
Therefore, the study is assessed to be of high quality. The receptor binding in the transgenic larvae is 
observed at concentrations below the LC50 and EC50s of developmental effects. The MoA was 
investigated by an ER-mediated GFP response, and the evidence for ED MoA is considered to be 
strong. 
 
Cano-Nicolau et al. (2016) 
Summary: The effects of BPA and BPA analogs including BPAF (CAS no. not provided but 
purchased from Sigma-Aldrich, 98% purity) were investigated both in vivo in zebrafish larvae (4-7 
dpf) and in vitro. The effects on the (xeno)estrogen-sensitive marker cyp19a1b gene (Aromatase B), 
which is mainly expressed in the radial glial cells of the brain, were investigated in vivo by: 1) 
cyp19a1b induction levels by RT-qPCR, 2) distribution of cyp19a1b transcripts by in situ 
hybridization, and 3) cyp19a1b promoter activity in transgenic cyp19a1b-GFP larvae. The binding 
capacity of the test compounds to estrogen nuclear receptors (ERα, ERβ1, and ERβ2) was 
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investigated in vitro in 1) a transfected human glial cell culture and 2) a zebrafish estrogen receptor 
competitive binding assay. 
Neither BPA nor the BPA analogs (1 µM) affected the survival rate and motility and teratogenicity 
was not observed. Exposure of zebrafish larvae between 1-7 dpf to BPAF (1 µM) caused significant 
up-regulation of cyp19a1b expression at 7 dpf compared with the solvent control (n=70 pooled heads 
and the exposure was repeated six times). This was confirmed by significant induction of cyp19a1b 
promoter activity in the brain of cyp19a1b-GFP transgenic larvae exposed to the same BPAF 
concentration from 2 hpf to 4 dpf (n=20 larvae per treatment). By in situ hybridization it was shown, 
that cyp19a1b transcripts of larvae exposed to BPAF (1-7 dpf) were detected in the same brain 
regions as in larvae exposed to EE2 and BPA (n=10 larvae per treatment), and thereby demonstrating 
a similar MoA for EE2, BPA and the BPAF.  Human U251MG cells (an ER-negative human glial cell 
line) transfected with zfERα, zfERβ1, or zfERβ2, and the zebrafish cyp19a1b promoter upstream of 
luciferase as the reporter gene, were used to investigate which of the three estrogen nuclear receptors 
mediated the up-regulation of the cyp19a1b gene. BPA and BPAF significantly stimulated cyp19a1b 
promoter activity in ERα-containing cells but not in cells transfected with ERβ1 or ERβ2, which 
demonstrates that cyp19a1b activation is mediated by the zfERα. Further, simultaneous treatment with 
the estrogen nuclear receptor antagonist ICI 182 780 completely abolished the BPA and BPAF 
stimulations observed in ERα-containing cells. Taken together, the reporter gene assay provides 
evidence that BPA, BPF, and BPAF are ERα agonists in brain glial cells. A competitive receptor-
binding assay was used to examine the receptor-binding affinity of BPA and BPA analogs for the 
three ERs (zfERα, zfERβ1, and zfERβ2). In perfect agreement with the reporter gene assay, they 
found that BPA, BPF, and BPAF bind in vitro to ERα, and BPAF had the highest binding affinity - 
also higher than BPA. An up-regulation of cyp19a1b (brain aromatase) leads to increased enzyme 
activity and therefore, increased levels of endogenous estrogen in the brain are expected. Elevated 
estrogen levels are likely to affect brain development at a functional level e.g. mating behavior. 
Study quality and assessment: Both in vivo and in vitro experiments are generally very well described 
and the experimental setups, including group sizes, replicates, and positive (1 nM EE2)/negative 
(DMSO v/v: 0.1%) controls are solid and well described. However, the exposure concentrations were 
not verified by chemical analysis. The study quality is assessed as high. It is clearly demonstrated that 
the MoA for BPAF involves the ERα, and that the estrogenic effect of BPAF on the developing brain 
involves induction of the cyp19a1b gene (Aromatase B) similar to EE2 and BPA, but other estrogen 
sensitive responses in the brain and other tissues could also be involved. 
 
Kwon et al. (2016)  
Summary: The effects of BPAF (CAS no. 1478-61-1, >97% purity) or a combination of BPAF and 
SMX (Sulfamethoxazole) on the thyroid endocrine system in adult male zebrafish (Danio rerio) were 
investigated. The exposure period was 21 days and with the following exposure concentrations: BPAF 
24.7 µg/L, SMX 5.6 µg/L or BPAF 24.7 µg/L + SMX 5.6 µg/L (n=12; four males in three replicates).  
Effects on thyroxine (T4) plasma levels were investigated (n=3 from each group). Changes in thyroid 
gene transcription of brain and thyroid tissue (homogenate of the gill region) were investigated by 
microarray analysis (n=6 for each treatment group)1 The expression of 10 genes related to the 
hypothalamic-pituitary-thyroid (HPT) axis in brain or thyroid tissue was investigated by qPCR and 
the transcription of four genes in thyroid homogenate samples from the microarray (n=4 for each 
treatment group) was verified by qPCR. 
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Total plasma T4 levels were unaffected by exposure to BPAF and SMX alone but increased 
significantly in the combined BPAF/SMX exposure (n=3). BPAF altered the transcription of genes 
related to thyroid hormone production and receptor activity, thyroid gland development, and 
deiodinase activity. The expression of trh, trhr1 and tshβ in brain tissue was increased by BPAF and 
in the thyroid tissue dio2 and tpo expression increased and decreased, respectively.  
Study quality and assessment: The study was designed to investigate if BPAF exposure affects the 
thyroid hormone system of male zebrafish. The experiment has several shortcomings: 1) Low number 
of n: Three replicates with four fish each, but n is 3 to 6 in the analyses of hormone levels and gene 
expression, and it is very difficult to figure out if samples are pooled or not 2) Only one exposure 
concentration, 3) Discrepancy in the concentration units: the text says "µg/L" but Figure 1 says 
"mg/L" and 4) the exposure concentrations were determined by LC-MS/MS "24 h before and after 
exposure", but it is unclear how many times the concentrations were determined during the 21 d 
exposure period (daily renewal of water). Based on these issues the overall quality of the study is 
assessed as low. The present study indicated that BPAF exposure alters the transcription of genes 
associated with the thyroid endocrine system, but BPAF alone has no effect on T4 levels. A clear link 
to the MoA related to the increased T4 levels in the combined BPAF/SMX exposure is not provided 
and the evidence for an ED MoA is weak. 
1 There is a mismatch in the information about sample size: they state that n=6/treatment but later they 
write that the samples were pooled three and three. 
 
Tišler et al. (2016)  
Summary: In this study, lethal and sublethal effects of BPF and BPAF (CAS no. not provided but 
purchased from Sigma-Aldrich, 99% purity) on bacteria (Vibrio fischeri), algae (Desmodesmus 
subspicatus), crustacea (Daphnia magna) and zebrafish embryos (Danio rerio) were investigated. 
Also, the effects of BPA (0.63-10.0 mg/L), BPF (0.84-13.4 mg/L), and BPAF (0.11, 0.23, 0.45, 0.90 
and 1.8 mg/L)1 on the reproduction of D. Magna were investigated after 21 days of exposure (n=10 
individuals per treatment, repeated at least three times). BPAF was the most toxic compound to D. 
magna, D. rerio and D. subspicatus. The hatching success of zebrafish embryos was the most 
sensitive parameter in all the investigated species (The EC50 value for hatching of zebrafish embryos 
was 2.2 mg/L). A concentration of 0.45 mg BPAF/L reduced several reproductive parameters in D. 
magna significantly e.g. number of young/female, brood size, days to first brood and number of 
broods/female. The mortality was not increased at 0.45 mg/L but the body length of females was 
reduced, which could indicate general toxicity. 
Study quality and assessment: The experimental setups are adequately described and the exposure 
concentrations were determined by chemical analysis. However, the test concentrations are very high 
and most endpoints are related to acute toxicity. The study is assessed to be of moderate quality. A 
possible ED MoA linked to the reproductive parameters was not investigated.  
1 The solubility of BPAF in water is 0.84 mg/L but no solvent was used (US EPA Estimation program 
interface (EPI), referred in Choi & Lee, 2017) 
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Yang et al. (2016)  
Summary: The endocrine-disrupting effects of BPAF (CAS no. not provided, 98% purity) were 
studied by exposing 2-month-old zebrafish to 0, 0.05, 0.25, or 1 mg/L BPAF (n=4 tanks/group, 9 
males or 9 females per tank (sexes held separately), each group in duplicate) for 28 days and 
evaluating the effect on growth, histopathology (liver, gonads, gills, and intestine), enzyme activity 
(SOD and MDA)1, hormone levels (testosterone, estradiol and free T3), and gene expression 
(vitellogenin). Semi-static exposure with 50% water renewal every day and a solvent control group 
(0.1% DMSO) but no control group. 
Estradiol levels increased in a concentration-dependent manner in males but only the highest 
concentration (1 mg/L) was significantly different from the control. BPAF (1 mg/L) increased free T3 
levels of females significantly, but no effect was observed at the lower concentrations and also no 
effects on male T3 level. Male testosterone levels tended to decrease in a monotonic concentration-
dependent manner, whereas in females an increase was observed at the lowest two concentrations 
(0.05 and 0.25 mg/L) and a decrease at the highest concentration (1 mg/L), but none of these changes 
in testosterone levels were significant. Also, no significant difference in T/E2 ratios between the 
groups was observed. Hormone levels were measured in whole-body homogenate of males or females 
(n=6 males or females per treatment from duplicate tanks). 
Vitellogenin gene expression was increased significantly in male livers at 1 mg/L and in females at 
0.25 mg/L (n=6 males or 6 females per treatment). 
The authors state that "the overall fitness of the fish was not significantly affected" but male body 
length was significantly reduced at the two highest test concentrations, and exposure to 1 mg/L BPAF 
caused liver damage but only in male fish, which could indicate better detoxification in females. The 
liver damage was characterized by hepatocellular swelling and vacuolation and indicates liver 
toxicity. Histological examination of the male gonads indicated that exposure to 1 mg BPAF/L lead to 
acellular areas in the seminiferous tubules of the testes, which was in contrast to control males where 
the seminiferous tubules were filled with spermatids. Histological examination of the female gonads 
revealed significant inhibition of oocyte maturation as an increase in stage I oocytes and a decrease in 
stage IV oocytes was observed after exposure to 0.25 and 1 mg BPAF/L. It is not clear how many fish 
they used for the histological examination of the gills, intestine, liver, and gonads. 
Study quality and assessment: The experiment is adequately described but n is either small (n=6 males 
or 6 females from two replicates) or not defined and the results are sometimes over-interpreted. The 
abstract describes effects on hormone levels but according to the figures most of these effects are not 
significant. The study is assessed to be of medium quality.  
The histological effects observed in the gonads could be related to general toxicity. It is unclear if the 
effects on hormone levels are related to the observed effects on oocyte maturation and acellular areas 
in the seminiferous tubules. The increase in the expression of male vitellogenin at the highest 
concentration indicates an ER-mediated MoA, and the evidence for ED MoA is considered weak-
moderate because n is low and the increase is only significant at the highest concentration.  
1 SOD: Superoxide dismutase, marker of antioxidant enzyme activity.  
MDA: Malondialdehyde, marker of oxidative stress.  
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Shi et al. (2015)  
Summary: In this study, zebrafish were exposed to BPAF (Product no B0945 - corresponds to CAS no 
1478-61-1, 99% purity) at 5, 25 and 125 μg/L (n=50 per tank, three replicates), from 4 hour-post-
fertilization (hpf) to 120 day-post-fertilization (dpf). The plasma levels of 17β-estradiol (E2) and 
testosterone (T) were measured, and the expression of several genes in the hypothalamus-pituitary-
gonad (HPG) axis was examined in liver (vtg1), brain (ERα and β, cyp19b, lhβ, fshβ, and gnrh2) and 
gonad tissue (fshr, lhr, star, cyp11a1, cyp17, cyp19a, hsd3β, hsd17β, hmgra, and hmbrb). The 
exposure was semi-static with complete water renewal every 24 hours until 14 dpf and thereafter 50% 
renewal every day, and with a solvent control group (0,01% ethanol) but no control group. Hormone 
measurements: n=3 (for each sex) per exposure but 10 fish of same sex are pooled.Gene expression: 
n=3 (gonads) or 6 (liver and brain) organs from fish of the same sex are pooled from each tank. 
In males, the concentration of E2 increased and the concentration of T decreased both in a monotonic 
concentration-response relationship and with significant differences in the two highest test 
concentrations compared with the controls. The female E2 concentration was significantly increased 
in the highest exposure group. The E2/T ratio increased significantly in males (25 and 125 μg/L) and 
females (125 μg/L). Liver vtg1 increased significantly in males (25 and 125 μg/L) but not in females. 
Several genes involved in steroid synthesis were significantly increased or reduced in males, and star 
expression was down regulated in both sexes. The concomitant changes in hormone levels and mRNA 
expression levels of genes in the HPG axis demonstrated that the steroid hormonal balances of 
zebrafish were at least partly modulated through alteration of steroidogenesis. Effects on survival and 
malformation rate in the F1 generation were observed at the highest test concentration, and also 
reduced fertilisation rate in the highest exposure group, which could suggest sperm deterioration in 
males. The higher occurrence of malformations and lower survival rate in the offspring from the 
exposure groups suggested a possibility of maternal transfer of BPAF, which could be responsible for 
the increased prevalence of malformations in the offspring.  
 
Study quality and assessment: Overall, the study is well described and the samples sizes are 
acceptable however, the tissue and plasma samples are pooled for hormone (n=3; 10 males or females 
are pooled) and mRNA measurements (n=3-6; 3 (gonads) or 6 (liver and brain) samples from males or 
females are pooled). By pooling the samples the individual variation is lost, and the study is assessed 
to be of medium-high quality. Male E2 level increase and T levels decrease The link between changes 
in gene expression and hormone alterations are well argued for, and indicative of an ED MoA 
involving effects on the expression of vitellogenin and steroidogenic enzymes e.g. star and the cyp 
enzymes.  
 
Tang et al. (2015) 
Summary: The purpose of this study was to elucidate the disruptive effects of BPAF (0, 5, 50 and 500 
μg/L) on thyroid function and expression of the representative genes along the HPT axis in zebrafish 
embryos. The embryos were exposed BPAF (CAS no. 1478-61-1, >99,5% purity) dissolved in DMSO 
from 2 hpf to 168 hpf (n=300 with 3 replicates). The exposure was semi-static with 50% water 
renewal every 12 hours and a solvent control group (0.1% DMSO) but no control group. BPAF 
exposure did not affect survival, body length or weight, but hatchability at 72 hpf was significantly 
increased at the two highest concentrations. 
Total 3,3',5-triiodothyronine (TT3), total 3,5,3',5'-tetraiodothyronine (TT4), free 3,3',5-
triiodothyronine (FT3) and free 3,5,3',5'-tetraiodothyronine (FT4) levels were measured by ELISA 
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(commercial kits) in whole-body homogenate (homogenate of 200 of the 300 larvae). The remaining 
100 larvae were homogenized and used for mRNA analyses (RT-qPCR) of the following genes: β-
actin (reference gene), tsh-β, dio1, dio2, sclc5a5, tg, ttr, tr-α, and tr-β.  
Generally, BPAF reduced the levels of the investigated thyroid hormones. Whole-body total T3 (TT3) 
and total T4 (TT4) decreased significantly at the intermediate and high exposure concentration. 
Whole-body free T3 (FT3) and free T4 (FT4) levels decreased in a monotonic concentration response-
relationship: FT3 was decreased significantly in the intermediate and high concentration but FT4 
levels were decreased significantly in all three exposure concentrations. 
The exposure to BPAF affected several genes in the HPT axis e.g. the expression of ttr and dio1 was 
significantly increased and the expression of trα and slc5a51 decreased in all or the two highest 
exposure groups.  
 
Study quality and assessment: The experiments are well described and follow the OECD TG 236. The 
variation in the gene expression results is generally high and the responses are non-monotonic. The 
quality of the study is assessed to be medium-high. Overall, this study demonstrates that BPAF affects 
the whole-body concentrations of thyroid hormones and the transcription of genes involved in the 
HPT axis in zebrafish larvae. Decreased expression of slc5a5 can lead to a decreased iodide transport 
and the thyroid cannot accumulate iodide, which might reduce the production of T4. The HPT gene 
expression results provide a possible underlying MoA of the decreased T3/T4 levels found in 
zebrafish larvae.   
1 slc5a5 encodes a sodium/iodide transporter in the thyroid. The transporter plays a role in the iodine 
uptake from the blood into the thyroid where iodide is incorporated in T3 and T4. 
 
Yamaguchi et al. (2015) 
Summary: The objective of this study was to evaluate the potential estrogenic effects of BPA and 
BPA analogs including BPAF (CAS no. not provided, >97% purity) in Japanese medaka (Oryzias 
latipes) using in vivo assays and in silico docking simulation analysis. Male medaka were exposed for 
8 hours to BPAF (0.05, 0.5, 5 and 50 µM, n=3 males per treatment, repeated at least twice) and 
mRNA expression levels of estrogen-responsive genes (Vtg1, Vtg2, ChgH, ChgL, and ERα)1 in the 
livers were determined. Males died of abdominal swelling when exposed to 50 µM BPAF. Both 
negative control (0.01% DMSO) and positive control (E2: 3.7 nM) groups were included. 
 
The expression of Vtg1 increased significantly in a monotonic concentration-response relationship in 
all three exposure groups and Vtg2 expression increased significantly in the highest exposure group (5 
µM). Expression levels of ChgH, ChgL and ERα increased significantly in the two highest exposure 
groups. The interaction potential of BPA and BPA analogs with medaka ERα was investigated in 
silico in a three-dimensional model of the ERα ligand-binding domain (LBD) and docking 
simulations were performed. The docking simulations showed that BPA and BPAF are agonists of 
ERα LBDs in both the medaka and the common carp (Cyprinus carpio) but the medaka ERα is more 
sensitive to binding of BPs. BPA and BPA analogs including BPAF probably induce the expression 
levels of Vtgs and Chgs by activation of the ERα; at least ERα is partially involved in the regulation of 
liver Vtg and Chg genes in male medaka. 
 
225 
 
Study quality and assessment: The experimental setup and data are well described but the group size 
is small (n=3 males per treatment; repeated twice) and the chemical concentrations are not 
determined. The study quality is assessed as medium-high. 
 
1 ChgH and ChgL encode the female specific proteins choriogenin H and L. The choriogenins are 
precursor proteins for proteins in the inner egg envelope and they are synthesized in response to E2. 
 
Song et al. (2014)  
Summary: The toxicity of bisphenol A (BPA), tetrabromobisphenol A (TBBPA), tetrachlorobisphenol 
A (TCBPA), and BPAF (CAS no. not provided, 98% purity) was investigated in zebrafish 
embryos/larvae and the endocrine related endpoints were investigated in adult male zebrafish. Two-
month-old male zebrafish were exposed to BPAF concentrations of 0.5, 1.0 and 1.5 mg/L (n= 10/tank, 
3 replicates) for 21 days in a semi-static exposure (100% water renewal every day) with control and 
solvent control groups (0.5% DMSO). Plasma vitellogenin levels increased significantly in a 
monotonic concentration-response relationship (n=10) and reached the same level as the positive 
control (5 µg/L E2) in the highest exposure group (1.5 mg/L). The in vitro estrogenic activity of 
BPAF (0.5, 1, 5 and 10 µM) was investigated in the MVLN assay1. The estrogenic activity increased 
with increasing exposure concentration, but the increase was only significant at the highest test 
concentration. Both the in vivo and in vitro assay showed a stronger estrogenic activity of BPAF 
compared with BPA.  
Study quality and assessment: The material and methods section is inadequate e.g. lack of information 
about exposure concentrations, and the number of experimental animals in this section does not 
comply with information in the figure legends. Overall, the study is assessed to be of medium quality. 
Both BPA and BPAF induce a significant monotonic concentration-dependent increase in vtg levels in 
vivo and clearly illustrate an ER-mediated MoA, and the in vitro assay shows a clear ER activity of 
BPA and BPAF. The link is assessed to be moderate to strong. Both the in vivo and in vitro assay 
showed a stronger estrogenic activity of BPAF compared with BPA.  
 
1 A human reporter gene assay: MCF-7 cells with endogenous estrogen receptors and transfected with 
an estrogen-responsive reporter gene) 
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5.6.2.4 Summary of the plausible link between adverse effects and endocrine mode of action 
 
Studies investigating the link between endocrine effects of BPAF and population relevant endpoints in 
non-mammalian vertebrates like phenotypic sex ratio and reproduction are unfortunately not 
available. Therefore, it is not possible to link the very well documented estrogenic mechanistic effects 
of BPAF to population relevant adverse effects non-mammalian vertebrates. 
Adverse effects like skewed sex ratio have been documented in fish species after BPA exposure (e.g. 
Drastichova et al. 2005, OhSooNa et al. 2002) and since several studies report similar ER-mediated 
MoA for BPA and BPAF a read-across approach could be relevant. Especially because several of the 
studies demonstrate a stronger ER-binding affinity of BPAF compared with BPA. 
With the current lack of information on population relevant endpoints in non-mammalian vertebrates 
(Table 3) BPAF is not an endocrine disrupting compound according to the IPCS/WHO definition. 
However, clear ER-mediated MoA is established in in vitro and in vivo studies of BPAF. In 
mammalian species there is strong evidence for marked effects on fertility and these are evaluated as   
population relevant (see 4.10.3.4 above). Therefore BPAF meet the WHO definition of an endocrine 
disruptor.  
 
5.6.2.5 Environmental relevance   
 
BPAF has been detected in environmental samples but in lower concentrations than BPA, but because 
BPA is substituted with BPA analogs there is an increasing concern that environmental concentrations 
of BPA analogs might increase in the future. BPAF is normally detected in sediment and water 
samples in the low ng/g and ng/L range, but concentrations several orders of magnitude higher have 
been detected in sediment and water samples in China e.g. close to a BPAF manufacturing plant (Liao 
et al. 2012, Song et al. 2012, Yang et al. 2014). The environmental BPAF concentrations are 
generally lower than the effect concentrations in the studies described above, but because BPA and 
BPA analogs have similar ER-mediated MoA a combined environmental exposure could cause 
concern. 
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Table 3. Overview of in vitro and in vivo endocrine disruptive (ED) mode(s) of action (MoA(s)) of BPAF.  
Reference MoA Quality of 
study  
Evidence for 
ED MoA In vitro In vivo 
Moreman et al. 
(2017) 
 BPAF (0.01 mg/L) induced GFP in the estrogen-
responsive transgenic larvae (0-120 hpf). It is 
clearly demonstrated that the MoA is ER-
mediated. 
High 
 
Strong 
Cano-Nicolau et al. 
(2016) 
The binding capacity of BPAF to zfERs 
was investigated in human glial cell culture 
and a zebrafish estrogen receptor 
competitive binding assay, and it was 
shown that BPA and BPAF are ERα 
agonists in vitro. BPAF has a higher 
binding affinity compared with BPA. 
The induction of the cyp19a1b gene (aromatase 
B) by BPAF exposure was investigated by RT-
qPCR, in situ hybridization and a cyp19a1b-GFP 
zebrafish, and showed that exposure to BPAF 
induced the cyp19a1b gene (aromatase B) in the 
brain in a pattern similar to EE2 and BPA. 
High Strong 
Kwon et al. (2016)  Several genes related to the thyroid system are 
affected but only significantly increased T4 levels 
in males after combined BPAF and SMX 
exposure  
Low Weak 
Tišler et al. (2016)  Several reproductive parameters in D. magna 
significantly but MoA was not investigated 
Medium Weak 
Yang et al. (2016)  Increased female T3 levels and increased male E2 
levels and vtg gene expression at the highest test 
concentration. Damage of male liver cells at the 
highest concentration. Effects on spermatid 
concentration and oocyte development. The MoA 
is weak-moderate. 
Medium Weak-
moderate 
Shi et al. (2015)  Concentration dependent increase/decrease in 
E2/T plasma levels of males. Increased vtg1 
expression in male liver tissue at the two highest 
concetrations. The expression of several genes in 
the steroidogenic pathway was affected. 
 
Medium-high Moderate 
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Reference MoA Quality of 
study  
Evidence for 
ED MoA In vitro In vivo 
Tang et al. 2015  Monotonic concentration-response decrease in 
TT3, TT4, FT3 and FT4 in whole-body 
homogenate of zebrafish larvae. The expression of 
several genes related to the thyroid system was 
affected. 
Medium-high Moderate 
Yamaguchi et al 
(2015) 
In silico: Docking simulations revealed that 
BPA and BPAF are agonists of ERα LBDs 
in both the medaka and the common carp 
but the medaka ERα is more sensitive to 
binding of BPs. 
Short-term exposure (8 hours) of adult male 
medaka to BPAF (0.05-5 µM) significantly 
increased the expression levels of liver Vtgs, 
Chgs, and ERα.  
Medium-high Weak-
moderate 
Song et al. (2014) Activation of ER by BPAF in the MVLN 
assay (significant at the highest test 
concentration) 
Plasma vtg increase in a monotic concentration-
response relationship in male zebrafish. BPAF has 
a stronger estrogenic activity compared with BPA. 
Medium Moderate 
Fic et al. (2014) BPAF has both estrogenic (agonistic ER-
binding) and anti-androgenic properties 
(antagonistic AR-binding) in modified 
YES/YAS assays. Clear ER-mediated MoA 
but no link of MoA to physiological effects. 
 High Strong 
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Isobutyl paraben, CAS no. 4247-02-3 
Synonyms: Isobutyl 4-hydroxybenzoate, isobutyl-p-hydroxybenzoate, isobutyl 
parahydroxybenzoate, 2-methylpropyl 4-hydroxybenzoate, IBP 
Isobutyl paraben (C11H14O3) (Figure 1) is a nonlinear 
paraben (Figure 1). Parabens are a group of alkyl esters 
of p-hydroxybenzoic acid, and many different parabens 
exist, e.g. methylparaben, ethylparaben and 
butylparaben. Isobutyl parabens is used as preservatives 
in foods, pharmaceuticals and cosmetics and is used in 
0-10 tonnes per annum. Isobutyl paraben has been 
classified in ECHA as a skin sensitiser 1B (H317: May 
cause an allergic skin reaction). Moreover, it has been 
classified as a skin (H315: causes skin irritation) and eye 
irritant (H318: causes serious eye damage and H319: 
causes serious eye irritation) 
 
4. Human health hazard assessment 
4.10.3 Endocrine disruption 
4.10.3.1 General approach – human health 
 
4.10.3.2 In vitro information indicative of endocrine activity 
Kim et al. (2012)  
Summary: The aim of the study was to investigate the additive, synergistic or antagonistic effects on 
estrogenic activity of isobutyl paraben and octylphenol using GH3 rat pituitary cells. Isobutyl paraben 
was tested at 0, 0.1, 1 or 10 µM and gene expression and protein expression of Calbindin-D9k (CaBP-
9k) and progesterone receptor (PR) and estrogen receptors (ER) reporter gene expression was assessed 
in the cells. Expression of the ER reporter gene and expression of CaBP-9k gene and protein was 
upregulated at all tested doses of isobutyl paraben. The PR gene was also upregulated in all the tested 
doses of isobutylparaben but only the highest dose (10 µM) upregulated expression of PR protein.  
Study quality and assessment: The study is well-described and thorough. The methods section 
describes the concentrations of isobutyl paraben tested and the incubation conditions and they used 
positive and negative controls and performed duplicate or triplicate samples. Information on 
cytotoxicity was apparently not tested and the CAS-number of the chemicals used is not provided. 
Based on this, the study is assessed to be of medium quality. The study provides moderate evidence of 
an estrogenic mode of action of isobutyl paraben involving estrogen receptors. 
 
 
Figure 1: 2D structure from 
PubChem 
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Kim et al. (2011)  
Summary: The objective of this study was to validate the estrogenic activity of a range of chemicals, 
including parabens, using the stably transfected transcriptional activation assay. Isobutyl paraben was 
tested in a hERα-HeLa-9903 cell line transfected with a human ERα gene with a firefly luciferase 
gene as a reporter gene. The study showed (22,000 fold) lower estrogenic activity of isobutyl paraben 
compared to 17β-estradiol. Compared to other parabens tested, isobutyl and butyl paraben were the 
two parabens with highest estrogenic activity.  
Study quality and assessment: The study is well-described and well-structured and it provides much 
information on the cell assay performed such as positive and negative controls, incubation conditions, 
dilutions etc. However, information on cytotoxicity or triplicates is not described and no CAS number 
or purity of isobutyl paraben is given. The study is therefore assessed to be of medium quality. The 
present study investigated the activity of isobutyl paraben in a single assay and the resulting 
information on the estrogenic mode of action of isobutyl paraben is limited. The data provide weak 
evidence of an estrogenic mode of action of isobutyl paraben 
 
Kim et al. (2010)  
Summary: In this study, the aim was to determine the relative androgen receptor (AR) binding affinity 
of a range of chemicals, e.g. parabens, phthalates and testosterone. Isobutyl paraben showed higher 
competitive affinity to AR than other parabens tested. The binding affinity relative to 
dihydrotestosterone was almost 17000 times lower for isobutyl paraben. 
Study quality and assessment: The description of the methods and the interpretation of the findings 
are poor. The CAS-numbers of chemicals or of the radioligand are not given and controls are not 
used. The concentrations tested can be read with some difficulty from a figure of low graphical 
quality. Technical notes for the user in the laboratory are included in the description of the methods 
giving the impression that the materials and methods section is not written with the reader of the 
article in mind. However, other details are included such as a description of the AR used, a 
description of the preparation of the assay buffer and the experiment was performed in triplicates. The 
study is assessed to be of medium quality. This study investigated the relative binding affinity to AR 
but does not investigate other antiandrogenic mechanisms of action and the knowledge provided on 
the antiandrogenic properties of isobutyl paraben are limited. The data provide weak evidence of an 
antiandrogenic mode of action of isobutyl paraben. 
 
Vo et al. (2010)  
Summary: In this study a competitive ligand binding assay was performed in addition to a female 
pubertal assay to assess the estrogenic effects of several parabens in vitro and in female rats. The 
binding affinity of isobutyl paraben to ERα and ERβ was investigated. Isobutyl paraben showed 
affinity to both receptors and no preference to any of the receptors could be determined.  
Study quality and assessment: The in vitro study is described very briefly and it is not mentioned 
where the receptors used in the assay originate from (e.g. rat or human) or whether triplicates were 
performed. The quality of the in vitro part of the study is assessed to be of low quality. The study 
provides weak evidence of an estrogenic mode of action of isobutyl paraben. 
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Dabre et al. (2002)  
Summary: This study investigated the estrogenic activity of isobutyl paraben and n-butyl paraben in 
an array of in vivo and in vitro assays. In vitro studies were performed in three different human breast 
cancer cell lines. A competitive ERα binding assay in and the ability to regulate gene expression 
oestrogen responsive genes were performed in MCF-7 cells. Oestrogen dependent growth was 
assessed in MCF-7 and ZR-75-1 cells lines and MDA-MB-231 cells were used as a negative control.  
Isobutyl paraben increased expression of oestrogen regulated genes, stimulated oestrogen dependent 
growth of cell lines and inhibited binding of oestradiol to ERα. These in vitro data support each other 
and altogether they indicate an estrogenic activity of isobutyl paraben at receptor, gene and at a 
cellular physiologic response level. 
Study quality and assessment: The study is well-described and much information is included for the in 
vitro part of the study, such as source of cell lines, use of negative and positive controls and clear 
descriptions of the interpretation and objective of each study. Although the CAS number and purity of 
isobutyl paraben is not reported, the in vitro study is assessed to be of high quality. The in vitro 
studies investigated the estrogenic activity of isobutyl paraben at several levels, including at receptor, 
at gene and at a cellular physiologic response level. The in vitro part of the study provides strong 
evidence of an estrogenic mode of action of isobutyl paraben. 
 
Okubo et al. (2001)  
Summary: In the present study the estrogenic activity of parabens was investigated in vitro. MCF-7 
cells were used to study estrogenic induced cellular proliferation, gene expression levels of ERα and 
PR and the protein expression of ERα. A competitive receptor binding assay was performed to 
investigate the affinity to human ERα and ERβ. 
Proliferation of MCF-7 cells was increased by isobutyl paraben. Compared to the positive control, 
17β-estradiol, the effect of isobutyl paraben was 170,000 times lower. Suppression of the proliferative 
effect by the antiestrogen ICI 182,780 interacting with ER, suggested an estrogenic mode of action of 
isobutyl paraben on proliferation of MCF-7 cells. Gene expression of ERα was decreased and PR was 
increased by isobutyl paraben. Although the effects were lower than the effects of 17β-estradiol, gene 
expression of ERα and PR were changed in the same directions as for 17β-estradiol. Protein 
expression of ERα was decreased by isobutyl paraben although not in the same extent as for 17β-
estradiol. This is in good accordance with the findings on gene expression level of ERα. Isobutyl 
paraben had 1000-fold lower affinity to human ERα and ERβ compared to the positive control DES, 
indicating that the paraben does not have specific preference for ERα or ERβ. 
Study quality and assessment: The study is well-described and thorough. Although Okubo and co-
workers did not mention whether they assessed cytotoxicity, this does not affect the reliability of the 
study as the results indirectly imply that there was no cytotoxicity at the relevant doses. Proliferation 
was observed and proliferation levels were not suppressed below control levels at dilutions of ICI 
182,780 below 10-8. Although the CAS-number and purity of isobutyl paraben is not described, the 
study is assessed to be of high quality. Based on the data on estrogenic activity of isobutyl paraben at 
the gene, protein and cellular proliferation levels together with the study on affinity to human 
oestrogen receptors, the study provides strong evidence of an estrogenic mode of action of isobutyl 
paraben. 
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4.10.3.3 In vivo effects with regard to an endocrine mode of action  
 
Yang et al. (2016)  
Summary: The aim was to investigate reproductive effects in male rats of a low dose of a mixture of 
bisphenol A and isobutyl paraben after developmental exposure. The two compounds were tested 
separately and in a mixture. Pregnant rat dams (n=3/group) were dosed by oral gavage with 2.5 
mg/kg/day isobutyl paraben from gestation day 6 to post-natal day 12. At delivery, birth weight, 
number of pups and the sex ratio were recorded. Male pups were assessed for anogenital distance 
(AGD), nipple retention, preputial separation, testis descent, body weight, pinna detachment, incisor 
eruption and eye opening. The litters were adjusted to 8 male pups per group from PND4. Male pups 
were killed on PND70 and blood was sampled for hormone analysis (LH, FSH, testosterone and 17β-
estradiol), testis and epididymis were weighed and stored for histopathological analysis and 
epididymal sperm count and motility (n=5/group) was assessed. The hormone level of 17β-estradiol 
was decreased by isobutyl paraben in adult male pups. Sperm count and motility was reduced 
compared to controls in adult male offspring in the isobutyl paraben group. No other endpoints 
investigated were affected by isobutyl paraben. 
Study quality and assessment: The study is well described and although the chow was not tested for 
phytoestrogen content, oestrogen contamination was minimized from other sources (stainless steel 
cage, glass water bottles and wood bedding). Only 3 pregnant dams were used for this developmental 
study and data from littermates were analysed but the litter effect was not included in the statistical 
analysis. The study is assessed to be of low to medium quality. This study showed adverse effects on 
sperm motility and sperm numbers, but the underlying mode of action is not clear. Effects on sperm 
count have been seen for several endocrine disrupters after developmental exposure suggesting an 
endocrine mode of action of isobutyl paraben. Moreover, the study showed effects on the intrinsic 
oestrogen levels indicating an endocrine mode of action of isobutyl paraben in vivo. The study 
provides weak evidence of an endocrine mode of action and adverse effects of isobutyl paraben. 
 
Kim et al. (2015)  
Summary: In this study, a 28-day repeated dose toxicity study with dermal exposure to isobutyl 
paraben, isopropyl paraben or a mixture of the two was performed. The test followed the OECD test 
guideline 410. Male and female rats (5 weeks old) were dermally exposed to 0, 100, 300 or 600 mg/kg 
isobutyl paraben (10 rats per group) for 28 days (5 days per week) by topical application to the skin in 
a shaved dorsal area of the trunk. Body weight and food and water consumption was measured. At 
necropsy, blood was sampled (for haematological parameters, biochemical parameters and hormone 
analysis of T3, FSH, estradiol, testosterone and insulin) and livers, kidneys, hearts, brains, testes, 
prostates, ovaries and vaginas were weighed. Skin, liver, kidney brain and heart were assessed 
histopathologically. Histopathological evaluation of the skin showed changes in the females. 
Epidermal hyperplasia with hyperkeratosis (1 out of 3 examined in the 100mg/kg dose-group and 3/3 
in the 300 and 600 mg/kg groups) and pustules (1/3 in the 100 and 300 mg/kg dose-groups and 3/3 in 
the 600 mg/kg dose-group) were seen. Biochemical parameters measured in the blood showed 
increased levels of Na+ in a dose-dependent manner in males from 50mg/kg and higher and increased 
levels of Cl- in females from the 600 mg/kg group compared to controls; however these changes were 
within the normal range. The lack of changes in organ weights and haematological parameters 
indicated no signs of heamatotoxic, hepatotoxic or nephrotoxic effects of isobutyl paraben in the 
tested doses. 
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Study quality and assessment: The study is well-described and thorough and follows the OECD TG 
410 for repeated dose dermal toxicity. It is unclear how many male and female rats were used in the 
study (5 or 10 of each sex per group), and a little more details on the housing conditions would have 
been preferred. The study is assessed to be of medium quality. Due to the lack of effects on 
endocrine-related organs and hormonal parameters, the study provides no evidence of adverse effects 
with an endocrine mode of action. 
 
Kawaguchi et al. (2010)  
Summary: In this study the effects of perinatal exposure to isobutyl paraben on social behaviour was 
analysed. Pregnant rat dams were continuously exposed to isobutyl paraben sc. through a Silastic 
capsule implanted 3 weeks before mating. Female offspring (n=5-6) were tested for social recognition 
at 16 weeks of age. 
Treated rats showed impaired social recognition. After repeated presentation to a rat, females exposed 
to isobutyl paraben spent the same time interacting with the rat compared to the first presentation, 
whereas control females spent less time interacting with the rat on the 4th trial.  
Study quality and assessment: The study is well-described and relevant information is given. The 
study is assessed to be of high quality. The study provides evidence of effects on social behaviour, but 
it is not clear if the adverse effects are due to an endocrine mode of action. This study provides strong 
evidence of adverse effects.  
 
Vo et al. (2010)  
Summary: In this study a female pubertal assay was performed to investigate the effects of parabens 
(methyl-, ethyl-, propyl-, isopropyl- butyl- and isobutyl paraben) in female rats and an affinity ligand 
binding assay was performed to assess the estrogenic activity in vitro. Female prepubertal rats 
(10/group) were dosed PND21-40 with 0, 62.5, 250 or 1000 mg/kg/day isobutyl paraben by oral 
gavage. 17α-ethynylestradiol was used as an estrogenic positive control. Oestrous cycle was assessed 
during the exposure period. At necropsy on PND41 blood was sampled for hormone analysis 
(estradiol, prolactin, tetra-iodothyronine (T4) and TSH) and organs (uterus, ovary, liver, kidneys, 
adrenal glands and thyroid glands) were weighed and stored for histopathology. 
At all doses of isobutyl paraben myometrial hyperplasia was seen in uteri. It is less clear what changes 
were observed histologically in ovaries, but a decreased number of corpora lutea, increased number of 
cystic follicles and thinning of the follicular epithelium was apparently seen. Serum levels of T4 were 
decreased in the low-dose isobutyl paraben group but not at higher doses.  
Study quality and assessment: The present study has some limitations and missing information. 
Although animals were fed a soy-free diet to limit contamination of phytoestrogens through the feed, 
other sources of oestrogen contamination such as cage material or drinking bottles were not avoided. 
The rats were bred in-house but it is not described whether some of the 200 female prepubertal rats 
used in the study were littermates. The description of histopathological findings in ovaries is 
confusing and it is unclear what kind of changes they found in this organ. Vaginal opening was 
assessed, but is not described in the materials and methods section. Finally, the relevance of assessing 
the regularity of the oestrous cycle in vaginal smears from PND21 is not clear as the female rats are 
not sexually mature at this age and the mean day of vaginal opening in some of the exposure groups 
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was above 36 meaning that they had less than 4 days to assess vaginal smears in some of the animals 
in those groups. As a consequence, the study is assessed to be of low quality. The histopathological 
changes observed in female reproductive organs may be related to estrogenic effects of isobutyl 
paraben, but the underlying mechanism of action is not clear. The role of isobutyl paraben on thyroid 
hormones is unclear and the changes in T4 levels may be a chance finding. The study provides weak 
evidence of adverse effects in female reproductive system with an estrogenic mode of action of 
isobutyl paraben. Also, a weak evidence of a thyroid disrupting mode of action of isobutyl paraben is 
provided based on the hormonal effects seen at the lowest dose.  
 
Kawaguchi et al. (2009a)  
Summary: In this study, the effects of isobutyl paraben on emotional behaviour and learning 
performance were analysed in rats. From 3 weeks before mating, mated dams were exposed 
continuously to isobutyl paraben through an implanted Silastic capsule. Offspring were tested for 
neurobehavioral function. In the open field test, 5 weeks old offspring (one male and one female per 
litter from 7 treated and 8 control litters) were tested. The same animals were tested in the elevated 
plus maze at 6 weeks of age. In the passive avoidance test, females were ovarectomised (ovx) at 7 
weeks of age and treated with or without oestrogen and 11 weeks old males and ovx females with or 
without oestrogen from 8 treated and 8 control dams (one of each per litter) were tested. The same 
animals were used in the Morris water maze. The amount of isobutyl paraben released from the 
Silastic capsule was estimated by incubation of capsules in saline at 37°C for 42 days. 
Approximately 4.36 mg/L/day of isobutyl paraben was released from the capsule in vitro. Behavioural 
testing showed sex-specific effects. Male offspring exposed to isobutyl paraben perinatally spent 
shorter time in the open arms of the elevated plus maze and showed decreased performance in the 
passive avoidance test. No effects of isobutyl paraben on offspring behaviour were seen in the open 
field or the Morris water maze. Developmental exposure to isobutyl paraben affected emotionality but 
not activity levels. Long-lasting effects on behaviour appeared to be present in male rats after 
developmental exposure to isobutyl paraben and the anxiogenic affects observed in male offspring 
may be comparable to behavioural effects seen for gonadal hormones or compounds that mimic 
oestrogen. The results indicate that the estrogenic action of isobutyl paraben shown in the literature 
may feminise the male brain.  
Study quality and assessment: This study is well-described and the relevant information is given in the 
text. Although no CAS-number of the compound is reported, the study is assessed to be of high 
quality. The adverse effects on male behaviour are in good accordance with the estrogenic activity of 
isobutyl paraben reported by others and this study provides strong evidence of adverse effects linked 
to an estrogenic mode of action of isobutyl paraben. 
 
Kawaguchi et al. (2009b)  
Summary: The aim was to clarify the estrogenic effects of gestational and through lactation exposure 
to isobutyl paraben on the endocrine system of pregnant dams and offspring. This study was the same 
as for Kawaguchi et al. (2009a), but with assessments of other effects. Pregnant rat dams were 
continuously exposed to isobutyl paraben sc. through a Silastic capsule. Dams were killed after 
weaning and blood was collected and pituitary glands, adrenal glands and uterus were weighed. AGD 
was measured in 7 days old offspring (4 males and 4 females per litter) and vaginal opening and 
oestrous cycle from 7 weeks of age were assessed in female offspring (1 female per litter). Offspring 
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were killed at 3 weeks of age (1 of each sex per litter) and at 12 weeks of age (1 male per litter). At 
necropsy of offspring blood was collected and pituitary glands, adrenal glands, testis and uterus were 
weighed. One testis from 12 weeks old male offspring was used for sperm count. The 12 weeks old 
males were stressed before necropsy and adrenal glands were collected. One 7 weeks old female per 
litter was ovariectomised and implanted with Silastic capsules with or without estradiol. At 12 weeks 
of age (5 weeks after implantation of the capsules) female offspring treated with estradiol were killed 
and blood was collected and pituitary glands and uterus were weighed. Blood samples from 
ovariectomised females not treated with estradiol were collected at 13 and 17 weeks of age. Blood 
was analysed for hormone levels (LH, FSH, testosterone, estradiol, prolactin, ir-inhibin, TT3, TT4 
and corticosterone). 
No overt signs of toxicity were seen. There were no effects on litter size or ratio of male pups. Plasma 
corticosterone levels in dams were decreased after isobutyl paraben exposure and uterus weight was 
increased. No effects were found in the offspring. 
Study quality and assessment: The study is well-described and all relevant information is given in the 
text except for the CAS number of the tested isobutyl paraben. The study is assessed to be of high 
quality. The data from the study show evidence of effects of isobutyl paraben on uterus weights of 
dams but not in female offspring. The study provides weak evidence of adverse effects related to an 
estrogenic mode of action and no evidence an antiandrogenic or a thyroid disrupting mode of action. 
 
Koda et al. (2005)  
Summary: The objective of the study was to test the oestrogenic activity of the agents in UV filters, 
including isobutyl paraben, using ethinyl estradiol and bisphenol A (BPA) as positive controls in a 
uterotrophic assay. Ovariectomised female rats (13-14 weeks old at study start, n=6) were dosed s.c. 
daily for 3 days with 0, 100, 250 or 625 mg/kg/day. Body weight, wet and blotted uterine weight was 
assessed. Wet and blotted uterine weights were increased with 250 mg/kg isobutyl paraben per day or 
more, indicating an estrogenic activity of the chemical in vivo.  
Study quality and assessment: The study is well-described, the estrognic activity of the feed was 
tested and aluminium cages and water supply without plastic were used to minimize contamination 
with BPA. The study is assessed to be of high quality. This study provides strong evidence of an 
estrogenic mode of action of butyl paraben in vivo.  
 
Dabre et al. (2002)  
Summary: This study investigates the estrogenic activity of isobutyl paraben and n-butyl paraben in 
an array of in vivo and in vitro assays. The immature rodent uterotrophic assay was used in the in vivo 
study. Immature (18 days of age) female CD1 mice (7 per group) were dosed s.c. with 0, 1.2 or 12 
mg/kg/day for 3 days. Body weight and uterus wet weight were assessed at necropsy.  
Isobutyl paraben increased uterus weight relative to body weight at 1.2 and 12 mg/kg/day. The results 
indicate an estrogenic activity of isobutyl paraben in vivo. 
Study quality and assessment: In the in vivo part of the study, information on housing conditions is 
missing. In a study with focus on oestrogen activity of a compound like in the present study, some 
information on (phyto)oestrogen content in the feed, cage material or cage enrichment would be 
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preferred. However, in the present case with a very short exposure period (3 days), this information is 
less critical and the remaining work is very well described. Although CAS-number and purity of the 
compound is not reported, the quality of the in vivo study is assessed to be high. The in vivo data show 
an estrogenic mode of action of isobutyl paraben and provides strong evidence of an estrogenic mode 
of action of isobutyl paraben. 
 
REACH registration dossier 
The REACH dossier did not include data on reproductive toxicity studies or other in vivo or in vitro 
data. Acute toxicity and skin sensitisation and irritation were evaluated based on QSAR prediction 
using the Danish QSAR database. Genetic toxicity was assessed based on an in vitro study. No other 
information on toxicity testing is available in the REACH dossier. 
 
4.10.3.4 Summary of the plausible link between adverse effects and endocrine mode of 
action  
Several in vitro and in vivo studies were performed with focus on the endocrine mode of action of 
isobutyl paraben (Table 1). Most of the in vitro studies investigated the estrogenic mode of action of 
isobutyl paraben and showed estrogenic activity at different levels. The paraben has been shown to 
bind ERα and ERβ, to upregulate oestrogen regulated genes and proteins and to induce oestrogen 
regulated proliferation of cells (Kim et al. 2012; Kim et al. 2011; Vo et al. 2010; Dabre et al. 2002; 
Okubo et al. 2001). In vivo studies confirmed the estrogenic mode of action of isobutyl paraben in 
uterotrophic assays with s.c. exposure (Koda et al. 2005; Dabre et al. 2002). At the hormonal level, 
there are some discrepancies between the studies. Yang et al. (2016) showed decreased 17β-estradiol 
in adult male pups in a developmental study (Yang et al. 2016). In contrast, no effects on serum 
estradiol levels were seen in rat studies with adult exposure in males or females (Kim et al. 2015), 
peripubertal exposure in females (Vo et al. 2010) or developmental exposure in females (Kawaguchi 
et al. 2009b). Taken together, the data provide strong evidence of an estrogenic mode of action of 
isobutyl paraben. 
The in vivo data on endocrine-related adverse effects of isobutyl paraben are scarce (Table 2). Two 
studies showed adverse effects that may be related to the estrogenic mode of action shown in vitro and 
in vivo. Histopathological changes in female reproductive organs were observed in a female pubertal 
assay and may be related to an estrogenic effect of the compound (Vo et al. 2010). However, the 
changes reported in the study are not well-described in an extent that makes it unclear what changes 
were found in the ovaries and the underlying mechanism of action can not readily be discussed. 
Another study showed adverse effects on male behaviour after perinatal exposure and according to 
Kawaguchi et al (2009a) the sex-specific anxiogenic affects observed were comparable to behavioural 
effects seen for gonadal hormones or compounds that mimic oestrogen (Kawaguchi et al. 2009a). 
Another study on behaviour showed impaired social recognition in female offspring exposed 
perinatally to isobutyl paraben, but it is not clear if the adverse effects are due to an endocrine mode 
of action.  (Kawaguchi et al. 2010). Adverse effects on sperm motility and sperm numbers in male 
pups (Yang et al. 2016) suggest an endocrine mode of action of isobutyl paraben that may be 
oestrogenic. Altogether, the published data provide moderate evidence of adverse effects linked to an 
estrogenic mode of action of isobutyl paraben.  
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The androgenic activity of isobutyl paraben has been investigated to a lesser extent. An in vitro 
androgen receptor binding assay showed activity of isobutyl paraben (Kim et al. 2010). On the other 
hand isobutyl paraben does not appear to affect testosterone levels in in vivo studies. No effects on 
testosterone levels were found in male offspring at weaning or as adults after developmental exposure 
(Yang et al. 2016; Kawaguchi et al. 2009b) and no effects on testosterone levels were seen in males in 
a 28-days repeated dose toxicity study with dermal exposure (Kim et al. 2015). Adverse effects on 
sperm motility and sperm numbers in male pups (Yang et al. 2016) suggest an endocrine mode of 
action of isobutyl paraben that may be anti-androgenic. All in all there is weak evidence of adverse 
effects linked to an anti-androgenic mode of action of isobutyl paraben. 
Few studies investigated effects of isobutyl paraben on thyroid hormones in vivo. A single study 
showed effects on serum T4 at PND41 in a female pubertal assay (Vo et al. 2010), whereas other 
studies showed no effects on TT3, TT4 or T3 levels in a 28-days repeated dose toxicity study with 
dermal exposure and in young and adult pups from a developmental toxicity study (Kim et al. 2015; 
Kawaguchi et al. 2009b). The role of isobutyl paraben on the thyroid hormones is unclear and the 
changes in T4 levels found by Vo et al. (2010) may be a chance finding or due to a possible litter 
effect. Thyroid hormones are known to be important for brain development and the long-lasting 
effects on behaviour reported by Kawaguchi and co-workers (2010 and 2009a) showing impaired 
social recognition in female offspring (Kawaguchi et al. 2010) could be linked to thyroid disruption. 
The mechanisms underlying the behavioural changes were not investigated and the link between these 
effects and thyroid disruption is unclear.  
In summary, data provide strong/moderate evidence of an estrogenic mode of action of isobutyl 
paraben. Adverse effects on sperm motility and sperm numbers in male pups and effects on sexual 
dimorphic behaviour suggest an endocrine mode of action of isobutyl paraben that may be 
oestrogenic. Thus, there is weak to moderate evidence for a causal link. Altogether, the published data 
provide moderate evidence of adverse effects linked to an endocrine (estrogenic) mode of action of 
isobutyl paraben. 
In conclusion, isobutyl paraben does meet the WHO definition of an endocrine disruptor with an 
estrogenic mode of action and with a possible anti-androgenic and thyroid disrupting mode of action.   
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Table 1. Overview of in vitro and in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of isobutyl paraben.  
Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
Yang et al. 
2016 
 Decreased 17β-estradiol in male pups after 
developmental exposure to isobutyl paraben.  
Medium Weak 
Kim et al. 
2012 
Expression of the ER reporter gene and 
expression of CaBP-9k gene and protein 
was upregulated in all tested doses of 
isobutyl paraben. The PR gene was 
upregulated in all the tested doses of 
isobutyl paraben but only the highest dose 
(10 µM) upregulated expression of PR 
protein in GH3 rat pituitary cells. 
 Medium Moderate 
Kim et al. 
2011 
22000 fold lower estrogenic activity of 
isobutyl paraben compared to 17β-
oestradiol in a stably transfected 
transcriptional activation assay in a hERα-
HeLa-9903 cell line. 
 Medium Weak 
Kim et al. 
2010 
The AR binding affinity relative to 
dihydrotestosterone was almost 17000 
times lower for isobutyl paraben in an  
androgen receptor binding assay.  
 Medium Weak 
Vo et al. 2010 Isobutyl paraben had affinity to ERα and 
ERβ, but did not appear to have a 
preference to one of the receptors. 
Serum levels of T4 were decreased in the 
low-dose group but not at higher doses. 
Low Weak-weak 
Koda et al. 
2005 
 Increased wet and blotted uterus weight in 
uterotrophic assay with s.c. exposure in 
ovariectomised rats (n=6/group) 
 
High Strong 
Dabre et al. 
2002 
Estrogenic activity was seen on binding to 
ERα, upregulation of oestrogen regulated 
genes in MCF-7 cells and on oestrogen 
regulated proliferation in MCF-7 and ZR-
75-1 cell lines. 
Increased uterus weight (relative to body 
weight) in uterotrophic study in immature 
female rats (n=7/ group) with s.c. exposure. 
High Strong 
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Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
Okubo et al. 
2001 
Increased proliferation of MCF-7 cells, 
which was suppressed by the antioestrogen 
ICI 182,780 interacting with ER, 
suggesting an estrogenic mode of action of 
isobutyl paraben. Gene and protein 
expression of ERα was decreased and gene 
expression of PR was increased by isobutyl 
paraben. Isobutyl paraben had 1000-fold 
lower affinity to human ERα and ERβ 
compared to the positive control DES. 
 High Strong 
ER: estrogen receptor; AR: androgen receptor; T4: tetra-iodothyronine; PR: progesterone receptor; s.c.: subcutaneous; DES: diethylstilbestrol 
 
Table 2. Overview of potential endocrine-related adverse effects of isobutyl paraben. 
Reference Species, n Adverse effects Quality of study  Evidence for 
adverse effects 
Yang et al. 
2016 
Rat, n=3 
litters/group 
Sperm count and motility was reduced by isobutyl paraben in adult male 
pups after developmental exposure to isobutyl paraben. 
Low - Medium Weak 
Kim et al. 
2015 
Rat, 
n=10/group 
No effects were seen on hormone levels or organ weights in adult rats 
exposed dermally for 28 days. 
Medium Weak 
Kawaguchi 
et al. 2010 
Rat, n=5-6 Female offspring exposed perinatally to isobutyl paraben showed impaired 
social recognition compared to controls. 
High Strong 
Vo et al. 2010 Rat, 
n=10/group 
At all doses myometrial hyperplasia was seen in uteri and in ovaries a 
decreased number of corpora lutea, increased number of cystic follicles and 
thinning of the follicular epithelium was apparently observed 
histologically.  
Low Weak 
Kawaguchi 
et al. 2009a 
Rat, 
n=8/group 
Male offspring spent shorter time in the open arms of the elevated plus 
maze and showed decreased performance in the passive voidance test after 
developmental exposure to isobutyl paraben.   
High Strong 
Kawaguchi 
et al. 2009b 
Rat, n=7-8 
litters 
Plasma corticosterone levels in dams were decreased after isobutyl paraben 
exposure and uterus weight was increased. 
High Weak 
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Hexachlorophene (HCP), CAS no. 70-30-4 
 
Synonyms: HCP  
The substance Hexachlorophene (Figure 1) is a white free-flowing odorless powder. The poiwder is 
insoluble in water and denser than water. It is an organochlorine compound used as a detergent 
cleanser, and it is an antibacterial emulsion for topical administration. It has bacteriostatic action 
against staphylococci and other gram-positive bacteria. Cumulative antibacterial action develops with 
repeated use. Cleansing with alcohol or soaps containing 
alcohol removes the antibacterial residue. Used as a surgical 
scrub and a bacteriostatic skin cleanser. It may also be used to 
control an outbreak of gram-positive infection where other 
infection control procedures have been unsuccessful. It is also 
used in agriculture as a soil fungicide, plant bactericide and 
acaricide. Since no registration dossiers on Hexachlorophene 
are available, it is assumed that it is produced and/or imported 
to EU in tonnages less than 100 tpa 
 
                                  
4. Human health hazard assessment 
4.10.3 Endocrine disruption 
4.10.3.1 General approach – human health 
4.10.3.2 In vitro information indicative of endocrine activity 
Jung et al. (2004)  
Summary: This study investigated the anti-estrogenic effect of 50 chemicals, including 
hexachlorophene (HCP),), using 3 in vitro assays. First the yeast two-hybrid assay with the rat 
estrogenic receptor (ER) α and the coactivator TIF2 (transcriptional intermediary factor 2)  was used 
to investigate the anti-estrogenic activity of HCP at concentration ranging from 10-3 to 10-9 M. 
Toxicity of HPC in the assay was assessed and found at concentrations of  >5 µM. Next, the 
inhibitory effect of HPC on the transcriptional activity of 17β-estradiol was tested in a reporter gene 
assay system using ER-positive human breast cancer cells (MCF-7).  Finally, the binding activity of 
HCP to human ERα was examined in a competitive binding assay. HCP showed a dose-dependent 
anti-estrogenic activity against rat ERα in the two-hybrid assay at concentrations below toxicity 
(IC50=1 µM). This result could not be confirmed in the MCF-7 reporter gene assay at concentrations 
below toxicity. In the competitive binding assay, however, it was found that HCP can bind to human 
ERα.  
Study quality and assessment: The study is well-described although purity and CAS number of the 
substance used could not be found.  The number of experimental replicates and tested doses are not 
specifically given in the material and methods section but can be found in the figures. Overall, the 
study is assessed to be of high quality, and provides moderate evidence for an anti-estrogenic MoA of 
HCP in multiple in vitro screening systems. 
Figure 1: 2D structure from PubChem     
 245 
 
4.10.3.3 In vivo effects with regard to an endocrine mode of action  
Erdos et al. (2013)  
Summary: This study aims to evaluate the suitability and performance of circulating Inhibin B as a 
biomarker of seminiferous tubule damage in rats. In that context HCP was administrated as one of 
eight testicular toxicants - only the data collected regarding HCP will be addressed in this summery. 
HCP (Sigma-Aldrich;CAS#70-30-4; purity by NaOH titration 99,1 %; lot#053K3603) was 
administrated by oral gavage to male Wistar Han rats (n=15 / age 8-10 weeks) at doses of 0 or 25 
mg/kg/day for 4 or 9 days. A higher dose group (n=4-9) received decreasing doses of HCP due to 
toxicity, starting with 50 mg/kg/day on day 1 and 2, 40 mg/kg/day on the 3rd day and 30 mg/kg/day on 
day 4-9.  On day 5 or 10 plasma samples were collected for Inhibin B analysis and necropsy was 
conducted. Data was collected from terminal body weight, histology of testicular tissue (seminiferous 
tubule degeneration, degeneration/necrosis of the round and elongated spermatids, seminiferous 
tubule vacuolation and spermatogenesis) and ELISA was used to determine plasma concentrations of 
Inhibin B. The study result for HCP showed a statistically significant correlation (p˂0.05) between 
decreases in Inhibin B and seminiferous tubule toxicity but only observed at the early time points.  In 
the animals from the HCP study exposed to 25 mg/kg/day brain lesions of white matter degeneration 
was observed in 5/5 in the postmortem examination and significant adverse physical signs was noted.     
Study quality and assessment: Although the effect of HCP on testis was not the main focus, the study 
is well-described and thorough and is assessed to be of high quality. It is unsure if the observation 
regarding white matter degeneration and the adverse physical signs could have an unknown effect on 
inhibin B levels. On the basis of that, the study provides a weak evidence for an ED MoA of HCP.  
 
James et al. (1980)  
Summary: This study aimed to examine the spermatogenesis in Dawley rats (n=30) and Beagle dogs 
(n=4) after oral exposure to HCP. At the time of study no literature was available for a suitable HCP 
dose for dogs so a dose-range study was conducted on 4 sexually mature male beagle dogs. On the 
basis of that study a dose of 3 mg/kg/day was used in the primary study. For the canine part, HCP was 
administrated by gelatin capsules at the level of 3 mg/kg/day for 9 weeks, no additional groups and no 
control group. Two dogs was killed after 9 weeks and 2 dogs were retained for additional 13 weeks 
after last dose and no HCP was administrated. The rats were exposed to HCP by oral gavage at levels 
of 0 mg/kg/day (control), 5 mg/kg/day for 9 weeks. In each group 5 rats was killed after 4 and 9 
weeks and 5 rats were retained for 13 weeks after last dose and no HCP was administrated For the 
canine study length and breadth of testis were measured and semen collected, starting pre-dose with 
one measurement then 2, 4 and 8 weeks of exposure and finally after 4, 8 and 12 weeks in the 
withdrawal period. Ejaculates were examined for Vol., motility, density, sperm concentration and 
morphology. The concentration of Na+ and K+ ions, alanine aminotransferase, aspartate 
aminotransferase and acid phosphatase was determined in each sample of seminal plasma. Canine 
luteinizing hormone (LH) was assayed using a heterologous ovine double antibody system. For the rat 
study sera were obtained after 1, 4 and 9 weeks of exposure and in week 13 of the withdrawal period. 
Serum testosterone concentrations, Follicle-stimulating hormone (FSH) and LH were assayed. For 
both species High-power light microscope was used for visual germ cell count of type B 
spermatogonia, pachytene spermatocytes, early or late spermatids and sertoli cells. In addition to 
macroscopic post mortem evaluation, the pituitary glands, testis and secondary sex organs were 
weighed and preserved for histological examination. The results detected no clinical change in 
pituitary-testicular relationship and the semen production of dogs was unaffected. In the counting of 
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germinal cells in the seminiferous tubules, some statistically significant differences (P˂0,05) were 
found for both dogs and rats. For dogs, decreased numbers of B spermatogonia were recorded after 9 
weeks of exposure. For rats a decrease in the number of all germinal cell types counted was apparent 
at 4 weeks examination, but not at 9 weeks. After 13 weeks of HCP withdrawal, no effect on cell 
counts was apparent in dog or rat.    
Study quality and assessment The description of this study has some shortcomings for example are 
there no control group for the dog study and even though it is mentioned in the text, that nothing was 
found, there is no presentation of the values measured regarding the concentration of Na+ and K+ ions, 
alanine aminotransferase, aspartate aminotransferase, acid phosphatase and FSH/LH assays. For the 
chemical used no report of the purity and CAS no. could be found. The study is assessed to be of 
medium quality and it provides a weak evidence for HCP’s adverse effect on the spermatogenesis in 
rats and dogs   
 
Gellert et al. (1978)  
Summary: This study investigates effects on mating behavior and prostatic development in Sprague-
Dawley rats after exposure to HCP (3 %) by topical application. The study was separated into a 
female and a male part. In both studies the rats were lathered for 10 minutes a day through day 1- 8 of 
their life. The wash was conducted with pHisoHex, 3% HCP (n= 25), pHisoDerm, 0% HCP (control, 
n=7) or they remained unwashed 0 % HCP (control, n=8). All pups were kept separated 1.5 h after 
exposure to minimize ingestion of HCP due to nuzzling and licking on the skin. In the female part 
following parameters were noted; Onset of puberty by vaginal opening, estrus cycle by vaginal smear, 
fertility and delivery of normal pups. Body weight and changes in pituitary, ovary and adrenals were 
noted post mortem.  All female rats were sacrificed at the age of 6 month. In the male study the 
mating behavior and fertility was assessed at several ages. At 7 month of age each male were placed 
with two normal females (proven fertility) in a period of two weeks. Progeny was counted, sex 
determined at birth and mortality up to 5 days was noted. At 9,5th month of age each male were 
placed with two primed (100 μg estradiol benzoate, 48 h before testing) females for two consecutive 
overnight cohabitation periods. Conclusion of intromission and/or ejaculation was made if a vaginal 
plug, sperm or a bloody vaginal smear were registered. At 11 month of age, each male was placed 
with a primed female for a test-period of 35 min. Number and frequency of behaviors (mounting, 
intromission and ejaculation) was noted. Heart blood was taken under light ether-anesthesia and a 
radioimmunoassay for testosterone was carried out. At 12th month of age all rats were 
orchidectomized and a saline smear was made from the cut surface of the caudal epididymis to 
evaluate motile sperm. The weight of testis was noted. At 13th month of age all rats were sacrificed, 
weight of the adrenals was noted and selected portions of the internal genitalia were removed and 
fixed for histologic examination. During the exposure period, all pups washed with pHisoHex showed 
ataxia and tremor by the age of day 9 and increased mortality by day 14  . No clinical signs or 
mortality was seen in the control groups (pHisoDerm and unwashed). The result from the female 
study revealed no changes in onset of puberty, estrus cycle, fertility, pituitary, ovary, adrenals and 
body weight in any group. In the male study the two control groups were combined for statistical 
analysis of data, since no significant differences existed between them. Neonatal male rats exposure to 
pHisoHex, 3%HCP showed inhibition of reflex ejaculation, infertility and prostatic cysts and fibrosis. 
Spermatogenesis was not affected. 
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Study quality and assessment :      
I general, the study is well-described, although information regarding the number of rats in the control 
group of the female study and housing condition would have been preferred. No report of the purity 
and CAS no. of the used chemical could be found. The study is assessed to be of medium quality and 
provides no evidence for adverse effect on female reproduction and a moderate evidence for effects 
on mating behavior and prostatic development in male rats.  
 
Kennedy et al. (1976)  
Summary: This study evaluated the effects on reproductive performance, perinatal and postnatal 
development of rats in two parts. In the first part, COBS random bred albino rats were used to 
investigate the effects on reproduction. HCP (G-11 brand) was administrated by gavage as a 3% 
suspension in 1% aqueous methylcellulose to three groups (n=30) at levels of 0 mg/kg/day, 5 mg/kg/, 
10 mg/kg/day. For males the administration of HCP started 63 days prior to mating and females 
received the compound 14 days before mating and continued until weaning of the litter at day 21. 
Mating was done at the age of 100 days by rotation of males within each group. Parameters registered 
were fertility, mating behavior, pregnancy, length of gestation and lactation behavior. At day 14 of the 
gestation 10 females from each dose group were killed and examination of the ovaries, uteri and fetus 
were conducted. The remaining females continued until weaning at day 21. Registration of weight 
was obtained at 0, 1, 4 and 21 days after delivery, a complete examination for external defects was 
conducted. In the second study regarding peri- and postnatal development HCP was administrated 
orally by gavage to three groups (n=20) at levels of 0 mg/kg/day (control), 15 mg/kg/day30 
mg/kg/day Exposure started at day 15 of gestation and continued throughout lactation. Parameters 
examined were maternal body weight, length of gestation, number of progeny, death, behavior and 
survival rate. Body weight was assessed on day 0, 1, 4 and 21 after birth. The result from the internal 
examination at day 14 of gestation showed an increase in resorption sites in females receiving HCP 10 
mg/kg/day. In the same dose group, pups surviving the later stage of lactation were reduced. In the 
group exposed to HCP at levels of 30 mg/kg/day maternal toxicity (weight loss) was observed and a 
pharmacotoxic response of hindlimb weakness and severe hypo-activity with a following comatose 
stage was observed in two animals. In the same group the number of viable pups delivered was 
decreased and the number of stillborn pups increased. 
Study quality and assessment. The study is well-described and thorough, although the study is old it 
provides information on housing, number and age of animals. The CAS no. and purity of the HCP 
compound was not reported. Overall, the study quality is assessed to be high and it provides  moderate 
evidence of the adverse effect on the reproductive performance (resorption sites, viable and stillborn 
pups) and the peri- and postnatal development of rats.  
 
Kennedy et al. (1975)  
Summary: This study investigated the influence of HCP on reproduction in rats (albino CD strain) 
after exposure by feeding. HCP was administrated to 4 groups (n=24/dose) in the daily feeding at 
levels of 0 ppm), 12.5 ppm 25 ppm and 50 ppm All dose-groups started on the experimental diet at the 
age of 21 days. Preparation of diet was as followed; HCP acetone solution was added to a commercial 
ration to reach the final concentration of 12,5 ppm, 25 ppm and 50 ppm. Diet was available ad libitum 
until sacrifice and prepared fresh on a weekly basis. At the age of 100 days the F0 generation was 
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housed for breeding with two females per male. F1A were retained for 21 days. The female rats of F0 
were allowed 10 day rest period before mating again. At weaning of the F1B, 8 males and 16 females 
were randomly selected for breeding of F2. This procedure continued for 3 successive two litter 
generations. Registrations were obtained for weight gain, gestation time, no. of viable and stillborn 
progeny and external physical abnormalities. At sacrifices, examination for gross pathological 
changes was done on all parental animals and tissue was retained for histologic examination. The 
result of the study revealed no change in any parameters measured. 
Study quality and assessment: The study is generally well-described but information about the 
absolute exposure doses of HCP are not explicitly stated for the individual animal. The compound 
was administrated as a component in the diet and all tested animals had ad libitum access to the 
feeding -  body weight gain was registered to be normal but no information on food consumption is 
described. The material and method section does not report CAS no and purity of the chemical used 
or information on housing conditions. The study is assessed to be of low quality and since no change 
was measured in any parameter it provides no relevant evidence for the adverse effect of HCP on 
reproduction.  
 
Kimmel et al. (1974)  
Summary: This study investigates the teratogenicity of HCP in pregnant rats (Charles River strain). 
The study consist of two parts, the first part investigate the effect on the developing rat embryo after 
absorption of HCP from the vaginal mucosa, the second part covers the kinetics of HCP by comparing 
the uptake, distribution and excretion of HCP labeled with radioactive carbon after oral, dermal and 
intravaginal administration. The first part will be of concern to this summary. In the study mating of 
rats were conducted and day 0 of gestation was designated by vaginal presence of sperm. At the 7th 
day of gestation, 0.2 ml vehicle (control,n= 12) , 300 mg/kg (45%) HCP suspension (n=12), 80 mg/kg 
(12%) HCP suspension (n=5), 20 mg/kg (3%) HCP suspension (n=6) or commercial 3% HCP (n=6) 
was inserted into the vaginal lumen under ether anesthesia. A gaze plug was inserted into the vagina 
and the orifice was partially closed by suture. An additional 0.2 ml of HCP or vehicle was applied by 
tuberculin syringe on day 8, 9 and 10 of gestation and at the 11th day the plug was removed. All 
animals were killed at day 20 of gestation. Parameters registered for the maternal rats were implants 
and resorption sites, weight and gross abnormalities of fetus. Two thirds of the fetuses were fixed in 
alcohol and stained with alizarin red and parts (brain and eyes) were prepared by routine for histology. 
The result revealed an apparent dose-response relationship in the rate of offspring malformations 
(urogenital defects like chryptorchidism and missing uterine horn, hydrocephaly, anopthalmia,  
microphthalmia and wavy ribs). In rats exposed to 45 % suspension almost half the surviving fetuses 
were affected. The group exposed to 12 % showed less teratogenic effect and the 3 % group showed 
no effect. In the two groups of highest concentration, the pregnant rats developed a moderate to severe 
toxicity during treatment (weakness, weight loss and diarrhea).  
Study quality and assessment: It is an old study but it is well described and thorough. The CAS no. 
and purity for the chemical used was not reported and information regarding housing conditions 
would have been preferred. Overall the study is assessed to be of medium quality and it provides a 
strong evidence for the teratogenic adverse effects of HCP.  For some of the malformations produced, 
i.e. urogenital defects like chryptorchidism and missing uterine horn, there may be a plausible link to 
an ED MoA. Thus the study provides weak evidence for endocrine-related adverse effects.   
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Frederic R. Alleva (1973)  
Summary: The aim of this study was to evaluate the effect of HCP on reproduction in hamsters 
(Lakeview strain) after exposure of a near lethal dose. HCP was dissolved in Mazola corn oil and the 
solution was injected subcutaneously (SC). A dose-range study on HCP lethality was conducted prior 
to the main study were male and female neonatal hamsters was exposed to HCP doses at 0, 1.56, 3.12, 
6.25, 12.0, 12.5, 24,  25 mg/kg, adm was subcutaneous injection at the age of  0 or 2 days. It was 
concluded that the maximal non-lethal dose of HCP in neonatal hamsters were 6 mg/kg bw. In the 
main study male and female groups were exposed to a single dose at different age (0, 2, 4 and 12 
days). The compound was administrated at three levels (0, 3 or 6 mg/kg) with two control groups 
(untreated or only oil); untreated (control, n=14 oil with 0 mg/kg/0 days of age (control, n=11), oil 
with 0 mg/kg/2 days of age (control, n=7),  3 mg/kg/0 days of age (n=31),  3 mg/kg/2 days of age ( 
n=25), 3 mg/kg/4 days of age (n=34 3 mg/kg/12 days of age (n=5), 6 mg/kg/0days of age (n=12), 6 
mg/kg/2 days of age (n=19), 6 mg/kg/4 days of age (n=20 and 6 mg/kg/12 days of age (n=2). Two 
additional groups received three SC injections of 3 mg/kg at the age of 0, 1 and 2 days (n=46 the dose 
was administrated as one injection each day. At the age of 20 days vaginal washing were obtained 
daily and puberty was assigned when a 4-day cycle of the vaginal discharge signaling ovulation was 
found. Mating was done at the age of 85-88 days between similarly treated partners and fertility was 
considered successful when delivery of pups was registered. The result showed no effect on fertility 
and body weight and for the female groups there was no effect on time of puberty and estrus cycle 
regularity.   
Study quality and assessment: Only very limited written information was presented in the article and 
all details of the experiment were outlined in 3 tables. No purity or CAS no. for the chemical could be 
found and more information on housing condition would have been preferred. Overall the study is 
assessed to be of medium quality and since the study did not find any effect it provides no relevant 
evidence for adverse effects on reproductive after exposure to HCP.   
 
Gaines et al. (1973)  
Summary: This study evaluated the effect of HCP in five different setups. Three of them are of 
relevance to reproduction The aim of the three reproduction studies was to evaluate the toxicity after 
oral exposure regarding to the size of litter, survival to weaning, body wt., brain lesions and 
determination of HCP excreted in the milk of lactating rats. Study 1- a two- generation study, F0: 
HCP was administrated to the groups (n=20) in the diet at levels of 0 (control, 20 and 100  ppm 
starting from the age of 4-5 weeks. All rats were euthanized after 258 days of exposure. Breeding of 
F1a was conducted after 54 days and breeding of F1b after 166 days (all mating was done among rats 
of same dietary level). F1b continue with the feeding like F0 and 72 animals from F1b were used for 
breeding of F2 at the age of 95 days. F1 was euthanized after 145 days of exposure and F2 after 
weaning at the age of 21 days.  Number of litters born and weaned, average no. per litter, survival (%) 
and mean body weight and organ weight were registered and tissues from selected organs was 
preserved for microscopy. Study 2 – Administration of HCP by oral intubating to female rats at the 
age of 100 days, during the organogenesis, day 7-15 of pregnancy. Five groups (n=8-10) were given 0 
, 1, 5 , 10 and 20 mg/kg/day. Measurements were obtained for numbers of litters born and weaned, 
average no. per litter, survival (%) and body wt. Study 3 – Determination of HCP in the milk of 
lactating rats. Female rats (n=2 in each group) were exposed to HCP for 241 days by diet at levels of 0 
ppm 20 ppm and 100 ppm Concentrations level was evaluated from a whole milk sample (2 ml) taken 
from the stomach of each pup (age 3-4 days) in the litter. Results from the two-generation study 
revealed that abnormal findings by microscopic examination of the organs were limited to the brain in 
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the group fed 100 ppm. Findings included small vacuolated areas in the white matter and mild status 
spongiosus. Reproduction was not affected in rats exposed to 20 ppm but in the group fed 100 ppm 
the survival to weaning in F1b was significantly reduced to 62.5 %. Reproduction data of the study 
where HCP was administrated on day 7-15 of gestation, no still births was observed and pups was 
evaluated to be normal. Analysis of stomach content revealed 0.007 and 0.33 ppm in the milk of rats 
fed 20 ppm and 100 ppm respectively. 
Study quality and assessment: The material and method section dose not report the purity and CAS 
no. of HCP but it is mentioned that all test were conducted with the same batch of USP grade. A 
description of housing conditions would have been preferred and only limited statistical significant 
results are presented in the figures. The absolute dose of HCP administrated to the individual rat is a 
point of concern in the two studies where rats were fed by diet because the mixing technique was 
done by grinding using a mechanical mixer. The question about even distribution of HCP in the diet 
remains unanswered but weight gain was normal during the study.  Overall, the study quality is 
assessed to be medium and it provides weak evidence of the adverse effect on reproduction (decreased 
pup survival) after HCP exposure. 
  
Thorpe et al. (1969)  
Summary: In this study HCP (2,2 methylene bis [3,5,6-trichlorophenol]) was tested in 8 month old 
rams. The aim of the study was to examine the effect on the liver and the seminiferous epithelium 
(SE) in testis. HCP (5% solution in arachis oil) was admministrated by stomach tube in all cases. HCP 
was given in three groups (n=3-6) as a single oral dose at the levels of 0 mg/kg (control), 25 mg/kg 
and 50 mg/kg In each group a unilateral orchiectomy was performed under regional local anesthesia at 
intervals of 2, 7 and 21 days after exposure. Atrophy of the SE was registered at both HCP doses of 
25 mg/kg and 50 mg/kg. Depletion of the SE was less obvious at day 7 post-exposure in the low 
concentration group compared to the high concentration group but lesions was indistinguishable in 75 
% of the samples by day 21. Liver biopsy revealed periportal fatty changes in the groups that received 
multiple doses of HCP. Enzyme histochemical results suggested that the hepatic lesions were a direct 
result of the toxic properties of HCP.   
Study quality and assessment:  In general, the study is well-described, although more information on 
the housing conditions would have been preferred and  there is no report of the purity and CAS no. of 
the tested chemical. The study is assessed to be medium quality and provides a moderate evidence for 
a toxic adverse effect in the testis and liver of rams after exposure to HCP. 
 
Thorpe et al. (1967)  
Summary: This study examines the pathological effect of HCP in male wistar rat (albino strain) using 
3 different experiments. In the first study HCP was administered to 4 groups (n=20-30/group) as a 
single oral dose given by catheter at 0 mg/kg (control) 25 mg/kg , 75 mg/kg, and 125 mg/kg  A 
minimum of 4 rats from each group were euthanized at 1, 2, 5, 12 and 21 days post-dose. The second 
study tested the effect of 5 doses where HCP was administered to 3 groups (n=12) orally by catheter 
on 5 consecutive days at levels of 0 mg/kg (control), 25 mg/kg and 75 mg/kg and all animals were 
euthanized on the 5th day.  In both studies, blocks of testis, liver, kidney, small and large intestine 
were fixed for microscopically examination. In the 3rd study the teratogenic effect in female rats were 
investigated. The results from the first two studies showed atrophy of the seminiferous epithelium 
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after exposure to a single dose of 125 or 5 days of exposure to 75 mg/kg and these results were in 
concordance with findings of reduced sperm in epididymides. Lesions was detected at the 2nd day 
post-dosing but were found to be reversible since the epithelium was observed to be restored by day 
21 post-dosing. The third study, looking at the structure of the major viscera and skeleton of fetuses 
the results revealed no interference with pregnancy or development.              
Study quality and assessment:  The material and method section is not explicit, about the report of the 
purity and CAS no. of the tested chemical and the age of the tested animals and more information on 
the housing conditions would have been preferred. The study is overall assessed to be of medium 
quality. The lesions in the testis were evaluated quantitatively by the method of Chalkley (1943) and 
the results provide strong evidence for adverse effects on the seminiferous epithelium after exposure 
to HCP. 
 
4.10.3.4 Summary of the plausible link between adverse effects and endocrine mode of action  
 
To our knowledge one in vitro study (Jung et al, 2004) (Table 1) addressing the anti-estrogenic effect 
of HCP is currently available. This study is of high quality and showed a dose-dependent anti-
estrogenic activity against rat ERα in the two-hybrid assay at concentrations below toxicity (IC50=1 
µM). The result could not be confirmed in the MCF-7 reporter gene assay at concentrations below 
toxicity but in the competitive binding assay, however, it was found that HCP can bind to human 
ERα. Thus, there is moderate evidence for ED MoA, i.e. anti-estrogenic activity. 
The majority of research regarding HCP consists of older publications and encounters several in vivo 
studies looking at the adverse effect of HCP exposure (Table 2). None of the in vivo studies have 
included known sensitive endpoints for anti-oestrogenic effects in females, but the studies provide 
strong evidence for adverse effects on testis histology manifested as seminiferous toxicity. Treatment 
with anti-estrogens can lead to lower sperm numbers, abnormal sperm morphology and reduced 
fertility in male rodents, changes also seen for ERα knockout mice (reviewed by Hess et al. 2003). 
The effects on testis and epididymides reported for hexachlorophene may thus be related to an anti-
estrogenic mode of action. However, ERα receptors have been reported to be absent in human testis 
and epididymides and the link between the ERα activity observed in vitro and the adverse effects 
observed in the reproductive organs in vivo for hexachlorophene is weak. It should be noted, that the 
data on the ED modes of action (in vivo and in vitro) of HCP are scarce, and other mechanisms 
besides of ERα activity or other modes of action of the substance that could explain the adverse 
effects observed cannot be excluded. 
In conclusion, hexachlorophene meets the WHO definition of a potential endocrine disruptor. 
According to the DK-EPA suggested ED criteria, hexachlorophene is assessed as a suspected 
endocrine disruptor. 
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Table 1. Overview of in vitro and in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of Hexachlorophene  
Reference MoA Quality of study  Evidence for ED 
MoA In vitro In vivo 
Jung et al. 
2004 
HCP showed a dose-dependent anti-
estrogenic activity against rat ERα in the 
two-hybrid assay at concentrations below 
toxicity (IC50=1 µM). This result could 
not be confirmed in the MCF-7 reporter 
gene assay at concentrations below 
toxicity. In the competitive binding assay, 
however, it was found that HCP can bind 
to human ERα.  
 
  
High 
 
Moderate 
Erdos et al. 
2013 
 The study result for HCP showed a 
statistically significant correlation (p˂0.05) 
between decreases in Inhibin B and 
seminiferous tubule toxicity but only 
observed at the early time points.  
 
 
High 
 
weak 
Hexachlorophene (HCP), estrogen receptor α (ERα) 
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Table 2. Overview of in vitro and in vivo endocrine disrupting (ED) mode(s) of action (MoA(s)) of Hexachlorophene (HCP) 
Reference Species,  
N 
Adverse effects Quality of study  Evidence for 
adverse effects 
Erdos et al. 
2013 
n=15 Postmortem findings showed white matter degeneration in the brain in 
5/5 rats. Histomorphologic testicular findings included seminiferous 
tubular degeneration   
         
High Weak 
James et al. 
1980 
Rats 
n=30 
 
Dogs 
n=4 
Semen production of dogs were unaffected. In the counting of germinal 
cells in the seminiferous tubules, some statistically significant differences 
(P ˂ 0,05) were found of both dogs and rats. For dogs, decreased 
numbers of B spermatogonia were recorded after 9 weeks of exposure. 
For rats a decrease of all cell types counted was apparent at 4 weeks 
examination. After 13 weeks of HCP withdrawal, no effect on cell counts 
was apparent in dog or rat.    
 
 
 
Medium 
 
 
 
weak 
Gellert et al. 
1978 
Rats  
Female, n= 
10-30 
Male, n= 
min.10 
 
During the exposure period, all pups washed with pHisoHex showed 
ataxia and tremor by the age of day 9 and mortality by day 14 was 
male=25% and female=13%. No clinical signs was seen in the control 
groups (pHisoDerm and unwashed) and mortality by day 14 = 0%.  
 
The result of the female study revealed no changes in onset of puberty, 
estrus cycle, fertility, pituitary, ovary, adrenals and body weight in any 
group.  
 
In the male study the two control groups were combined for statistical 
analysis of data, since no significant differences existed between them. 
Neonatal male rats exposure to pHisoHex, 3% HCP showed inhibition of 
reflex ejaculation, infertility and prostatic cysts and fibrosis. 
Spermatogenesis was not affected. 
 
 
 
Mediun 
 
no evidence 
for the female 
study 
 
Moderate  
for the male study  
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Reference Species,  
N 
Adverse effects Quality of study  Evidence for 
adverse effects 
Kennedy et 
al. 1976 
Rats 
Female,n=120 
Malen=30 
The result from the internal examination at day 14 of gestation showed 
an increase in resorption sites in females receiving HCP 10 mg/kg/day. In 
the same dose group, pups surviving the later stage of lactation were 
reduced. In the group exposed to HCP at levels of 30 mg/kg/day maternal 
toxicity (weight loss) was observed and a pharmacotoxic response of 
hindlimb weakness and severe hypo-activity with a following comatose 
stage was observed in two animals. In the same group the number of 
viable pups delivered was decreased and the number of stillborn pups 
increased. 
 
High 
 
Moderate 
Kennedy et 
al. 1975 
Rats 
n=32-64 
 
The study revealed no change in any parameters measured. 
It should be noted that the diet containing HCP was administrated ad 
libitum with no record of individual intake.  
 
Low 
 
None  
Kimmel et al. 
1974  
Rats 
n=41 
The result from the first part revealed an apparent dose-response 
relationship in the rate of offspring malformations (hydrocephaly, 
anopthalmia and microphthalmia). Rats exposed to 45% suspension 
affected almost half the surviving fetuses. The group exposed  to 12% 
showed less teratogenic effect and the 3% group showed no effect. In the 
two groups of highest concentration, the pregnant rats developed a 
moderate to severe toxicity during treatment (weakness, weight loss and 
diarrhea). 
 
Medium  
 
High 
Alleva, 
frederic R. 
1973 
Rats 
n= 106 - 120 
 
After a single subcutaneous injection, the result showed no effect on 
fertility and body weight and for the female groups there was no effect on 
time of puberty and estrus cycle regularity.   
 
Medium 
 
 None 
Gaine et al.  
1973 
Rats 
females, n= 
76-86 
Males n= 30 
Results from the two-generation study revealed that abnormal findings 
by microscopic examination of the organs were limited to the brain in the 
group fed 100 ppm. Findings included small vacuolated areas in the 
white matter and mild status spongiosus. Reproduction was not affected 
in rats exposed to 20 ppm but in the group fed 100 ppm the survival to 
weaning in F1b was significantly reduced to 62,5 %. Reproduction data 
of the study where HCP was administrated on day 7-15 of gestation, no 
still births was observed and pups was evaluated to be normal. Analysis 
of stomach content revealed 0,007 and 0,33 ppm in the milk of rats fed 
20 ppm and 100 ppm respectively.  
 
Medium 
 
 Weak 
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Reference Species,  
N 
Adverse effects Quality of study  Evidence for 
adverse effects 
Thorpe et al. 
1969 
Sheeps 
n= 15 
In the testis study atrophy of the SE was registered at HCP rates of 25 
mg/kg and 50 mg/kg. Depletion of the SE was less obvious at day 7 post-
exposure in the low concentration group compared to the high 
concentration group but lesions was indistinguishable in 75 % of the 
samples by day 21. Liver biopsy revealed periportal fatty changes in the 
groups that received multiple doses of HCP. Enzyme histochemical 
results suggested that the hepatic lesions were a direct result of the toxic 
properties of HCP.   
  
 
Medium 
 
Moderate 
 
Thorpe et al. 
1967 
Rats  
Female, n= 84 
Male, n=122 
The results from the first two studies showed atrophy of the seminiferous 
epithelium after exposure to a single dose of 75 mg/kg. Lesions was 
detected at the 2nd day post-dosing but were found to be reversible since 
the epithelium was observed to be restored by day 21 post-dosing. In the 
third study, looking at the structure of the major viscera and skeleton of 
fetuses the results revealed no interference with pregnancy or 
development.              
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